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Abstract	  Background:	  Posttraumatic	  Stress	  Disorder	  (PTSD)	  is	  a	  common	  disorder	  that	  causes	  a	  significant	  health,	  social	  and	  economic	  burden	  for	  the	  individuals	  who	  suffer	  from	  it	  and	  consequently,	  for	  society	  as	  a	  whole.	  	  However,	  little	  is	  known	  about	  the	  consequences	  of	  PTSD,	  and	  in	  particular	  there	  is	  a	  lack	  of	  empirical	  data	  in	  relation	  to	  its	  economic	  impact	  on	  individuals	  and	  health	  systems,	  or	  on	  the	  treatments	  that	  might	  be	  provided.	  Aims:	  The	  aim	  of	  this	  research	  is	  to	  assess	  the	  health,	  social,	  and	  economic	  impacts	  of	  PTSD	  by	  focusing	  on	  the	  individuals	  exposed	  to	  the	  London	  bombings	  by:	  a)	  reviewing	  the	  current	  evidence	  and	  measures	  of	  the	  health,	  social	  and	  economic	  impact	  of	  PTSD;	  b)	  assessing	  the	  impact	  of	  the	  London	  bombings	  in	  terms	  of	  service	  use	  and	  the	  impact	  on	  health,	  social,	  and	  economic	  activity	  of	  those	  affected;	  c)	  conducting	  an	  economic	  evaluation	  of	  the	  ‘screen	  and	  treat’	  programme	  implemented	  as	  a	  mental	  health	  response	  after	  the	  London	  bombings;	  and	  d)	  assessing	  the	  broader	  implications	  and	  feasibility	  of	  screening	  for	  PTSD	  in	  primary	  care.	  Method:	  Semi-­‐structured	  interviews	  with	  230	  participants,	  screen	  and	  treat	  programme	  users	  and	  potential	  users	  conducted	  as	  a	  part	  of	  the	  evaluation	  of	  the	  NHS	  mental	  health	  response	  to	  the	  London	  bombings,	  analysis	  of	  the	  dataset	  on	  the	  outcomes	  collected	  as	  a	  part	  of	  the	  programme,	  and	  semi-­‐structured	  interviews	  on	  the	  benefits	  of	  and	  barriers	  to	  implementing	  screening	  for	  PTSD	  in	  the	  primary	  care	  sector.	  Analysis:	  A	  range	  of	  quantitative	  and	  qualitative	  methods	  are	  conducted	  including:	  estimation	  of	  the	  costs	  associated	  with	  exposure	  to	  the	  London	  bombings,	  analysis	  of	  cost	  and	  outcome	  variation	  between	  individuals	  exposed	  to	  the	  bombings,	  economic	  evaluation	  of	  the	  screen	  and	  treat	  programme	  distinguishing	  three	  comparator	  groups,	  and	  directed	  qualitative	  content	  analysis	  of	  fourteen	  interviews	  on	  the	  benefits	  of	  and	  barriers	  to	  screening	  for	  PTSD	  in	  primary	  care.	  Results:	  The	  higher	  prevalence	  of	  London	  bombing-­‐related	  problems	  for	  individuals	  who	  were	  not	  treated,	  even	  as	  long	  as	  two	  and	  a	  half	  years	  after	  the	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bombings,	  confirms	  the	  benefits	  of	  long-­‐term	  screening	  after	  exposure	  to	  traumatic	  events.	  	  Participants	  who	  used	  the	  screen	  and	  treat	  programme	  reported	  significantly	  higher	  average	  direct	  and	  total	  costs.	  	  The	  treated	  group	  reported	  up	  to	  three	  times	  higher	  total	  costs	  in	  comparison	  to	  individuals	  who	  were	  screened	  and	  assessed	  only,	  with	  work-­‐related	  costs	  making	  the	  highest	  contribution	  to	  the	  total	  cost,	  followed	  by	  the	  programme	  itself,	  and	  then	  other	  health	  care	  costs.	  	  Similar	  service	  use	  patterns	  were	  found	  between	  the	  treated,	  and	  the	  screened	  and	  assessed	  only	  groups.	  	  The	  main	  cost	  drivers	  identified	  in	  the	  analysis	  for	  the	  full	  sample	  of	  individuals	  exposed	  to	  the	  London	  bombings	  were	  being	  of	  female	  gender,	  being	  in	  a	  non-­‐white	  British	  ethnicity	  group,	  experiencing	  injury,	  old	  age,	  and	  feeling	  one	  might	  be	  killed	  and/or	  injured.	  	  The	  treated	  group	  consisted	  of	  individuals	  who	  were	  more	  severely	  affected	  by	  the	  London	  bombings	  when	  compared	  to	  the	  group	  who	  were	  screened	  and	  assessed	  only.	  	  Conclusions:	  The	  effects	  of	  trauma	  exposure	  and	  PTSD	  have	  a	  wide-­‐ranging	  and	  long-­‐term	  health-­‐related	  and	  economic	  impact	  on	  exposed	  individuals.	  	  The	  findings	  suggest	  that	  the	  screen	  and	  treat	  programme	  was	  successful	  in	  identifying	  participants	  with	  greater	  mental	  health	  needs	  and	  providing	  them	  with	  treatment.	  	  Providing	  the	  best	  evidence-­‐based	  treatment	  early	  in	  the	  form	  of	  the	  ‘screen	  and	  treat’	  approach	  does	  not	  seem	  to	  be	  cost-­‐effective.	  	  However,	  without	  having	  a	  proper	  waiting	  list	  comparison	  group	  the	  questions	  on	  effectiveness	  and	  cost-­‐effectiveness	  of	  the	  ST	  programme	  are	  difficult	  to	  answer	  with	  certainty.	  	  This	  study	  has	  pointed	  out	  vulnerable	  groups	  such	  as	  minority	  ethnic	  groups	  and	  women	  who	  are	  likely	  to	  experience	  worse	  outcomes	  and	  generate	  higher	  direct	  and	  indirect	  costs.	  	  There	  is	  a	  need	  for	  timely,	  rigorously-­‐implemented	  economic	  evaluations	  of	  mental	  health	  interventions	  for	  PTSD.	  	  There	  is	  a	  role	  for	  non-­‐RCT	  study	  designs	  in	  economic	  evaluations	  of	  PTSD	  interventions.	  	  There	  is	  also	  a	  need	  for	  economic	  evaluation	  of	  screening	  for	  PTSD	  intervention	  in	  primary	  care.	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Chapter	  1	   	  Introduction	  
1.1	  	   The	  impact	  of	  PTSD:	  importance	  and	  relevance	  of	  the	  subject	  Terrorist	  attacks	  are	  increasingly	  frequent	  global	  phenomena	  with	  wide-­‐reaching	  behavioural,	  health	  and	  economic	  consequences.	  	  The	  intent	  to	  harm	  and	  cause	  as	  much	  disruption	  as	  possible	  is	  the	  key	  feature	  of	  terrorist	  attacks	  and	  is	  associated	  with	  a	  particularly	  high	  risk	  of	  psychopathology	  (Norris	  et	  al.,	  2002).	  	  Posttraumatic	  stress	  disorder	  (PTSD)	  is	  often	  cited	  in	  literature	  as	  one	  of	  the	  most	  common	  consequences	  of	  exposure	  to	  terrorism	  and	  indeed	  one	  of	  the	  best	  documented	  (Neria	  et	  al.,	  2008;	  DiMaggio	  &	  Galea,	  2007;	  Boscarino,	  2002).	  	  	  PTSD	  is	  a	  common	  mental	  health	  disorder	  that	  is	  associated	  with	  significant	  health,	  social	  and	  economic	  burdens	  for	  individuals,	  their	  families	  and	  society	  as	  a	  whole.	  	  PTSD	  is	  associated	  with	  high	  levels	  of	  social,	  occupational	  and	  physical	  disability	  (McFarlane,	  2010;	  Coughlin,	  2011;	  Vieweg,	  2007;	  Kessler,	  2000),	  considerable	  economic	  cost	  (Marciniak	  et	  al.,	  2004),	  high	  levels	  of	  health	  service	  utilization	  (Marshall	  et	  al.,	  2014;	  Elhai,	  North	  and	  Frueh,	  2005;	  Erbes	  et	  al.,	  2007),	  poor	  social	  and	  family	  relationships,	  absenteeism	  from	  work	  (Fineberg	  et	  al.,	  2013),	  lower	  income,	  and	  lower	  educational	  and	  occupational	  success	  (Kessler,	  2000;	  Iversen	  et	  al.,	  2008).	  
Traumatic	  events	  are	  quite	  common	  among	  the	  general	  population,	  with	  population	  lifetime	  cumulative	  exposure	  to	  any	  traumatic	  event	  ranging	  from	  20%	  to	  87%	  (Kessler	  et	  al.,	  2000),	  but	  fortunately	  not	  everyone	  exposed	  will	  go	  on	  to	  develop	  PTSD	  (Breslau,	  1998;	  Ferry	  et	  al.,	  2008).	  	  Lifetime	  prevalence	  rates	  of	  PTSD	  range	  from	  3.5-­‐6.3	  for	  men	  and	  7.9-­‐13.8	  for	  women	  (Breslau,	  2009;	  Helzer	  et	  al.,	  1987;	  Kessler	  et	  al.,	  1995).	  	  The	  UK	  2007	  Adult	  Psychiatric	  Morbidity	  Survey	  reported	  a	  conditional	  probability	  of	  8.9%	  that	  those	  who	  experienced	  trauma	  will	  screen	  positive	  for	  PTSD	  and	  reported	  a	  best	  estimate	  whole	  population	  PTSD	  point	  prevalence	  of	  3%	  (APMS,	  2007).	  	  
Conditional	  PTSD	  prevalence	  of	  those	  directly	  affected	  in	  terrorist	  attacks	  has	  been	  estimated	  to	  range	  between	  12%	  and	  40%	  (Whaley	  &	  Brewin,	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2007;	  Gidron,	  2002;	  DiMaggio	  &	  Galea,	  2006).	  	  In	  comparison,	  reported	  PTSD	  prevalence	  rates	  among	  rescue	  workers	  range	  between	  10%	  and	  20%,	  while	  for	  the	  general	  population	  reported	  prevalence	  rates	  range	  between	  5%	  and	  10%	  (Neria	  et	  al.,	  2007).	  	  Whalley	  &	  Brewin	  (2007)	  reported	  that	  30-­‐40%	  of	  individuals	  directly	  affected	  by	  terrorist	  attacks	  continue	  to	  experience	  significant	  problems	  two	  years	  later.	  	  Neria	  and	  colleagues	  (2008)	  confirmed	  this	  finding	  in	  a	  systematic	  literature	  review	  looking	  at	  PTSD	  following	  disasters.	  Upon	  exposure	  to	  traumatic	  event(s),	  most	  individuals	  will	  present	  symptoms	  of	  distress	  and	  anxiety	  that	  will	  decline	  naturally	  after	  a	  few	  weeks	  (Rubin	  et	  al.,	  2005;	  Rubin	  et	  al.,	  2007;	  Whalley	  &	  Brewin,	  2007).	  	  Depending	  on	  several	  factors	  discussed	  in	  the	  next	  section,	  a	  number	  of	  individuals	  will	  fail	  to	  recover	  and	  will	  require	  treatment	  (APA,	  2013).	  	  In	  addition,	  a	  number	  of	  individuals	  might	  exhibit	  sub-­‐threshold	  PTSD	  or	  there	  could	  be	  a	  delay	  in	  presentation	  of	  symptoms	  ranging	  from	  a	  couple	  of	  months	  to	  years,	  defined	  as	  delayed	  expression	  in	  DSM-­‐5	  (APA,	  2013).	  	  The	  new	  fifth	  edition	  of	  DSM	  (APA,	  2013)	  has	  introduced	  changes	  to	  both	  the	  diagnostic	  criteria	  and	  the	  classification	  of	  the	  disorder.	  	  Firstly,	  it	  has	  removed	  PTSD	  from	  the	  anxiety	  disorders	  group	  and	  re-­‐classified	  it	  under	  trauma	  and	  stressor-­‐related	  disorders.	  	  In	  regard	  to	  diagnostic	  criteria,	  DSM-­‐5	  has	  taken	  a	  step	  away	  from	  the	  traditional	  view	  of	  PTSD	  as	  “primarily	  a	  fear-­‐based	  anxiety	  disorder”	  (Bryant	  &	  Wessely,	  2013,	  p.	  202).	  	  Instead,	  DSM-­‐5	  presented	  a	  four	  factorial	  model	  supported	  by	  the	  majority	  of	  confirmatory	  factor	  analysis	  studies	  (Duhamel	  et	  al.,	  2004;	  McWilliams	  et	  al.,	  2005;	  Palmieri	  et	  al.,	  2005).	  	  The	  DSM-­‐5	  diagnostic	  criteria	  for	  PTSD	  include	  the	  following:	  	  
• exposure	  to	  trauma	  involving	  actual	  or	  threatened	  death,	  serious	  injury	  or	  sexual	  violence	  by	  direct	  experience,	  witnessing	  or	  learning	  about	  an	  event	  that	  occurred	  to	  a	  close	  family	  or	  a	  friend,	  or	  through	  repeated	  exposure	  to	  aversive	  details	  of	  a	  traumatic	  event	  (Criterion	  A).	  	  
• intrusion	  (Criterion	  B).	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• avoidance	  (Criterion	  C).	  
• negative	  alterations	  in	  cognitions	  and	  mood	  (Criterion	  D).	  
• alterations	  in	  arousal	  and	  reactivity	  with	  the	  traumatic	  event	  (Criterion	  E).	  The	  risk	  of	  developing	  PTSD	  is	  higher	  for	  individuals	  with	  a	  personal	  and/or	  family	  psychiatric	  history,	  reported	  childhood	  abuse,	  low	  social	  support	  and	  life	  stress	  both	  pre-­‐	  and	  post-­‐trauma,	  or	  an	  emotional	  response	  to	  the	  traumatic	  event	  such	  as	  guilt,	  helplessness	  and	  shame	  (Brewin,	  2000;	  Ozer,	  2003;	  DeLisi,	  2003).	  	  	  The	  nature	  and	  severity	  of	  the	  traumatic	  event,	  being	  of	  female	  gender,	  being	  of	  a	  young	  age	  at	  time	  of	  exposure	  have	  also	  been	  frequently	  reported	  as	  risk	  factors	  for	  PTSD	  (Breslau,	  2002;	  Breslau	  et	  al.,	  1999;	  Brewin	  et	  al.,	  2000;	  Ozer,	  2003).	  	  The	  latest	  edition	  of	  DSM	  presents	  risk	  factors	  associated	  with	  PTSD	  as	  pre-­‐traumatic,	  peri-­‐traumatic,	  and	  post-­‐traumatic	  as	  presented	  in	  Table	  2.1	  (APA,	  2013).	  	  Table	  2.1	  PTSD	  predictive	  factors	  from	  DSM	  5	  (APA,	  2013)	  
Pre-­‐traumatic	  risk	  factors	  
•	  	  Previous	  psychiatric	  disorder	  •	  	  Gender	  (female	  greater	  than	  male)	  •	  	  Personality	  (external	  locus	  of	  control	  greater	  than	  internal	  locus	  of	  control)	  •	  	  Lower	  socioeconomic	  status	  •	  	  Lack	  of	  education	  •	  	  Race	  (minority	  status)	  •	  	  Previous	  trauma	  •	  	  Family	  psychiatric	  history	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Peri-­‐traumatic	  risk	  factors	  
•	  	  Trauma	  severity	  •	  	  Perceived	  life	  threat	  •	  	  Peri-­‐traumatic	  emotions	  •	  	  Peri-­‐traumatic	  dissociation	  
Post-­‐traumatic	  risk	  factors	  
•	  	  Perceived	  lack	  of	  social	  support	  •	  	  Subsequent	  life	  stress	  Bonnano	  et	  al	  (2010)	  suggested	  that	  the	  outcome	  of	  the	  disaster	  is	  shaped	  by	  a	  particular	  combination	  of	  risk	  and	  resilience	  factors,	  rather	  than	  by	  a	  particular	  predictor.	  	  This	  view	  of	  PTSD	  is	  in	  line	  with	  the	  latest	  understanding	  that	  interaction	  of	  genes	  and	  environmental	  factors	  –	  a	  combination	  of	  multiple	  neurobiological	  mechanisms	  alongside	  their	  interactions	  with	  social,	  biological,	  contextual	  and	  psychological	  factors	  that	  “increase	  risk	  or	  support	  recovery”	  (Breslau,	  2009,	  p.	  205)	  –	  are	  responsible	  for	  PTSD.	  For	  individuals	  involved	  in	  a	  terrorist	  attack,	  the	  risk	  is	  highest	  among	  those	  closest	  to	  the	  incident,	  those	  exposed	  to	  grotesque	  death,	  and	  those	  with	  the	  most	  severe	  injuries	  (Whaley	  &	  Brewin,	  2007).	  	  Members	  of	  minority	  groups,	  as	  well	  as	  people	  experiencing	  multiple	  stressors	  such	  as	  employment	  and	  property	  loss	  have	  a	  higher	  risk	  of	  developing	  PTSD	  and	  a	  higher	  number	  of	  symptoms	  (Galea	  et	  al.,	  2008).	  	  In	  the	  study	  of	  stress	  levels	  experienced	  after	  the	  London	  bombings	  of	  the	  London-­‐based	  population,	  non-­‐white	  and	  Muslim	  Londoners	  reported	  substantially	  greater	  levels	  of	  stress	  in	  comparison	  to	  the	  other	  respondents	  (Rubin	  et	  al.,	  2005).	  	  Groups	  that	  are	  particularly	  at	  risk	  from	  PTSD	  are	  refugees	  and	  asylum	  seekers	  due	  to	  their	  exposure	  to	  a	  wide	  range	  of	  traumatic	  events,	  with	  reported	  PTSD	  prevalence	  ranging	  from	  4%	  to	  86%	  depending	  on	  the	  study	  population	  (Hollifield	  et	  al.,	  2002).	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Among	  all	  anxiety	  disorders,	  PTSD	  is	  considered	  to	  generate	  the	  highest	  cost	  to	  individuals,	  their	  family	  and	  wider	  society	  (Marciniak	  et	  al.,	  2004).	  	  A	  recent	  study	  looking	  at	  the	  economic	  impact	  of	  PTSD	  in	  Northern	  Ireland	  (NI)	  estimated	  the	  total	  cost	  of	  PTSD	  in	  2008	  to	  be	  £172.8	  million,	  including	  direct	  and	  indirect	  costs	  (Ferry	  et	  al.,	  2008).	  	  The	  authors	  concluded	  that	  this	  was	  a	  conservative	  estimate,	  as	  they	  did	  not	  include	  the	  economic	  impact	  of	  premature	  mortality	  or	  short-­‐term	  sickness.	  	  Kessler	  (2000)	  estimated	  that	  PTSD	  is	  associated	  with	  $3	  billion	  of	  lost	  productivity	  per	  year	  in	  the	  US.	  	  	  Although	  there	  is	  a	  general	  consensus	  that	  PTSD	  has	  a	  significant	  impact,	  supporting	  evidence	  is	  limited	  and	  mostly	  originates	  from	  a	  heterogeneous	  methodological	  background,	  which	  affects	  comparability	  and	  generalisability.	  	  Evidence-­‐based	  treatment,	  as	  recommended	  by	  NICE	  guidelines,	  consists	  of	  up	  to	  12	  sessions	  of	  cognitive	  behavioural	  therapy	  (CBT)	  or	  eye	  movement	  desensitisation	  reprocessing	  (EMDR)	  starting	  after	  one	  month	  for	  severe	  cases,	  or	  watchful	  waiting	  and	  treatment	  three	  months	  after	  trauma	  for	  mild	  or	  moderate	  cases	  (Bisson	  et	  al.,	  2010;	  Ehlers	  et	  al.,	  2003,	  NICE,	  2005).	  	  The	  latest	  Cochrane	  review	  on	  psychological	  therapies	  for	  chronic	  posttraumatic	  stress	  disorder	  confirmed	  the	  main	  recommendations	  of	  the	  NICE	  guidelines	  (Bisson	  et	  al.,	  2013).	  	  Therefore,	  early	  detection	  and	  treatment	  of	  PTSD	  are	  important	  in	  order	  to	  avoid	  it	  becoming	  a	  chronic	  condition	  with	  potentially	  profound	  consequences.	  	  For	  this	  reason,	  the	  ‘screen	  and	  treat’	  approach	  has	  been	  proposed	  in	  recent	  years.	  	  This	  approach	  focuses	  on	  identifying	  and	  screening	  all	  individuals	  exposed	  to	  a	  traumatic	  event	  in	  order	  to	  refer	  them,	  if	  needed,	  for	  evidence-­‐based	  treatment.	  	  However,	  the	  screen	  and	  treat	  approach	  had	  not	  been	  implemented	  or	  evaluated	  following	  a	  major	  disaster	  in	  the	  UK	  until	  the	  2005	  London	  bombings.	  	  	  
1.2	  	   The	  London	  bombings	  and	  the	  screen	  and	  treat	  programme	  The	  2005	  London	  bombings	  (LB)	  happened	  on	  July	  7	  at	  8.50	  a.m.,	  at	  the	  peak	  of	  the	  morning	  commute,	  on	  train	  routes	  that	  included	  transport	  hubs	  to	  and	  out	  of	  London	  Edgware	  Road,	  Kings	  Cross,	  and	  Aldgate	  underground	  stations	  and	  a	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bus	  in	  Tavistock	  Square.	  	  This	  was	  the	  largest	  mass	  casualty	  in	  the	  UK	  since	  the	  World	  War	  II,	  with	  52	  deaths	  and	  775	  other	  injured	  individuals.	  	  Another	  terrorist	  attack	  in	  London	  on	  21	  July	  involved	  unsuccessful	  bomb	  attempts	  and	  the	  shooting	  of	  an	  innocent	  passenger	  in	  the	  days	  following	  the	  bombings.	  	  Due	  to	  the	  timings	  and	  location	  of	  the	  bombings,	  they	  affected	  on	  average	  a	  young,	  working	  population	  on	  their	  morning	  commute	  to	  work	  and	  possibly	  also	  visitors	  to	  London.	  	  The	  mental	  health	  response	  programme	  to	  the	  LB	  -­‐	  known	  as	  the	  screen	  and	  treat	  programme	  (ST)	  -­‐	  started	  within	  two	  months	  of	  the	  bombings	  in	  September	  2005	  at	  three	  London	  locations.	  	  The	  ST	  programme’s	  steering	  group	  established	  that	  around	  4000	  individuals	  were	  affected	  in	  the	  incident,	  of	  which	  around	  one	  third	  would	  need	  psychological	  treatment	  according	  to	  the	  existing	  literature	  (Brewin	  et	  al,	  2009).	  	  The	  number	  of	  affected	  individuals	  was	  calculated	  on	  the	  basis	  of	  the	  underground	  train	  carriages	  and	  bus	  capacity,	  and	  the	  number	  of	  members	  of	  the	  emergency	  services	  involved. Due	  to	  the	  lack	  of	  capacity	  within	  existing	  services	  to	  meet	  that	  need,	  the	  Department	  of	  Health	  (DH)	  committed	  to	  fund	  the	  screen	  and	  treat	  programme	  guided	  by	  the	  programme’s	  steering	  group	  recommendations.	  	  With	  the	  rationale	  that	  existing	  services	  would	  be	  overburdened	  by	  screening	  and	  not	  have	  the	  resources	  for	  outreach,	  a	  dedicated	  screening	  team	  was	  set	  up	  within	  the	  London	  Traumatic	  Stress	  Clinic	  (TSC).	  	  This	  novel	  approach	  to	  trauma	  response	  was	  grounded	  in	  research	  findings	  indicating	  the	  low	  effectiveness	  of	  the	  commonly	  used	  ‘first	  aid’	  psychological	  interventions	  after	  traumatic	  events	  such	  as	  debriefing	  (NICE	  2005),	  alongside	  lessons	  learned	  from	  other	  mental	  health	  responses	  after	  traumatic	  events	  such	  as	  the	  King’s	  Cross	  fire	  (Rosser	  et	  al.,	  1991;	  Turner	  et	  al.,	  1989),	  and	  the	  1998	  Omagh	  bombing	  (Gillespie	  et	  al.,	  2002).	  	  This	  decision	  was	  also	  based	  on	  evidence	  that	  only	  a	  number	  of	  the	  exposed	  individuals	  would	  need	  treatment,	  as	  the	  majority	  were	  likely	  to	  recover	  naturally	  within	  a	  couple	  of	  weeks	  of	  the	  traumatic	  event	  (Rubin	  et	  al.,	  2005;	  Whalley	  &	  Brewin,	  2007).	  	  Secondly,	  PTSD	  can	  have	  a	  profound	  adverse	  impact	  on	  the	  health	  and	  social	  functioning	  of	  those	  individuals	  affected,	  as	  well	  as	  their	  families,	  and	  can	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become	  chronic,	  lasting	  up	  to	  several	  decades	  after	  the	  event	  if	  left	  undiagnosed	  and	  untreated	  (Yule,	  2001).	  	  The	  aim	  of	  the	  ST	  programme	  was	  to	  systematically	  follow-­‐up	  as	  many	  survivors	  and	  affected	  individuals	  as	  possible,	  provide	  them	  with	  information	  about	  posttraumatic	  responses	  and	  immediate	  sources	  of	  help,	  screen	  them	  at	  regular	  intervals	  using	  validated	  instruments	  to	  detect	  individuals	  whose	  symptoms	  have	  failed	  to	  remit	  naturally,	  and	  deliver	  appropriate	  therapy	  to	  that	  subset	  of	  people.	  	  The	  programme	  consisted	  of	  a	  psychiatrist,	  two	  psychological	  assistants	  and	  an	  administrator,	  and	  ran	  for	  two	  years,	  until	  September	  2007.	  	  	  
1.3	   	  The	  main	  contribution	  of	  the	  thesis	  Given	  the	  evidence	  on	  prevalence	  of	  PTSD	  and	  its	  economic,	  health	  and	  social	  effects,	  there	  are	  great	  incentives	  on	  both	  micro	  and	  macro	  policy	  levels	  to	  complement	  existing	  policies	  with	  the	  data	  coming	  from	  the	  implementation	  of	  evidence-­‐based	  practice	  in	  a	  real	  world	  context.	  	  	  This	  thesis	  takes	  an	  interdisciplinary	  approach	  and	  integrates	  the	  perspectives	  of	  clinical	  psychology,	  health	  economics	  and	  social	  policy	  in	  describing	  the	  effects	  of	  exposure	  to	  the	  LB.	  	  Such	  interdisciplinary	  approach	  is	  well	  suited	  for	  describing	  the	  effects	  of	  PTSD.	  	  It	  demonstrates	  how	  the	  effects	  of	  PTSD	  are	  not	  one-­‐dimensional	  and	  how	  they	  affect	  different	  aspects	  of	  individuals’	  lives	  and	  society	  as	  a	  whole.	  	  Each	  perspective	  offers	  a	  different	  outlook	  and	  answers	  a	  different	  set	  of	  questions,	  thus	  providing	  a	  rounded	  view	  of	  PTSD	  and	  its	  effects.	  	  The	  clinical	  psychology	  perspective	  defines	  and	  describes	  PTSD,	  its	  symptoms,	  prevalence	  rates,	  defines	  risk	  factors	  and	  treatment,	  and	  describes	  the	  health	  and	  social	  effects	  of	  PTSD.	  	  The	  health	  economics	  perspective	  offers	  an	  insight	  into	  the	  economic	  effects	  of	  the	  LB	  and	  PTSD,	  measures	  direct	  and	  indirect	  costs	  associated	  with	  the	  LB	  and	  expenditure	  associated	  with	  setting-­‐up	  and	  running	  a	  mental	  health	  response,	  and	  highlights	  methodological	  challenges	  in	  evaluating	  mental	  health	  interventions	  in	  the	  observational	  study	  context.	  	  Social	  policy	  provides	  a	  wider	  context	  for	  understanding	  and	  implementing	  the	  results	  of	  the	  study.	  	  It	  helps	  in	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answering	  questions	  such	  as	  what	  lessons	  from	  the	  ST	  programme	  can	  be	  implemented	  in	  future	  mental	  health	  responses,	  and	  whether	  the	  screen	  and	  treat	  approach	  be	  applied	  in	  a	  wider	  context	  such	  as	  primary	  care	  and	  the	  IAPT	  programme.	  	  The	  production	  of	  welfare	  approach	  (POW),	  developed	  primarily	  as	  an	  evaluative	  technique	  (Knapp,	  1984),	  offers	  a	  useful	  framework	  for	  exploring	  the	  burden	  of	  PTSD.	  	  The	  production	  of	  welfare	  approach	  draws	  on	  economic	  concepts	  and	  terminology,	  and	  applies	  them	  to	  social	  care	  or	  health	  contexts.	  	  It	  provides	  a	  framework	  for	  identifying	  and	  exploring	  the	  interrelationships	  between	  costs,	  both	  resource	  and	  non-­‐resource	  inputs,	  and	  their	  effect	  on	  intermediate	  (service)	  outputs	  and	  final	  outcomes.	  	  This	  study	  will	  apply	  the	  framework	  of	  the	  ‘production	  of	  welfare	  approach’	  in	  examining	  the	  evidence	  behind	  the	  burden	  of	  PTSD	  on	  individuals	  exposed	  to	  trauma	  and	  society	  as	  a	  whole.	  	  The	  POW	  framework	  postulates	  a	  causal	  relationship	  between	  the	  changes	  in	  levels	  of	  inputs	  and	  levels	  of	  outputs	  mediated	  by	  the	  role	  of	  other	  factors	  (Davies,	  1985,	  p.3).	  	  	  Identification	  and	  measurement	  of	  ‘other	  factors’	  is	  of	  great	  importance	  as	  they	  are	  likely	  the	  cause	  of	  variation	  in	  the	  model	  (Fernandez,	  2005).	  	  Furthermore,	  information	  on	  mediating	  factors	  presented	  in	  the	  model	  as	  ‘non-­‐resource	  inputs’	  will	  allow	  us	  to	  ‘control’	  for	  them	  when	  examining	  the	  relationship	  between	  costs	  and	  outcomes	  using	  the	  cost	  function.	  	  Similarly,	  utilisation	  functions	  will	  serve	  as	  another	  tool	  in	  the	  analysis,	  enabling	  me	  to	  examine	  the	  relationship	  between	  non-­‐resource	  inputs	  and	  intermediate	  outcomes	  such	  as	  the	  BDI,	  PDS	  and	  EQ5D	  scores	  at	  the	  end	  of	  the	  treatment.	  	  Figure	  1.1	  (Davies	  &	  Knapp,	  1981;	  Kendall	  &	  Knapp,	  2000)	  depicts	  the	  key	  elements	  of	  the	  POW	  framework	  applied	  to	  the	  provision	  of	  treatment	  for	  PTSD	  within	  the	  ST	  programme.	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Figure	  1.1	  The	  production	  of	  welfare	  from	  Kendall	  &	  Knapp,	  2000	  
Costs%or%budget Resource%inputs Intermediate%outputs
Non5resource%inputs Final%outcomes 	  -­‐ Costs	  expressed	  in	  the	  form	  of	  opportunity	  costs,	  represent	  the	  total	  amount	  of	  resources	  used.	  -­‐ Resource	  inputs	  used	  for	  providing	  treatment	  and	  health	  services,	  such	  as	  buildings,	  programme’s	  staff,	  and	  capital.	  -­‐ Non-­‐resource	  inputs	  refer	  to	  the	  characteristics	  of	  service	  users	  (gender,	  age,	  ethnicity,	  health	  status,	  mental	  health	  history,	  informal	  care	  support),	  providers,	  service	  environment,	  type	  of	  trauma,	  prevalence	  of	  the	  disorder	  and	  its	  aetiology	  such	  as	  comorbidity	  rates,	  characteristics	  of	  the	  traumatic	  event.	  	  Non-­‐resource	  inputs	  are	  ”likely	  to	  explain	  the	  majority	  of	  variations	  in	  outcomes”	  (Fernandez,	  2005,	  p.	  35).	  -­‐ Intermediate	  outputs	  include	  the	  number	  of	  direct	  and	  indirect	  hours	  of	  therapist	  work	  and	  number	  of	  sessions	  provided.	  -­‐ Final	  outcomes	  represent	  the	  impact	  of	  the	  treatment	  on	  the	  individuals	  and	  their	  families	  and	  society	  as	  a	  whole,	  for	  example,	  as	  measured	  in	  terms	  of	  improved	  quality	  of	  life,	  averted	  productivity	  loss,	  reduced	  comorbidity	  and	  increased	  welfare.	  	  As	  illustrated	  by	  the	  POW	  approach,	  in	  exploring	  the	  burden	  of	  PTSD	  in	  the	  context	  of	  terrorism	  there	  are	  a	  number	  of	  important	  factors	  that	  should	  be	  considered:	  PTSD	  prevalence/incidence	  rates,	  the	  range	  of	  services	  used	  by	  people	  with	  PTSD,	  the	  cost	  of	  treatment	  including	  training	  of	  the	  clinicians,	  the	  prevalence	  of	  comorbid	  conditions,	  the	  effects	  on	  individuals	  and	  families	  such	  as	  the	  cost	  of	  informal	  care,	  deterioration	  of	  QoL,	  lost	  employment	  and	  education	  opportunities,	  cost	  of	  suicide,	  burden	  of	  homelessness,	  and	  the	  costs	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associated	  with	  productivity	  loss	  including	  unemployment,	  reduced	  hours	  of	  work,	  presenteeism	  and	  absenteeism.	  	  Data	  collected	  as	  a	  part	  of	  the	  ST	  programme	  and	  its	  consequent	  evaluation	  provide	  an	  opportunity	  to	  explore	  the	  health,	  social	  and	  economic	  effects	  of	  a	  terrorist	  attack	  and	  specifically	  the	  effects	  of	  PTSD	  on	  the	  individuals	  involved.	  	  These	  data	  include	  information	  on	  the	  socio-­‐demographic	  characteristics	  of	  participants,	  type	  of	  exposure	  to	  traumatic	  events,	  the	  type	  and	  frequency	  of	  the	  services	  used	  by	  individuals	  as	  a	  consequence	  of	  their	  exposure	  to	  the	  LB,	  and	  data	  on	  treatment	  outcomes,	  thus	  providing	  an	  insight	  into	  mental	  health	  recovery	  pathways	  for	  individuals	  exposed	  to	  such	  stressors.	  	  Furthermore,	  this	  dataset	  and	  the	  use	  of	  econometric	  tools	  enables	  an	  economic	  evaluation	  of	  the	  ST	  programme	  in	  the	  form	  of	  a	  cost-­‐effectiveness	  analysis,	  as	  well	  as	  a	  piloting	  of	  the	  evaluation	  methodology	  in	  the	  context	  of	  an	  observational	  study.	  	  The	  research	  presented	  in	  this	  thesis	  aims	  to	  contribute	  to	  the	  existing	  evidence	  in	  a	  following	  way:	  -­‐ Describe	  the	  health,	  economic	  and	  social	  effects	  of	  the	  London	  bombings	  and	  PTSD.	  -­‐ Explore	  how	  the	  costs	  and	  services	  used	  relate	  to	  the	  characteristics	  of	  the	  participants	  and	  exposure	  factors.	  -­‐ Determine	  the	  cost	  of	  being	  diagnosed	  with	  PTSD.	  -­‐ Investigate	  which	  factors	  are	  associated	  with	  being	  diagnosed	  with	  PTSD	  and	  how	  PTSD	  diagnosis	  affects	  services	  used.	  -­‐ Compare	  costs	  and	  outcomes	  of	  the	  ST	  programme	  and	  conduct	  an	  economic	  evaluation	  of	  the	  ST	  programme.	  -­‐ Explore	  the	  benefits	  and	  barriers	  of	  introducing	  screening	  for	  PTSD	  in	  primary	  care.	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1.4	   	  Research	  question	  The	  aim	  of	  this	  research	  is	  to	  assess	  the	  health,	  social,	  and	  economic	  impact	  of	  PTSD	  by	  focusing	  on	  individuals	  exposed	  to	  the	  London	  bombings.	  In	  order	  to	  achieve	  this	  aim,	  the	  following	  objectives	  were	  chosen:	  -­‐ To	  review	  and	  assess	  the	  current	  evidence	  and	  measures	  of	  health,	  social	  and	  economic	  impact	  of	  PTSD.	  	  -­‐ To	  assess	  the	  impact	  of	  the	  London	  bombings	  in	  terms	  of	  service	  use	  and	  the	  impact	  on	  health,	  social,	  and	  economic	  activity	  of	  those	  affected.	  	  -­‐ To	  conduct	  an	  economic	  evaluation	  of	  the	  screen	  and	  treat	  programme	  implemented	  as	  a	  mental	  health	  response	  after	  the	  London	  bombings.	  	  -­‐ To	  assess	  the	  broader	  implications	  and	  feasibility	  of	  screening	  for	  PTSD	  in	  primary	  care.	  	  According	  to	  the	  POW	  framework,	  I	  expect	  to	  find	  that	  participants’	  characteristics,	  treatment	  timing	  and	  trauma	  context	  will	  affect	  the	  service	  use.	  I	  expect	  that	  participants	  with	  PTSD	  will	  have	  significantly	  larger	  costs	  in	  all	  cost	  categories	  when	  compared	  to	  participants	  with	  no	  PTSD.	  	  Furthermore,	  I	  expect	  a	  positive	  correlation	  between	  costs	  and	  the	  timing	  of	  the	  treatment	  start,	  all	  things	  being	  equal.	  	  Finally,	  my	  hypothesis	  is	  that	  it	  is	  cost-­‐effective	  to	  treat	  individuals	  early	  (within	  the	  first	  year	  after	  the	  LB	  exposure)	  as	  the	  provision	  of	  early	  best	  evidence-­‐based	  treatment	  prevents	  the	  onset	  of	  chronic	  PTSD	  and	  associated	  costs.	  
1.5	  	   Thesis	  outline	  The	  next	  chapter	  (Chapter	  2)	  will	  start	  with	  identification	  of	  existing	  literature	  and	  its	  gaps,	  and	  review	  the	  current	  evidence	  on	  the	  health,	  social	  and	  economic	  impact	  of	  PTSD.	  	  After	  the	  Literature	  Review	  in	  Chapter	  3,	  I	  will	  present	  my	  study	  methods,	  including	  the	  aim	  and	  objectives	  of	  the	  thesis,	  and	  an	  overview	  of	  the	  evaluation	  study	  within	  which	  this	  economic	  analysis	  was	  carried	  out,	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including	  sample	  structure,	  choice	  of	  instruments	  used	  and	  choice	  of	  statistical	  analysis.	  	  Chapter	  4	  will	  focus	  on	  describing	  and	  exploring	  the	  costs	  of	  exposure	  to	  the	  LB	  from	  several	  perspectives.	  	  I	  will	  assess	  the	  impact	  of	  the	  LB	  in	  terms	  of	  service	  use	  and	  the	  effects	  on	  the	  health,	  social,	  and	  economic	  activity	  of	  those	  affected,	  and	  present	  the	  costs	  and	  outcomes	  associated	  with	  exposure	  to	  the	  LB.	  	  This	  chapter	  will	  explore	  how	  to	  quantify	  the	  effects	  of	  the	  LB	  in	  the	  form	  of	  a	  costing	  study.	  	  	  Following	  that,	  in	  Chapter	  5	  I	  will	  explore	  costs	  and	  their	  relationship	  to	  participants’	  characteristics,	  exposure	  factors	  and	  service	  types.	  	  I	  will	  also	  investigate	  the	  factors	  associated	  with	  being	  diagnosed	  with	  PTSD	  and	  the	  related	  costs.	  As	  the	  next	  step	  in	  the	  analysis	  I	  will	  use	  the	  data	  from	  Chapter	  4	  to	  conduct	  an	  economic	  evaluation	  of	  the	  ST	  programme	  by	  comparing	  costs	  and	  outcomes	  for	  three	  distinct	  participant	  groups.	  	  Each	  analysis	  will	  display	  a	  different	  level	  of	  complexity	  due	  to	  the	  availability	  of	  the	  data	  and	  offer	  a	  different	  perspective	  on	  the	  effectiveness	  of	  the	  ST	  programme.	  	  Due	  to	  the	  difference	  in	  the	  type	  of	  available	  data	  for	  each	  comparator	  group,	  I	  have	  divided	  the	  work	  on	  economic	  evaluation	  of	  the	  ST	  programme	  into	  two	  separate	  chapters.	  	  	  Chapter	  6	  will	  present	  two	  partial	  economic	  evaluations	  of	  the	  ST	  programme	  and	  compare	  participants	  who	  used	  the	  ST	  programme	  to	  those	  who	  did	  not	  use	  it.	  	  Following	  on	  from	  this,	  Chapter	  7	  will	  introduce	  the	  third	  available	  comparator	  group	  and	  compare	  participants	  who	  have	  received	  treatment	  within	  the	  first	  ten	  months	  after	  the	  LB	  with	  participants	  who	  were	  treated	  later	  in	  the	  programme,	  and	  will	  present	  a	  cost-­‐effectiveness	  analysis	  of	  the	  ST	  programme.	  In	  Chapter	  8	  I	  will	  explore	  the	  benefits	  of,	  and	  barriers	  to	  screening	  for	  PTSD	  in	  a	  broader	  context.	  	  This	  chapter	  will	  take	  forward	  the	  idea	  of	  screening	  for	  PTSD	  in	  a	  primary	  care	  context	  as	  a	  valid	  method	  of	  disorder	  detection,	  and	  the	  prevention	  of	  chronic	  PTSD	  and	  its	  role	  as	  a	  possible	  pathway	  into	  treatment.	  	  I	  will	  present	  results	  and	  discuss	  policy	  implications	  from	  a	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qualitative	  study	  looking	  into	  the	  feasibility	  of	  screening	  for	  PTSD	  within	  primary	  care	  services,	  particularly	  in	  the	  context	  of	  the	  recently	  introduced	  Improving	  Access	  to	  Psychological	  Therapies	  (IAPT)	  programme.	  My	  final	  chapter	  will	  summarise	  the	  empirical	  findings,	  set	  out	  the	  limitations	  and	  strengths	  of	  the	  study,	  and	  then	  discuss	  the	  research,	  policy	  and	  practice	  implications	  of	  the	  work.	  Existing	  evidence	  on	  the	  economic	  burden	  and	  cost-­‐effectiveness	  of	  PTSD	  treatment	  is	  quite	  limited,	  which	  means	  there	  is	  little	  to	  inform	  policy	  or	  provision	  in	  response	  to	  this	  serious	  and	  potentially	  costly	  disorder.	  	  While	  no	  single	  research	  project	  can	  provide	  the	  answers	  to	  all	  outstanding	  questions,	  the	  findings	  presented	  in	  this	  thesis	  add	  to	  the	  evidence	  base	  on	  the	  health,	  social	  and	  economic	  impact	  of	  PTSD	  as	  experienced	  by	  those	  individuals	  involved	  in	  the	  London	  bombings	  of	  2005,	  and	  on	  the	  cost-­‐effectiveness	  of	  the	  ST	  programme.	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Chapter	  2	   The	  burden	  of	  PTSD	   	  
2.1	   Introduction	  According	  to	  available	  evidence,	  PTSD	  is	  associated	  with	  high	  levels	  of	  social,	  occupational	  and	  physical	  disability	  (McFarlane,	  2010;	  Coughlin,	  2011;	  Vieweg,	  2007;	  Kessler,	  2000),	  considerable	  economic	  cost	  (Marciniak	  et	  al.,	  2004),	  high	  levels	  of	  health	  service	  utilisation	  (Marshall	  et	  al.,	  2014;	  Elhai,	  North	  and	  Frueh,	  2005;	  Erbes	  et	  al.,	  2007),	  poor	  social	  and	  family	  relationships,	  absenteeism	  from	  work	  (Fineberg	  et	  al.,	  2013),	  lower	  income,	  and	  lower	  educational	  and	  occupational	  success	  (Kessler,	  2000;	  Iversen	  et	  al.,	  2008).	  However,	  to	  understand	  the	  true	  impact	  of	  PTSD,	  it	  is	  important	  to	  start	  by	  reviewing	  and	  understanding	  where	  the	  evidence	  on	  PTSD	  effects	  comes	  from	  and	  what	  it	  implies.	  	  This	  chapter	  aims	  to	  outline	  the	  current	  knowledge	  about	  the	  burden	  of	  PTSD	  by	  examining	  the	  health,	  social	  and	  economic	  effect	  of	  PTSD	  on	  individuals	  and	  society	  by	  reviewing	  the	  available	  literature.	  	  Due	  to	  scarcity	  of	  available	  literature,	  particularly	  on	  the	  economic	  effects	  of	  PTSD,	  the	  review	  will	  not	  focus	  exclusively	  on	  disasters	  and	  terrorist	  attacks,	  but	  will	  include	  a	  wide	  array	  of	  traumatic	  events.	  	  Although	  the	  dataset	  used	  in	  this	  research	  is	  based	  on	  individuals	  affected	  by	  the	  LB,	  there	  is	  no	  evidence	  on	  the	  difference	  in	  the	  disorder’s	  aetiology,	  symptoms,	  or	  treatment	  for	  different	  traumatic	  events.	  	  The	  review	  of	  the	  literature	  will	  cover	  two	  broad	  areas:	  a.	  the	  health,	  social	  and	  economic	  impact	  of	  PTSD,	  	  	  b.	  the	  evidence	  behind	  screening	  for	  PTSD	  in	  the	  primary	  care.	  
2.2	   Search	  strategy	  In	  agreement	  with	  my	  supervisors,	  I	  conducted	  a	  rapid	  review	  of	  the	  literature,	  rather	  than	  a	  standard	  systematic	  literature	  review.	  	  The	  rapid	  review	  of	  the	  literature	  used	  systematic	  review	  methods	  to	  search	  the	  available	  literature,	  and	  critically	  assess	  what	  is	  already	  known	  on	  the	  subject	  of	  the	  health,	  social	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and	  economic	  impact	  of	  PTSD,	  and	  then	  to	  identify	  the	  gaps	  in	  the	  literature,	  but	  did	  not	  include	  mapping	  of	  the	  evidence.	  	  	  In	  the	  evidence	  search,	  I	  decided	  to	  adopt	  a	  broad	  search	  strategy	  without	  very	  strict	  inclusion	  criteria	  for	  two	  reasons.	  	  Firstly,	  the	  economic	  evaluation	  approach	  has	  been	  introduced	  relatively	  recently	  as	  a	  tool	  in	  the	  mental	  health	  arena.	  	  Consequently,	  there	  are	  relatively	  few	  economic	  evaluations	  conducted	  in	  the	  mental	  health	  domain,	  and	  certainly	  very	  few	  in	  the	  PTSD	  niche.	  	  Secondly,	  there	  are	  few	  studies	  attempting	  to	  measure	  the	  economic	  and	  social	  effects	  of	  PTSD,	  and	  the	  evidence	  base	  describing	  its	  effects	  is	  still	  developing.	  	  I	  wanted	  to	  identify	  published	  and	  unpublished	  studies	  on	  the	  economic,	  health	  and	  social	  effect	  of	  PTSD	  by	  thoroughly	  searching	  electronic	  databases,	  books,	  grey	  literature,	  unpublished	  materials	  obtained	  directly	  from	  authors,	  hand-­‐searching	  recent	  issues	  of	  relevant	  journals	  such	  as	  Journal	  of	  Traumatic	  Stress,	  BMJ,	  JAMA,	  Journal	  of	  Clinical	  Psychology	  and	  reference	  lists	  of	  identified	  studies	  and	  reviews.	  	  I	  followed	  the	  guidelines	  suggested	  by	  the	  NHS	  Centre	  for	  Reviews	  and	  Dissemination	  (2001)	  in	  developing	  the	  search	  strategy.	  	  I	  started	  by	  identifying	  the	  keywords	  for	  the	  literature	  search	  for	  each	  area	  of	  the	  review.	  	  I	  used	  the	  keywords	  alone	  and	  in	  the	  following	  combinations:	  “PTSD”	  AND	  	  “anxiety	  disorder”,	  “prevention”,	  “detection”,	  “screening”,	  “QoL”,	  “health	  effects”,	  “social	  effects”,	  “comorbidities”,	  “health	  care	  costs”,	  “health	  service	  use”,	  	  “treatment	  costs”,	  “societal	  cost”,	  “opportunity	  costs”,	  “voluntary	  sector	  services	  costs”,	  “cost-­‐effectiveness”,	  “economic	  evaluation”,	  “economic	  burden”,	  “economic	  effect”.	  I	  used	  the	  following	  data	  sources	  in	  reviewing	  the	  literature:	  electronic	  databases	  such	  as	  Medline,	  Cochrane	  library,	  PsychINFO,	  DARE	  abstracts,	  Pilots,	  Health-­‐Evidence	  Canada,	  the	  NHS	  economic	  evidence	  database,	  and	  Google	  Scholar.	  	  I	  focused	  on	  systematic	  reviews,	  review	  of	  the	  reviews	  and	  meta-­‐analyses	  in	  the	  first	  step	  to	  identify	  key	  studies	  in	  the	  area.	  	  Following	  on	  from	  there,	  I	  focused	  on	  primary	  studies	  to	  ensure	  I	  covered	  all	  the	  relevant	  recently-­‐published	  studies.	  	  I	  initially	  identified	  relevant	  papers	  by	  screening	  their	  titles	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and	  abstracts	  and	  only	  obtained	  full	  papers	  for	  papers	  meeting	  inclusion	  criteria.	  	  	  The	  review	  included	  systematic	  reviews	  and	  meta-­‐analyses	  of	  randomised	  controlled	  trials,	  randomised	  controlled	  trials	  themselves,	  non-­‐randomised	  intervention	  studies,	  observational	  studies,	  longitudinal,	  cross-­‐sectional	  and	  case	  studies,	  and	  expert	  opinion	  if	  applicable.	  	  The	  review	  included	  studies	  published	  after	  1980,	  the	  year	  of	  formal	  recognition	  of	  PTSD	  by	  American	  Psychiatric	  Association’s	  Diagnostic	  and	  Statistical	  Manual	  of	  Mental	  Disorders	  (DSM).	  The	  review	  included	  both	  civilian	  and	  non-­‐civilian	  populations.	  	  The	  scope	  of	  traumatic	  stressors	  was	  not	  limited	  to	  exposure	  to	  terrorism.	  	  I	  excluded	  non-­‐English	  articles,	  and	  studies	  on	  children,	  adolescent	  and	  elderly	  populations.	  	  	  This	  review	  of	  current	  literature	  on	  PTSD	  includes	  a	  variety	  of	  studies	  differing	  in	  their	  target	  populations,	  methodology,	  sampling	  methods	  and	  causes	  of	  PTSD.	  	  This	  potentially	  has	  implications	  for	  the	  comparability	  and	  generalisability	  of	  the	  findings,	  which	  will	  be	  further	  discussed.	  
2.3	  The	  health,	  social	  and	  economic	  effect	  of	  PTSD	  –	  the	  state	  of	  the	  
evidence	  PTSD	  is	  a	  prevalent	  disorder	  characterised	  by	  high	  comorbidity	  and	  well-­‐documented	  effects	  on	  physical	  health	  and	  the	  social	  domains.	  	  As	  change	  in	  each	  domain	  affects	  other	  domains,	  it	  is	  important	  to	  present	  the	  disorder	  within	  this	  multidimensional	  context	  in	  order	  to	  assess	  its	  full	  impact.	  	  If	  left	  undiagnosed	  and	  untreated,	  PTSD	  can	  become	  chronic	  and	  last	  for	  decades	  (Yule,	  2001).	  	  Consequently	  the	  economic	  effects	  of	  PTSD	  on	  individuals	  and	  society	  as	  a	  whole	  can	  be	  significant.	  	  Trauma	  exposure	  and	  PTSD	  increase	  costs	  to	  individuals,	  the	  health	  system	  and	  society	  as	  a	  whole	  (Walker	  et	  al.,	  2003).	  	  In	  2010,	  anxiety	  disorders	  were	  in	  the	  top	  five	  most	  costly	  brain	  disorders	  in	  the	  UK,	  with	  estimated	  costs	  of	  £11.687	  million.	  	  Approximately	  50%	  of	  the	  costs	  were	  attributable	  to	  indirect	  costs,	  and	  25%	  to	  direct	  healthcare	  costs	  (Fineberg	  et	  al.,	  2013).	  	  The	  latest	  NICE	  guideline	  has	  reported	  that	  social	  and	  welfare	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costs	  of	  claims	  for	  incapacitation	  and	  severe	  disablement	  from	  severe	  stress	  and	  PTSD	  amounted	  to	  £103	  million	  in	  2003/4	  (NICE,	  2005).	  	  As	  the	  burden	  of	  PTSD	  ranges	  widely,	  it	  is	  important	  to	  include	  all	  associated	  direct	  and	  indirect	  costs	  in	  assessing	  its	  impact	  on	  individuals,	  the	  health	  system	  and	  society	  as	  a	  whole	  (Knapp,	  2003).	  	  	  In	  contrast	  to	  the	  large	  evidence	  base	  on	  the	  effectiveness	  of	  the	  treatment	  for	  PTSD,	  the	  review	  of	  the	  literature	  has	  confirmed	  scarcity	  of	  studies	  assessing	  wider	  economic	  consequences	  and	  exact	  costs	  of	  both	  treated	  and	  untreated	  PTSD.	  	  	  High	  comorbidity	  is	  a	  distinctive	  characteristic	  of	  PTSD,	  although	  the	  nature	  of	  the	  relationship	  between	  PTSD,	  exposure	  to	  traumatic	  events	  and	  comorbid	  disorders	  is	  still	  unclear	  (Ferry,	  2008).	  	  People	  suffering	  from	  PTSD	  are	  more	  likely	  to	  develop	  other	  anxiety,	  mood,	  and	  substance	  misuse	  disorders	  than	  non-­‐PTSD	  respondents	  (Kessler,	  2000;	  Brewin	  et	  al.,	  1996;	  Vermetten	  &	  Lanius,	  2012;	  APA,	  2013).	  	  Studies	  report	  that	  around	  80%	  of	  PTSD	  sufferers	  have	  more	  than	  one	  diagnosis	  (McFarlane,	  1989),	  and	  point	  to	  pre-­‐existing	  PTSD	  as	  a	  risk	  factor	  for	  the	  subsequent	  onset	  of	  drug	  use	  disorder	  (Breslau	  et	  al.,	  2003;	  Reed	  et	  al.,	  2007)	  and	  major	  depression	  (Breslau	  et	  al.,	  2000).	  	  30-­‐40%	  of	  individuals	  with	  PTSD	  are	  reported	  to	  have	  substance	  use	  disorder	  (Brady	  et	  al.,	  2004).	  	  	  	  The	  extensive	  health	  effects	  of	  the	  PTSD	  have	  been	  widely	  reported	  and	  include	  a	  long	  list	  of	  conditions	  such	  as	  asthma	  (Spitzer,	  2009),	  cardiovascular	  disease	  (Breslau	  et	  al.,	  2003),	  coronary	  arterial	  disease,	  hyperlipidaemia,	  obesity,	  hypertension,	  and	  coronary	  heart	  disease	  (McFarlane,	  2010;	  Coughlin,	  2011;	  Vieweg,	  2007),	  anaemia,	  arthritis,	  asthma,	  back	  pain,	  diabetes,	  eczema,	  kidney	  and	  lung	  disease,	  and	  ulcers	  (Weisberg	  et	  al.,	  2002).	  	  	  Review	  of	  the	  literature	  identified	  two	  systematic	  reviews	  and	  one	  meta-­‐analysis	  study	  investigating	  the	  relationship	  between	  PTSD	  and	  physical	  health.	  One	  review	  explored	  the	  physical	  health	  consequences	  of	  PTSD	  and	  reported	  on	  significantly	  greater	  general	  health	  symptoms,	  general	  medical	  conditions,	  and	  poorer	  HR-­‐QOL	  for	  PTSD	  (Pacella,	  Hruska	  and	  Delahanty,	  2012).	  	  A	  meta-­‐analysis	  of	  functional	  somatic	  syndrome	  (FSS)	  and	  psychological	  trauma	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revealed	  individuals	  who	  reported	  exposure	  to	  trauma	  were	  2.7	  times	  more	  likely	  to	  have	  FSS	  regardless	  of	  type	  of	  trauma	  or	  type	  of	  condition.	  	  A	  systematic	  review	  on	  the	  link	  between	  PTSD	  and	  physical	  comorbidities	  identified	  evidence	  on	  association	  between	  PTSD	  and	  arthritis	  (Quereshi	  et	  al.,	  2009).	  	  PTSD	  is	  often	  reported	  as	  having	  more	  pronounced	  and	  longer-­‐lasting	  detrimental	  effects	  on	  health	  and	  quality	  of	  life	  (QoL)	  in	  comparison	  to	  other	  anxiety	  disorders.	  	  Patients	  with	  PTSD	  reported	  poorer	  physical	  health	  and	  more	  medical	  conditions	  when	  compared	  to	  healthy	  controls	  or	  controls	  with	  other	  mental	  health	  conditions	  such	  as	  depression	  or	  other	  anxiety	  conditions	  (Zayfert	  et	  al.,	  2002;	  Frayne	  et	  al.,	  2004).	  	  	  However,	  measuring	  and	  interpreting	  these	  effects	  is	  not	  straightforward.	  	  An	  underlying	  characteristic	  of	  the	  available	  evidence	  is	  that	  it	  comes	  from	  cross-­‐sectional	  and	  low	  quality	  studies	  (Afari	  et	  al.,	  2014)	  and	  this	  causes	  difficulties	  in	  establishing	  causality	  and	  determining	  whether	  reported	  conditions	  are	  a	  consequence	  of	  exposure	  to	  a	  particular	  traumatic	  event,	  a	  pre-­‐existing	  condition,	  or	  a	  personal	  predisposition.	  Measuring	  health	  effects	  demands	  careful	  examination	  of	  and	  access	  to	  the	  information	  on	  the	  pre-­‐trauma	  health	  status	  of	  the	  individuals	  in	  the	  form	  of	  GP	  or	  hospital	  records,	  which	  can	  be	  time	  and	  resource	  consuming.	  	  In	  the	  large	  number	  of	  cases	  available,	  evidence	  on	  the	  relationship	  between	  PTSD	  and	  physical	  health	  is	  characterised	  by	  great	  heterogeneity	  among	  study	  populations	  ranging	  from	  the	  general	  population,	  to	  veteran	  and	  military	  samples	  or	  special	  populations	  such	  as	  victims	  of	  disasters	  (Ullman	  &	  Siegel,	  1996).	  	  In	  addition,	  there	  is	  a	  great	  diversity	  among	  methods	  employed	  which	  further	  limits	  generalisability	  and	  comparability	  of	  findings.	  	  	  The	  finding	  that	  PTSD	  sufferers	  use	  more	  health	  services	  when	  compared	  to	  controls	  with	  similar	  sociodemographic	  characteristics	  has	  been	  replicated	  in	  studies	  on	  general,	  military	  and	  veteran	  populations	  (Marshall	  et	  al.,	  2014;	  Elhai,	  North	  and	  Frueh,	  2005;	  Marciniak	  et	  al.,	  2005;	  Erbes	  et	  al.,	  2007).	  	  Interestingly,	  these	  patients	  seek	  help	  mainly	  for	  physical	  health	  issues	  (Marciniak,	  2004)	  meaning	  frequent	  physical	  health	  problems	  are	  therefore	  identified	  as	  an	  important	  marker	  of	  undiagnosed	  PTSD	  and	  are	  an	  important	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indicator	  for	  PTSD	  screening	  in	  primary	  care.	  	  Review	  of	  the	  literature	  covering	  health	  service	  use	  associated	  with	  exposure	  to	  traumatic	  events	  and	  PTSD	  diagnosis	  has	  identified	  only	  one	  critical	  review	  by	  Elhai,	  North	  and	  Frueh	  (2005)	  that	  explored	  health	  service	  use	  predictors	  among	  trauma	  survivors.	  	  Their	  findings	  highlighted	  female	  gender,	  previous	  trauma	  history	  and	  PTSD	  diagnosis	  as	  predictors	  of	  increased	  mental	  health	  service	  use,	  while	  PTSD	  was	  a	  significant	  predictor	  of	  medical	  service	  use.	  	  In	  an	  earlier	  study	  looking	  at	  health	  care	  costs	  in	  women,	  Walker	  et	  al	  (2003)	  observed	  that	  PTSD	  was	  associated	  with	  total	  and	  component	  care	  costs	  and	  suggested	  that	  detection	  and	  treatment	  of	  PTSD	  in	  primary	  care	  would	  be	  a	  potentially	  cost-­‐effective	  way	  in	  reducing	  PTSD	  prevalence	  rates.	  	  Tagay	  et	  al	  (2005)	  reported	  that	  patients	  with	  PTSD	  had	  significantly	  higher	  rates	  of	  medical	  consultations,	  psychotropic	  medication	  and	  psychotherapy	  when	  compared	  to	  patients	  without	  PTSD.	  	  The	  total	  medical	  spending	  of	  a	  sub-­‐sample	  of	  individuals	  with	  PTSD	  was	  five	  times	  higher	  than	  for	  individuals	  with	  other	  anxiety	  and	  adjustment	  disorders,	  when	  controlling	  for	  age	  and	  sex	  (Berndt	  et	  al.,	  2000).	  	  Similarly	  a	  US	  study	  looking	  at	  cost	  and	  resource	  use	  connected	  with	  PTSD	  diagnosis	  for	  a	  sample	  of	  Medicare	  or	  private	  insurance	  users	  found	  that	  users	  with	  PTSD	  had	  significantly	  higher	  mental	  health	  resource	  use	  and	  service	  costs	  in	  comparison	  to	  matched	  control	  insurance	  users	  with	  major	  depressive	  disorder	  (Ivanova	  et	  al.,	  2011).	  	  	  Answering	  questions	  on	  the	  relationship	  between	  trauma	  exposure	  and	  PTSD	  with	  health	  services	  use	  is	  crucial	  for	  health	  providers,	  planners	  and	  funders,	  as	  it	  provides	  valuable	  information	  for	  immediate	  aftermath	  response	  as	  well	  as	  long-­‐term	  service	  provision	  and	  funding.	  	  Evidence	  is	  needed	  on	  demand,	  type	  and	  cost	  of	  services	  used	  by	  the	  population	  exposed	  to	  a	  traumatic	  event,	  both	  for	  the	  immediate	  aftermath	  of	  the	  event	  and	  from	  the	  long-­‐term	  perspective.	  	  Another	  valuable	  question	  for	  policy	  makers	  is	  whether	  reduction	  in	  PTSD	  symptoms	  would	  result	  in	  reduction	  in	  health	  care	  service	  use.	  	  An	  observational	  study	  on	  veterans’	  service	  utilisation	  reported	  that	  treatment	  completion	  resulted	  in	  a	  32%	  reduction	  in	  service	  use	  in	  comparison	  to	  pre-­‐treatment	  service	  use,	  which	  consequently	  resulted	  in	  a	  39%	  reduction	  in	  direct	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costs	  (Meyers	  et	  al.,	  2013).	  	  Future	  studies	  should	  examine	  this	  relationship	  carefully	  by	  using	  a	  well-­‐designed	  experimental	  study	  that	  will	  control	  for	  other	  predictors	  and	  mediating	  factors	  of	  service	  use.	  An	  important	  and	  often	  overlooked	  cost	  in	  the	  context	  of	  PTSD	  (and	  other	  mental	  health	  disorders)	  is	  the	  burden	  of	  the	  disorder	  on	  family	  and	  caregivers.	  A	  study	  exploring	  the	  caregiver	  burden	  in	  partners	  of	  veterans	  with	  PTSD	  reported	  a	  greater	  burden	  in	  this	  group	  when	  compared	  to	  caregivers	  of	  veterans	  without	  PTSD,	  after	  controlling	  for	  a	  set	  of	  variables	  including	  PTSD	  symptom	  severity,	  hostility,	  major	  depression,	  and	  health	  complaints	  and	  caregiver	  sociodemographic	  factors	  (Calhoun	  et	  al.,	  2002).	  	  A	  study	  by	  Manguno-­‐Mire	  et	  al.	  (2007,	  p.	  147)	  reported	  that	  “severe	  levels	  of	  overall	  psychological	  distress,	  depression,	  and	  suicidal	  ideation”	  were	  prevalent	  among	  female	  partners	  of	  veterans	  with	  PTSD.	  	  Although	  there	  is	  a	  strong	  indication	  of	  the	  adverse	  impact	  of	  PTSD	  on	  families	  looking	  after	  individuals	  with	  PTSD	  (Kalra	  et	  al.,	  2008),	  few	  studies	  have	  explored	  the	  caregiver	  burden	  in	  anxiety	  disorders	  and	  even	  fewer	  have	  looked	  specifically	  at	  the	  relationship	  between	  PTSD	  and	  the	  caregiver	  burden.	  	  One	  of	  the	  conclusions	  of	  this	  finding	  is	  the	  fact	  that	  is	  still	  “difficult	  to	  put	  an	  economic	  value	  on	  informal	  care”	  (Knapp,	  2003,	  p.	  477).	  	   A	  link	  between	  increased	  suicide	  risk	  and	  PTSD	  has	  been	  suggested	  by	  several	  studies.	  	  Studies	  have	  warned	  that	  PTSD	  sufferers	  have	  a	  high	  rate	  of	  suicide	  attempts,	  reported	  as	  up	  to	  19%	  (Nutt,	  2000),	  and	  that	  they	  are	  six	  times	  more	  likely	  to	  attempt	  suicide	  than	  demographically	  matched	  controls	  (Kessler,	  2000).	  	  A	  Danish	  population-­‐based	  study	  on	  the	  link	  between	  PTSD	  and	  completed	  suicide	  reported	  an	  odds	  ratio	  of	  9.8	  linking	  suicide	  with	  PTSD,	  and	  5.3	  after	  controlling	  for	  psychiatric	  and	  demographic	  confounders;	  it	  concluded	  that	  a	  diagnosis	  of	  PTSD	  is	  a	  risk	  factor	  for	  completed	  suicide	  (Gradus,	  2010).	  	  A	  number	  of	  disaster	  studies	  have	  reported	  what	  appear	  to	  be	  elevated	  rates	  of	  both	  suicide	  and	  suicidal	  ideation	  (Quin	  et	  al.,	  2003;	  Vehid	  et	  al.,	  2006;	  Bonnano	  et	  al.,	  2010).	  	  However,	  one	  needs	  to	  be	  careful	  in	  conclusions	  about	  causality	  between	  exposure	  to	  disaster	  and	  suicide,	  as	  the	  findings	  are	  conflicting.	  	  For	  example,	  no	  increase	  in	  suicide	  was	  detected	  after	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the	  September	  11th	  terrorist	  attack	  in	  New	  York	  City	  (Mezuk	  et	  al.,	  2009;	  Bonnano	  et	  al.,	  2010).	  	  The	  role	  of	  pre-­‐existing	  risk	  factors	  needs	  to	  be	  carefully	  examined	  when	  assessing	  the	  relationship	  between	  trauma	  exposure	  and	  suicide	  (Warheit	  et	  al.,	  1996;	  Bonnano	  et	  al.,	  2010).	  	  Assessing	  the	  suicide-­‐related	  costs	  of	  premature	  mortality	  related	  to	  PTSD	  is	  not	  an	  easy	  task	  and	  that	  is	  a	  likely	  reason	  for	  the	  scarcity	  of	  this	  type	  of	  data	  in	  relation	  to	  PTSD	  and	  other	  mental	  health	  disorders	  in	  general.	  	  If	  one	  were	  to	  get	  an	  accurate	  picture	  of	  the	  economic	  impact	  of	  suicide	  on	  society,	  direct	  costs	  (e.g.,	  police,	  funeral	  services,	  healthcare	  use),	  lost	  productivity	  and	  intangible	  costs	  of	  pain,	  grief	  and	  premature	  loss	  of	  life	  would	  need	  to	  be	  assessed,	  which	  is	  methodologically	  very	  challenging.	  	  Negative	  effects	  of	  PTSD	  that	  pose	  a	  burden	  to	  individuals	  and	  society	  include	  a	  strong	  association	  between	  PTSD	  and	  low	  educational	  attainment	  (Iversen	  et	  al.,	  2008),	  higher	  odds	  of	  school	  failure,	  elevated	  odds	  of	  teenage	  pregnancies	  and	  a	  high	  impact	  on	  family	  and	  marriage	  (Kessler,	  2000).	  	  Risky	  behaviour	  such	  as	  reckless	  driving	  and	  risky	  sexual	  behaviour	  has	  been	  recognised	  relatively	  recently	  as	  PTSD	  (Miller	  et	  al.,	  2014).	  	  Evidence	  on	  the	  health,	  social	  and	  economic	  effects	  on	  the	  aforementioned	  factors	  are	  yet	  to	  be	  established.	  	  Quantifying	  the	  effects	  of	  these	  factors	  poses	  a	  significant	  challenge,	  as	  it	  is	  difficult	  to	  isolate	  and	  measure	  them,	  establish	  a	  causal	  relationship	  with	  PTSD	  and	  allocate	  economic	  value.	  	  Nevertheless,	  it	  is	  important	  to	  recognise	  and	  acknowledge	  the	  role	  of	  these	  factors	  in	  assessing	  the	  burden	  of	  PTSD.	  	  PTSD	  also	  has	  considerable	  effects	  on	  employment.	  Work	  loss	  and	  impaired	  functioning	  are	  greater	  with	  co-­‐morbid	  disorders	  than	  with	  pure	  disorders,	  and	  PTSD	  is	  associated	  with	  3.6	  days	  of	  work	  impairment	  per	  month	  for	  affected	  individuals	  (Kessler,	  1995).	  	  When	  considering	  the	  effects	  of	  PTSD	  on	  the	  workforce,	  the	  following	  factors	  should	  be	  taken	  into	  account:	  work	  loss,	  cutback	  and	  impairment,	  and	  forgone	  work	  opportunities	  and	  benefits	  claims	  (Kessler,	  2000;	  CEP,	  2006).	  	  Individuals	  with	  PTSD	  exhibited	  200%	  higher	  absenteeism	  rates	  in	  comparison	  to	  a	  non-­‐mental	  health	  disorder	  group	  in	  another	  study	  (Berndt	  et	  al.,	  2000).	  	  A	  study	  looking	  at	  work	  productivity	  for	  a	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sample	  of	  individuals	  exposed	  to	  the	  9/11	  event	  in	  New	  York	  reported	  that	  PTSD	  was	  associated	  with	  lower	  quality	  workdays	  even	  after	  controlling	  for	  baseline	  status	  (Boscarino	  et	  al.,	  2006).	  Furthermore,	  it	  has	  been	  estimated	  that	  about	  40%	  of	  all	  disabilities	  and	  about	  40%	  of	  all	  incapacity	  benefit	  claims	  are	  due	  to	  mental	  illness	  (CEP,	  2006).	  People	  with	  depression,	  anxiety	  or	  severe	  mental	  illness	  are	  more	  likely	  to	  be	  unemployed	  or	  economically	  inactive	  than	  the	  healthy	  population	  (SCMH,	  2006),	  and	  it	  has	  been	  reported	  that	  less	  than	  25%	  of	  people	  with	  a	  mental	  illness	  have	  a	  job	  (CEP,	  2006;	  SCMH,	  2003).	  	  	  Early	  detection	  and	  provision	  of	  best-­‐evidence	  treatment	  is	  of	  the	  utmost	  importance	  in	  reducing	  costs	  of	  PTSD,	  not	  only	  for	  individuals	  with	  the	  disorder	  but	  to	  society	  as	  a	  whole.	  	  This	  is	  supported	  by	  the	  findings	  from	  studies	  looking	  at	  the	  effects	  of	  PTSD	  symptom	  reduction	  on	  employment	  gains.	  	  In	  a	  study	  of	  Vietnam	  veterans	  with	  severe	  and	  very	  severe	  PTSD,	  Smith,	  Schnurr	  &	  Rosenbeck	  (2005)	  concluded	  that	  modest	  reductions	  in	  symptoms	  can	  lead	  to	  employment	  gain	  even	  if	  symptoms	  still	  persist.	  	  This	  conclusion	  is	  consistent	  with	  findings	  from	  an	  older	  study	  from	  Berndt	  et	  al.	  (2000)	  looking	  at	  health-­‐care	  use	  and	  work	  productivity	  among	  employees	  with	  mental	  health	  disorders.	  	  After	  considering	  the	  relationship	  between	  PTSD	  and	  service	  use,	  it	  is	  important	  to	  explore	  whether	  the	  reduction	  in	  PTSD	  symptoms	  is	  associated	  with	  a	  reduction	  in	  health	  care	  service	  use.	  	  Available	  evidence	  on	  the	  PTSD	  burden	  is	  characterised	  by	  great	  heterogeneity	  and	  covers	  a	  wide	  continuum	  of	  populations	  ranging	  from	  the	  general	  population,	  veteran	  and	  military	  samples	  or	  special	  populations	  such	  as	  victims	  of	  disasters	  (Ullman	  &	  Siegel,	  1996).	  	  In	  addition,	  there	  is	  a	  great	  diversity	  among	  methods	  employed,	  which	  further	  limits	  generalisability	  and	  comparability	  of	  findings.	  	  An	  underlying	  characteristic	  of	  the	  available	  evidence	  is	  that	  it	  comes	  from	  cross-­‐sectional	  and	  low	  quality	  studies	  that	  vary	  greatly	  in	  the	  methodology	  used	  (Afari	  et	  al.,	  2014).	  	  Each	  study	  provides	  a	  snapshot	  of	  some	  of	  the	  aspects	  of	  the	  disorder.	  	  These	  findings	  could	  be	  potentially	  influenced	  by	  the	  wide	  scope	  of	  the	  literature	  search.	  However,	  what	  is	  clear	  is	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that	  there	  is	  a	  paucity	  of	  studies	  taking	  a	  holistic	  approach	  to	  measuring	  the	  burden	  of	  PTSD,	  looking	  at	  the	  health,	  social	  and	  economic	  effect	  of	  the	  disorder,	  utilising	  reliable	  measures,	  and	  comparing	  costs	  and	  outcomes	  of	  the	  intervention	  in	  question.	  	  	  Over	  the	  past	  two	  decades,	  the	  economic	  burden	  of	  mental	  health	  disorders	  has	  increasingly	  been	  recognised	  by	  policy	  makers,	  providers	  and	  funders.	  	  There	  has	  been	  a	  shift	  from	  a	  predominant	  health	  perspective	  of	  the	  disorders	  into	  the	  economic	  and	  social	  domains,	  which	  has	  been	  fuelled	  by	  the	  increased	  interest	  and	  application	  of	  health	  economics	  principles	  and	  methods	  in	  the	  mental	  health	  area.	  	  	  Slowly,	  this	  shift	  has	  been	  reflected	  in	  the	  type	  of	  research	  questions	  and	  commissioned	  and	  conducted	  studies,	  which	  have	  increasingly	  adopted	  an	  economic	  perspective.	  	  Evidence-­‐based	  decision-­‐making	  demands	  economic	  evaluations	  and	  examination	  of	  “cost	  impacts	  and	  differences	  in	  the	  context	  of	  outcome	  differences”	  (McCrone,	  2003,	  p.	  10).	  	  	  At	  this	  moment,	  the	  evidence	  base	  on	  the	  cost-­‐effectiveness	  of	  mental	  health	  response	  after	  the	  terrorist	  events	  is	  still	  developing.	  	  Although	  the	  social	  and	  economic	  impacts	  of	  PTSD	  have	  been	  increasingly	  recognised	  and	  documented,	  high-­‐quality	  evidence	  in	  the	  form	  of	  cost-­‐effectiveness	  or	  cost-­‐benefit	  analyses,	  alongside	  systematic	  reviews	  and	  meta-­‐analysis	  on	  these	  impacts	  on	  individuals,	  is	  still	  scarce.	  	  My	  own	  updated	  review	  of	  the	  literature	  on	  the	  social	  and	  (in	  particular)	  economic	  impacts	  of	  PTSD	  did	  not	  yield	  many	  new	  studies	  since	  my	  own	  preliminary	  search	  (for	  my	  Major	  Review)	  in	  2007.	  	  In	  total,	  I	  have	  identified	  only	  three	  studies	  examining	  some	  aspects	  of	  the	  costs	  and	  outcomes	  of	  PTSD.	  	  A	  cost	  of	  illness	  study,	  conducted	  by	  NICE	  to	  feed	  into	  guidelines,	  estimated	  that	  the	  total	  annual	  cost	  of	  implementing	  the	  recommendations	  on	  best	  evidence-­‐based	  treatment	  for	  PTSD	  would	  be	  £33.4	  million	  (NICE,	  2005).	  	  In	  a	  5-­‐year	  proposed	  plan	  this	  cost	  would	  be	  reduced	  by	  savings	  if	  pharmacotherapy	  was	  replaced	  by	  psychotherapy,	  NICE	  stated	  that	  the	  recurrent	  annual	  net	  cost	  of	  fully	  implemented	  recommendations	  in	  England	  would	  amount	  to	  as	  much	  as	  £26	  million	  at	  2005	  prices.	  	  Although	  this	  is	  a	  conservative	  estimate,	  as	  the	  model	  did	  not	  take	  into	  account	  costs	  averted	  by	  timely	  provision	  of	  the	  treatment,	  nevertheless	  this	  study	  provides	  an	  insight	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into	  costs	  the	  health	  system	  is	  facing	  associated	  with	  provision	  of	  treatment	  for	  PTSD.	  	  However,	  for	  making	  an	  informed	  decision	  on	  funding	  PTSD	  treatment	  data	  on	  treatment	  outcomes	  along	  data	  on	  costs	  averted	  is	  needed.	  	  More	  helpful	  information	  for	  policy-­‐makers	  is	  presented	  in	  a	  cost-­‐effectiveness	  study	  looking	  into	  the	  timing	  of	  the	  provision	  of	  therapy,	  commissioned	  by	  the	  National	  Collaborating	  Centre	  for	  Mental	  Health	  (NCCMH),	  concluded	  that	  the	  CBT	  and	  EMDR	  treatment	  at	  12	  weeks	  is	  a	  cost-­‐effective	  option	  in	  comparison	  to	  treatment	  at	  2	  weeks	  post-­‐trauma,	  operating	  under	  the	  assumption	  that	  remission	  is	  worth	  more	  than	  £2420	  (NICE,	  2005).	  	  The	  third	  available	  study	  looked	  into	  the	  evaluation	  of	  implementation	  of	  the	  best	  evidence-­‐based	  practice	  as	  recommended	  by	  the	  NICE	  guidelines,	  delivered	  by	  the	  Improving	  Access	  to	  Psychological	  Therapies	  (IAPT)	  services.	  	  The	  study	  compared	  an	  IAPT	  site	  to	  two	  matched	  comparator	  sites.	  	  Individuals	  at	  the	  IAPT	  site	  received	  treatment	  via	  a	  stepped-­‐care	  approach,	  as	  recommended	  by	  the	  NICE	  guidelines	  on	  treatment	  of	  PTSD	  in	  primary	  and	  secondary	  care,	  while	  the	  comparator	  sites	  offered	  treatment	  as	  usual	  consisting	  of	  GP	  services,	  primary	  care	  counselling	  and	  referral	  to	  secondary	  care	  services.	  	  Although	  the	  authors	  of	  the	  study	  concluded	  that	  IAPT	  services	  were	  “probably	  cost	  effective	  within	  NICE	  guidelines	  threshold	  of	  £20,000-­‐30,000”	  they	  remarked	  on	  uncertainty	  regarding	  the	  cost	  and	  outcome	  differences	  (Mukuria	  et	  al.,	  2013,	  p.	  226).	  	  	  Economic	  data	  on	  the	  direct	  and	  indirect	  costs	  of	  PTSD,	  or	  on	  its	  treatment,	  are	  limited,	  with	  data	  from	  general	  mental	  health	  or	  depression	  studies	  usually	  being	  used	  as	  proxies.	  	  Although	  there	  have	  been	  a	  number	  of	  studies	  that	  have	  focused	  on	  anxiety	  disorders	  in	  general	  or	  on	  depression,	  which	  are	  common	  comorbid	  conditions	  to	  PTSD	  (McCrone	  et	  al.,	  2008;	  Layard	  et	  al.,	  2008;	  Thomas	  &	  Morris,	  2003;	  NICE,	  2005),	  there	  is	  still	  a	  scarcity	  of	  studies	  looking	  at	  the	  wider	  economic	  consequences	  of	  PTSD,	  on	  data	  on	  the	  exact	  economic	  burden	  of	  PTSD	  and	  on	  the	  cost-­‐effectiveness	  of	  its	  treatment	  (McCrone	  et	  al.,	  2003).	  	  For	  example,	  a	  systematic	  review	  by	  Lewis,	  Pearce	  and	  Bisson	  (2012)	  on	  efficacy,	  cost-­‐effectiveness	  and	  acceptability	  of	  self-­‐help	  interventions	  for	  anxiety	  disorder	  including	  PTSD,	  did	  not	  find	  a	  single	  study	  that	  included	  an	  economic	  evaluation.	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2.4	   To	  screen	  or	  not	  to	  screen	  for	  PTSD	  -­‐	  benefits	  of	  early	  detection	  and	  
screening	  	  There	  is	  now	  considerable	  evidence	  that	  mass	  early	  intervention	  for	  trauma	  survivors	  (using	  critical	  incident	  stress	  debriefing	  or	  related	  techniques)	  is	  unlikely	  to	  reduce	  later	  psychopathology	  and	  is	  an	  inefficient	  use	  of	  resources	  (McNally	  et	  al.,	  2003;	  Roberts	  et	  al.,	  2010).	  	  The	  majority	  of	  survivors	  will	  not	  require	  mental	  health	  treatment.	  	  However,	  a	  minority	  is	  likely	  to	  develop	  chronic	  conditions	  and	  to	  have	  significant	  work	  and	  social	  impairments	  unless	  appropriately	  treated.	  	  	  The	  NICE	  (2005)	  PTSD	  Guidelines	  recommend	  the	  routine	  use	  of	  a	  brief	  screening	  instrument	  for	  PTSD	  at	  one	  month	  post-­‐disaster.	  	  Screening	  should	  involve	  all	  individuals	  exposed	  to	  the	  traumatic	  event	  and	  continue	  up	  to	  a	  year	  after	  the	  event	  at	  regular	  intervals.	  	  The	  purpose	  of	  screening	  is	  to	  identify	  all	  individuals	  at	  risk	  and	  refer	  them	  for	  evidence-­‐based	  treatment	  if	  needed.	  	  In	  light	  of	  the	  evidence	  presented	  in	  the	  NICE	  guidelines,	  experiencing	  a	  number	  of	  PTSD	  symptoms	  within	  the	  first	  month	  after	  the	  traumatic	  event	  is	  part	  of	  the	  natural	  recovery	  pathway.	  	  Early	  detection	  and	  treatment	  for	  PTSD	  will	  reduce	  the	  impact	  of	  PTSD	  on	  individuals,	  their	  family	  and	  society	  in	  terms	  of	  suffering	  as	  well	  as	  costs	  to	  the	  health	  and	  social	  care	  systems.	  	  However,	  many	  PTSD	  cases	  go	  unnoticed	  by	  both	  individuals	  and	  general	  practitioners.	  	  A	  US	  study	  has	  reported	  that	  around	  10%	  of	  affected	  individuals	  received	  help	  in	  the	  year	  after	  PTSD	  onset,	  after	  which	  there	  is	  an	  average	  delay	  of	  12	  years	  before	  receiving	  any	  kind	  of	  help	  (Wang	  et	  al.,	  2005).	  	  These	  are	  lower	  treatment	  rates	  than	  for	  other	  common	  mental	  health	  disorders.	  One	  UK	  community	  survey	  (Bebbington	  and	  al.,	  1997)	  found	  that	  about	  10%	  of	  an	  inner-­‐city	  population	  had	  a	  need	  for	  psychiatric	  treatment	  in	  the	  past	  year,	  with	  only	  50%	  of	  these	  needs	  being	  met.	  Unmet	  needs	  were	  particularly	  high	  for	  anxiety	  disorders.	  Evidence	  assessed	  highlights	  the	  lack	  of	  recognition	  of	  the	  nature,	  seriousness,	  and	  chronicity	  of	  PTSD,	  both	  among	  sufferers	  themselves	  (Kessler,	  2000)	  and	  among	  UK	  general	  practitioners	  (Munro	  et	  al.,	  2003;	  Duxbury,	  2006).	  	  A	  survey	  reporting	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awareness	  of	  NICE	  guidelines	  and	  PTSD	  in	  practice	  patients	  has	  concluded	  that	  there	  is	  a	  poor	  rate	  of	  case-­‐recognition	  in	  both	  primary	  and	  secondary	  care.	  	  Furthermore,	  the	  estimated	  prevalence	  of	  PTSD	  cases	  in	  both	  GP	  practices	  and	  CMHTs	  were	  much	  lower	  than	  prevalence	  expected	  from	  epidemiological	  studies	  (Ehlers,	  2006).	  	  According	  to	  the	  PTSD	  prevalence	  data,	  GP	  practices	  with	  a	  catchment	  area	  of	  5,000	  people	  should	  expect	  75	  –	  150	  cases	  annually.	  	  The	  GP’s	  lack	  of	  knowledge	  (Munro	  et	  al.,	  2003;	  Duxbury,	  2006;	  Zimmerman,	  1999)	  is	  a	  possible	  explanation	  as	  studies	  report	  only	  2%	  of	  GPs	  recognise	  PTSD	  (Taubman,	  2001)	  and	  GPs	  often	  do	  not	  ask	  about	  traumatic	  experiences	  (Duxbury,	  2006).	  The	  results	  of	  a	  GP	  survey	  reveal	  a	  lack	  of	  information	  about	  NICE	  guideline	  recommendations	  for	  PTSD.	  	  As	  a	  result,	  the	  majority	  of	  patients	  with	  PTSD	  did	  not	  receive	  or	  were	  not	  referred	  to	  recommended	  psychological	  treatment.	  	  Instead,	  patients	  were	  most	  often	  prescribed	  medication,	  most	  frequently	  selective	  serotonin	  reuptake	  inhibitors	  (SSRIs;	  Ehlers,	  2006),	  which	  is	  exactly	  the	  opposite	  of	  what	  is	  recommended	  by	  NICE	  guidelines.	  	  Another	  explanation	  for	  poor	  treatment	  rates	  could	  be	  that	  PTSD	  sufferers	  are	  not	  aware	  of	  the	  cause	  of	  their	  symptoms;	  the	  avoidance	  symptoms	  associated	  with	  PTSD,	  thinking	  the	  problem	  will	  get	  better	  by	  itself,	  wanting	  to	  solve	  the	  problem	  by	  him/herself	  (Kessler,	  2000),	  long	  treatment	  waiting	  lists,	  costs	  and	  availability	  of	  treatment	  	  (CEP,	  2006;	  SCMH,	  2006).	  	  The	  literature	  highlights	  the	  need	  for	  increased	  awareness	  and	  greater	  recognition	  of	  PTSD,	  especially	  in	  primary	  care.	  	  There	  is	  a	  need	  for	  increased	  availability	  of	  psychological	  treatment,	  as	  studies	  report	  30%	  of	  people	  seen	  at	  GP	  surgeries	  have	  mental	  health	  problems	  (CEP,	  2006).	  	  Two-­‐thirds	  to	  three-­‐quarters	  of	  people	  identified	  in	  epidemiological	  surveys	  who	  meet	  criteria	  for	  mental	  disorder	  are	  not	  receiving	  treatment	  (Andrews	  et	  al.,	  2000).	  	  The	  2007	  general	  population	  Adult	  Psychiatric	  Morbidity	  Survey	  reported	  that	  only	  one	  quarter	  of	  the	  individuals	  who	  screened	  positive	  for	  PTSD	  were	  receiving	  treatment	  for	  a	  mental	  or	  emotional	  problems	  (National	  Centre	  for	  Social	  Research,	  2007).	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Due	  to	  the	  high	  prevalence	  of	  the	  disorder	  and	  its	  significant	  impact	  on	  individuals,	  their	  families,	  the	  health	  system	  and	  society	  as	  a	  whole,	  the	  prospect	  of	  screening	  for	  PTSD	  has	  been	  suggested	  by	  numerous	  authors	  with	  the	  purpose	  of	  early	  detection	  and	  to	  prevent	  the	  onset	  of	  chronic	  PTSD	  in	  various	  contexts	  from	  emergency	  department	  to	  post-­‐disaster	  mental	  health	  response	  (Liebschutz	  et	  al.,	  2007;	  Kimerling	  et	  al.,	  2006;	  Ouimette	  et	  al.,	  2007;	  Van	  Dam	  et	  al.,	  2013;	  Lang	  &	  Stein,	  2005;	  Foa	  et	  al.,	  2008;	  Breslau	  et	  al.,	  2003;	  Silove	  et	  al.,	  2009;	  Ivanova	  et	  al.,	  2011).	  	  Kessler	  et	  al.	  (2009)	  argued	  that	  screening	  at	  the	  workplace	  and	  treatment	  of	  anxiety	  disorders	  might	  have	  a	  positive	  return	  on	  investment	  by	  increasing	  workplace	  performance	  and	  reducing	  healthcare	  costs	  associated	  with	  the	  disorder	  and	  comorbid	  disorders,	  and	  might	  be	  cost-­‐effective	  from	  the	  societal	  perspective	  in	  reducing	  its	  effects	  in	  health	  and	  social	  functioning.	  	  Another	  benefit	  of	  screening	  lies	  in	  the	  opportunity	  to	  detect	  subsyndromal	  PTSD	  (Duffy	  et	  al.,	  2009).	  	  	  As	  with	  other	  health	  problems	  such	  as	  cervical	  cancer	  or	  depression,	  screening	  for	  PTSD	  at	  general	  practice	  level	  could	  be	  a	  way	  forward	  to	  ensuring	  identification	  and	  access	  to	  treatment	  for	  individuals	  exposed	  to	  traumatic	  events	  by	  employing	  valid,	  reliable	  and	  brief	  measures.	  	  This	  would	  ensure	  that	  individuals	  exposed	  to	  traumatic	  events	  are	  identified,	  informed	  about	  PTSD	  and	  the	  help	  available,	  screened	  for	  symptoms	  at	  regular	  intervals	  with	  reliable	  and	  valid	  measures	  and	  referred	  for	  treatment,	  if	  and	  when	  necessary.	  	  This	  way	  the	  GP	  could	  serve	  as	  a	  triage	  point	  by	  minimising	  unnecessary	  referrals	  for	  treatment.	  	  Furthermore,	  screening	  for	  PTSD	  at	  general	  practice	  level	  could	  complement	  the	  work	  of	  the	  Improving	  Access	  to	  Psychological	  Therapies	  (IAPT)	  programme,	  which	  aims	  to	  provide	  evidence-­‐based	  treatment	  for	  depression	  and	  anxiety	  disorders.	  	  The	  introduction	  of	  screening	  for	  PTSD	  demands	  a	  careful	  consideration	  of	  numerous	  factors	  such	  as:	  	  a.	  Who	  should	  be	  screened?	  	  Should	  screening	  be	  aimed	  only	  at	  high-­‐risk	  populations,	  such	  as	  refugees	  and	  asylum	  seekers,	  or	  at	  individuals	  suffering	  from	  high-­‐risk	  conditions	  often	  comorbid	  with	  PTSD,	  such	  as	  alcoholism	  or	  domestic	  violence,	  or	  the	  general	  population?	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b.	  Should	  screening	  focus	  on	  the	  identification	  of	  people	  with	  new	  PTSD	  (predictive	  screening)	  or	  only	  on	  identifying	  already-­‐existing	  cases?	  c.	  In	  which	  context	  (setting)	  should	  people	  be	  screened?	  	  d.	  Which	  instruments	  should	  be	  used	  for	  screening?	  e.	  Once	  screening	  has	  taken	  place,	  what	  is	  the	  best	  way	  to	  ensure	  that	  individuals	  are	  referred	  for	  and	  provided	  with	  appropriate	  treatment?	  When	  assessing	  the	  implications	  and	  feasibility	  of	  screening	  for	  PTSD,	  the	  criteria	  devised	  by	  National	  Screening	  Committee	  provide	  valuable	  guidelines.	  A	  summary	  of	  the	  guidelines	  is	  presented	  in	  Table	  7.1	  and	  they	  cover	  the	  criteria	  around	  the	  condition,	  available	  instruments,	  treatment,	  and	  characteristics	  of	  the	  screening	  programme.	  	  
Table	  2.1	  National	  Screening	  Committee	  Criteria	  (NSCC)	  	  The	  Condition	  	  	  1.	  The	  condition	  should	  be	  an	  important	  health	  problem.	  2.	  The	  epidemiology	  and	  natural	  history	  of	  the	  condition,	  including	  	  	  	  	  	  	  	  development	  from	  latent	  to	  declared	  disease,	  should	  be	  adequately	  	  	  	  	  	  	  understood	  and	  there	  should	  be	  a	  detectable	  risk	  factor,	  disease	  marker,	  	  	  	  	  	  	  	  	  latent	  period	  or	  early	  symptomatic	  stage.	  	  3.	  All	  the	  cost-­‐effective	  primary	  prevention	  interventions	  should	  have	  been	  	  	  	  	  	  implemented	  as	  far	  as	  practicable.	  	  	  4.	  If	  the	  carriers	  of	  a	  mutation	  are	  identified	  as	  a	  result	  of	  screening	  the	  natural	  	  	  	  	  	  history	  of	  people	  with	  this	  status	  should	  be	  understood,	  including	  the	  	  	  	  	  	  psychological	  implications.	  	  	  	  The	  Test	  	  	  5.	  There	  should	  be	  a	  simple,	  safe,	  precise	  and	  validated	  screening	  test.	  	  6.	  The	  distribution	  of	  test	  values	  in	  the	  target	  population	  should	  be	  known	  and	  a	  	  	  	  	  	  	  suitable	  cut-­‐off	  level	  defined	  and	  agreed.	  	  7.	  The	  test	  should	  be	  acceptable	  to	  the	  population.	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8.	  There	  should	  be	  an	  agreed	  policy	  on	  the	  further	  diagnostic	  investigation	  of	  	  	  	  	  	  individuals	  with	  a	  positive	  test	  result	  and	  on	  the	  choices	  available	  to	  those	  	  	  	  	  	  individuals.	  	  9.	  If	  the	  test	  is	  for	  mutations	  the	  criteria	  used	  to	  select	  the	  subset	  of	  mutations	  	  	  	  	  	  to	  be	  covered	  by	  screening,	  if	  all	  possible	  mutations	  are	  not	  being	  tested,	  	  	  	  	  	  should	  be	  clearly	  set	  out.	  	  	  	  	  The	  Treatment	  	  	  10.	  There	  should	  be	  an	  effective	  treatment	  or	  intervention	  for	  patients	  	  	  	  	  	  	  	  	  	  	  	  	  	  identified	  	  through	  early	  detection,	  with	  evidence	  of	  early	  treatment	  leading	  	  	  	  	  	  	  	  	  	  to	  better	  outcomes	  than	  late	  treatment.	  	  	  11.	  There	  should	  be	  agreed	  evidence	  based	  policies	  covering	  which	  individuals	  	  	  	  	  	  	  	  should	  be	  offered	  treatment	  and	  the	  appropriate	  treatment	  to	  be	  offered.	  	  	  12.	  Clinical	  management	  of	  the	  condition	  and	  patient	  outcomes	  should	  be	  	  	  	  	  	  	  	  	  optimised	  in	  all	  programme.	  	  The	  Screening	  Programme	  	  	  13.	  There	  should	  be	  evidence	  from	  high	  quality	  Randomised	  Controlled	  Trials	  	  	  	  	  	  	  	  that	  the	  screening	  programme	  is	  effective	  in	  reducing	  mortality	  or	  morbidity.	  	  14.	  There	  should	  be	  evidence	  that	  the	  complete	  screening	  programme	  (test,	  	  	  	  	  	  	  	  	  diagnostic	  procedures,	  treatment/	  intervention)	  is	  clinically,	  socially	  and	  	  	  	  	  	  	  	  	  ethically	  acceptable	  to	  health	  professionals	  and	  the	  public.	  	  	  15.	  The	  benefit	  from	  the	  screening	  programme	  should	  outweigh	  the	  physical	  	  	  	  	  	  	  	  	  	  and	  psychological	  harm	  (caused	  by	  the	  test,	  diagnostic	  procedures	  and	  	  	  	  	  	  	  	  	  	  treatment).	  	  	  16.	  The	  opportunity	  cost	  of	  the	  screening	  programme	  (including	  testing,	  	  	  	  	  	  	  	  	  diagnosis	  and	  treatment,	  administration,	  training	  and	  quality	  assurance)	  	  	  	  	  	  	  	  	  should	  be	  economically	  balanced	  in	  relation	  to	  expenditure	  on	  medical	  care	  	  	  	  	  	  	  	  	  as	  a	  whole	  (ie.	  value	  for	  money).	  	  	   With	  regard	  to	  PTSD,	  the	  available	  supporting	  evidence	  demanded	  by	  the	  NSCC	  is	  even	  scarcer	  than	  in	  the	  case	  of	  depression.	  As	  outlined	  earlier	  in	  the	  chapter,	  there	  is	  ample	  evidence	  on	  the	  burden	  of	  the	  condition	  itself	  and	  arguments	  as	  to	  why	  it	  constitutes	  an	  important	  health	  problem.	  	  However,	  as	  discussed	  earlier,	  the	  evidence	  on	  the	  cost-­‐effectiveness	  of	  primary	  care	  preventive	  interventions	  is	  scarce.	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With	  regard	  to	  the	  screening	  instruments,	  a	  good	  number	  of	  available	  tests	  with	  good	  psychometric	  properties	  are	  available.	  	  However,	  in	  the	  UK	  there	  are	  no	  validated	  translations	  of	  the	  screening	  instruments	  to	  the	  other	  languages	  frequently	  spoken	  by	  refugees	  and	  asylum-­‐seeking	  groups.	  	  Furthermore,	  a	  review	  of	  the	  evidence	  on	  routine	  screening	  for	  PTSD	  in	  the	  refugee	  and	  asylum-­‐seeker	  population	  concluded	  that	  there	  is	  not	  enough	  evidence	  of	  the	  benefits	  of	  the	  screening	  programme	  outweighing	  the	  potential	  harm	  (Rousseau	  et	  al,	  2011).	  	  The	  study	  concluded	  that	  there	  is	  a	  limited	  number	  of	  screening	  instruments	  that	  have	  been	  validated	  for	  this	  particular	  group.	  	  Moreover,	  the	  psychometric	  properties	  of	  the	  available	  screeners,	  along	  with	  their	  cut-­‐off	  scores,	  are	  on	  the	  whole	  established	  only	  for	  a	  specific	  group	  of	  respondents,	  which	  limits	  its	  application	  and	  accuracy	  (Hollifield	  et	  al,	  2002).	  With	  regard	  to	  the	  treatment	  of	  PTSD,	  NICE	  guidelines	  (2005)	  have	  identified	  trauma-­‐focused	  CBT	  along	  with	  EMDR	  as	  effective.	  Furthermore,	  there	  is	  evidence	  that	  the	  early	  detection	  of	  the	  disorder,	  along	  with	  timely	  and	  effective	  treatment	  three	  to	  six	  months	  after	  trauma	  exposure,	  prevents	  the	  development	  of	  chronic	  PTSD	  and	  its	  consequent	  burden.	  The	  NICE	  guidelines	  (2005)	  are	  also	  clear	  on	  who	  should	  be	  offered	  treatment	  and	  on	  the	  treatment	  protocols.	  	  There	  is	  a	  big	  gap	  in	  the	  existing	  knowledge	  about	  the	  implementation	  of	  screening	  for	  PTSD	  at	  the	  general	  practice	  level.	  	  This	  literature	  review	  has	  identified	  only	  two	  studies	  with	  evidence	  of	  the	  benefits	  of	  predictive	  screening	  for	  PTSD	  in	  the	  UK	  or	  internationally,	  in	  addition	  to	  evidence	  presented	  in	  the	  2005	  NICE	  guidelines.	  	  However	  there	  seems	  to	  be	  a	  consensus	  around	  screening	  high-­‐risk	  groups	  rather	  than	  the	  general	  population.	  	  The	  latest	  NICE	  guidelines	  on	  PTSD	  (NICE,	  2005,	  p.	  101)	  suggest	  there	  is	  “no	  sound	  evidence	  to	  support	  a	  national	  or	  large	  population	  screening	  programme	  for	  PTSD”.	  	  Instead,	  following	  available	  evidence,	  NICE	  advocates	  screening	  only	  of	  high-­‐risk	  groups	  (NICE,	  2005).	  	  More	  recently,	  NICE	  has	  supported	  screening	  for	  PTSD	  after	  a	  major	  disaster,	  as	  well	  as	  the	  screening	  of	  refugees	  and	  asylum	  seekers	  (NICE,	  2012).	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A	  recent	  example	  of	  predictive	  screening	  after	  a	  major	  disaster	  was	  the	  NHS	  Mental	  Health	  Response	  after	  the	  London	  bombings	  study,	  also	  known	  as	  the	  ‘screen	  and	  treat’	  programme.	  	  An	  independent	  evaluation	  of	  the	  programme	  concluded	  that	  screening	  was	  an	  effective	  way	  of	  identifying	  individuals	  with	  mental	  health	  problems	  following	  exposure	  to	  this	  traumatic	  event	  (Brewin	  et	  al.,	  2008).	  The	  second	  identified	  study	  on	  predictive	  screening	  for	  PTSD	  by	  Bisson	  et	  al	  (2010)	  looked	  at	  the	  benefits	  of	  predictive	  screening	  for	  victims	  of	  violent	  crime	  in	  an	  emergency	  unit	  using	  the	  Trauma	  Screening	  Questionnaire	  (TSQ;	  Brewin	  et	  al.,	  2002).	  	  Given	  the	  reported	  prevalence	  of	  PTSD	  following	  violent	  crime,	  the	  authors	  expected	  that	  for	  every	  two	  people	  who	  screened	  positive	  on	  the	  TSQ	  two	  weeks	  post-­‐exposure,	  one	  would	  develop	  symptoms	  of	  PTSD	  one	  month	  after	  exposure.	  Unfortunately,	  there	  was	  a	  low	  response	  rate,	  with	  only	  17%	  of	  those	  who	  used	  emergency	  services	  being	  screened.	  	  Of	  these,	  338	  (57%)	  screened	  positive,	  but	  only	  26	  (7.7%)	  were	  formally	  assessed	  and	  nine	  individuals	  (2.7%)	  received	  therapy	  for	  PTSD.	  	  The	  main	  reason	  for	  rejecting	  the	  assessment	  following	  a	  positive	  screen	  was	  unwillingness	  to	  discuss	  trauma	  and	  a	  lack	  of	  concern	  about	  the	  screening	  results.	  	  The	  authors	  concluded	  that	  the	  screening	  was	  not	  as	  valuable	  as	  expected,	  due	  to	  the	  low	  response	  rate	  and	  relatively	  high	  costs	  of	  screening.	  	  However	  this	  study	  has	  a	  very	  high	  ecological	  validity	  and	  offers	  valuable	  insights	  into	  the	  practicalities	  of	  setting	  up	  screening,	  alongside	  the	  outcomes	  of	  such	  programmes.	  	  A	  review	  of	  the	  evidence	  on	  routine	  screening	  for	  PTSD	  in	  the	  refugee	  and	  asylum-­‐seeker	  population	  concluded	  there	  is	  not	  enough	  evidence	  of	  the	  benefits	  of	  the	  screening	  programme	  outweighing	  the	  potential	  harm	  (Rousseau	  et	  al.,	  2011).	  	  Predictive	  screening	  for	  acute	  stress	  disorder	  (ASD)	  or	  a	  broad	  range	  of	  biological	  and	  cognitive	  factors	  has	  been	  suggested	  as	  a	  way	  forward	  in	  identifying	  future	  PTSD	  cases.	  	  Two	  separate	  studies,	  one	  by	  Bryant	  (2003)	  and	  one	  by	  Creamer	  (2004),	  concluded	  that	  ASD	  does	  not	  offer	  sufficient	  predictive	  power	  to	  diagnose	  later	  chronic	  PTSD.	  	  Instead,	  Bryant	  et	  al	  (2011)	  concluded	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that	  a	  more	  accurate	  predictor	  of	  PTSD	  could	  be	  found	  in	  a	  broad	  range	  of	  biological	  and	  cognitive	  factors.	  	  Biological	  markers,	  such	  as	  an	  elevated	  resting	  heart	  rate,	  elevated	  respiration	  and	  lower	  cortisol	  rate	  in	  the	  days	  after	  trauma	  exposure,	  have	  been	  explored	  in	  numerous	  studies	  as	  PTSD	  predictors	  (Bryant,	  2006;	  Bryant	  et	  al.,	  2008;	  Yehuda,	  2001).	  	  However,	  studies	  to	  date	  investigating	  biological	  and	  cognitive	  factors	  have	  not	  yielded	  unequivocal	  results	  and	  there	  is	  still	  uncertainty	  behind	  the	  reliability	  of	  those	  measures	  as	  predictors	  of	  PTSD.	  	  Evidence	  on	  effective	  screening	  programmes,	  especially	  in	  the	  context	  of	  primary	  care,	  is	  scarce	  and	  even	  when	  available	  is	  presented	  in	  the	  form	  of	  observation	  studies,	  rather	  than	  RCTs.	  	  Furthermore,	  many	  questions	  on	  the	  role,	  acceptability	  and	  appropriate	  design	  of	  the	  screening	  as	  a	  pathway	  into	  treatment	  in	  the	  context	  of	  primary	  care	  are	  still	  open	  and	  demand	  careful	  consideration	  and	  more	  supporting	  evidence.	  	  Finally,	  a	  review	  of	  existing	  literature	  on	  PTSD	  screening	  has	  not	  identified	  a	  single	  economic	  evaluation.	  	  In	  conclusion,	  there	  is	  no	  straightforward	  answer	  to	  what	  seems	  a	  simple	  question.	  	  However,	  the	  identification	  of	  the	  relevant	  questions	  nevertheless	  provides	  a	  useful	  template	  for	  future	  studies.	  	  Numerous	  factors	  behind	  the	  decision	  to	  introduce	  a	  screening	  policy	  are	  discussed	  in	  Chapter	  8.	  	  	  
2.5	  Summary	  In	  this	  chapter,	  my	  aim	  was	  to	  demonstrate	  how	  the	  health,	  social	  and	  economic	  effects	  of	  PTSD	  are	  interconnected	  and	  that,	  in	  order	  to	  account	  for	  the	  full	  extent	  of	  the	  impact	  of	  the	  disorder,	  one	  needs	  to	  include	  effects	  and	  costs	  in	  all	  three	  domains.	  	  The	  POW	  approach	  helps	  us	  in	  identifying	  all	  the	  relevant	  factors	  and	  the	  patterns	  of	  their	  interrelationships	  in	  evaluating	  the	  effects	  of	  PTSD.	  	  This	  is	  a	  resource-­‐	  and	  time-­‐consuming	  endeavour	  with	  numerous	  methodological	  and	  practical	  difficulties,	  including	  availability	  of	  service	  use	  data,	  reliance	  on	  self-­‐reporting	  in	  service	  use,	  difficulties	  in	  measuring	  productivity	  loss	  and	  presenteeism	  data	  in	  particular,	  and	  difficulties	  
	   53	  
in	  capturing,	  measuring	  and	  costing	  effects	  of	  trauma	  exposure	  and	  PTSD	  on	  the	  social	  domain.	  Evidence	  is	  scarce	  on	  the	  demand,	  type	  and	  cost	  of	  services	  used	  by	  the	  population	  exposed	  to	  a	  traumatic	  event,	  both	  for	  the	  immediate	  aftermath	  of	  the	  event	  and	  from	  the	  long-­‐term	  perspective.	  	  Information	  on	  the	  type,	  frequency	  and	  costs	  of	  service	  use	  associated	  with	  PTSD	  is	  needed	  alongside	  information	  on	  the	  cost-­‐effectiveness	  of	  available	  mental	  health	  interventions.	  	  In	  order	  to	  prevent	  chronic	  PTSD	  and	  its	  associated	  burden,	  the	  literature	  suggests	  screening	  for	  PTSD	  as	  a	  way	  of	  identifying	  people	  in	  need	  of	  treatment,	  and	  as	  a	  pathway	  into	  treatment.	  	  However	  evidence	  on	  screening	  for	  PTSD,	  in	  particular	  in	  the	  primary	  care	  context,	  is	  scarce	  and	  many	  questions	  on	  the	  role,	  acceptability	  and	  appropriate	  design	  of	  screening	  remain	  to	  be	  answered.	  	  	  The	  presented	  findings	  support	  the	  relevance	  of	  the	  key	  questions	  this	  study	  aims	  to	  explore.	  	  There	  is	  a	  need	  for	  high-­‐quality	  evidence	  of	  the	  social	  and	  economic	  effects	  of	  PTSD,	  the	  costs	  and	  effects	  of	  implementing	  best	  evidence-­‐based	  treatment	  protocols,	  and	  information	  on	  costs	  and	  benefits	  of	  early	  screening	  for	  PTSD	  alongside	  the	  practicalities	  of	  setting-­‐up	  such	  practice.	  	  In	  particular,	  there	  is	  a	  demand	  for	  evidence	  coming	  from	  comprehensive	  economic	  evaluation	  studies	  that	  comply	  with	  study	  design,	  data	  collection	  and	  analysis	  protocol	  recommendations.	  	  On	  the	  other	  hand,	  there	  is	  a	  need	  for	  recognition	  and	  integration	  of	  innovative	  non-­‐experimental	  study	  designs	  into	  economic	  evaluation	  in	  order	  to	  reflect	  the	  real-­‐world	  setting	  and	  widen	  the	  framework	  of	  the	  analysis	  to	  areas	  and	  questions	  not	  easily	  evaluated	  by	  experimental	  design.	  	  This	  study	  attempts	  to	  offer	  a	  comprehensive	  view	  of	  the	  effects	  of	  PTSD	  on	  individuals,	  their	  families	  and	  society	  as	  a	  whole.	  	  Moreover,	  the	  study	  aims	  to	  explore	  what	  it	  means	  for	  individuals	  to	  be	  involved	  in	  a	  terrorist	  attack,	  what	  are	  their	  needs	  in	  the	  intermediate	  aftermath	  and	  longer-­‐run	  after	  exposure	  to	  trauma,	  how	  to	  structure	  and	  deliver	  an	  evidence-­‐based	  mental	  health	  response	  in	  an	  efficient	  and	  cost-­‐effective	  manner,	  and	  how	  to	  prevent	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chronic	  PTSD	  in	  the	  general	  population	  by	  setting-­‐up	  screening	  protocols	  in	  the	  general	  practice	  context	  as	  a	  pathway	  into	  treatment.	  	  Each	  of	  these	  questions	  contributes	  a	  piece	  of	  evidence	  and	  offers	  a	  different	  perspective	  on	  the	  array	  of	  effects	  PTSD	  has	  on	  individuals	  and	  society	  as	  a	  whole.	  	  In	  my	  opinion,	  such	  a	  multidimensional	  and	  comprehensive	  approach	  is	  justified	  by	  the	  complexity	  of	  the	  subject	  and	  demands	  for	  a	  diverse	  and	  heterogeneous	  methodological	  approach,	  which	  is	  presented	  in	  the	  next	  chapter.	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Chapter	  3	   Methods	  
3.1	   Introduction	  This	  study	  is	  based	  on	  an	  evaluation	  of	  the	  NHS	  mental	  health	  response	  introduced	  shortly	  after	  the	  7	  July	  2005	  London	  bombings.	  	  The	  NHS	  mental	  health	  response	  was	  delivered	  in	  the	  form	  of	  a	  screen	  and	  treat	  programme	  (ST).	  	  This	  chapter	  aims	  to	  set	  the	  context	  for	  the	  study	  by	  providing	  a	  general	  overview	  of	  both	  the	  ST	  programme	  and	  its	  subsequent	  evaluation.	  	  I	  will	  start	  by	  setting	  out	  my	  study	  aim	  and	  objectives,	  and	  follow	  with	  an	  overview	  of	  the	  NHS	  mental	  health	  response,	  the	  ST	  programme,	  and	  a	  brief	  description	  of	  the	  evaluation	  study.	  	  In	  order	  to	  address	  the	  questions	  outlined	  in	  my	  study	  objectives	  I	  will	  employ	  a	  number	  of	  different	  methods.	  	  I	  will	  begin	  by	  outlining	  possible	  ways	  to	  address	  the	  questions	  and	  explain	  my	  choice	  of	  methods.	  	  For	  each	  study	  objective,	  and	  in	  separate	  sub-­‐sections,	  I	  will	  describe	  the	  sampling	  procedure,	  the	  choice	  of	  instruments,	  data	  collection	  protocol	  and	  the	  analysis	  plan.	  	  	  
3.2	   Aim	  and	  objectives	  The	  aim	  of	  this	  research	  is	  to	  assess	  the	  health,	  social,	  and	  economic	  impacts	  of	  PTSD	  by	  focusing	  on	  individuals	  exposed	  to	  the	  London	  bombings.	  In	  order	  to	  achieve	  this	  aim,	  the	  following	  objectives	  were	  chosen:	  
• To	  review	  and	  assess	  the	  current	  evidence	  and	  measures	  of	  health,	  social	  	  	  and	  economic	  impact	  of	  PTSD.	  (Chapter	  2)	  
• To	  assess	  the	  impact	  of	  the	  London	  bombings	  in	  terms	  of	  service	  use	  and	  the	  impact	  on	  health,	  social,	  and	  economic	  activity	  of	  those	  affected.	  (Chapters	  4	  and	  5)	  
• To	  conduct	  an	  economic	  evaluation	  of	  the	  screen	  and	  treat	  programme	  implemented	  as	  a	  mental	  health	  response	  after	  the	  London	  bombings.	  (Chapters	  6	  and	  7)	  
	   56	  
• To	  assess	  the	  broader	  implications	  and	  feasibility	  of	  screening	  for	  PTSD	  in	  primary	  care.	  (Chapter	  8)	  	  
3.3	   The	  study	  context	  –	  the	  screen	  and	  treat	  programme	  
3.3.2	   Structure	  and	  outcome	  measures	  The	  screen	  and	  treat	  programme	  ran	  for	  two	  years,	  between	  September	  2005	  and	  September	  2007,	  at	  three	  locations	  in	  London.	  	  All	  the	  screening,	  assessment	  and	  treatment	  data	  was	  collected	  by	  clinicians	  and	  the	  screening	  team,	  and	  archived	  in	  the	  form	  of	  an	  ACCESS	  database.	  	  The	  role	  of	  the	  Screening	  team	  was	  to	  coordinate	  outreach	  and	  screening,	  to	  contact	  and	  screen	  all	  individuals	  exposed,	  and	  to	  refer	  those	  who	  screened	  positive	  for	  detailed	  assessment	  or	  treatment,	  if	  needed.	  	  The	  screening	  team	  was	  responsible	  for	  collecting	  contact	  details	  of	  the	  exposed	  individuals	  from	  the	  Metropolitan	  police,	  A&E	  departments	  at	  London	  hospitals	  and	  other	  statutory	  and	  non-­‐statutory	  organisations	  involved	  in	  the	  various	  forms	  of	  response	  and	  support	  after	  the	  LB.	  	  All	  identified	  individuals	  exposed	  to	  the	  London	  bombings	  were	  contacted	  by	  letter	  or	  telephone	  and	  sent	  a	  questionnaire	  on	  the	  nature	  of	  their	  involvement	  with	  the	  bombings,	  as	  well	  as	  information	  on	  gender,	  age,	  GP	  details	  and	  any	  children	  living	  with	  them.	  	  In	  addition,	  the	  questionnaire	  contained	  a	  set	  of	  screening	  questions	  in	  order	  to	  detect	  any	  symptoms	  of	  psychopathology.	  	  Following	  up	  the	  initial	  questionnaires	  at	  one,	  three,	  six	  and	  nine	  month	  intervals,	  additional	  screening	  questionnaires	  were	  sent	  to	  the	  individuals.	  	  The	  questionnaires	  included	  the	  Trauma	  Screening	  Questionnaire	  (TSQ;	  Brewin	  et	  al.,	  2002),	  a	  brief	  screening	  measure	  for	  posttraumatic	  stress	  disorder.	  	  The	  questionnaire	  has	  a	  yes-­‐no	  response	  scale	  and	  contains	  ten	  questions	  on	  whether	  there	  has	  been	  a	  presence	  of	  PTSD	  symptoms	  at	  least	  twice	  in	  the	  last	  week.	  	  Previous	  research	  has	  demonstrated	  that	  this	  instrument	  has	  excellent	  performance	  relative	  to	  other	  instruments	  and	  that	  endorsement	  of	  6	  or	  more	  symptoms	  yields	  high	  levels	  of	  sensitivity	  and	  specificity	  (Brewin,	  2010;	  Walters	  et	  al.,	  2007).	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The	  TSQ	  was	  supplemented	  by	  additional	  screening	  questions:	  two	  on	  depression	  (Kroenke	  et	  al.,	  2003),	  one	  on	  travel	  phobia	  and	  three	  more	  general	  questions	  on	  elevated	  levels	  of	  distress	  including	  questions	  on	  increased	  drinking	  or	  smoking.	  	  All	  individuals	  were	  given	  feedback	  upon	  the	  receipt	  of	  the	  screener	  and	  were	  provided	  with	  any	  additional	  information	  they	  needed.	  	  In	  the	  event	  that	  respondents	  replied	  positively	  to	  at	  least	  six	  questions	  on	  the	  TSQ,	  or	  to	  any	  of	  the	  additional	  screening	  questions,	  they	  were	  considered	  to	  screen	  positive	  and	  were	  invited	  for	  a	  detailed	  clinical	  assessment	  at	  one	  of	  the	  clinics.	  	  Individuals	  who	  screened	  negative	  were	  informed	  that	  they	  were	  recovering	  well	  and	  were	  screened	  again	  in	  three	  months	  to	  monitor	  their	  progress	  and	  detect	  potential	  delayed-­‐onset	  PTSD.	  The	  screening	  questionnaire	  is	  given	  in	  Appendix	  A.	  	  The	  detailed	  clinical	  assessments	  and	  the	  treatment	  were	  delivered	  at	  one	  of	  the	  three	  clinics	  within	  London	  that	  took	  part	  in	  the	  project;	  the	  Traumatic	  Stress	  Clinic	  (TSC),	  Camden	  &	  Islington	  Mental	  Health	  and	  Social	  Care	  Trust;	  the	  Centre	  for	  Anxiety	  Disorders	  and	  Trauma,	  South	  London	  and	  Maudsley	  NHS	  Trust	  (SLAM);	  and	  the	  Institute	  for	  Psychotrauma,	  East	  London	  and	  City	  Mental	  Health	  Trust	  (ELCMHT).	  	  The	  purpose	  of	  the	  longer	  clinical	  assessment	  was	  to	  identify	  individuals	  in	  need	  of	  treatment	  exclusively	  due	  to	  their	  exposure	  to	  the	  LB.	  	  Individuals	  with	  pre-­‐existing	  mental	  health	  conditions	  were	  referred	  to	  their	  respective	  clinicians.	  Secondly,	  the	  assessment	  aimed	  to	  determine	  an	  individual’s	  suitability	  for	  trauma-­‐focused	  cognitive	  therapy	  by	  employing	  the	  criteria	  set	  by	  DSM-­‐IV	  and	  ICD-­‐10	  disorder	  due	  to	  exposure	  to	  LB,	  which	  has	  not	  been	  resolved	  on	  its	  own.	  	  Assessment	  included	  the	  following	  instruments:	  
• Structured	  Clinical	  Interview	  for	  DSM-­‐IV	  (SCID)	  (First	  et	  al.,	  1997)	  	  
• CAGE	  alcohol	  abuse	  screening	  instrument	  (Mayfield	  et	  al.,	  1974)	  	  
• SF-­‐12	  Health	  Survey	  (Ware	  et	  al.,	  1996)	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• Short	  McGill	  Pain	  Questionnaire	  (Melzack,	  1987)	  where	  appropriate,	  and	  
• Inventory	  of	  Complicated	  Grief	  –	  Revised	  (Prigerson	  &	  Jacobs,	  2001).	  Individuals	  with	  persistent	  and	  distressing	  conditions	  were	  referred	  for	  treatment	  even	  if	  not	  meeting	  criteria	  set	  by	  DSM-­‐IV	  and	  ICD-­‐10.	  Assessed	  individuals	  who	  were	  not	  referred	  for	  treatment	  were	  followed	  up	  at	  3-­‐month	  intervals	  at	  three,	  six	  and	  nine	  months,	  in	  order	  to	  monitor	  their	  progress	  and	  detect	  delayed-­‐onset	  PTSD	  that	  occurs	  in	  about	  15%	  of	  the	  exposed	  civilian	  population	  (Andrews	  et	  al.,	  2007).	  Psychological	  treatment	  was	  delivered	  in	  three	  psychological	  trauma	  centres	  in	  London:	  the	  TSC,	  Camden	  and	  Islington	  Mental	  Health	  and	  Social	  Care	  Trust;	  the	  Centre	  for	  Anxiety	  Disorders	  and	  Trauma,	  SLAM;	  and	  the	  ELCHMT.	  	  The	  location	  of	  the	  ST	  programme	  affected	  access	  to	  the	  programme:	  many	  individuals	  based	  outside	  London	  avoided	  using	  transportation	  services	  because	  of	  the	  nature	  and	  location	  of	  the	  traumatic	  event	  and	  had	  to	  rely	  on	  services	  available	  in	  their	  local	  area.	  	  However,	  all	  non-­‐London	  residents	  who	  were	  unable	  to	  travel	  to	  London,	  and	  who	  contacted	  the	  ST	  programme	  and	  needed	  treatment	  were	  referred	  by	  the	  programme	  to	  their	  local	  treatment	  centres.	  The	  main	  aim	  of	  the	  ST	  programme	  was	  the	  early	  identification	  and	  treatment	  of	  PTSD.	  	  However,	  in	  practice	  the	  ST	  programme	  only	  started	  receiving	  larger	  numbers	  of	  referrals	  from	  September	  2005	  (although	  the	  first	  referrals	  were	  made	  in	  July	  2005)	  due	  to	  delays	  in	  obtaining	  the	  contact	  details	  from	  police	  and	  hospitals	  caused	  by	  the	  Data	  Protection	  Act	  (1998).	  	  The	  treatment	  provided,	  as	  recommended	  by	  the	  most	  recent	  NICE	  guidelines	  (NICE,	  2005),	  was	  trauma-­‐focussed	  cognitive-­‐behaviour	  therapy	  (TFCBT)	  and	  eye	  movement	  desensitisation	  and	  reprocessing	  (EMDR).	  The	  level	  of	  treatment	  provided	  was	  recorded	  by	  clinicians	  on	  a	  monthly	  basis	  in	  two	  separate	  data	  collection	  systems;	  as	  the	  total	  number	  of	  hours	  of	  direct	  and	  indirect	  time	  spent	  (data	  needed	  for	  the	  DH),	  and	  in	  a	  clinic’s	  own	  system	  that	  
	   59	  
monitored	  each	  client’s	  progress	  and	  included	  data	  on	  the	  start	  and	  end	  dates	  of	  treatment,	  the	  type	  of	  treatment,	  the	  total	  number	  of	  sessions	  attended	  and	  missed,	  as	  well	  as	  depression	  and	  PTSD	  assessments	  at	  the	  start	  and	  end	  of	  treatment.	  	  At	  the	  end	  of	  the	  screen	  and	  treat	  funding,	  patients	  still	  receiving	  treatment	  were	  referred	  to	  the	  usual	  NHS	  psychological	  services.	  	  The	  progress	  of	  the	  treatment	  and	  the	  level	  of	  the	  symptoms	  were	  monitored	  by	  administering	  the	  Posttraumatic	  Diagnostic	  Scale	  (PDS;	  Foa	  et	  al.,	  1997)	  and	  the	  Beck	  Depression	  Inventory	  (BDI;	  Beck	  et	  al.,	  1961)	  at	  the	  start	  and	  the	  end	  of	  the	  treatment	  for	  each	  patient.	  	  The	  initial	  goal	  was	  to	  administer	  both	  questionnaires	  at	  each	  treatment	  session.	  	  However,	  this	  protocol	  was	  not	  followed	  strictly	  due	  to	  a	  variety	  of	  practical	  reasons	  such	  as	  time	  constraints	  or	  a	  patient’s	  unwillingness	  to	  go	  through	  the	  same	  questionnaire	  each	  session.	  	  Therefore,	  in	  order	  to	  address	  problems	  introduced	  by	  the	  missing	  BDI	  and	  PDS	  data	  I	  have	  only	  used	  scores	  from	  the	  start	  and	  end	  of	  the	  treatment.	  	  In	  the	  case	  where	  the	  start	  and/or	  end	  of	  treatment	  scores	  were	  missing	  I	  have	  used	  the	  available	  score	  from	  the	  next	  available	  treatment	  session.	  	  The	  ST	  programme	  sent	  screening	  materials	  to	  910	  adults	  (and	  a	  further	  7	  children	  whose	  details	  are	  not	  reported	  here).	  	  The	  ST	  programme	  received	  contact	  details	  of	  910	  individuals	  exposed	  to	  the	  LB	  from	  Metropolitan	  police,	  hospital	  lists,	  organisations	  involved	  in	  the	  mental	  health	  response,	  or	  through	  self	  referral.	  Out	  of	  910	  individuals	  who	  were	  sent	  screeners	  and	  information	  on	  PTSD,	  only	  596	  individuals	  returned	  a	  screener.	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Figure	  3.1	  Referrals	  to	  the	  screening	  team	  diagram	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Figure	  3.1	  shows	  that	  of	  the	  910	  adults,	  65.5%	  returned	  at	  least	  one	  screening	  questionnaire	  and,	  of	  these,	  56.7%	  screened	  positive	  at	  some	  stage.	  	  A	  majority	  of	  those	  receiving	  a	  more	  detailed	  clinical	  assessment	  (76%)	  were	  judged	  to	  require	  psychological	  treatment	  and	  most	  were	  referred,	  248	  within	  the	  programme	  and	  30	  outside	  the	  programme.	  	  Of	  those	  treated	  within	  the	  programme,	  189	  completed	  a	  course	  of	  therapy.	  	  Thus,	  just	  under	  one	  third	  of	  those	  who	  were	  originally	  screened	  entered	  and	  completed	  treatment.	  Individuals	  who	  required	  monitoring	  only	  continued	  to	  be	  screened	  in	  three	  month	  intervals	  until	  they	  were	  discharged	  from	  the	  programme	  or	  referred	  to	  assessment	  and/or	  treatment	  within	  the	  programme	  or	  elsewhere.	  	  
3.4	   Evaluation	  of	  the	  ST	  programme	  The	  DH	  commissioned	  and	  funded	  both	  the	  ST	  programme	  and	  its	  evaluation,	  which	  was	  structured	  and	  delivered	  by	  UCL’s	  Department	  of	  Health,	  Clinical	  and	  Educational	  Psychology.	  	  The	  evaluation	  looked	  into	  the	  acceptability	  of	  the	  ST	  programme,	  satisfaction	  and	  service	  use,	  and	  the	  nature	  of	  the	  health,	  social,	  and	  economic	  impact	  of	  exposure	  to	  the	  London	  bombings.	  	  The	  evaluation	  aimed	  to	  contact	  a	  sub-­‐sample	  of	  ST	  programme	  users	  alongside	  a	  sample	  of	  the	  individuals	  who	  were	  exposed	  to	  the	  London	  bombings	  but	  did	  not	  use	  the	  services	  offered	  by	  the	  programme	  either	  out	  of	  choice	  or	  lack	  of	  knowledge.	  	  In	  addition,	  the	  evaluation	  aimed	  to	  interview	  the	  main	  stakeholders	  who	  contributed	  to	  the	  set-­‐up,	  running	  and	  funding	  of	  the	  programme.	  	  In	  total,	  the	  evaluation	  study	  planned	  to	  interview	  around	  200	  individuals	  who	  were	  exposed	  to	  the	  LB.	  	  
3.4.1	   Evaluation	  timeframe	  Evaluation	  of	  the	  NHS	  response	  after	  the	  London	  bombings	  project	  ran	  from	  June	  2006	  until	  November	  2008.	  	  During	  that	  period,	  two	  research	  psychologists	  (ZH	  and	  this	  researcher)	  from	  UCL’s	  Department	  for	  Clinical,	  Educational	  and	  Health	  Psychology	  collected	  data	  on	  the	  treatment	  follow-­‐up,	  and	  the	  social	  and	  economic	  impact	  of	  the	  London	  bombings.	  	  At	  the	  outset	  of	  the	  evaluation	  it	  was	  agreed	  that	  all	  collected	  data	  on	  service	  use,	  and	  the	  social	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and	  economic	  effects	  of	  the	  LB	  will	  constitute	  a	  core	  part	  of	  this	  thesis.	  	  Although	  data	  were	  collected	  as	  a	  part	  of	  the	  evaluation	  study,	  I	  was	  solely	  responsible	  for	  data	  cleaning,	  entry	  and	  analysis.	  	  Furthermore,	  I	  have	  contributed	  to	  the	  design	  of	  the	  modified	  version	  of	  the	  CSRI	  questionnaire	  used	  in	  the	  evaluation	  study.	  
3.4.2	   Evaluation	  data	  collection	  protocol	  An	  NHS	  Research	  Ethics	  Committee	  granted	  ethical	  clearance	  prior	  to	  the	  start	  of	  the	  evaluation.	  	  Participants	  were	  initially	  contacted	  via	  letter,	  which	  briefly	  outlined	  the	  aim	  of	  the	  study	  and	  invited	  them	  to	  take	  part.	  	  Participants	  had	  two	  weeks	  to	  opt	  out	  of	  the	  study	  by	  sending	  back	  the	  form	  in	  a	  pre-­‐paid	  envelope	  enclosed	  with	  the	  letter.	  	  After	  two	  weeks,	  if	  no	  opt-­‐out	  response	  was	  received,	  participants	  were	  contacted	  in	  order	  to	  arrange	  a	  telephone,	  face-­‐to-­‐face	  or	  postal	  interview	  depending	  on	  the	  participant’s	  preference,	  and	  at	  a	  convenient	  time	  and	  place.	  	  All	  the	  participants	  received	  study	  information	  sheets	  containing	  study	  details	  and	  the	  evaluation’s	  team	  contact	  details.	  	  All	  participants	  also	  signed	  the	  consent	  form	  and	  were	  informed	  that	  they	  could	  opt	  out	  of	  the	  research	  at	  any	  time,	  and	  that	  opting	  out	  would	  not	  influence	  their	  future	  care.	  	  All	  data	  collected	  as	  a	  part	  of	  the	  screening,	  assessment	  and	  treatment	  were	  stored	  by	  the	  ST	  team	  in	  both	  paper	  and	  electronic	  form.	  	  All	  collected	  data	  was	  checked	  for	  inconsistencies	  and	  re-­‐entered	  into	  ACCESS	  and	  SPSS	  electronic	  databases.	  	  61%	  of	  the	  interviews	  were	  conducted	  via	  telephone,	  while	  32%	  were	  conducted	  face-­‐to-­‐face	  and	  took	  place	  either	  at	  the	  evaluation	  team’s	  office	  or	  at	  a	  convenient	  location	  of	  the	  participant’s	  choosing	  (office,	  home,	  coffee	  shop).	  	  The	  rest	  of	  the	  questionnaires	  were	  returned	  by	  post	  (6%)	  or	  email	  (1%).	  Interviews,	  both	  face-­‐to-­‐face	  or	  telephone,	  took	  on	  average	  30	  minutes.	  	  
3.4.3	   Evaluation	  sub-­‐sample	  In	  order	  to	  have	  an	  accurate	  representation	  of	  the	  sample	  recorded	  on	  the	  screening	  team	  database,	  the	  evaluation	  sampled	  participants	  from	  all	  segments	  of	  the	  ST	  programme	  (screened,	  assessed,	  and	  treated	  participants)	  alongside	  a	  group	  of	  participants	  who	  declined	  to	  take	  part	  in	  the	  ST	  programme.	  	  In	  total,	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the	  evaluation	  interviewed	  230	  users,	  potential	  users	  and	  non-­‐users	  of	  the	  ST	  programme.	  	  Users	  are	  defined	  as	  the	  individuals	  who	  used	  any	  part	  of	  the	  ST	  programme.	  	  Individuals	  who	  never	  used	  the	  programme	  out	  of	  personal	  choice	  are	  referred	  to	  as	  non-­‐users,	  while	  potential	  users	  are	  the	  individuals	  who	  were	  not	  aware	  of	  the	  existence	  of	  the	  programme.	  	  The	  study	  recruited	  individuals	  from	  the	  ST	  programme	  database.	  	  In	  order	  to	  recruit	  the	  programme’s	  potential	  and	  non-­‐users,	  the	  research	  team	  sent	  out	  letters	  to	  individuals	  on	  Metropolitan	  Police	  witness	  and	  wounded	  lists	  who	  were	  not	  already	  included	  in	  the	  ST	  programme’s	  database.	  	  A	  number	  of	  individuals	  contacted	  the	  evaluation	  team	  directly,	  having	  heard	  about	  it	  by	  word	  of	  mouth.	  	  The	  evaluation	  study	  received	  a	  list	  of	  623	  individuals	  from	  the	  Metropolitan	  police	  that	  had	  not	  been	  shared	  with	  the	  ST	  programme.	  	  77	  individuals	  from	  that	  list	  were	  interviewed	  during	  the	  evaluation	  as	  a	  part	  of	  a	  category	  of	  participants	  who	  did	  not	  use	  the	  ST	  programme.	  	  Again	  it	  is	  difficult	  to	  assess	  how	  representative	  that	  sub-­‐sample	  was,	  as	  the	  evaluation	  did	  not	  have	  any	  socio-­‐demographic	  data	  on	  the	  group	  of	  623	  individuals	  to	  begin	  with.	  	  Moreover,	  for	  the	  same	  reasons	  it	  is	  not	  possible	  to	  assess	  how	  representative	  623	  individuals	  were	  of	  all	  the	  individuals	  who	  were	  exposed	  to	  the	  bombings	  and	  did	  not	  use	  the	  ST	  programme.	  	  The	  analysis	  of	  this	  particular	  dataset	  is	  a	  reminder	  of	  how	  research	  in	  this	  area	  is	  fraught	  with	  methodological	  and	  practical	  difficulties.	  	  However,	  at	  the	  same	  time	  it	  offers	  high	  ecological	  validity	  and	  insight	  into	  applied	  clinical	  interventions	  in	  a	  real	  world	  setting.	  	  The	  evaluation	  also	  attempted	  to	  contact	  the	  users	  of	  standard	  NHS	  Direct	  services.	  	  This	  service	  was	  set	  up	  within	  hours	  of	  the	  London	  bombings,	  aimed	  at	  identifying	  individuals	  involved	  in	  the	  LB	  and	  directing	  them	  to	  appropriate	  services	  within	  the	  NHS.	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Figure	  3.2	  Study	  sample	  break	  down	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As	  Figure	  3.2	  demonstrates,	  a	  total	  of	  230	  interviews	  were	  conducted	  as	  a	  part	  of	  the	  evaluation,	  103	  with	  individuals	  who	  were	  referred	  to	  treatment	  within	  the	  London	  bombings	  programme,	  35	  with	  individuals	  who	  were	  screened	  only,	  15	  with	  individuals	  who	  were	  screened	  and	  assessed	  only,	  and	  77	  with	  individuals	  who	  did	  not	  use	  programme.	  	  The	  sizes	  of	  the	  evaluation	  follow-­‐up	  sub-­‐samples	  were	  not	  determined	  by	  the	  power	  calculations	  and	  therefore	  the	  evaluation	  sample	  cannot	  be	  regarded	  as	  representative,	  only	  indicative	  of	  the	  ST	  programme	  users	  and	  individuals	  exposed	  to	  the	  LB.	  	  The	  sample	  size	  was	  determined	  by	  the	  possibility	  of	  identifying	  and	  contacting	  individuals,	  depending	  on	  their	  availability	  and	  willingness	  to	  engage	  in	  the	  study	  after	  a	  considerable	  time	  had	  elapsed	  since	  the	  event	  (from	  17	  up	  to	  38	  months	  after	  the	  LB).	  	  	  The	  sample	  size	  for	  each	  participant	  category	  was	  determined	  in	  the	  study	  proposal	  and	  approved	  by	  the	  study	  funder	  prior	  to	  the	  start	  of	  the	  evaluation.	  	  The	  aimed	  sample	  sizes	  were	  50	  for	  participants	  who	  did	  not	  use	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the	  programme,	  70	  individuals	  who	  have	  received	  treatment	  under	  the	  ST	  programme,	  and	  40	  for	  participants	  who	  were	  screened	  and	  assessed	  only.	  	  However,	  during	  the	  course	  of	  the	  study,	  and	  in	  agreement	  with	  the	  main	  investigator,	  we	  have	  continued	  with	  the	  data	  collection	  even	  after	  reaching	  the	  sample	  size	  quotas.	  	  The	  ST	  programme	  released	  the	  contact	  details	  of	  the	  participants	  to	  the	  evaluation	  team	  once	  individuals	  were	  discharged	  from	  the	  ST	  programme,	  while	  most	  of	  the	  participants	  in	  the	  programme	  non-­‐user	  category	  come	  from	  the	  large	  Metropolitan	  police	  list	  which	  was	  originally	  not	  shared	  with	  the	  ST	  programme	  for	  unknown	  reasons.	  	  	  The	  sampling	  structure	  and	  response	  rate	  is	  presented	  in	  Table	  3.1.	  	  The	  eligible	  participant	  category	  in	  Table	  3.1	  represents	  all	  the	  individuals	  whose	  details	  were	  available	  to	  the	  evaluation,	  while	  the	  contactable	  number	  of	  participants	  represents	  all	  individuals	  whose	  actual	  contact	  details	  were	  available	  to	  the	  evaluation.	  	  The	  response	  rate,	  presented	  in	  Table	  3.1,	  was	  just	  over	  60%	  for	  programme	  users	  and	  12%	  for	  non-­‐users.	  	  The	  evaluation	  interviews	  were	  conducted	  on	  average	  731	  days	  after	  the	  London	  bombings,	  ranging	  from	  422	  to	  1181	  days.	  	  I	  will	  present	  the	  results	  in	  later	  chapters,	  but	  it	  can	  be	  noted	  here	  that	  different	  methods	  of	  data	  collection	  did	  not	  produce	  higher	  or	  lower	  costs.	  	  The	  difference	  between	  face	  to	  face	  interviews	  and	  indirectly	  conducted	  interviews	  was	  tested	  using	  the	  Mann-­‐Whitney	  test	  (U=5456.00,	  Z=-­‐0.496,P=0.62)	  I	  wanted	  to	  explore	  what	  a	  suitable	  sample	  size	  would	  be,	  based	  on	  a	  conventional	  power	  calculation.	  	  For	  this	  purpose	  I	  have	  used	  a	  specific	  online	  power	  calculation	  tool	  developed	  by	  Soper	  (2013)	  to	  estimate	  the	  minimal	  sample	  size	  for	  a	  multiple	  regression	  model	  with	  three	  to	  six	  predictors.	  	  A	  suitable	  sample	  based	  on	  medium	  effect	  size	  for	  three	  predictors	  model	  would	  be	  76,	  for	  a	  four	  predictors	  model	  a	  minimum	  of	  84,	  for	  five	  predictors	  model	  a	  minimum	  sample	  would	  be	  91,	  and	  finally	  for	  six	  predictors	  model	  the	  sample	  would	  need	  to	  be	  at	  least	  97	  (Soper,	  2013).	  	  However,	  one	  must	  be	  cautious	  in	  interpreting	  the	  quoted	  power	  calculations	  as	  the	  sample	  size	  required	  in	  order	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to	  find	  significant	  effects	  will	  depend	  on	  the	  variability	  of	  the	  dependent	  variable	  and	  of	  the	  covariates.	  The	  sampling	  structure	  and	  response	  rates	  for	  each	  sub-­‐sample	  are	  presented	  in	  Table	  3.1.	  Table	  3.1	  Sampling	  structure	  
	   Eligible	  N	   Contactable	  N	   Interviews	  conducted	   Effective	  response	  rate	  (%)	  Screened	  and/or	  assessed	  only	   124	   76	   50	   65.8	  Treated	   189	   161	   103	   64.0	  Did	  not	  use	  the	  programme	  (second	  Met	  police	  list)	   623	   611	   77	   12.6	  Total	   935	   848	   230	   27.3	  	  	   The	  majority	  of	  the	  participants	  were	  involved	  in	  the	  7	  July	  events	  at	  the	  King’s	  Cross,	  Edgware	  Road,	  Aldgate	  and	  Russell	  Square	  locations.	  	  Three-­‐quarters	  of	  them	  had	  personally	  witnessed	  the	  effects	  of	  one	  of	  the	  bombings	  and	  around	  one	  third	  of	  the	  participants	  reported	  they	  had	  been	  injured.	  	  Half	  of	  the	  participants	  reported	  that	  they	  had	  seen	  someone	  who	  was	  injured	  or	  killed.	  	  Participants	  who	  did	  not	  witness	  personally	  the	  effects	  of	  the	  bombings	  were	  bereaved	  or	  had	  a	  family	  member	  or	  a	  close	  friend	  involved	  in	  the	  LB.	  	  The	  sub-­‐sample	  of	  the	  ST	  programme	  users	  and	  individuals	  followed	  up	  by	  the	  evaluation	  study	  is	  in	  many	  ways	  different	  from	  the	  usual	  users	  of	  NHS	  mental	  health	  services	  due	  to	  the	  nature	  of	  their	  exposure	  to	  the	  traumatic	  event.	  	  They	  were	  predominantly	  from	  white	  British	  or	  ‘white	  other’	  ethnic	  categories,	  aged	  in	  their	  early	  forties,	  mostly	  caught	  up	  in	  the	  early	  morning	  London	  commute	  on	  their	  way	  to	  work;	  although	  this	  finding	  is	  limited	  by	  the	  fact	  that	  around	  half	  of	  the	  ST	  programme	  users	  and	  around	  15	  per	  cent	  of	  evaluation	  sub-­‐sample	  did	  not	  report	  their	  ethnicity.	  	  A	  small	  percentage	  of	  the	  230	  people	  followed	  up	  in	  the	  evaluation	  reported	  previous	  mental	  or	  physical	  health	  problems,	  11.3%	  reported	  psychiatric	  comorbidity	  while	  3%	  reported	  physical	  comorbidity.	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Although	  the	  evaluation	  sub-­‐sample	  cannot	  be	  directly	  compared	  to	  the	  ST	  programme	  user	  sample,	  for	  descriptive	  purposes	  it	  is	  interesting	  to	  note	  that	  the	  evaluation	  study	  participants’	  age,	  gender,	  profession	  and	  ethnicity	  distribution	  closely	  resemble	  the	  ST	  programme	  users’	  distribution	  (Table	  3.2).	  	  However,	  it	  needs	  to	  be	  pointed	  out	  that	  the	  evaluation	  sample	  had	  a	  larger	  percentage	  of	  white	  British	  participants.	  	  Around	  half	  of	  the	  participants	  in	  the	  evaluation	  sub-­‐sample	  were	  white	  British	  and	  female,	  on	  average	  41	  years	  of	  age.	  	  Table	  3.2	  Demographic	  characteristics	  -­‐	  study	  sub-­‐samples	  
	   	  	  	  	  	  	  	  	  	  	  As	  Table	  3.3	  shows,	  around	  40%	  of	  participants	  were	  contacted	  via	  details	  on	  the	  Metropolitan	  Police	  witness	  lists	  followed	  by	  referrals	  from	  NHS	  hospitals,	  organisations	  affiliated	  with	  the	  response	  to	  the	  London	  bombings	  and	  self-­‐referrals	  (data	  from	  the	  ST	  programme	  records).	  	  It	  is	  interesting	  to	  point	  out	  that	  there	  was	  a	  low	  GP	  referral	  rate,	  even	  though	  the	  programme	  disseminated	  information	  on	  available	  services	  to	  London-­‐based	  GP	  practices	  on	  several	  occasions.	  	  
	   ST	  Programme	  N=596	   Evaluation	  N=230	  	   N	  (%)	   N	  (%)	  Age	  	  M	  (range,	  SD)	   41.67	  	  	  (19.16-­‐92.04,	  12.20)	   	  41.76	  	  	  (21.65-­‐82.58,	  11.48)	  Gender	  male	   270	  (45.3)	   114	  (49.6)	  Ethnicity	  	  	  	   	  Asian	  Indian	   13	  (1.4)	   8	  (3.5)	  Asian	  Pakistani	   1	  (0.2)	   1	  (0.4)	  Black	  African	   7	  (1.2)	   4	  (1.7)	  Black	  Caribbean	   11	  (1.8)	   3	  (1.3)	  Black	  Other	   1	  (0.2)	   1	  (0.4)	  Chinese	   3	  (0.5)	   2	  (0.9)	  White-­‐British	   193	  (32.4)	   134	  (58.3)	  White-­‐Irish	   11	  (1.8)	   6	  (2.6)	  White-­‐Other	   36	  (6.0)	   18	  (7.8)	  Other	   33	  (5.6)	   15	  (6.5)	  Not	  stated	   287	  	  (48.2)	   35	  (15.2)	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Table	  3.3	  Source	  of	  referrals	  to	  ST	  programme	  
Referral	  Source	   N	   %	  Metropolitan	  Police	  Witness	  List	  1	   23	   10.00	  NHS	  Hospitals*	   14	   6.09	  7th	  July	  Assistance	  Centre	   12	   5.22	  Health	  Protection	  Agency	   4	   1.74	  Self-­‐referral	   17	   7.39	  NHS	  Direct	   11	   4.78	  GP	  referral	   8	   3.48	  London	  Mayor’s	  Fund	   3	   1.30	  Red	  Cross	   12	   5.22	  British	  Transport	  Police	  Occupational	  Health	  Dept.	   9	   3.91	  Friend/Relative	   4	   1.74	  Other	  NHS**	   2	   0.87	  Metropolitan	  Police	  Occupational	  Health	  Dept.	   4	   1.74	  Other***	   37	   16.08	  Metropolitan	  Police	  Witness	  List	  2	   70	   30.43	  
Total	   230	   100	  	  *NHS	  Hospitals:	  Accident	  &	  Emergency	  lists	  and	  individual	  referrals	  from	  Whittington,	  Royal	  Free,	  Royal	  London	  Hospital,	  UCH,	  King’s	  College	  Hospital,	  North	  Middlesex	  Hospital	  **Other	  NHS:	  London	  mental	  health	  trusts	  and	  ambulance	  services	  ***Other:	  Victim	  Support,	  Welfare	  Unit	  City	  of	  London,	  family	  liaison	  officers,	  Kings	  Cross	  United,	  Criminal	  Injuries	  Compensation	  Authority	  In	  total,	  97	  participants	  received	  treatment,	  of	  which	  60%	  were	  male	  with	  an	  average	  age	  of	  41	  years	  (24-­‐68).	  Participants	  received	  on	  average	  12.5	  sessions	  (range	  0-­‐64,	  s.d.	  11.6	  sessions)	  and	  missed	  1.6	  sessions	  (range	  0-­‐22,	  s.d.	  2.7	  sessions).	  	  Table	  3.4	  shows	  PTSD	  was	  the	  predominant	  primary	  diagnosis;	  67	  participants	  were	  diagnosed	  with	  PTSD	  DSM-­‐IV	  (29%)	  and	  10	  with	  PTSD	  ICD-­‐10	  (4.3).	  	  Participants	  with	  PTSD	  DSM-­‐IV	  diagnosis	  also	  satisfied	  the	  ICD-­‐10	  criteria	  for	  PTSD.	  	  Other	  reported	  diagnoses	  were	  travel	  phobia	  (2.6%),	  adjustment	  disorder	  (2.6%),	  complicated	  grief	  (2.2%)	  and	  depression	  (0.9%).	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In	  total,	  82	  participants	  completed	  treatment	  and	  around	  70%	  received	  trauma-­‐focused	  CBT	  alone	  or	  in	  combination	  with	  EMDR	  (Table	  3.5).	  They	  attended	  on	  average	  13.6	  sessions	  (range	  1-­‐64,	  s.d.	  11.71).	  Table	  3.4	  Primary	  diagnosis	  for	  evaluation	  sub-­‐sample	   	   	  	  	  	  	  	  	  	  	  Table	  3.5	  Type	  of	  treatment	  applied	  
Type	  of	  intervention	   N	   %	  Trauma	  focused	  CBT	   53	   64.6	  EMDR	   6	   7.3	  Both	   17	   20.7	  None	   4	   4.9	  Missing	   2	   2.4	  
Total	   82	   100	  
	  
Primary	  diagnosis	  	   N	   %	  PTSD	  DSM-­‐IV	   67	   29.1	  PTSD	  ICD-­‐10	   10	   4.3	  Depression	   2	   0.9	  Travel	  Phobia	   6	   2.6	  Adjustment	  Disorder	   6	   2.6	  Generalised	  anxiety	  disorder	   1	   0.4	  Complicated	  Grief	   5	   2.2	  Other	   1	   0.4	  None	   130	   56.5	  Missing	   2	   0.9	  
Total	   230	   100.0	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3.4.4	   Evaluation	  measures	  Evaluation	  was	  not	  built	  into	  the	  ST	  programme	  from	  the	  outset.	  	  As	  Figure	  3.3	  shows,	  it	  was	  only	  introduced	  to	  the	  programme	  from	  November	  2007,	  during	  the	  last	  nine	  months	  of	  the	  programme.	  	  The	  aim	  was	  to	  follow-­‐up	  a	  convenience	  sample	  of	  all	  the	  groups	  within	  the	  programme	  (depending	  on	  which	  aspect	  of	  the	  programme	  they	  used).	  	  The	  timing	  and	  the	  set-­‐up	  affected	  the	  data	  collection	  methods	  significantly	  as	  they	  only	  allowed	  for	  one	  point	  of	  data	  collection	  for	  both	  costs	  and	  outcomes	  of	  the	  programme,	  and	  relied	  on	  the	  participants’	  recollection	  of	  the	  services	  they	  used	  for	  often	  long	  periods	  of	  time	  after	  the	  LB	  event.	  	  Consequently	  the	  timing	  of	  the	  evaluation	  limited	  the	  scope	  and	  generalisability	  of	  the	  evaluation	  study.	  	  Access	  to	  the	  independent	  sources	  of	  the	  information	  such	  as	  GP	  records,	  which	  would	  increase	  the	  quality	  and	  ensure	  collected	  data	  did	  not	  rely	  solely	  on	  the	  participants’	  recollection	  of	  the	  services	  used,	  was	  not	  planned	  within	  the	  scope	  of	  the	  study.	  	  Furthermore,	  the	  evaluation	  study	  did	  not	  have	  access	  to	  data	  on	  pre-­‐LB	  functioning	  of	  the	  participants.	  Figure	  3.3	  The	  ST	  programme	  and	  evaluation	  timeline	  and	  outcome	  measures	  	   	   	   	   	  	  	  	  	  	  
	   71	  
In	  total,	  the	  evaluation	  interviewed	  230	  participants.	  	  Each	  sub-­‐group	  of	  the	  participants	  was	  followed	  up	  with	  the	  specific	  measures	  already	  used	  in	  the	  ST	  programme	  for	  that	  particular	  group.	  	  To	  be	  precise,	  participants	  who	  did	  not	  take	  part	  in	  the	  ST	  programme	  and	  those	  who	  were	  screened	  only	  as	  a	  part	  of	  the	  programme	  were	  followed	  up	  with	  the	  screening	  measure	  (TSQ);	  individuals	  who	  were	  assessed	  and	  individuals	  who	  received	  treatment	  were	  followed	  up	  with	  the	  BDI	  and	  PDS.	  	  Data	  on	  service	  use	  and	  quality	  of	  life	  measure	  were	  collected	  for	  all	  evaluation	  participants.	  	  Table	  3.6	  presents	  indicators	  of	  interest	  to	  this	  study.	  	  Table	  3.6	  Indicators	  collected	  during	  screening,	  assessment,	  treatment	  and	  evaluation	  
Screening	  related	  information:	  	  
• source	  and	  timing	  of	  referral	  
• socio-­‐demographic	  information:	  age,	  gender,	  ethnicity,	  occupation	  
• total	  number	  of	  screeners	  received	  
• total	  score	  per	  screener	  Assessment	  and	  treatment	  information:	  	  
• mental	  health	  history	  	  
• physical	  health	  concerns	  
• primary	  diagnosis	  	  	  
• medication	  use	  
• total	  number	  of	  sessions	  	  	  
• therapy	  type	  	  	  
• treatment	  centre	  and	  clinician	  	  	  
• treatment	  outcomes:	  treatment	  start	  and	  end	  score	  for	  BDI	  	  PDS	  and	  QoL	  	  Evaluation	  follow-­‐up:	  	  
• whole	  sub-­‐sample:	  
-­‐ source	  and	  timing	  of	  referral	  	  
-­‐ socio-­‐demographic	  information:	  age,	  gender,	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ethnicity,	  occupation	  
-­‐ exposure	  information:	  nature	  of	  involvement,	  day	  and	  location	  
-­‐ QoL	  	  
-­‐ Client	  Service	  Receipt	  Inventory	  	  
• participants	  who	  did	  not	  use	  the	  ST	  programme	  or	  who	  were	  only	  	  screened	  and	  assessed:	  TSQ	  
• participants	  who	  received	  treatment:	  PDS	  and	  BDI	  	   The	  TSQ	  questionnaire	  was	  used	  with	  individuals	  who	  were	  screened	  only,	  potential	  users	  and	  people	  who	  did	  not	  use	  the	  ST	  programme.	  	  The	  Beck	  Depression	  Index	  score	  (BDI)	  and	  the	  Posttraumatic	  Stress	  Scale	  (PDS)	  was	  used	  for	  individuals	  who	  were	  assessed	  only	  and	  for	  those	  who	  finished	  treatment.	  	  A	  modified	  version	  of	  the	  Client	  Service	  Receipt	  Inventory	  (CSRI)	  (Beecham	  &	  Knapp,	  1992)	  was	  administrated	  to	  all	  programme	  users	  to	  measure	  service	  use	  associated	  with	  the	  impact	  of	  the	  bombings,	  and	  subsequently	  to	  measure	  the	  costs.	  	  The	  CSRI	  was	  complemented	  with	  two	  additional	  questions	  on	  impact	  on	  employment,	  one	  question	  on	  effects	  on	  physical	  health	  and	  one	  question	  on	  effects	  on	  social	  life.	  	  The	  copy	  of	  the	  questionnaire	  is	  presented	  in	  Appendix	  B.	  	  The	  CSRI	  is	  a	  widely	  employed	  research	  tool	  developed	  for	  use	  in	  mental	  health	  evaluations	  nationally	  and	  internationally	  (McCrone,	  2007).	  	  Initially	  developed	  for	  evaluating	  community	  care,	  it	  has	  since	  been	  used	  in	  a	  variety	  of	  settings	  from	  evaluations	  of	  new	  drugs	  and	  specialist	  work	  schemes	  to	  children’s	  mental	  health	  and	  social	  care	  (Beecham	  &	  Knapp,	  2001).	  	  The	  original	  version	  of	  the	  CSRI	  covers	  the	  following	  domains:	  client	  detail	  and	  information,	  followed	  by	  accommodation	  and	  living	  situation,	  information	  on	  employment,	  earnings	  and	  other	  personal	  information,	  and	  finally	  information	  on	  the	  receiving	  of	  service	  (Beecham	  &	  Knapp,	  2001).	  	  The	  CSRI	  was	  slightly	  modified	  in	  collaboration	  with	  a	  health	  economist	  from	  the	  Institute	  of	  Psychiatry,	  King’s	  College	  London	  (IoP)	  to	  reflect	  the	  particular	  needs	  of	  this	  evaluation.	  	  The	  modified	  CSRI	  collected	  a	  mix	  of	  quantitative	  and	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qualitative	  data	  on	  the	  health,	  social	  and	  economic	  impact	  of	  the	  LB	  and	  was	  piloted	  to	  ensure	  questions	  were	  worded	  and	  ordered	  appropriately.	  	  The	  CSRI	  enquired	  about	  the	  nature	  of	  the	  involvement	  in	  the	  LB,	  followed	  by	  questions	  on	  how	  the	  person	  was	  feeling	  now,	  using	  questions	  on	  feedback	  and	  changes	  in	  their	  outlook	  on	  the	  world	  as	  a	  result	  of	  involvement	  in	  the	  LB.	  	  The	  next	  section	  of	  the	  questionnaire	  covered	  the	  use	  of	  special	  services	  set	  up	  for	  people	  affected	  by	  the	  bombings.	  	  This	  was	  followed	  by	  questions	  about	  experiences	  with	  the	  use	  of	  the	  ST	  programme,	  including	  details	  on	  the	  type	  and	  length	  of	  treatment,	  as	  well	  as	  satisfaction	  with	  it.	  	  The	  next	  section	  asked	  about	  all	  statutory	  and	  non-­‐statutory	  health-­‐related	  services	  that	  respondents	  had	  used	  due	  to	  the	  exposure	  to	  the	  LB,	  including	  reason,	  number	  of	  hospitalisations	  and	  duration	  of	  contact.	  	  In	  addition,	  details	  were	  recorded	  on	  medication	  use	  due	  to	  exposure	  to	  LB	  (type	  and	  frequency).	  	  These	  questions	  were	  followed	  by	  a	  set	  of	  questions	  on	  the	  impact	  of	  the	  bombings	  on	  work	  and	  leisure,	  employment	  status	  and	  occupation;	  participants	  were	  asked	  to	  report	  the	  number	  of	  sick	  leave	  days,	  hours	  reduced	  or	  weeks	  of	  unemployment	  due	  to	  the	  LB.	  	  The	  CSRI	  enquired	  about	  statutory	  benefits	  that	  participants	  were	  receiving	  due	  to	  their	  involvement	  in	  the	  LB.	  	  Finally	  an	  open-­‐ended	  question	  was	  introduced	  on	  the	  effects	  of	  the	  LB	  on	  work	  and	  leisure	  activities.	  The	  CSRI	  relied	  on	  participants’	  recollection	  of	  LB-­‐related	  service	  use,	  between	  17	  and	  37	  months	  after	  the	  LB	  event.	  	  Health-­‐related	  quality	  of	  life	  was	  assessed	  with	  two	  measures,	  SF-­‐12	  (Ware	  et	  al.,	  1996)	  and	  EuroQol	  EQ5D	  (EuroQol	  group,	  1990),	  administrated	  to	  all	  programme	  users.	  	  The	  EQ5D	  was	  initially	  employed	  due	  to	  its	  wide	  use	  and	  short,	  user-­‐friendly	  format.	  	  This	  is	  a	  standardised	  instrument	  for	  health	  outcomes	  and	  is	  frequently	  employed	  in	  health	  economic	  evaluation.	  	  It	  assesses	  five	  domains	  of	  health:	  mobility,	  self-­‐care,	  usual	  activities,	  pain/discomfort	  and	  anxiety/depression.	  	  After	  a	  couple	  of	  months	  of	  application	  the	  evaluation	  team	  had	  concerns	  that	  the	  EQ5D	  was	  not	  reflecting	  the	  actual	  state	  of	  respondents’	  well-­‐being.	  	  Researchers	  found	  that	  the	  EQ5D	  was	  often	  unrepresentative	  of	  the	  problems	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that	  participants	  reflected	  on	  in	  completing	  the	  other	  instruments	  or	  that	  they	  expressed	  verbally	  during	  the	  interviews.	  	  One	  of	  the	  criticisms	  made	  of	  the	  EQ5D	  is	  poor	  sensitivity	  in	  detecting	  improvements	  in	  low-­‐morbidity	  conditions	  (Brazier	  et	  al.,	  2002).	  	  Therefore	  the	  evaluation	  team	  decided	  to	  introduce	  SF-­‐12	  Version	  1	  due	  to	  its	  wider	  scope	  and	  good	  psychometric	  properties	  (Brooks,	  1996).	  	  SF-­‐12	  Version	  1	  contains	  12	  questions	  that	  cover	  participant	  assessment	  of	  both	  their	  physical	  (PCS-­‐12)	  and	  mental	  health	  (MCS-­‐12)	  domains.	  	  The	  physical	  health	  domain	  covers	  physical	  functioning,	  role-­‐functioning,	  bodily	  pain,	  and	  general	  health.	  	  The	  mental	  health	  domain	  covers	  vitality,	  social	  functioning,	  role-­‐emotional	  and	  mental	  health.	  	  Another	  advantage	  of	  the	  SF-­‐12	  measure	  is	  the	  norm-­‐based	  scoring,	  which	  enables	  comparisons	  between	  different	  populations,	  conditions	  and	  other	  generic	  health	  measures	  (Brooks,	  1996).	  	  However,	  introducing	  another	  QoL	  measure	  after	  the	  evaluation	  had	  started	  created	  problems	  later	  on	  in	  the	  data	  analysis	  due	  to	  the	  issue	  of	  comparability	  of	  the	  two	  measures,	  consequently	  reducing	  the	  sample	  size	  in	  some	  analyses.	  	  Fortunately,	  it	  was	  possible	  to	  address	  this	  problem	  and	  compare	  the	  two	  measures	  with	  the	  help	  of	  the	  transformation	  algorithm	  developed	  by	  Gray,	  Rivero	  and	  Clarke	  at	  the	  Health	  Economics	  Research	  Centre	  (HERC),	  University	  of	  Oxford	  (2006).	  	  The	  algorithm	  translates	  raw	  SF-­‐12	  values	  into	  estimated	  EQ5D	  responses	  and	  utilities	  (Gray	  et	  al.,	  2006)	  by	  using	  regression	  analysis.	  	  	  
3.5.	   Methods	  to	  calculate	  and	  explore	  the	  costs	  of	  being	  involved	  in	  the	  
London	  bombings	  (Objective	  2)	  In	  addressing	  Objective	  2	  the	  focus	  is	  on	  identification,	  measurement,	  and	  exploration	  of	  all	  costs	  associated	  with	  exposure	  to	  the	  LB.	  	  I	  have	  divided	  this	  work	  into	  two	  chapters.	  Chapter	  4	  looks	  at	  theory	  and	  practice	  in	  cost	  calculation	  and	  offers	  descriptive	  findings.	  	  Chapter	  5	  examines	  the	  relationship	  between	  costs	  and	  their	  potential	  determinants,	  and	  factors	  associated	  with	  the	  diagnosis	  of	  PTSD.	  	  Although	  the	  societal	  perspective	  has	  the	  advantage	  as	  it	  covers	  all	  the	  costs,	  it	  was	  not	  possible	  to	  adopt	  this,	  as	  I	  did	  not	  capture	  all	  
	   75	  
costs	  such	  as	  costs	  to	  the	  families.	  	  Instead	  I	  took	  a	  perspective	  of	  the	  health	  and	  social	  care	  system	  by	  analysing	  all	  the	  costs	  associated	  with	  setting-­‐up	  and	  running	  of	  the	  ST	  programme.	  	  In	  addition,	  I	  attempted	  to	  measure	  all	  the	  costs	  associated	  with	  private	  and	  voluntary	  sector	  services.	  	  The	  extent	  to	  which	  I	  was	  successful	  in	  measuring	  those	  costs	  depends	  on	  the	  methods	  used.	  	  Due	  to	  the	  nature	  of	  the	  study	  I	  relied	  heavily	  on	  recollections	  of	  service	  use	  even	  after	  a	  considerable	  time	  had	  since	  elapsed,	  which	  could	  result	  in	  under-­‐	  or	  over-­‐estimation	  of	  costs.	  Nor	  did	  I	  use	  any	  independent	  source	  of	  data	  such	  as	  hospital	  or	  GP	  records	  to	  rectify	  the	  individual	  accounts	  as	  there	  was	  no	  scope	  for	  this	  in	  the	  study.	  	  	  
3.5.1	   Methods	  for	  costing	  LB	  associated	  service	  use	  Identifying	  and	  allocating	  robust	  and	  reliable	  costs	  is	  often	  not	  a	  straightforward	  task.	  	  In	  order	  to	  describe	  the	  costs	  associated	  with	  exposure	  to	  the	  LB	  I	  have	  used	  two	  data	  sources:	  one	  on	  costs	  associated	  with	  the	  set-­‐up	  and	  running	  the	  ST	  programme,	  and	  a	  separate	  dataset	  on	  all	  services	  used	  by	  individuals	  due	  to	  their	  exposure	  to	  the	  LB,	  collected	  during	  the	  evaluation	  of	  the	  ST	  programme.	  	  Data	  on	  costs	  associated	  with	  the	  set-­‐up	  and	  running	  of	  the	  ST	  programme	  were	  collected	  during	  the	  programme	  by	  a	  programme	  manager	  based	  at	  the	  London	  Development	  Centre	  (LDC).	  	  At	  the	  end	  of	  the	  first	  year	  of	  the	  programme,	  the	  collection	  of	  the	  programme	  cost	  data	  was	  passed	  on	  to	  the	  evaluation	  team	  direct.	  	  Screening	  costs	  included	  staff	  costs,	  general	  non-­‐pay	  costs	  (8%	  of	  staffing	  costs),	  clinical/management	  support	  costs	  (12%)	  and	  premises	  overheads	  (20%).	  	  	  Treatment	  costs	  consisted	  of	  staff	  costs,	  general	  non-­‐pay	  costs	  (8%	  of	  staffing	  costs),	  treatment-­‐specific	  non-­‐pay	  costs,	  clinical/management	  support	  costs	  (12%),	  and	  premises	  overheads	  (20%).	  	  Other	  included	  costs	  were	  patient	  travel	  reimbursement.	  	  Start-­‐up	  costs	  consisted	  of	  hardware	  purchase,	  advertising,	  furniture	  and	  fittings.	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All	  treatment	  costs	  were	  collected	  using	  the	  top-­‐down	  approach	  by	  dividing	  total	  cost	  by	  the	  total	  number	  of	  provided	  sessions	  (including	  did-­‐not-­‐attend	  sessions).	  	  Data	  on	  the	  ST	  programme	  outcomes,	  including	  information	  collected	  during	  screening	  and	  assessment	  were	  collected	  by	  the	  ST	  programme	  administrator.	  	  Treatment	  outcome	  data,	  including	  records	  on	  treatment	  type,	  start	  and	  end	  dates,	  treatment	  outcome	  type	  and	  number	  of	  therapy	  sessions	  in	  the	  form	  of	  direct	  and	  indirect	  half-­‐hour	  units,	  were	  collected	  by	  the	  therapists	  on	  a	  monthly	  basis.	  	  Data	  was	  stored	  in	  the	  form	  of	  an	  Excel	  document	  and	  passed	  on	  to	  the	  evaluation	  team	  who	  pooled	  all	  the	  data	  and	  stored	  it	  in	  the	  SPSS	  database.	  	  The	  next	  step	  was	  to	  list	  all	  the	  services	  used	  alongside	  their	  appropriate	  units	  of	  measurement	  and	  to	  allocate	  costs.	  	  I	  used	  two	  published	  sources	  of	  costs	  –	  Personal	  Social	  Services	  Research	  Unit’s	  (PSSRU)	  Unit	  Costs	  of	  Health	  and	  Social	  Care	  and	  NHS	  Reference	  Costs	  -­‐	  as	  they	  presented	  unit	  costs	  based	  on	  UK	  national	  figures	  and	  “are	  taken	  as	  a	  good	  approximation	  of	  long-­‐run	  marginal	  opportunity	  costs”	  (Knapp	  et	  al.,	  2008).	  	  For	  costs	  not	  presented	  in	  those	  two	  publications	  I	  used	  data	  from	  sources	  such	  as	  annual	  reports,	  published	  studies	  and	  in	  a	  few	  cases,	  market	  prices.	  	  For	  the	  purpose	  of	  the	  analysis	  I	  re-­‐categorised	  services	  into	  the	  following	  groups:	  medication,	  hospitalisation,	  statutory	  sector	  services,	  private	  sector	  services	  and	  voluntary	  sector	  services.	  In	  addition,	  I	  listed	  all	  occupation	  and	  earnings-­‐associated	  costs	  in	  a	  separate	  category.	  The	  costing	  method	  and	  prices	  per	  unit	  for	  each	  service	  category	  are	  outlined	  below.	  	  All	  the	  costs	  collected	  by	  the	  CSRI	  were	  measured	  from	  an	  individual	  perspective	  and	  allocated	  to	  services	  in	  a	  bottom-­‐up	  approach.	  	  All	  costs	  are	  standardised	  to	  2007/2008	  prices	  and	  presented	  in	  pounds	  sterling	  at	  2007/08	  prices.	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3.5.2	   Methods	  for	  exploring	  cost	  and	  outcome	  variations	  	  Understanding	  factors	  behind	  differences	  in	  costs	  is	  important	  for	  service	  planners,	  funders	  and	  implementers.	  	  Differences	  in	  costs	  can	  sometimes	  be	  attributed	  to	  systematic	  factors	  such	  as	  participant	  characteristics	  and	  needs,	  type	  of	  service	  provision,	  as	  well	  as	  non-­‐systematic	  factors	  otherwise	  known	  as	  random	  or	  stochastic	  factors	  (Knapp	  et	  al.,	  1995,	  p.	  12).	  	  The	  cause	  of	  the	  latter	  is	  usually	  random	  fluctuations	  in	  data	  recording,	  participants’	  responses	  or	  measurement	  errors.	  	  
a.	  Cost	  function	  A	  useful	  tool	  in	  exploring	  cost	  variation	  is	  the	  cost	  function.	  	  This	  technique	  allows	  us	  to	  explore	  cost	  fluctuations	  and	  describe	  relationships	  between	  costs,	  as	  dependent	  variable,	  and	  one	  or	  more	  explanatory	  variables	  such	  as	  service	  outcomes,	  while	  controlling	  for	  participants’	  and	  service	  characteristics.	  	  This	  statistical	  technique	  is	  useful	  in	  the	  context	  of	  a	  naturalistic	  observational	  study	  such	  as	  this	  one,	  where	  randomisation	  is	  not	  practically	  or	  ethically	  possible,	  as	  it	  "allow[s]	  multiple	  marginal	  effects	  to	  be	  examined	  in	  order	  to	  remove	  influences	  of	  stochastic	  factors"	  (Knapp,	  1995,	  p.	  14).	  	  However,	  this	  is	  only	  possible	  for	  the	  variations	  for	  which	  there	  are	  data,	  otherwise	  those	  influences	  will	  be	  included	  in	  the	  stochastic	  or	  unexplained	  variation	  (Knapp,	  1998).	  	  The	  approach	  gives	  insight	  into	  cost	  drivers,	  and	  in	  addition	  it	  enables	  us	  to	  hold	  other	  factors	  constant	  and	  thus	  compare	  different	  dependent	  variables	  under	  the	  same	  circumstances.	  	  This	  task	  is	  often	  complicated	  by	  the	  fact	  that	  service	  use	  costs	  are	  usually	  not	  normally	  distributed,	  usually	  because	  a	  large	  number	  of	  participants	  have	  zero	  cost	  and/or	  a	  small	  number	  of	  individuals	  have	  very	  high	  costs	  (Knapp	  et	  al.,	  2002;	  Manning	  &	  Mullahy,	  2001).	  	  Consequently,	  this	  results	  in	  a	  long-­‐tailed	  and	  skewed	  cost	  distribution	  (either	  positively	  or	  negatively)	  and	  affects	  data	  analysis	  and	  interpretation	  as	  it	  asks	  for	  a	  departure	  from	  standard	  methods,	  and	  perhaps	  the	  use	  of	  non-­‐parametric	  methods.	  	  
b.	  Approaches	  in	  analysing	  data	  which	  is	  not	  normally	  distributed	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The	  literature	  points	  to	  several	  approaches	  to	  data	  analysis	  under	  these	  conditions	  (Kilian	  et	  al.,	  2002).	  	  The	  first	  is	  to	  use	  bootstrapping	  methods	  that	  ‘augment’	  the	  study	  sample	  by	  drawing	  a	  large	  number	  of	  small	  samples	  from	  the	  original	  sample	  with	  replacement	  and	  providing	  estimates	  of	  the	  true	  distribution.	  	  The	  ordinary	  least	  square	  (OLS)	  method	  can	  then	  be	  applied	  (Byford	  et	  al.,	  2001).	  	  Bootstrapping	  is	  useful	  for	  checking	  the	  robustness	  of	  the	  confidence	  intervals	  and	  p-­‐values	  (Byford	  et	  al.,	  2001)	  and	  for	  providing	  “robust	  inferences	  not	  dependent	  on	  the	  distribution	  assumptions”	  (Dunn	  et	  al.,	  2003,	  p.	  400;	  Barber	  &	  Thompson,	  2000,	  p.	  3232)	  providing	  the	  sample	  is	  large	  enough.	  OLS	  has	  an	  advantage	  as	  it	  analyses	  data	  in	  its	  original	  units	  of	  measurement	  and	  provides	  information	  on	  the	  percentage	  of	  variance	  explained	  by	  included	  predictors	  (Kilian	  et	  al.,	  2002).	  	  However,	  OLS	  is	  not	  the	  best	  model	  to	  fit	  data	  that	  is	  not	  distributed	  normally	  or	  in	  case	  of	  heteroscedasticity	  of	  the	  residuals	  (non-­‐constant	  variance	  between	  observed	  and	  modelled	  costs)	  (Dunn	  et	  al.,	  2003,	  Kilian	  et	  al.,	  2002).	  	  The	  second	  option	  suggested	  by	  Kilian	  (2002)	  is	  to	  transform	  costs	  using	  logarithms	  (Knapp	  et	  al.,	  2002;	  Knapp	  et	  al.,	  1998)	  or	  by	  taking	  the	  square	  root.	  	  Both	  methods	  reduce	  skewing	  in	  the	  data	  and	  stabilise	  the	  variance	  so	  that	  “the	  variability	  of	  the	  observed	  costs	  will	  not	  increase	  with	  their	  mean”	  (Dunn	  et	  al.,	  2003,	  p.	  400)	  and	  use	  OLS	  regression	  approaches.	  	  The	  difficulty	  with	  this	  approach	  lies	  in	  interpretation	  of	  the	  transformed	  costs	  as	  the	  regression	  coefficients	  are	  expressed	  in	  the	  unit	  of	  transformation	  rather	  than	  costs,	  and	  require	  retransformation	  to	  the	  original	  scale.	  	  Another	  potential	  issue	  with	  this	  approach	  is	  with	  participants	  with	  zero	  costs,	  where	  the	  recommended	  remedy	  is	  to	  add	  a	  small	  constant	  before	  transforming	  the	  data	  (Dunn	  et	  al.,	  2003).	  	  Retransformation	  of	  the	  costs	  back	  to	  their	  original	  measured	  value	  within	  OLS	  introduces	  a	  bias	  and	  consequently	  the	  predicted	  transformed	  costs	  will	  be	  underestimated	  unless	  a	  bias-­‐reduction	  method	  such	  as	  ‘smearing’	  is	  applied	  (Dunn	  et	  al.,	  2003;	  Duan,	  1983).	  	  The	  third	  recommended	  option	  is	  to	  use	  a	  generalised	  linear	  model	  (GLM).	  	  GLM	  builds	  on	  the	  linear	  regression	  model	  used	  by	  OLS,	  but	  allows	  for	  non-­‐
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random	  and	  stochastic	  model	  components	  (Jackman,	  2004).	  	  GLM	  uses	  the	  same	  regression	  function	  form	  as	  OLS:	  	  Yi=α	  +	  Σβixi	  called	  “linear	  predictor”	  (Dunn	  et	  al,	  2003,	  p.	  401)	  which	  includes	  a	  stochastic	  and	  systematic	  component	  and	  a	  link	  between	  them	  (Jackman,	  2004).	  	  To	  recapitulate	  briefly,	  the	  linear	  regression	  model	  assumes	  a	  normal	  distribution	  of	  dependent	  variable	  with	  a	  constant	  variance,	  and	  a	  linear	  combination	  of	  covariates	  and	  coefficients	  (Jackman,	  2004).	  	  However,	  unlike	  OLS	  which	  uses	  ‘raw’	  observed	  data,	  GLM	  uses	  a	  link	  function	  to	  connect	  the	  dependent	  variable	  with	  covariates	  (Clark	  &	  Thayer,	  2004).	  	  The	  ability	  to	  fit	  data	  to	  a	  broad	  family	  of	  distributions	  of	  the	  error	  term	  ranging	  from	  normal	  to	  gamma	  and	  exponential	  distribution,	  and	  use	  of	  various	  link	  functions	  depending	  on	  the	  distribution	  family	  (Clark	  &	  Thayer,	  2004)	  make	  this	  approach	  attractive	  in	  the	  context	  of	  analysing	  service	  use	  costs.	  	  GLM	  assumes	  that	  the	  relationship	  between	  cost	  and	  predictor	  is	  multiplicative	  and	  the	  final	  prediction	  outcomes	  do	  not	  need	  retransformation	  (Dunn	  et	  al.,	  2003)	  and	  uses	  a	  maximum	  likelihood	  method	  to	  fit	  the	  data	  instead	  of	  ordinary	  least	  squares	  (Dunn	  et	  al.,	  2003).	  	  The	  key	  to	  achieving	  robust	  results	  with	  this	  approach	  lies	  in	  the	  choice	  of	  the	  appropriate	  family	  of	  distributions	  that	  fit	  the	  data	  well,	  and	  to	  decide	  which	  link	  function	  to	  apply	  (Manning	  &	  Mullahy,	  2001).	  	  The	  Park	  Test	  is	  a	  useful	  tool	  in	  making	  those	  decisions	  as	  the	  test	  estimates	  λ,	  the	  true	  variance	  function	  (Manning	  &	  Mullahy,	  2001),	  and	  suggests	  whether	  the	  chosen	  family	  of	  distribution	  fits	  the	  data	  well.	  	  For	  example,	  for	  λ=0	  variance	  function	  is	  Gaussian,	  λ=1	  variance	  function	  is	  Poisson,	  λ=2	  function	  is	  Gamma,	  and	  λ=3	  function	  is	  inverse	  Gaussian	  (Manning	  &	  Mullahy,	  2001).	  	  These	  authors	  advise	  caution	  in	  model	  application	  as	  GLM	  can	  produce	  biased	  estimates	  and	  loss	  of	  model	  precision	  when	  using	  an	  inappropriate	  error	  distribution	  or	  link	  function	  or	  if	  the	  “error	  term	  is	  heavy	  tailed	  on	  the	  log	  scale”	  (Manning	  &	  Mullahy,	  2001,	  p.	  263).	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As	  cost	  data	  often	  follow	  a	  gamma	  distribution,	  the	  use	  of	  GLM	  using	  log	  link	  and	  gamma	  distribution	  is	  recommended	  in	  exploring	  variations	  in	  costs	  (Dunn	  et	  al.,	  2003).	  	  
3.6	   Methods	  to	  conduct	  economic	  evaluation	  of	  the	  ST	  programme	  
(Objective	  3)	  
3.6.1	   Types	  of	  economic	  evaluation	  Costs	  and	  outcomes	  of	  an	  intervention	  represent	  valuable	  information.	  	  However,	  when	  presented	  on	  their	  own,	  they	  provide	  only	  a	  limited	  perspective	  to	  service	  providers,	  commissioners	  and	  funders	  in	  their	  task	  to	  “identify	  the	  most	  efficient	  way	  in	  achieving	  policy	  objectives”	  (Sefton	  et	  al.,	  2003,	  p.	  43).	  	  Economic	  evaluation	  offers	  a	  set	  of	  useful	  tools	  and	  techniques	  and	  enables	  one	  to	  answer	  an	  array	  of	  questions	  by	  exploring	  the	  relationship	  between	  the	  costs	  and	  outcomes	  (outputs)	  of	  an	  intervention	  within	  a	  context	  of	  comparison	  with	  alternative	  intervention(s)	  (Byford	  et	  al.,	  2003).	  	  Drummond	  et	  al.	  (2005)	  define	  economic	  evaluation	  as	  “comparative	  analysis	  of	  alternative	  courses	  of	  action	  in	  terms	  of	  both	  their	  costs	  and	  consequences”(p.	  65).	  	  Economic	  evaluation	  in	  mental	  health	  is	  a	  relatively	  young	  field	  which	  took	  off	  in	  terms	  of	  its	  application	  only	  in	  the	  late	  1980s	  (Knapp,	  1999;	  Blumenschein	  &	  Johannesson,	  1996).	  	  As	  a	  consequence,	  many	  different	  approaches	  have	  been	  reported	  under	  the	  umbrella	  of	  economic	  evaluation,	  which	  is	  evident	  from	  the	  analysis	  of	  earlier	  publications	  in	  the	  field.	  	  However,	  over	  time,	  economic	  evaluation	  has	  become	  more	  widely	  accepted	  and	  applied,	  and	  as	  a	  result	  its	  boundaries	  have	  become	  clearer.	  	  Drummond	  et	  al	  (2005)	  distinguish	  three	  types	  of	  full	  economic	  evaluation:	  cost-­‐effectiveness	  (CEA),	  cost-­‐benefit	  (CBA)	  and	  cost-­‐utility	  (CUA)	  analysis.	  	  Although	  the	  literature	  on	  economic	  evaluation	  includes	  cost	  minimisation	  (CMA)	  in	  this	  category,	  Briggs	  and	  O’Brien	  (2001)	  argue	  that	  CMA	  “cannot	  be	  considered	  as	  a	  unique	  study	  design	  due	  to	  uncertainty	  around	  cost	  and	  outcome	  estimates”(p.	  182).	  	  The	  factor	  that	  differentiates	  between	  the	  different	  types	  of	  economic	  evaluation	  is	  the	  type	  of	  the	  outcome	  data	  they	  are	  comparing.	  	  The	  nature	  of	  the	  outcome	  data,	  alongside	  its	  target	  audience	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(health	  care	  users,	  providers	  or	  funders)	  determines	  the	  type	  of	  questions	  economic	  evaluation	  is	  trying	  to	  answer	  and	  consequently	  its	  comprehensiveness.	  	  CEA	  can	  be	  “performed	  on	  any	  alternatives	  that	  have	  a	  common	  effect”	  (Drummond	  et	  al,	  2005,	  p.	  54).	  	  CEA	  compares	  costs	  of	  two	  or	  more	  interventions	  with	  their	  effects,	  traditionally	  by	  calculating	  an	  incremental	  cost-­‐effectiveness	  ratio	  (ICER)	  that	  divides	  the	  difference	  in	  costs	  of	  two	  interventions	  by	  the	  difference	  in	  their	  effects:	  ICER=Cost	  treatment	  group	  –	  Cost	  control	  group	  /	  Effect	  treatment	  group	  –	  Effect	  control	  group	  (Petrou	  &	  Gray,	  2011).	  	  The	  net	  benefit	  approach	  supplements	  information	  provided	  by	  the	  ICER	  and	  puts	  the	  comparison	  of	  cost	  and	  effectiveness	  within	  the	  context	  of	  willingness	  to	  pay	  for	  a	  unit	  of	  improvement	  (Hoch	  et	  al.,	  2006).	  	  The	  net-­‐benefit	  regression	  framework	  introduces	  cost-­‐effectiveness	  acceptability	  curves	  (CEAC),	  which	  combine	  information	  on	  the	  probability	  of	  an	  intervention	  being	  cost-­‐effective	  for	  a	  defined	  unit	  of	  outcome	  improvement	  (Knapp,	  2007;	  Fenwick	  et	  al,	  2006;	  Hoch,	  2002)	  and	  address	  the	  uncertainty	  around	  estimation	  of	  both	  costs	  and	  outcomes	  (Hoch	  et	  al.,	  2006).	  	  A	  CEAC	  offers	  a	  comprehensive	  yet	  visually	  clear	  presentation	  of	  uncertainty	  around	  cost-­‐effectiveness	  estimates.	  	  Furthermore,	  it	  provides	  valuable	  information,	  particularly	  for	  decision-­‐makers,	  on	  the	  probability	  that	  an	  intervention	  is	  cost-­‐effective	  in	  comparison	  to	  the	  alternative	  (Fenwick	  et	  al.,	  2006).	  	  	  Alongside	  CEA,	  cost-­‐consequences	  analysis	  has	  been	  developed	  to	  address	  and	  capture	  multiple	  outcomes	  and	  their	  costs,	  and	  this	  feature	  makes	  it	  particularly	  suitable	  for	  evaluation	  of	  complex	  interventions	  (Byford	  et	  al.,	  2003).	  	  However,	  one	  of	  the	  limitations	  of	  this	  cost-­‐consequences	  approach	  lies	  in	  its	  inability	  to	  compare	  interventions	  by	  their	  cost-­‐effectiveness	  and	  the	  final	  decision	  is	  left	  to	  policy/decision-­‐makers	  to	  select	  from	  the	  presentation	  of	  all	  available	  scenarios.	  	  Nevertheless,	  as	  Byford	  et	  al.	  (2003)	  suggest,	  such	  an	  approach	  is	  well	  suited	  for	  applied	  policymaking.	  Cost-­‐utility	  analysis	  (CUA)	  introduces	  concepts	  of	  utility	  and	  personal	  preferences	  to	  economic	  evaluation	  (Drummond	  et	  al.,	  2005).	  	  Some	  of	  the	  
	   82	  
authors	  in	  the	  field	  argue	  that	  this	  is	  a	  sub-­‐type	  of	  CEA	  (Hoch	  &	  Smith,	  2006).	  	  In	  CUA,	  costs	  of	  alternative	  interventions	  are	  compared	  to	  the	  measures	  of	  the	  value	  of	  a	  programme’s	  effects	  expressed	  often	  as	  quality-­‐adjusted	  life-­‐year	  gains	  (QALY)	  or	  disability-­‐adjusted	  life-­‐year	  gains	  (DALY).	  	  For	  example,	  a	  QALY	  measure	  combines	  information	  on	  the	  length	  of	  time	  in	  that	  state	  with	  the	  perceived	  utility	  value	  for	  that	  health	  state	  expressed	  between	  values	  0	  and	  1,	  where	  0	  signifies	  death	  and	  1	  full	  health	  (Drummond	  et	  al.,	  2005;	  Phillips,	  2005).	  	  In	  contrast	  to	  CEA,	  which	  uses	  programme-­‐specific	  (or	  disease-­‐specific)	  outcomes,	  CUA	  involves	  generic	  measures	  of	  outcomes	  (Drummond	  et	  al.,	  2005)	  such	  as	  EQ-­‐5D	  (EuroQoL	  Group,	  1990),	  SF-­‐12	  (Ware	  et	  al.,	  1996),	  Health-­‐Utilities	  Index	  (Furlong	  et	  al.,	  2001),	  and	  enables	  cross-­‐disciplinary	  (cross-­‐disease)	  comparisons	  of	  interventions	  with	  different	  health	  benefits	  (McCabe,	  2009).	  	  	  CUA	  provides	  a	  broader	  perspective	  and	  is	  therefore	  well	  suited	  for	  policy	  and	  decision-­‐makers	  as	  it	  “facilitates	  transparency	  of	  resource	  allocation	  process”	  (McCabe,	  2009,	  p.	  2).	  	  Decision-­‐making	  based	  on	  CUA	  relies	  on	  the	  value	  or	  specific	  preference	  individuals	  or	  society	  place	  on	  the	  different	  health	  states	  (McCabe,	  2009),	  individuals’	  characteristics	  and	  experiences	  such	  as	  health	  condition	  type	  (chronic	  or	  acute),	  length	  of	  symptoms,	  age,	  and	  sensitivity	  of	  instrument	  used	  to	  measure	  utilities	  behind	  health	  states	  in	  question	  (McCabe,	  2009;	  Brazier	  et	  al.,	  2007;	  McCabe	  et	  al.,	  2008).	  	  This	  illustrates	  that	  although	  CUA	  is	  indeed	  a	  useful	  tool,	  it	  has	  its	  limitations	  which	  need	  to	  be	  addressed	  and	  accounted	  for	  when	  interpreting	  the	  evaluation	  findings	  and	  translating	  them	  into	  policy	  recommendations.	  	  Cost-­‐benefit	  analysis	  (CBA)	  measures	  both	  outcomes	  and	  costs	  of	  intervention	  in	  monetary	  units	  (Michan	  et	  al.,	  2007).	  	  It	  is	  built	  on	  the	  principles	  of	  welfare	  economics	  (Drummond	  et	  al.,	  2005)	  and	  addresses	  the	  question	  as	  to	  “whether	  a	  certain	  intervention	  is	  worth	  doing	  while	  taking	  into	  account	  social	  opportunity	  costs	  of	  all	  resources	  consumed”	  (Drummond	  et	  al.,	  2005,	  p.	  24).	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Knapp	  (2007)	  concludes	  that	  “in	  general,	  the	  broader	  the	  research	  question,	  the	  more	  demanding	  are	  the	  data	  needs,	  and	  consequently	  CBA	  is	  tougher	  than	  CUA	  which	  is	  harder	  to	  conduct	  than	  CEA”	  (p.	  485).	  Another	  factor	  that	  determines	  the	  type	  of	  analysis	  -­‐	  in	  addition	  to	  the	  type	  of	  outcome	  and	  cost	  data	  collected	  -­‐	  is	  the	  evaluation	  perspective	  (Byford	  &	  Raftery,	  1998).	  	  Economic	  evaluation	  can	  address	  different	  perspectives	  in	  their	  design,	  data	  collection	  and	  analysis	  from	  service	  users,	  providers,	  and	  funders	  to	  the	  most	  comprehensive	  societal	  perspective	  (MRC,	  2010).	  	  	  A	  societal	  perspective	  encompasses	  the	  essence	  of	  welfare	  economics	  (Byford	  et	  al.,	  2003)	  and	  addresses	  the	  notion	  of	  opportunity	  cost,	  cost	  viewed	  as	  ‘opportunity	  forgone’	  (Knapp,	  2007),	  as	  a	  core	  principle	  behind	  resource	  allocation	  in	  the	  context	  of	  scarcity	  (Gold	  et	  al.,	  1996).	  	  
3.6.2	  	   The	  role	  of	  experimental	  and	  non-­‐experimental	  design	  in	  economic	  
evaluation	  Randomised	  controlled	  trials	  (RCT)	  are	  considered	  the	  methodological	  gold	  standard	  and	  are	  often	  used	  as	  “a	  vehicle	  for	  economic	  evaluation”	  (Petrou	  &	  Gray,	  2011a,	  p.1760).	  	  Although	  the	  preferred	  design	  for	  economic	  evaluation	  (Byford	  et	  al.,	  2003)	  RCTs	  are	  not	  always	  possible	  due	  to	  ethical,	  practical	  or	  methodological	  concerns.	  	  In	  the	  case	  of	  the	  ST	  programme,	  although	  it	  could	  be	  argued	  that	  an	  RCT	  study	  design	  would	  have	  been	  stronger	  methodologically,	  it	  was	  not	  considered	  ethically	  acceptable	  from	  clinical,	  policy-­‐making	  and	  political	  perspectives	  and	  was	  therefore	  abandoned	  for	  the	  observational	  study	  design.	  	  Depending	  on	  the	  research	  question	  and	  the	  context	  of	  the	  study,	  RCTs	  are	  not	  always	  necessarily	  a	  good	  methodological	  choice.	  	  Non-­‐experimental	  designs	  such	  as	  observational	  studies	  and	  decision	  modelling	  present	  alternative	  approaches	  often	  used	  for	  economic	  evaluation.	  	  Although	  a	  non-­‐experimental	  study	  design	  cannot	  control	  for	  unobserved	  systematic	  variable	  factors	  by	  random	  allocation	  of	  participants	  in	  treatment	  and	  control	  groups,	  and	  by	  blinding	  researchers	  and	  clinicians	  about	  treatment	  allocation,	  it	  provides	  an	  opportunity	  to	  evaluate	  real-­‐life	  situations	  that	  are	  not	  observable	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in	  an	  RCT	  context.	  	  In	  the	  example	  of	  mental	  health	  response	  after	  the	  LB,	  this	  approach	  was	  the	  only	  available	  ‘vehicle’	  for	  economic	  evaluation.	  	  	  Non-­‐experimental	  design	  is	  particularly	  useful	  in	  evaluating	  natural	  experiments,	  which	  allow	  researchers	  to	  investigate	  and	  evaluate	  events,	  policies	  or	  interventions	  that	  could	  not	  be	  evaluated	  within	  the	  remit	  of	  other	  methodological	  designs	  for	  ethical,	  practical	  or	  methodological	  reasons.	  	  Natural	  experimental	  studies	  “explore,	  evaluate	  and	  aim	  to	  make	  causal	  inferences	  about	  impacts	  of	  events,	  interventions	  or	  policies	  which	  are	  not	  undertaken	  for	  the	  purpose	  or/and	  under	  control	  of	  research”	  (MRC,	  2010,	  p.	  5).	  	  	  A	  useful	  ‘externality’	  from	  evaluations	  based	  on	  the	  non-­‐experimental	  studies	  lies	  in	  the	  development	  and	  application	  of	  diverse	  and	  creative	  methodological	  approaches	  to	  evaluate	  effects	  and	  outcomes.	  	  This	  approach	  aids	  in	  avoiding	  “evaluative	  bias”	  due	  to	  evaluating	  only	  specific	  types	  of	  interventions	  such	  as	  RCTs	  (MRC,	  2010).	  	  However,	  non-­‐experimental	  designs	  inherently	  suffer	  from	  problems	  with	  validity,	  namely	  validity	  of	  non-­‐randomised	  evidence	  and	  potential	  selection	  bias	  (Deeks	  et	  al.,	  2003).	  	  Moreover,	  as	  a	  consequence	  of	  the	  non-­‐randomisation,	  they	  often	  result	  in	  overestimation	  (Deeks	  et	  al.,	  2003;	  Sefton	  et	  al.,	  2010)	  or	  underestimation	  of	  treatment	  effects	  and	  increased	  variability	  of	  the	  results	  (Deeks,	  2003).	  	  Observational	  study	  designs	  offer	  an	  opportunity	  to	  evaluate	  an	  intervention	  under	  ‘real	  life’	  circumstances,	  and	  this	  is	  reflected	  in	  high	  ecological	  validity.	  	  However,	  at	  the	  same	  time	  there	  are	  often	  challenges	  with	  non-­‐randomization,	  lack	  of	  statistical	  power	  and	  sample	  size	  calculations.	  Use	  of	  a	  non-­‐experimental	  design	  calls	  for	  the	  use	  of	  appropriate	  statistical	  methods	  in	  order	  to	  deliver	  unbiased	  results	  and	  to	  control	  for	  all	  confounding	  factors	  and	  selection	  bias	  (Kreif	  et	  al.,	  2012).	  	  It	  is	  important	  to	  understand	  and	  examine	  the	  potential	  sources	  of	  variation	  in	  exposure	  (Meyer,	  1995)	  and	  control	  for	  potential	  confounders	  (MRC,	  2010).	  	  The	  literature	  offers	  different	  statistical	  approaches	  such	  as	  multivariate	  regression	  and	  propensity	  score	  matching	  (Rubin,	  1997)	  in	  addressing	  confounding	  factors	  and	  achieving	  robust	  estimates.	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Regression	  analysis	  is	  useful	  in	  testing	  whether	  difference	  in	  the	  outcomes	  is	  caused	  by	  difference	  in	  the	  exposure	  rather	  than	  confounding	  factors.	  However,	  it	  relies	  on	  the	  assumption	  that	  all	  the	  relevant	  factors	  have	  been	  captured	  and	  measured	  with	  valid	  instruments	  (MRC,	  2010).	  	  Sensitivity	  analysis	  is	  recommended	  to	  explore	  the	  uncertainty	  in	  the	  estimations	  (Briggs	  &	  Gray,	  2009).	  	  	  
3.6.3	  	   Best	  practice	  in	  economic	  evaluation	  Literature	  recommendations	  on	  best	  practice	  and	  elements	  of	  economic	  evaluation	  have	  resulted	  in	  a	  number	  of	  published	  guidelines.	  	  MRC	  (2010)	  highlights	  the	  importance	  of	  published	  guidelines	  on	  recommended	  practices	  for	  the	  conduct	  of	  observational	  studies	  in	  ensuring	  uniformity	  when	  reporting	  	  evaluation	  results	  and	  enabling	  quick	  and	  easy	  assessment	  of	  the	  quality	  of	  the	  conducted	  study.	  	  Guidelines	  differ	  in	  their	  comprehensiveness	  and	  approach;	  however,	  in	  general	  they	  all	  agree	  on	  the	  following:	  	  
-­‐ A	  need	  for	  integrating	  economic	  evaluation	  from	  the	  design	  stage	  of	  the	  study	  (Husereau	  et	  al.,	  2013;	  Drummond	  et	  al.,	  2005);	  
-­‐ Importance	  of	  transparent	  reporting	  	  (MRC,	  2010)	  –	  a	  description	  of	  the	  rationale	  behind	  the	  choice	  of	  the	  design	  and	  methods,	  transparency	  about	  possible	  sources	  of	  the	  bias	  and	  how	  the	  authors	  have	  addressed	  this,	  comparison	  of	  the	  results	  with	  results	  of	  similar	  interventions	  taking	  into	  account	  study	  context;	  
-­‐ Clear	  definition	  of	  target	  population,	  explicit	  sampling	  criteria,	  and	  valid	  and	  reliable	  measures	  of	  exposure	  and	  outcomes	  (MRC,	  2010);	  
-­‐ Use	  of	  sensitive	  and	  robust	  instruments	  for	  collecting	  costs	  and	  outcome	  data;	  
-­‐ Exploring	  the	  heterogeneity	  of	  the	  sample/trial	  population	  (Petrou	  &	  Gray,	  2011):	  
-­‐ Employing	  both	  qualitative	  and	  quantitative	  methods	  in	  establishing	  why	  and	  how	  programmes	  work	  (Byford	  et	  al.,	  2003);	  The	  consolidated	  health	  economic	  evaluation	  reporting	  standards	  (CHEERS)	  guidelines	  (2013)	  provide	  a	  thorough	  checklist	  that	  covers	  all	  important	  
	   86	  
questions	  and	  elements	  of	  the	  economic	  evaluation	  for	  each	  stage	  of	  the	  analysis.	  I	  have	  included	  the	  whole	  list	  in	  Figure	  3.5.	  Figure	  3.5	  CHEERS	  checklist	  –	  items	  to	  include	  when	  reporting	  economic	  evaluations	  of	  health	  interventions	  
Item	  No	  	  	  	  	  	  	  Section/item	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Recommendation	  
Title	  and	  abstract	   	   	   	  1	  Title	   	   	   	  2	  Abstract	   	  
Introduction	  3	  Background	  and	  objectives	   	  
Methods	  4	  Target	  population	  and	  subgroups	   	  5	  Setting	  and	  location	   	  6	  Study	  perspective	   	  7	  Comparators	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8	  Time	  horizon	  	  	  	   	  9	  Discount	  rate	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For	  consistency,	  the	  CHEERS	  statement	  checklist	  format	  is	  based	  on	  the	  format	  of	  
the	  CONSORT	  statement	  checklist.	  I	  would	  like	  to	  finish	  this	  section	  by	  noting	  that	  there	  is	  no	  flawless	  economic	  evaluation	  (Drummond	  et	  al.,	  2005).	  	  Each	  study	  has	  methodological	  challenges	  of	  some	  kind	  and	  the	  main	  point	  is	  to	  reflect	  those	  issues	  in	  the	  analysis	  and	  presentation	  of	  the	  findings	  with	  the	  aim	  to	  “lead	  to	  a	  better	  decision	  making	  (rather	  than)	  embody	  some	  ultimate	  truth”	  (Drummond	  et	  al.,	  2005,	  p.	  13).	  	  This	  should	  not	  be	  used	  as	  an	  excuse	  for	  poorly	  planned	  and	  executed	  evaluations;	  it	  is	  solely	  a	  reminder	  that	  evaluation	  results	  should	  be	  interpreted	  with	  caution	  and	  within	  the	  remit	  of	  the	  study	  design.	  	  
3.6.4	   How	  to	  evaluate	  the	  ST	  programme?	  After	  a	  brief	  overview	  and	  discussion	  of	  literature	  recommendations	  on	  economic	  evaluation,	  this	  section	  will	  address	  its	  application	  in	  the	  case	  of	  mental	  health	  response	  to	  the	  LB.	  	  	   One	  of	  the	  aims	  of	  the	  evaluation	  study	  was	  to	  conduct	  an	  economic	  evaluation	  of	  the	  ST	  programme.	  	  In	  the	  process	  I	  encountered	  several	  challenges.	  	  The	  evaluation	  was	  retrospective	  in	  its	  nature,	  as	  it	  was	  only	  introduced	  in	  the	  second	  year	  of	  the	  ST	  programme	  in	  July	  2006	  and	  ran	  until	  February	  2009.	  	  The	  evaluation	  was	  delivered	  in	  a	  form	  of	  an	  observational	  study	  that	  followed	  up	  153	  programme	  users	  and	  contacted	  another	  77	  individuals	  who	  did	  not	  use	  the	  ST	  programme,	  regarding	  services	  they	  have	  used	  due	  to	  exposure	  to	  LB	  and	  impacts	  on	  their	  social	  life	  and	  health.	  	  
	   88	  
Therefore,	  due	  to	  the	  timing	  of	  the	  evaluation	  and	  its	  retrospective	  nature,	  data	  on	  health,	  economic	  and	  social	  impacts	  of	  the	  LB	  were	  collected	  only	  on	  one	  occasion,	  between	  17	  and	  38	  months	  after	  the	  LB,	  and	  therefore	  relied	  solely	  on	  individuals’	  recollections.	  	  Another	  big	  challenge	  for	  the	  economic	  evaluation	  was	  the	  absence	  of	  a	  comparison	  group.	  	  Lastly,	  due	  to	  the	  nature	  of	  the	  intervention,	  each	  participant	  had	  a	  different	  time	  point	  for	  entry	  into	  the	  ST	  programme	  and	  evaluation	  study.	  	  Evaluation	  of	  the	  ST	  programme	  provides	  a	  good	  illustration	  of	  how	  often	  in	  the	  real	  world	  context	  implementation	  of	  the	  recommendations	  on	  the	  set-­‐up	  and	  delivery	  of	  economic	  evaluations	  is	  either	  not	  possible	  or	  practical.	  	  For	  example,	  even	  though	  it	  is	  recommended	  that	  the	  evaluation	  is	  embedded	  at	  the	  formative	  stage	  of	  the	  programme,	  this	  is	  often	  not	  possible	  for	  practical	  reasons.	  	  In	  the	  case	  of	  the	  LB,	  the	  ST	  programme	  stakeholder	  group	  (around	  20	  professionals	  representing	  various	  aspects	  and	  sides	  of	  the	  emergency	  and	  mental	  health	  response,	  from	  police,	  Transport	  for	  London,	  DH	  to	  clinicians	  and	  trauma	  specialists)	  had	  a	  priority	  to	  devise	  an	  acceptable	  plan	  from	  clinical,	  practical	  and	  financial	  perspectives,	  and	  evaluation	  was	  not	  a	  priority.	  	  This	  affected	  the	  collection	  of	  some	  of	  the	  outcome	  and	  service	  use	  measures,	  which	  could	  only	  be	  collected	  retrospectively	  at	  this	  point,	  and	  limited	  the	  scope	  of	  the	  evaluation	  considerably.	  	  However,	  these	  factors	  could	  be	  seen	  as	  challenges	  rather	  than	  limitations	  as	  they	  bring	  interesting	  and	  valuable	  insights	  into	  complex	  interventions,	  and	  help	  to	  answer	  questions	  on	  whether	  they	  are	  worth	  doing	  and	  in	  which	  way.	  	  The	  key	  question	  of	  the	  ST	  evaluation	  is	  whether	  the	  effect	  of	  the	  intervention	  can	  be	  evaluated	  with	  available	  data.	  	  Average	  treatment	  effect	  compares	  average	  treatment	  outcomes	  of	  the	  treated	  and	  comparator	  groups.	  	  However,	  the	  crucial	  task	  is	  to	  control	  for	  the	  heterogeneity	  in	  the	  sample,	  particularly	  for	  those	  factors	  that	  influence	  participant	  selection	  into	  treatment	  versus	  control	  groups.	  	  In	  the	  observational	  study	  paradigm	  some	  of	  those	  factors	  will	  be	  observable	  (and	  measured	  by	  the	  study).	  	  However,	  some	  of	  the	  factors	  are	  likely	  to	  be	  unobserved	  either	  due	  to	  the	  study	  design	  or	  the	  quality	  of	  the	  collected	  data.	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Comparison	  group	  choice	  was	  a	  central	  issue	  for	  the	  economic	  evaluation	  of	  the	  ST	  programme.	  	  In	  an	  ideal	  methodological	  world	  I	  would	  have	  a	  carefully-­‐chosen	  comparison	  group,	  which	  would	  match	  the	  treatment	  group	  on	  all	  relevant	  characteristics	  apart	  from	  exposure	  to	  the	  intervention	  in	  question.	  	  Allocation	  to	  the	  groups	  would	  be	  random,	  and	  both	  participants	  and	  evaluators	  would	  be	  kept	  blind	  to	  allocation	  to	  groups.	  	  However,	  such	  a	  scenario	  in	  the	  case	  of	  the	  ST	  programme	  has	  two	  problems	  –	  the	  first	  one	  is	  that	  it	  cannot	  be	  practically	  implemented	  for	  the	  reasons	  discussed	  earlier,	  and	  the	  second	  lies	  in	  the	  low	  ecological	  validity	  of	  such	  methodological	  design	  which	  questions	  the	  appropriateness	  of	  its	  use	  in	  the	  context	  of	  the	  mental	  health	  response	  to	  the	  LB.	  	  In	  such	  cases	  of	  absence	  of	  a	  comparison	  group	  as	  defined	  by	  experimental	  study	  design,	  Sefton	  et	  al	  (2001)	  suggest	  using	  the	  term	  ‘comparator	  group’	  to	  distinguish	  between	  the	  two.	  I	  will	  employ	  that	  suggested	  terminology	  in	  this	  chapter	  from	  now	  on.	  At	  an	  earlier	  stage	  of	  my	  research	  (at	  the	  time	  of	  my	  Major	  Review	  in	  2007),	  I	  identified	  several	  comparator	  groups	  and	  suggested	  back-­‐up	  alternatives	  should	  I	  need	  to	  deviate	  from	  my	  initial	  plan.	  	  This	  has	  proven	  to	  be	  a	  good	  strategy,	  as	  I	  soon	  had	  to	  abandon	  my	  initial	  and	  most	  comprehensive	  choice	  due	  to	  the	  absence	  of	  funding	  to	  support	  a	  study	  looking	  into	  the	  referral	  pathway,	  service	  use,	  costs	  and	  treatment	  timing	  for	  individuals	  seeking	  treatment	  for	  PTSD.	  	  The	  first	  comparator	  group	  choice	  included	  individuals	  on	  the	  waiting	  list	  for	  the	  NHS	  evidence-­‐based	  treatment	  in	  the	  form	  of	  trauma-­‐focused	  CBT	  or	  EMDR	  for	  PTSD	  at	  London’s	  Traumatic	  Stress	  Clinic	  (TSC).	  	  	  On	  the	  basis	  that	  there	  are	  no	  differences	  between	  the	  late	  and	  early	  treated	  participants	  other	  than	  the	  treatment	  timing,	  participants	  who	  received	  treatment	  later	  than	  8	  months	  after	  the	  exposure	  to	  the	  LB	  would	  make	  an	  alternative	  comparison	  group.	  	  The	  assumption	  behind	  the	  choice	  of	  this	  particular	  timing	  cut-­‐off	  is	  that	  individuals	  waited	  on	  average	  8	  months	  before	  receiving	  treatment	  under	  the	  standard	  NHS	  practices	  (in	  2010)	  for	  treatment	  for	  PTSD.	  	  This	  waiting	  time	  was	  confirmed	  in	  one	  of	  the	  interviews	  I	  conducted	  (with	  interviewee	  CL2),	  as	  described	  later	  in	  my	  qualitative	  study.	  	  However,	  the	  8	  month	  cut-­‐off	  when	  applied	  to	  the	  evaluation	  sub-­‐sample	  resulted	  in	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unbalanced	  sizes	  of	  the	  early	  and	  later	  treatment	  sub-­‐groups.	  	  In	  contrast,	  the	  cut-­‐off	  point	  of	  300	  days	  before	  and	  after	  the	  LB	  ensured	  a	  more	  balanced	  sample	  size	  and,	  in	  my	  opinion,	  10	  months’	  cut-­‐off	  time	  within	  the	  context	  of	  the	  two-­‐year	  programme	  should	  not	  affect	  the	  analysis	  significantly.	  	  However,	  results	  of	  the	  analysis	  need	  to	  be	  interpreted	  with	  caution	  as	  the	  cut-­‐off	  timing	  decision	  was	  taken	  prior	  to	  the	  data	  analysis.	  	  	  	  Another	  potential	  and	  available	  option	  was	  to	  explore	  differences	  between	  the	  ST	  programme	  users	  and	  individuals	  who	  did	  not	  use	  the	  ST.	  	  Although	  this	  option	  is	  not	  a	  good	  comparator	  group,	  it	  enables	  a	  closer	  look	  at	  reasons	  behind	  the	  programme	  use,	  alongside	  needs	  and	  costs.	  	  A	  third	  option	  is	  to	  investigate	  differences	  between	  individuals	  who	  were	  screened	  and	  assessed	  only	  and	  those	  who	  proceeded	  from	  the	  screen/assessment	  phase	  to	  the	  treatment.	  	  Again,	  this	  option	  provides	  for	  an	  interesting	  cost-­‐outcome	  analysis	  and	  offers	  an	  insight	  into	  how	  effective	  the	  ST	  programme	  was	  in	  identifying	  individuals	  with	  treatment	  needs.	  	  Furthermore,	  it	  provides	  follow-­‐up	  information	  on	  the	  mental	  health	  needs	  of	  individuals	  who	  were	  categorised	  by	  the	  ST	  programme	  as	  not	  needing	  treatment	  in	  comparison	  to	  those	  who	  were	  referred	  for	  treatment.	  	  The	  list	  of	  comparator	  groups	  used	  in	  the	  study	  is	  presented	  in	  Table	  3.7.	  	  Table	  3.7	  Evaluation	  comparator	  groups	  
a.	  Early	  treatment	  vs.	  Later	  treatment	  	  b.	  ST	  users	  vs.	  ST	  non-­‐users	  	  c.	  ST	  treated	  users	  vs.	  ST	  screened	  and	  assessed	  only	  users	  	  
3.6.5	   CEA	  protocol	  In	  order	  to	  minimise	  and	  adjust	  for	  observable	  biases	  potentially	  introduced	  by	  the	  observational	  study	  design	  –	  such	  as	  non-­‐random	  selection	  of	  participants	  and	  measurement	  error	  –	  and	  to	  enhance	  robustness	  of	  the	  analysis,	  I	  used	  a	  regression	  framework	  to	  predict	  both	  costs	  and	  effects	  while	  controlling	  for	  common	  measured	  factors.	  	  However,	  due	  to	  the	  study	  design	  there	  is	  significant	  uncertainty	  around	  unobservable	  and	  non-­‐measured	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effects	  that	  can	  influence	  the	  results	  of	  the	  analysis	  and	  potentially	  lead	  to	  omitted	  variable	  bias	  and	  unobserved	  regression	  coefficients.	  	  While	  a	  randomised	  design	  is	  likely	  to	  achieve	  “orthogonality	  of	  measured	  covariates	  and	  unobservables”	  (Jones,	  2007,	  p.	  5),	  in	  observational	  study	  designs	  one	  strategy	  to	  address	  unobservables	  in	  the	  context	  of	  the	  large	  samples	  with	  well	  observed	  characteristics	  could	  be	  to	  “assume	  a	  non-­‐systematic	  influence	  on	  the	  treatment	  effect”	  (Jones,	  2007,	  p.	  5).	  	  	  Another	  approach	  could	  be	  to	  use	  factors	  that	  predict	  treatment	  but	  have	  no	  effect	  on	  outcomes	  to	  mimic	  random	  assignment	  to	  treatment	  (Jones,	  2007,	  p.	  7).	  	  My	  strategy	  was	  to	  use	  multivariate	  regression	  to	  adjust	  both	  costs	  and	  outcomes	  for	  the	  same	  group	  of	  covariates	  based	  on	  theoretical	  and	  statistical	  criteria.	  As	  discussed	  in	  Section	  3.5.2,	  for	  all	  cost	  models	  I	  used	  GLM,	  as	  the	  literature	  highlighted	  its	  advantage	  in	  predicting	  average	  values	  of	  non-­‐normally	  distributed	  values	  in	  comparison	  to	  transformed	  OLS	  models	  (Glick	  et	  al.,	  2007).	  	  I	  will	  start	  the	  analysis	  with	  descriptive	  analyses	  of	  participants’	  sociodemographic	  characteristics,	  exposure	  and	  clinical	  characteristics.	  	  For	  costs	  and	  outcome	  categories	  for	  each	  participant	  group	  I	  will	  present	  unadjusted	  mean	  values	  before	  presenting	  models	  and	  adjusted	  estimates.	  	  Differences	  between	  participants’	  characteristics,	  unadjusted	  costs	  and	  outcomes	  are	  tested	  using	  Pearson’s	  chi–squared	  test,	  parametric	  (t-­‐test	  for	  independent	  samples),	  and	  non-­‐parametric	  test	  for	  independent	  samples	  (Mann-­‐Whitney).	  	  For	  descriptive	  analysis	  purposes,	  I	  will	  present	  the	  following	  cost	  categories:	  	  a.	  costs	  associated	  with	  the	  ST	  programme	  	  b.	  direct	  cost,	  which	  aggregates	  statutory-­‐provided	  health	  care	  services,	  hospitalisation,	  medication,	  voluntary	  and	  private	  sector	  provided	  services,	  and	  	  c.	  total	  costs,	  which	  aggregates	  the	  ST	  programme,	  direct	  costs	  and	  work-­‐related	  costs	  due	  to	  sick	  leave,	  unemployment	  and	  reduced	  work	  hours.	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The	  next	  step	  will	  be	  to	  present	  the	  model	  evaluation.	  	  First,	  I	  will	  explore	  potential	  interaction	  terms	  based	  on	  factors	  that	  have	  been	  identified	  by	  my	  Literature	  Review	  to	  affect	  either	  costs	  or	  outcomes,	  such	  as	  being	  diagnosed	  with	  PTSD,	  the	  number	  of	  previous	  traumatic	  events,	  female	  gender	  and	  premorbid	  conditions.	  In	  the	  second	  step	  I	  will	  assess	  the	  model	  fit.	  	  For	  the	  GLM	  model	  I	  will	  use	  the	  Park	  test	  to	  check	  the	  appropriateness	  of	  the	  family	  distribution,	  and	  re-­‐run	  the	  model	  with	  alternative	  families	  to	  check	  for	  a	  suitable	  fit.	  	  Next	  I	  will	  run	  a	  link	  test	  to	  assess	  the	  linearity	  of	  the	  response.	  	  This	  step	  will	  be	  followed	  by	  a	  check	  of	  the	  distribution	  of	  the	  residuals	  in	  order	  to	  observe	  any	  pattern	  in	  their	  distribution	  as	  a	  sign	  of	  heteroscedasticity,	  which	  occurs	  when	  variance	  of	  the	  error	  term	  is	  not	  constant	  (William,	  2012).	  	  This	  can	  be	  due	  to	  measurement	  errors,	  model	  misspecification,	  or	  sub-­‐population	  differences	  within	  the	  sample	  (William,	  2012).	  	  After	  identifying	  the	  best	  model	  fit	  I	  will	  proceed	  with	  estimating	  the	  final	  model.	  	  I	  will	  calculate	  average	  mean	  predicted	  costs	  and	  effects	  for	  both	  treatment	  and	  comparator	  groups,	  and	  subtract	  them	  to	  obtain	  the	  differences	  in	  group	  means.	  	  Both	  costs	  and	  effects	  (outcome)	  models	  will	  follow	  the	  same	  protocol	  detailed	  below.	  Both	  cost	  and	  outcome	  analyses	  have	  been	  conducted	  using	  SPSS	  12	  and	  STATA	  11	  statistical	  packages.	  
3.6.6	   Uncertainty	  analysis	  	  The	  next	  step	  in	  CEA	  is	  to	  present,	  describe	  and	  explore	  uncertainties	  around	  cost-­‐effectiveness	  analysis.	  	  The	  difference	  in	  mean	  predicted	  costs	  (incremental	  predicted	  costs)	  divided	  by	  the	  difference	  in	  mean	  predicted	  effects	  (incremental	  predicted	  effects)	  is	  known	  as	  the	  incremental	  cost	  effectiveness	  ratio	  (ICER)	  and	  describes	  the	  additional	  cost	  of	  achieving	  an	  incremental	  improvement	  in	  outcome	  from	  (say)	  early	  treatment	  compared	  to	  later	  treatment.	  	  However	  by	  calculating	  ICER	  in	  this	  manner,	  one	  does	  not	  have	  any	  information	  on	  uncertainty	  around	  the	  cost-­‐effectiveness	  estimate.	  	  	  
	   93	  
There	  are	  a	  number	  of	  methods	  to	  estimate	  confidence	  intervals	  around	  mean	  ICER	  values	  such	  as	  confidence	  box,	  confidence	  ellipses	  and	  use	  of	  Fieller’s	  theorem,	  and	  non-­‐parametric	  bootstrapping,	  each	  with	  its	  own	  merits	  and	  limitations	  (Gray	  et	  al.,	  2010).	  	  Among	  available	  methods,	  non-­‐parametric	  bootstrapping	  is	  the	  most	  frequently	  used	  approach.	  	  Non-­‐parametric	  bootstrapping	  starts	  with	  a	  sample	  from	  the	  population	  of	  interest	  and	  re-­‐draws	  a	  number	  of	  sub-­‐samples	  from	  it	  with	  replacements	  in	  order	  to	  estimate	  the	  distribution	  around	  the	  statistic	  of	  interest	  (Gray	  et	  al.,	  2010).	  	  This	  logic	  is	  applied	  in	  the	  case	  of	  the	  ICER	  in	  order	  to	  calculate	  a	  confidence	  interval	  around	  the	  mean	  ICER.	  	  	  However,	  in	  the	  case	  of	  small	  samples	  and	  skewed	  variables	  of	  interest,	  bootstrapping	  is	  not	  an	  ideal	  way	  to	  estimate	  population	  means	  (O’Hagan	  &	  Stevens,	  2003).	  	  Gray	  et	  al	  (2010)	  suggest	  that	  increasing	  the	  number	  of	  bootstrapped	  replication	  “only	  improves	  estimate	  of	  the	  sampling	  distribution,	  however	  it	  does	  not	  make	  point	  estimate	  more	  precise”(p.	  23).	  	  Another	  problem	  is	  associated	  with	  interpretation	  of	  negative	  ICERs,	  which	  will	  be	  identical	  for	  both	  more	  costly/less	  effective	  or	  more	  effective/less	  costly	  alternative	  interventions.	  	  Furthermore,	  the	  ICER	  does	  not	  address	  the	  question	  of	  willingness	  to	  pay	  for	  a	  unit	  of	  improvement	  and	  hence	  provides	  limited	  information.	  	  As	  discussed	  previously,	  cost	  effectiveness	  acceptability	  curves	  are	  a	  widely-­‐used	  supplement	  to	  the	  ICER	  (Fenwick	  &	  Byford,	  2005;	  Wilian	  et	  al.,	  2003;	  Fenwick	  et	  al.,	  2001;	  Fenwick	  et	  al.,	  2004)	  as	  they	  present	  uncertainty	  around	  cost-­‐effectiveness	  means	  without	  all	  the	  statistical	  challenges	  of	  calculating	  a	  confidence	  interval	  (CI)	  around	  the	  ICER	  (Briggs	  &	  Fenn,	  1998).	  	  The	  literature	  on	  CEACs	  discusses	  several	  methods	  of	  CEAC	  construction.	  	  The	  first	  method	  uses	  a	  joint	  distribution	  of	  bootstrapped	  incremental	  costs	  and	  incremental	  effects	  by	  plotting	  the	  proportion	  of	  cost-­‐effective	  pairs	  for	  the	  value	  society	  or	  that	  the	  policy	  funder	  is	  willing	  to	  pay	  per	  unit	  of	  improvement	  (Fenwick	  &	  Byford,	  2005).	  	  A	  second	  option	  discussed	  by	  Nixon	  et	  al	  (2005a)	  applies	  non-­‐parametric	  methods	  for	  establishing	  cost-­‐effectiveness	  by	  use	  of	  the	  central	  limit	  theorem	  (CLT).	  	  As	  those	  authors	  argue,	  the	  CLT	  can	  be	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successfully	  used	  with	  skewed	  distributions	  in	  prediction	  of	  a	  robust	  estimate	  of	  the	  population	  mean,	  however	  only	  in	  the	  case	  of	  large	  enough	  samples.	  	  Results	  from	  a	  later	  study	  by	  these	  same	  authors	  showed	  that	  with	  moderate	  to	  large	  data	  samples	  (>50),	  even	  with	  highly	  skewed	  data	  both	  non-­‐parametric	  bootstrapping	  and	  CLT	  performed	  equally	  well	  and	  accurately	  estimated	  standard	  errors	  (Nixon	  et	  al.,	  2010).	  	  After	  considering	  my	  options	  for	  the	  analysis	  I	  decided	  to	  present	  a	  table	  of	  ICERs	  calculated	  from	  predicted	  cost	  and	  outcomes	  without	  bootstrapping.	  	  This	  will	  serve	  as	  an	  illustration	  of	  predicted	  differences	  in	  costs	  and	  outcomes	  between	  the	  groups,	  and	  all	  possible	  difficulties	  in	  interpreting	  ICERs.	  	  I	  decided	  to	  use	  the	  approach	  advocated	  by	  Nixon	  et	  al	  (2010)	  based	  on	  the	  CLT	  method1.	  	  CLT	  starts	  with	  the	  premise	  that	  “whatever	  shape	  of	  the	  population	  distributions	  of	  the	  costs	  and	  effects,	  the	  distributions	  of	  the	  sample	  means	  will	  converge	  to	  normal	  population	  as	  sample	  size	  increases”(Nixon	  et	  al,	  2010,	  p.	  317).	  	  CLT	  assumes	  independence	  of	  the	  two	  comparison	  groups	  and	  calculates	  the	  covariance	  between	  the	  estimates	  of	  the	  population	  mean	  cost	  and	  effect	  difference	  based	  on	  the	  sum	  of	  the	  covariance	  between	  the	  cost	  and	  effects	  data	  in	  each	  arm	  divided	  by	  the	  respective	  sample	  sizes	  (Nixon	  et	  al.,	  2010).	  	  Nixon	  et	  al	  (2010)	  use	  incremental	  net	  monetary	  benefit	  (INB)	  of	  one	  treatment	  compared	  to	  another	  to	  represent	  the	  results	  of	  CEA.	  	  INB	  is	  defined	  as:	  INB(K)=Kµδe	  -­‐	  µδc	  Where	  K	  represents	  the	  decision-­‐maker’s	  willingness	  to	  pay	  for	  one	  unit	  gain	  in	  health	  outcome,	  while	  µδe	  and	  µδc	  represent	  mean	  parameters	  and	  are	  estimated	  by	  sample	  cost	  and	  effect	  means.	  	  New	  treatment	  is	  cost-­‐effective	  if	  and	  only	  if	  INB(K)>0.	  	  As	  the	  value	  of	  K	  is	  unknown	  the	  plot	  is	  estimated	  for	  various	  values	  of	  K	  (Nixon	  et	  al.,	  2005a,	  p.1220).	  	  In	  order	  to	  obtain	  CEACs	  I	  have	  entered	  predicted	  costs	  and	  effects	  into	  the	  CLT	  EXCELL	  model	  provided	  by	  Nixon	  et	  al.	  (2005b).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 CLT	  model	  in	  EXCEL	  spreadsheet	  can	  be	  downloaded	  from	  http://www.mrc-
bsu.cam.ac.uk/Software/download.html 
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When	  using	  the	  CLT	  to	  estimate	  CEACs,	  Nixon	  et	  al	  (2005a)	  suggest	  adjusting	  for	  baseline	  covariates	  in	  the	  case	  of	  non-­‐randomised	  studies.	  	  Furthermore,	  they	  discuss	  several	  methods	  from	  the	  recent	  literature:	  from	  net-­‐benefit	  approach	  applied	  to	  linear	  regression	  models	  to	  estimate	  individual-­‐net	  benefit	  (Hoch	  et	  al.,	  2002),	  or	  by	  seemingly	  unrelated	  regression	  equations	  (Willam	  et	  al.,	  2004)	  to	  the	  method	  presented	  by	  Nixon	  and	  Thompson	  (2005)	  that	  considers	  the	  joint	  distribution	  of	  costs	  and	  effects	  in	  the	  context	  of	  different	  distributions.	  As	  described	  earlier,	  in	  this	  particular	  study	  I	  have	  adjusted	  all	  costs	  and	  effects	  models	  for	  the	  following	  covariates:	  age;	  gender;	  ethnicity,	  if	  person	  was	  injured	  (Q1);	  if	  person	  thought	  they	  will	  be	  injured	  or	  killed	  (Q2);	  if	  person	  saw	  someone	  who	  was	  injured	  or	  killed	  (Q3);	  psychiatric	  comorbid	  conditions;	  treatment	  type;	  follow-­‐up	  timing	  (days	  since	  the	  LB)	  and	  total	  number	  of	  treatment	  sessions.	  	  The	  choice	  of	  covariates	  was	  guided	  by	  theoretical	  underpinning	  on	  the	  effects	  of	  the	  socio-­‐economic	  variables,	  exposure	  details,	  pre-­‐existing	  psychiatric	  comorbidity,	  effect	  of	  the	  treatment	  type,	  timing	  and	  length	  on	  both	  outcomes	  and	  costs,	  and	  finally	  on	  the	  available	  data.	  	  
3.7	   Methods	  to	  conduct	  qualitative	  study	  on	  implications	  and	  feasibility	  
of	  screening	  for	  PTSD	  within	  primary	  care	  (Objective	  4)	  	  In	  order	  to	  examine	  the	  benefits	  and	  practicalities	  of	  introducing	  screening	  for	  PTSD	  in	  general	  practice,	  a	  collaborative	  study	  between	  UCL	  and	  LSE,	  in	  partnership	  with	  a	  London-­‐based	  GP	  practice	  and	  the	  Traumatic	  Stress	  Clinic	  in	  London,	  was	  proposed	  in	  2008.	  	  This	  study	  was	  intended	  to	  build	  on	  the	  findings	  of	  evaluation	  of	  the	  ST	  programme.	  	  The	  study	  aimed	  to	  explore	  screening	  for	  PTSD	  in	  two	  ways.	  	  First,	  it	  was	  the	  intention	  to	  interview	  people	  with	  PTSD	  who	  had	  succeeded	  in	  accessing	  treatment,	  in	  order	  to	  learn	  how	  they	  were	  referred,	  what	  obstacles	  they	  faced,	  and	  how	  long	  the	  process	  took.	  	  Second,	  it	  was	  intended	  to	  test	  the	  process	  of	  identifying	  people	  with	  PTSD	  by	  carrying	  out	  screening	  in	  three	  general	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practices	  using	  validated	  screening	  instruments.	  	  This	  could	  have	  served	  as	  a	  pilot	  for	  a	  wider	  screening	  programme.	  	  	  Regrettably,	  after	  two	  unsuccessful	  grant	  applications,	  the	  original	  research	  plan	  was	  modified	  into	  a	  small	  qualitative	  study	  of	  experts	  working	  in	  the	  field	  to	  fit	  the	  PhD	  timescale	  and	  format.	  	  A	  short	  qualitative	  study	  was	  designed	  to	  explore	  the	  benefits	  and	  barriers	  of	  implementing	  screening	  for	  PTSD	  policy	  within	  primary	  care.	  	  The	  study	  sample	  was	  purposive	  and	  participants	  were	  identified	  through	  the	  relevance	  of	  their	  expertise	  and	  work	  in	  the	  following	  areas:	  clinical	  psychology,	  general	  practice,	  and	  mental	  health	  policy	  development,	  planning,	  implementation	  and	  funding.	  	  Participants	  were	  contacted	  in	  writing	  and	  invited	  to	  take	  part	  in	  short	  (30-­‐40	  minute)	  semi-­‐structured,	  face-­‐to-­‐face	  or	  telephone	  interviews	  depending	  on	  their	  preference.	  	  In	  consultation	  with	  my	  supervisors,	  I	  designed	  a	  questionnaire	  that	  included	  a	  core	  set	  of	  questions	  for	  all	  participants,	  and	  a	  set	  of	  specific	  questions	  for	  the	  following	  participant	  groups:	  a)	  clinicians,	  b)	  academics,	  c)	  general	  practitioners,	  and	  d)	  policy	  developers.	  	  The	  choice	  of	  questions	  was	  guided	  by	  the	  findings	  and	  recommendations	  from	  the	  review	  of	  the	  literature	  on	  prospects	  of	  screening	  for	  PTSD.	  	  The	  questions,	  set	  out	  in	  Appendix	  C,	  explored	  the	  perspectives	  of	  each	  stakeholder	  with	  the	  aim	  of	  providing	  a	  comprehensive	  view	  of	  the	  benefits	  and	  practicalities	  of	  introducing	  such	  policy.	  	  The	  core	  set	  of	  questions	  included	  six	  questions	  on	  participants’	  background	  information,	  two	  questions	  on	  participants’	  views	  of	  feasibility	  and	  the	  appropriate	  setting	  for	  screening	  for	  PTSD,	  logistical	  and	  organisational	  challenges	  in	  implementing	  screening	  policy	  and	  the	  ways	  to	  overcome	  them,	  and	  finally	  an	  open-­‐ended	  question	  on	  important	  aspects	  of	  this	  topic	  that	  I	  did	  not	  address	  in	  the	  interview.	  	  Questions	  for	  GPs	  explored	  the	  challenges	  of	  and	  ways	  to	  adapt	  screening	  for	  PTSD	  in	  a	  general	  practice	  setting,	  and	  suggestions	  for	  improving	  detection	  and	  pathways	  into	  treatment.	  	  Questions	  for	  clinicians	  involved	  issues	  around	  average	  waiting	  times	  for	  PTSD	  treatment,	  information	  on	  common	  pathways	  into	  treatment,	  and	  help-­‐seeking	  behaviour.	  	  Additional	  questions	  for	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clinicians	  discussed	  the	  proposal	  to	  include	  a	  PTSD	  screener	  into	  protocols	  already	  applied	  in	  general	  practice	  such	  as	  screening	  for	  depression,	  the	  appropriateness	  of	  screening	  the	  general	  population	  for	  PTSD,	  and	  the	  characteristics	  of	  a	  PTSD	  screening	  instrument	  suitable	  for	  use	  in	  general	  practice.	  	  Policy	  developers	  were	  asked	  about	  the	  role	  of	  evidence	  in	  service	  planning	  and	  development,	  and	  about	  the	  process	  of	  introducing	  a	  PTSD	  screening	  policy.	  	  In	  total,	  14	  interviews	  were	  carried	  out	  with	  a	  purposive	  sample	  of	  stakeholders,	  viewed	  as	  representative	  of	  the	  experts	  involved	  in	  the	  policy-­‐making	  process.	  	  Purposive	  sampling	  was	  used	  to	  maximise	  the	  likelihood	  of	  obtaining	  a	  complete	  range	  of	  views	  of	  all	  important	  stakeholders	  in	  the	  process	  of	  introducing	  the	  screening	  for	  PTSD	  policy.	  	  Participants	  were	  identified	  through	  the	  relevance	  of	  their	  expertise	  and	  work	  in	  the	  following	  areas:	  general	  practice,	  research	  in	  clinical	  psychology,	  and	  policy	  development,	  funding	  and	  implementation,	  or	  by	  employing	  a	  ‘snowballing’	  technique	  by	  asking	  those	  already	  taking	  part	  in	  the	  study	  to	  nominate	  other	  potential	  participants.	  	  All	  the	  contacted	  participants	  agreed	  to	  be	  interviewed	  as	  a	  part	  of	  the	  study.	  -­‐	  research	  in	  clinical	  psychology	  particularly	  in	  the	  context	  of	  PTSD:	  	  
• Professor	  of	  clinical	  psychology	  (CL	  1);	  	  
• Consultant	  clinical	  psychologist	  (CL	  2);	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
• Professor	  of	  Psychology	  (CL	  3);	  	  -­‐	  	  general	  practice:	  	  
• GP	  and	  Clinical	  Senior	  Lecturer	  (GP	  1);	  	  
• GP	  and	  Senior	  Clinical	  Lecturer	  (GP	  2);	  	  
• medical	  doctor	  (GP	  3);	  	  
• GP	  and	  adviser	  to	  IAPT	  (GP	  4);	  	  
• former	  GP	  and	  academic	  director	  for	  mood,	  anxiety	  and	  personality	  disorders	  at	  UK’s	  academic	  health	  science	  centre	  (GP	  5);	  	  
• GP	  and	  a	  partner	  at	  a	  London	  based	  practice	  (GP	  6);	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• GP	  and	  a	  collaborator	  on	  NICE	  guidelines	  for	  PTSD	  (GP	  7);	  	  
• GP	  (GP	  8);	  	  	  
-­‐ policy	  development,	  funding	  and	  implementation	  (PD):	  	  
• Clinical	  psychologist	  and	  an	  IAPT	  collaborator	  (PD	  1);	  	  
• former	  GP	  (PD	  2);	  
• National	  Programme	  Director	  for	  a	  NHS	  mental	  health	  programme	  (PD	  3);	  	  	   Interviews	  lasted	  between	  30	  and	  60	  minutes	  and	  each	  interview	  was	  recorded	  with	  the	  participant’s	  permission	  and	  transcribed	  for	  analysis.	  	  Questions	  employed	  in	  the	  interviews	  covered	  recommendations	  from	  the	  screening	  criteria	  presented	  by	  the	  UK	  National	  screening	  committee	  and	  literature	  on	  screening	  for	  depression	  and	  PTSD.	  	  Directed	  qualitative	  content	  analysis	  (Hsieh	  &	  Shannon,	  2005)	  was	  undertaken	  on	  the	  recorded	  material.	  	  This	  is	  a	  form	  of	  thematic	  analysis,	  which	  starts	  with	  a	  couple	  of	  themes	  identified	  by	  a	  specific	  theory	  or	  previous	  research,	  in	  this	  case	  the	  Literature	  Review.	  	  This	  method	  enables	  systematic	  analysis	  of	  the	  data	  by	  identifying	  and	  coding	  emerging	  themes	  (Hsieh	  &	  Shannon,	  2005).	  	  The	  main	  questions	  in	  the	  interview	  reflected	  the	  findings	  from	  the	  literature	  and	  presented	  the	  main	  themes	  in	  the	  coding	  process.	  	  The	  open-­‐ended	  form	  of	  questions	  along	  the	  semi-­‐structured	  format	  of	  the	  interview	  allowed	  new	  themes	  to	  emerge	  from	  the	  interviews	  and	  be	  added	  to	  the	  analysis	  (Fereday	  &	  Cochrane,	  2006).	  	  Validity	  of	  the	  emerging	  themes	  was	  tested	  by	  triangulation	  with	  data	  identified	  in	  the	  Literature	  Review,	  and	  exploration	  of	  participants’	  underlying	  views	  on	  the	  emerging	  themes	  and	  discussion	  of	  the	  themes.	  	  Table	  8.1	  Summary	  of	  the	  survey	  topics	  
• Screening	  as	  a	  valid	  method	  for	  detecting	  PTSD	  and	  as	  a	  pathway	  into	  treatment.	  
• The	  most	  common	  pathway	  into	  treatment	  for	  people	  with	  PTSD.	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• Implementing	  PTSD	  screening	  policy	  –	  best	  approach	  and	  setting.	  
• Screening	  the	  general	  population	  vs.	  targeted	  screening	  of	  high-­‐risk	  groups.	  
• Suggestions	  about	  screening	  procedures.	  
• Issues	  regarding	  referral	  to	  detailed	  assessment	  or	  treatment.	  
• Logistical	  and	  organisational	  challenges	  in	  implementing	  PTSD	  screening	  policy	  and	  how	  to	  overcome	  them.	  
• Views	  and	  suggestions	  on	  improvement	  of	  GP	  education	  on	  PTSD	  and	  pathway	  into	  treatment	  for	  people	  with	  PTSD.	  	  
3.8	   Summary	  This	  study	  used	  a	  mixed-­‐method	  approach.	  The	  choice	  of	  design	  was	  determined	  by	  the	  complexity	  of	  the	  subject	  and	  the	  attempt	  to	  provide	  a	  comprehensive	  outlook	  on	  the	  effects	  of	  PTSD.	  	  A	  heterogeneous	  methodological	  approach	  that	  included	  quantitative	  analysis	  (cost	  of	  illness	  study	  and	  cost-­‐effectiveness	  analysis)	  and	  a	  qualitative	  study,	  was	  best	  suited	  for	  this	  task.	  	  	  The	  downside	  of	  such	  an	  approach	  is	  a	  potentially	  fragmented	  chapter	  structure.	  	  The	  structure	  of	  this	  chapter	  (and	  thesis)	  reflects	  the	  intention	  for	  each	  objective	  to	  add	  another	  layer	  of	  complexity	  to	  the	  analysis,	  and	  serve	  as	  a	  building	  block	  for	  the	  next	  level	  of	  analysis.	  	  I	  start	  by	  describing	  and	  measuring	  all	  the	  costs	  and	  effects	  of	  the	  London	  bombings	  on	  exposed	  individuals.	  	  My	  intention	  was	  to	  try	  and	  comprehensively	  identify	  and	  measure	  all	  the	  costs	  individuals	  experienced	  due	  to	  their	  exposure	  to	  the	  LB.	  	  However,	  apart	  from	  the	  ST	  programme	  costs,	  which	  were	  collected	  by	  an	  independent	  source,	  all	  the	  other	  cost	  estimates	  rely	  heavily	  on	  the	  ability	  of	  the	  individuals	  to	  recall	  the	  services	  they	  used,	  facilitated	  by	  a	  set	  of	  questions	  covering	  exposure,	  injuries,	  service	  use	  and	  effects	  on	  individual’s	  productivity.	  	  Furthermore,	  although	  it	  was	  not	  possible	  for	  the	  evaluation	  study	  to	  rectify	  independently	  participants’	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accounts	  of	  their	  service	  use	  associated	  with	  the	  LB	  solely	  (and	  control	  for	  example	  pre-­‐existing	  conditions	  that	  could	  have	  been	  affected	  by	  exposure)	  the	  evaluation	  study	  made	  a	  great	  effort	  to	  highlight	  to	  the	  participants	  the	  need	  to	  only	  report	  service	  use	  due	  to	  their	  exposure	  to	  the	  LB.	  	  The	  next	  level	  of	  the	  analysis	  explores	  costs	  while	  controlling	  for	  exposure	  and	  sociodemographic	  characteristics	  of	  the	  participants.	  	  In	  the	  next	  step,	  I	  use	  cost	  and	  outcome	  data	  in	  the	  cost	  of	  illness	  and	  cost-­‐effectiveness	  analysis	  of	  the	  ST	  programme.	  	  Finally,	  building	  on	  economic	  evaluation	  of	  the	  ST	  programme,	  guided	  by	  the	  findings	  from	  the	  literature	  on	  the	  role	  of	  screening	  in	  prevention	  of	  chronic	  PTSD,	  I	  conduct	  a	  brief	  qualitative	  study	  that	  explored	  feasibility	  of	  screening	  for	  PTSD	  in	  general	  practice.	  	  	   The	  richness	  of	  the	  dataset	  allowed	  me	  to	  approach	  the	  subject	  from	  various	  angles	  including	  health,	  social	  and	  economic	  domains,	  as	  well	  as	  individual	  and	  societal	  perspectives.	  	  It	  allowed	  exploration	  of	  costs	  while	  controlling	  for	  exposure	  and	  sociodemographic	  characteristics	  of	  the	  participants.	  	  Furthermore,	  such	  a	  design	  allowed	  the	  comparison	  of	  participants	  from	  different	  segments	  of	  the	  programme	  in	  terms	  of	  their	  reported	  costs,	  mental	  health	  outcomes	  and	  type	  of	  services	  they	  used.	  	  This	  provides	  interesting	  material	  for	  service	  planners	  and	  funders	  as	  it	  offers	  a	  view	  into	  the	  programme	  running,	  costs	  and	  outcomes.	  	  This	  study	  represents	  an	  example	  of	  ‘real	  world	  research’	  and	  one	  that	  tries	  to	  turn	  methodological	  limitations	  imposed	  by	  observational	  study	  design	  into	  strengths.	  	  The	  main	  strength	  of	  this	  study	  lies	  in	  its	  high	  ecological	  validity.	  	  Secondly,	  in	  my	  view,	  the	  study	  has	  made	  an	  important	  contribution	  in	  evaluating	  mental	  health	  interventions	  in	  real	  world	  settings	  by	  innovatively	  approaching	  the	  challenges	  imposed	  by	  the	  observational	  study	  design.	  	  In	  order	  to	  achieve	  robust	  predictions,	  the	  study	  used	  a	  regression	  framework	  to	  control	  for	  the	  influences	  of	  various	  socio-­‐demographic	  and	  exposure	  factors	  on	  costs	  and	  outcomes.	  	  Furthermore,	  the	  study	  used	  a	  set	  of	  well-­‐known	  outcome	  and	  cost	  measures	  with	  high	  psychometric	  properties,	  which	  allow	  for	  comparison.	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Chapter	  4	   Costing	  impacts	  of	  the	  London	  bombings	  	  	  
4.1	   Introduction	  	  The	  foundation	  of	  any	  robust	  economic	  evaluation	  is	  reliable	  and	  valid	  information	  on	  costs	  and	  outcomes.	  	  The	  aim	  of	  this	  chapter	  is	  to	  describe	  and	  measure	  the	  health,	  social	  and	  economic	  impact	  of	  the	  London	  bombings	  on	  the	  survivors	  and	  society	  as	  a	  whole.	  I	  will	  do	  so	  by	  rigorously	  applying	  costing	  principles	  and	  rules	  to	  the	  context	  of	  the	  naturalistic	  observational	  study	  and	  describing	  all	  the	  challenges	  associated	  with	  this	  particular	  study	  design.	  	  This	  costing	  study	  will	  serve	  both	  as	  an	  introduction	  and	  foundation	  for	  exploring	  cost	  variations	  in	  Chapter	  5	  and	  for	  the	  economic	  evaluation	  of	  the	  ST	  programme	  in	  Chapters	  6	  and	  7.	  	  	  The	  first	  important	  task	  in	  this	  chapter	  is	  to	  list	  all	  the	  services	  used,	  and	  match	  them	  with	  an	  adequate	  unit	  of	  measurement.	  	  The	  next	  step	  involves	  allocating	  the	  costs	  to	  each	  service	  unit	  by	  consulting	  published	  and	  unpublished	  sources	  in	  order	  to	  be	  able	  to	  combine	  the	  two	  and	  derive	  total	  costs.	  	  In	  this	  chapter	  I	  will	  therefore	  provide	  an	  overview	  of	  the	  data	  collection	  and	  costing	  methodology	  before	  describing	  the	  cost	  impact.	  	  	  
4.2	   Costing	  health	  services	  	  
4.2.1	   Theory	  and	  practice	  Cost	  definition	  and	  consequently	  measurement	  depend	  on	  the	  purpose	  for	  which	  they	  are	  being	  used	  (Ellwood,	  1996).	  	  Depending	  on	  the	  aim	  and	  objectives	  of	  the	  study,	  costs	  can	  be	  measured	  in	  terms	  of	  their	  present	  market	  value	  (the	  accountant’s	  view),	  or	  in	  terms	  of	  their	  forgone	  opportunities	  (the	  economist’s	  view;	  Mogyrosy	  &	  Smith,	  2005).	  	  Furthermore,	  the	  perspective	  chosen	  for	  the	  study	  will	  determine	  the	  scope	  of	  the	  costing:	  service	  provider	  (such	  as	  the	  NHS),	  individual	  (costs	  to	  service	  users),	  government	  (all	  public	  spending)	  or	  societal	  perspective	  (the	  above,	  plus	  lost	  productivity,	  costs	  to	  families).	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There	  are	  two	  distinctive	  characteristics	  of	  economic	  evaluation	  seen	  from	  the	  theoretical	  viewpoint:	  the	  adoption	  of	  opportunity	  costing	  and	  a	  societal	  perspective.	  Economic	  evaluation	  aims	  to	  provide	  evidence	  to	  allow	  the	  maximisation	  of	  effectiveness	  in	  the	  context	  of	  a	  scarcity	  of	  resources	  and	  growing	  demands	  for	  health	  care	  services	  (Drummond,	  2005).	  	  Opportunity	  cost	  “reflects	  the	  resource	  implications	  of	  opportunities	  forgone	  rather	  than	  of	  amounts	  spent”	  (Beecham,	  2000,	  p.	  14).	  	  This	  definition	  underlines	  the	  ‘decision-­‐making’	  aspect	  of	  economic	  costing	  (Smith	  &	  Barnett,	  2003;	  Mogyorosy	  &	  Smith,	  2005),	  reflected	  in	  the	  view	  of	  cost	  in	  terms	  of	  value	  of	  resources	  in	  its	  “next	  best	  alternative	  use”	  (Drummond,	  1996,	  p.	  279).	  The	  principle	  of	  welfare	  economics	  is	  to	  maximise	  welfare	  (i.e.	  the	  wellbeing)	  of	  the	  society	  as	  a	  whole	  (Drummond,	  2005).	  	  Effectiveness	  and	  equity	  in	  resource	  allocation	  in	  the	  context	  of	  the	  scarce	  resources	  are	  the	  two	  main	  criteria	  that	  lie	  at	  the	  core	  of	  economic	  evaluation	  (Drummond,	  2005).	  	  Ideally,	  cost	  measurement	  should	  be	  based	  on	  long-­‐run	  marginal	  opportunity	  costs	  (Beecham,	  1995).	  However	  this	  is	  hard	  to	  achieve	  in	  practice.	  	  Defining	  and	  measuring	  long-­‐run	  marginal	  opportunity	  cost	  is	  both	  time-­‐	  and	  resource-­‐consuming,	  as	  one	  would	  need	  to	  measure	  all	  alternative	  uses	  and	  their	  utilities.	  	  If	  long-­‐run	  marginal	  costs	  have	  been	  measured	  they	  tend	  to	  be	  study-­‐specific,	  which	  limits	  their	  generalisability	  and	  use	  in	  other	  studies	  (Byford,	  2003;	  Mygorosy,	  2005).	  	  Therefore,	  the	  common	  approach	  in	  the	  economic	  costing	  field	  is	  to	  use	  short-­‐term	  average	  costs	  containing	  all	  capital,	  revenue	  and	  overhead	  costs	  as	  a	  proxy	  to	  long-­‐run	  marginal	  costs	  (Beecham,	  2000).	  Some	  ‘costing	  rules’	  have	  been	  suggested	  for	  economic	  evaluation	  (Beecham,	  1995;	  Knapp	  &	  Beecham,	  2000;	  Drummond	  et	  al.,	  1997;	  Beecham,	  2000;	  Knapp,	  1998):	  a. costs	  should	  be	  comprehensively	  measured	  and	  include	  all	  elements	  of	  a	  service	  or	  treatment/care	  package	  b. cost	  variations	  should	  be	  addressed	  (and	  examined)	  as	  they	  can	  be	  a	  source	  of	  important	  policy	  and	  practice	  information	  c. only	  like-­‐with-­‐like	  comparisons	  should	  be	  made	  (e.g.	  making	  adjustment	  for	  differences	  in	  the	  characteristics	  of	  people	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treated	  or	  supported	  when	  comparing	  two	  intervention	  strategies)	  d. costs	  should	  be	  presented	  and	  interpreted	  alongside	  outcomes	  	  	  These	  costing	  rules	  have	  foundation	  in	  economic	  theory	  applied	  to	  health	  and	  social	  care	  (Knapp,	  1995;	  Drummond	  et	  al.,	  2005).	  	  The	  first	  step	  in	  costing	  health	  care	  services	  is	  to	  define	  and	  describe	  all	  services	  provided	  over	  a	  specified	  time	  period.	  	  The	  next	  task	  is	  to	  define	  appropriate	  units	  of	  measurement	  for	  each	  service,	  such	  as	  cost	  per	  hour	  or	  per	  session	  depending	  on	  the	  nature	  of	  the	  service.	  	  The	  final	  step	  is	  to	  allocate	  a	  cost	  to	  each	  unit	  of	  service,	  ideally	  a	  long-­‐run	  opportunity	  cost	  (but	  see	  above	  for	  the	  practical	  approach	  usually	  taken),	  and	  to	  calculate	  unit	  cost	  (Beecham,	  1995).	  	  In	  this	  study,	  unit	  cost	  is	  defined	  as	  a	  cost	  per	  working	  hour	  of	  health	  and	  social	  care	  professionals,	  the	  cost	  per	  session	  of	  treatment,	  or	  cost	  per	  inpatient	  day.	  	  There	  are	  two	  approaches	  in	  cost	  calculation:	  top-­‐down	  and	  bottom-­‐up,	  and	  each	  comes	  with	  its	  advantages	  and	  disadvantages.	  	  Bottom-­‐up	  costing,	  known	  also	  as	  micro	  or	  activity-­‐based	  costing	  (Mygorosy	  et	  al.,	  2005),	  is	  individually	  based.	  	  It	  identifies	  all	  services,	  allocates	  a	  cost	  to	  each	  service	  and	  sums	  it	  up.	  	  The	  advantage	  is	  a	  detailed	  overview	  of	  the	  services	  and	  costs	  that	  reflects	  inter-­‐client	  variability	  and	  is	  readily	  comparable	  with	  clinical	  outcome	  measures	  also	  collected	  at	  the	  individual	  level	  (Beecham	  &	  Knapp,	  2001).	  The	  top-­‐down	  approach	  looks	  at	  all	  the	  costs	  associated	  with	  service	  provision	  and	  divides	  the	  total	  amount	  by	  a	  measure	  of	  the	  number	  of	  produced	  units	  (such	  as	  psychotherapy	  sessions	  or	  hospital	  bed-­‐days).	  It	  is	  less	  time-­‐	  and	  resource-­‐consuming,	  but	  consequently	  gives	  less	  detailed	  insight	  into	  elements	  of	  service	  provision,	  resulting	  in	  a	  potentially	  over-­‐simplistic	  view	  of	  service	  utilisation.	  	  Both	  approaches	  have	  valid	  contributions	  to	  make	  and	  can	  be	  combined	  in	  costing	  different	  service	  elements	  depending	  on	  the	  data,	  resources	  and	  time	  availability.	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The	  next	  section	  translates	  costing	  theory	  into	  practice	  and	  describes	  how	  I	  have	  allocated	  costs	  to	  the	  services	  used	  by	  individuals	  affected	  by	  the	  London	  bombings.	  	  To	  begin	  with,	  I	  will	  briefly	  recapitulate	  the	  study	  context	  and	  data	  collection	  methods.	  	  In	  order	  to	  describe	  all	  the	  costs	  associated	  with	  exposure	  to	  the	  London	  bombings	  I	  have	  used	  two	  data	  sources,	  one	  on	  costs	  associated	  with	  set-­‐up	  and	  running	  the	  ST	  programme	  as	  a	  mental	  health	  response	  to	  the	  LB,	  and	  a	  separate	  dataset	  on	  all	  services	  used	  by	  individuals	  due	  to	  their	  exposure	  to	  the	  LB.	  	  Data	  on	  costs	  associated	  with	  the	  set-­‐up	  and	  running	  of	  the	  ST	  programme	  were	  collected	  during	  the	  running	  of	  the	  programme,	  while	  data	  on	  service	  use	  were	  collected	  by	  administration	  of	  a	  modified	  version	  of	  CSRI	  (Chisholm	  et	  al.,	  2000;	  Knapp	  et	  al.,	  1990)	  during	  the	  evaluation	  of	  the	  ST	  project.	  	  A	  copy	  of	  the	  questionnaire	  is	  attached	  in	  Appendix	  B,	  and	  a	  detailed	  overview	  of	  the	  modifications	  is	  discussed	  in	  Chapter	  3,	  Section	  3.4.3.	  	  All	  the	  service	  use	  data	  were	  collected	  retrospectively,	  on	  average	  24.2	  months	  after	  the	  LB.	  Service	  use	  and	  productivity	  costs	  were	  measured	  from	  an	  individual	  perspective	  and	  allocated	  in	  a	  bottom-­‐up	  approach,	  while	  the	  ST	  programme	  costs	  were	  calculated	  using	  a	  top-­‐down	  approach.	  	  The	  ST	  programme	  specific	  unit	  costs	  are	  presented	  below,	  alongside	  unit	  costs	  per	  services	  used	  due	  to	  exposure	  to	  the	  London	  bombings.	  
4.2.2	   The	  screen	  and	  treat	  (ST)	  programme	  specific	  unit	  costs	  The	  aim	  of	  the	  screen	  and	  treat	  programme	  was	  to	  contact	  and	  follow	  up	  as	  many	  survivors	  and	  affected	  individuals	  as	  possible,	  to	  provide	  them	  with	  information	  about	  posttraumatic	  responses	  and	  immediate	  sources	  of	  help,	  to	  screen	  them	  at	  regular	  intervals	  using	  validated	  instruments	  to	  identify	  those	  who	  still	  had	  symptoms	  of	  PTSD,	  and	  to	  deliver	  appropriate	  therapy	  to	  that	  subset	  of	  people.	  	  Chapter	  3	  provides	  detailed	  information	  on	  screening,	  assessment	  and	  treatment	  protocol	  and	  instruments.	  	  The	  ST	  programme-­‐associated	  costs	  were	  collected	  from	  the	  invoices	  sent	  to	  the	  programme’s	  funders,	  containing	  data	  on	  the	  start-­‐up	  costs	  (hardware	  purchase,	  advertising,	  furniture	  and	  fittings),	  staff	  costs	  (general	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non-­‐pay	  costs	  and	  clinical/management	  support	  costs),	  premises	  overheads	  and	  other	  costs	  such	  as	  patient	  travel	  reimbursement.	  	  The	  costs	  of	  the	  set-­‐up	  and	  running	  of	  the	  ST	  programme	  are	  based	  on	  screening,	  assessment	  and	  provision	  of	  therapy	  for	  all	  users	  of	  the	  ST	  programme	  based	  on	  the	  intention-­‐to-­‐treat	  sample.	  Therapists	  in	  each	  clinic	  recorded	  type,	  number	  of	  therapy	  sessions	  and	  outcome	  in	  a	  form	  of	  direct	  and	  indirect	  half-­‐hour	  units.	  	  Data	  was	  collected	  on	  a	  monthly	  basis	  and	  stored	  in	  an	  Excel	  spreadsheet.	  	  During	  the	  running	  of	  the	  ST	  programme,	  a	  database	  containing	  all	  information	  on	  screening,	  assessment	  and	  treatment	  outcomes	  was	  set	  up	  and	  passed	  on	  to	  the	  evaluation	  team	  at	  the	  end	  of	  the	  programme.	  	  Treatment	  costs	  were	  collected	  using	  the	  top-­‐down	  approach	  by	  dividing	  total	  cost	  by	  the	  total	  number	  of	  provided	  sessions	  (including	  did-­‐not-­‐attend	  sessions).	  Table	  4.1	  Total	  cost	  break	  down	  for	  the	  screen	  and	  treat	  programme	  
	  	   Table	  4.1	  shows	  the	  costs	  for	  the	  2-­‐year	  screen	  and	  treat	  programme,	  identifying	  the	  start-­‐up	  costs,	  administrative	  costs	  incurred	  for	  managing	  the	  project,	  the	  costs	  of	  the	  centralised	  screening	  team	  and	  the	  treatment	  costs.	  	  The	  total	  cost	  of	  screening	  is	  based	  solely	  on	  recorded	  costs	  from	  the	  screen	  and	  treat	  programme	  and	  does	  not	  include	  costs	  incurred	  or	  recorded	  by	  other	  organisations.	  	  I	  have	  standardised	  the	  cost	  figures	  across	  years	  for	  inflation.	  	  The	  total	  cost	  was	  just	  under	  £1.4	  million,	  of	  which	  7%	  went	  on	  administration,	  
	  	   2005/2006	   2006/2007	   2007/2008	   Total	  
Start-­‐up	  costs	   32400	   0	   0	   32400	  
Management	   70498	   0	   0	   70498	  
Screening	  and	  
Assessment	   116577	   227177.38	   101377.74	   445132.12	  
Treatment	   	  	  
Clinic	  1	   131810	   267720.71	   107095.11	   506625.82	  
Clinic	  2	   38436	   64485.07	   15434.46	   118355.53	  
Clinic	  3	   60204	   83078.3	   38623.54	   181905.84	  
Treatment	  total	   230450	   415284.08	   161153.11	   806887.19	  
Total	   449925	   974667.24	   262	  530.86	   1354917.31	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33%	  on	  screening	  and	  assessment,	  and	  the	  remaining	  60%	  on	  direct	  (therapist	  time)	  and	  indirect	  (management,	  supervision,	  overheads)	  treatment	  costs.	  If	  we	  assume	  that	  start-­‐up	  costs	  and	  half	  of	  the	  management	  costs	  should	  be	  allocated	  to	  the	  screen/assessment	  part	  of	  the	  programme,	  these	  activities	  absorbed	  £523,125.50	  at	  2007-­‐08	  prices.	  	  This	  assumption	  was	  made	  in	  the	  absence	  of	  the	  other	  information	  on	  cost	  allocation	  in	  the	  programme.	  	  Figure	  3.1	  shows	  that	  596	  people	  were	  screened,	  there	  were	  363	  detailed	  assessments,	  and	  that	  304	  (276	  identified	  by	  the	  programme	  and	  28	  referred	  from	  other	  places)	  of	  them	  were	  considered	  to	  be	  in	  need	  of	  treatment.	  Unfortunately	  the	  data	  are	  not	  sufficiently	  detailed	  to	  allow	  us	  to	  estimate	  the	  costs	  of	  screening	  and	  assessment	  separately.	  	  Screening,	  for	  example,	  included	  collecting	  participants’	  details	  through	  negotiation	  with	  organisations	  involved	  in	  the	  London	  bombings	  response	  such	  as	  the	  Metropolitan	  Police	  or	  NHS,	  setting	  up	  the	  contacts	  database,	  contacting	  individuals,	  sending	  out	  screening	  questionnaires	  at	  several	  time-­‐points	  (up	  to	  five	  screeners	  per	  person)	  and	  referral	  management.	  	  Assessment	  activities	  included	  contacting	  participants,	  a	  clinical	  interview	  that	  could	  last	  up	  to	  1.5	  hours	  and	  liaising	  with	  treatment	  centres.	  	  However,	  I	  could	  estimate	  two	  unit	  costs	  from	  these	  data:	  	  
• The	  cost	  of	  finding,	  screening	  (up	  to	  five	  times)	  and	  assessing	  a	  person	  for	  PTSD	  following	  a	  traumatic	  event	  in	  2007/08	  prices	  is	  £877.70	  (£523,125.50	  /	  596)	  
• The	  cost	  of	  identifying	  a	  person	  who	  requires	  treatment	  following	  a	  traumatic	  event	  in	  2007/08	  prices	  is	  £1895.40	  (£523,125.50	  /	  276).	  	  In	  order	  to	  cost	  individuals	  who	  were	  screened	  only	  and/or	  screened	  and	  assessed,	  I	  made	  an	  assumption,	  after	  discussion	  with	  my	  supervisors,	  that	  50%	  of	  costs	  related	  to	  finding,	  screening	  and	  assessing	  individuals	  were	  allocated	  to	  assessment,	  and	  the	  other	  half	  to	  finding	  and	  screening	  the	  person.	  	  This	  translates	  to	  £438.85	  per	  screened	  and	  £435.85	  per	  assessed	  person	  only.	  	  It	  is	  important	  to	  point	  out	  that	  the	  cost	  of	  identifying	  a	  person	  who	  needed	  treatment	  included	  identifying,	  screening	  and	  managing	  their	  referral,	  which	  could	  be	  difficult	  if	  they	  lived	  elsewhere	  in	  UK.	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Better	  data	  on	  time	  use	  are	  available	  for	  the	  treatment	  component	  of	  the	  screen	  and	  treat	  programme.	  	  Clinicians	  spent	  68%	  of	  their	  time	  in	  direct	  contact	  with	  individuals	  in	  treatment,	  while	  32%	  of	  their	  time	  was	  accounted	  for	  by	  indirect	  activities	  such	  as	  preparation,	  supervision,	  travelling	  to	  the	  sites	  and	  in	  vivo	  therapy	  that	  included	  gradual	  exposure	  to	  the	  feared	  stimuli.	  	  Thus,	  on	  average	  for	  each	  hour	  of	  therapist	  direct	  contact	  time,	  there	  was	  a	  further	  half-­‐hour	  of	  indirect	  time.	  	  Both	  direct	  and	  indirect	  therapist	  time	  was	  recorded	  in	  half-­‐hour	  units,	  and	  the	  duration	  of	  the	  treatment	  sessions	  varied	  from	  one	  to	  12	  half-­‐hour	  units,	  depending	  on	  the	  stage	  and	  type	  of	  treatment	  offered.	  	  Although	  the	  range	  of	  direct-­‐time	  half-­‐hour	  units	  is	  very	  wide,	  on	  average	  there	  were	  2.94	  direct	  half-­‐hour	  units	  per	  session	  per	  client.	  	  	  As	  Table	  4.2	  shows,	  a	  total	  of	  9658.5	  half-­‐hours	  of	  direct	  time	  and	  4627	  half-­‐hours	  of	  indirect	  contact	  time	  were	  administered	  throughout	  the	  programme	  across	  all	  three	  clinics,	  which	  corresponds	  to	  7143	  hours	  of	  therapy.	  	  Clinic	  1	  treated	  more	  clients	  with	  a	  higher	  number	  of	  direct	  and	  indirect	  hours	  than	  the	  other	  two	  clinics,	  and	  there	  was	  some	  variation	  between	  the	  clinics	  in	  the	  balance	  of	  direct	  and	  indirect	  time.	  	  Table	  4.2	  also	  shows	  that	  in	  total,	  3277	  therapy	  sessions	  were	  provided	  through	  the	  screen	  and	  treat	  programme,	  an	  average	  13	  sessions	  per	  client,	  although	  this	  varied	  slightly	  between	  the	  clinics,	  as	  did	  the	  number	  of	  clients.	  	  Clients	  made	  decisions	  on	  the	  treatment	  location	  based	  on	  their	  personal	  preferences,	  perhaps	  location	  or	  transportation	  convenience.	  	  Treatment	  cost	  involved	  the	  costs	  of	  getting	  to	  and	  from	  treatment	  and	  parking	  facilities	  for	  individuals	  living	  outside	  London.	  Table	  4.2	  Total	  number	  of	  therapy	  sessions,	  hours	  and	  direct	  and	  indirect	  half-­‐hours	  
	  	   Direct	  1/2hrs	   Indirect	  1/2hrs	   Total	  1/2hrs	   Total	  hours	  per	  programme	   Sessions	  Used	   N	  of	  patients	   M	  sessions	  
All	  
clinics	   9658.5	   4627	   14285.5	   7142.75	   3277	   248	   13.2	  
CLINIC	  1	   6134	   2649	   8783	   4391.5	   2091	   160	   13.1	  
CLINIC	  2	   1516	   978	   2494	   1247	   456	   38	   12.0	  
CLINIC	  3	   2008.5	   1000	   3008.5	   1504.3	   730	   50	   14.6	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   These	  data	  on	  time	  use,	  client	  numbers	  and	  costs	  can	  again	  be	  combined	  to	  enable	  an	  estimation	  of	  unit	  costs.	  Using	  the	  assumption	  that	  half	  the	  management	  costs	  accrue	  to	  the	  treatment	  arm	  of	  the	  programme,	  and	  the	  total	  costs	  of	  treatment	  are	  £857,283.60	  at	  2007-­‐08	  prices,	  the	  following	  unit	  costs	  can	  be	  calculated:	  
• Costs	  per	  half-­‐hour	  of	  direct	  or	  indirect	  time:	  £60.01	  
• Cost	  per	  hour:	  £120.02	  (£857,283.60	  /	  7142.75)	  	  
• Cost	  per	  hour	  of	  treatment:	  £180.03	  (an	  hour	  of	  direct	  time,	  plus	  30	  	  	  	  	  	  	  minutes	  indirect	  activities)	  
• Average	  cost	  per	  session:	  £261.60	  (£857,283.6	  /	  3277)	  
• Average	  treatment	  cost	  per	  person:	  £3,453.20	  (average	  cost	  per	  session	  	  x	  13.2)	  	   When	  analysing	  the	  costs	  of	  the	  screen	  and	  treat	  programme	  one	  must	  bear	  in	  mind	  the	  context	  and	  novelty	  of	  the	  approach,	  as	  well	  as	  the	  difficulties	  involved	  in	  setting	  up	  and	  running	  the	  programme.	  	  This	  was	  the	  first	  time	  a	  mass	  mental	  health	  response	  had	  been	  set	  up	  in	  this	  manner;	  there	  was	  no	  previous	  experience	  on	  which	  to	  build,	  yet	  the	  situation	  demanded	  an	  urgent	  response.	  	  Nor	  was	  this	  programme	  set	  up	  as	  a	  research	  activity;	  its	  main	  focus	  was	  to	  deliver	  a	  mental	  health	  intervention.	  	  Thus	  caution	  is	  advised	  in	  interpreting	  the	  costs	  outside	  of	  the	  context	  of	  this	  programme.	  	  In	  the	  first	  place,	  the	  services,	  and	  therefore	  the	  associated	  costs,	  are	  not	  representative	  or	  comparable	  to	  routine	  clinical	  services.	  	  
4.2.3	   Costs	  of	  service	  use	  associated	  with	  exposure	  to	  the	  London	  
bombings	  	   As	  previously	  mentioned,	  I	  used	  a	  modified	  version	  of	  the	  CSRI	  questionnaire	  (Chisholm	  et	  al.,	  2000;	  Knapp	  et	  al.,	  1990),	  to	  identify	  all	  services	  used	  as	  a	  consequence	  of	  exposure	  to	  the	  LB	  alongside	  the	  units	  of	  measurement.	  	  Data	  on	  service	  use	  were	  collected	  as	  part	  of	  the	  evaluation	  of	  the	  ST	  programme	  which	  inquired	  into	  health,	  social	  and	  economic	  effects	  of	  the	  exposure	  to	  the	  London	  bombings	  on	  a	  sub-­‐sample	  of	  the	  programme	  users	  and	  potential	  users	  (please	  see	  Chapter	  3	  for	  details).	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   The	  CSRI	  measured	  all	  statutory	  and	  non-­‐statutory	  (voluntary	  and	  private	  sector)	  health-­‐related	  service	  use,	  medication	  intake	  and	  hospitalisation	  episodes.	  The	  CSRI	  also	  measured	  the	  effect	  of	  the	  bombings	  on	  work	  in	  terms	  of	  number	  of	  hours	  reduced,	  days	  of	  work	  lost	  due	  to	  sick-­‐leave	  and	  weeks	  of	  unemployment,	  and	  any	  effect	  on	  social	  and	  family	  domains	  of	  each	  participant’s	  life.	  	  	   One	  of	  the	  characteristics	  of	  the	  CSRI	  is	  that	  it	  is	  easily	  adapted	  to	  different	  study	  populations	  as	  well	  as	  different	  means	  of	  administration	  (Knapp	  &	  Beecham,	  2000).	  	  In	  the	  evaluation	  study	  we	  used	  various	  forms	  of	  data	  collection	  ranging	  from	  face-­‐to-­‐face,	  postal	  or	  telephone	  interviews	  in	  order	  to	  ensure	  flexibility	  in	  reaching	  participants	  and	  maximise	  participant	  response.	  	  	   The	  next	  step	  was	  to	  list	  all	  the	  services,	  alongside	  their	  appropriate	  units	  of	  measurement	  and	  assign	  costs.	  	  Firstly,	  I	  categorised	  reported	  services	  into	  sub-­‐categories	  for	  the	  purpose	  of	  data	  analysis	  and	  presentation.	  	  I	  used	  already-­‐published	  sources	  of	  costs	  such	  as	  PSSRU’s	  annual	  Unit	  Costs	  of	  Health	  and	  Social	  Care	  compendium	  and	  NHS	  Reference	  Costs	  alongside	  data	  from	  various	  sources	  such	  as	  annual	  reports,	  published	  studies	  and	  (in	  a	  few	  cases)	  market	  prices.	  	   	  It	  is	  important	  to	  highlight	  that	  service	  use	  data	  was	  collected	  only	  on	  a	  sub-­‐sample	  of	  153	  followed-­‐up	  ST	  programme	  users	  and	  77	  potential	  programme	  users	  who	  did	  not	  use	  the	  programme	  either	  by	  choice	  or	  because	  they	  were	  not	  aware	  of	  it.	  	  Evaluation	  was	  not	  planned	  for	  or	  built	  in	  from	  the	  outset	  of	  the	  ST	  programme	  and	  consequently	  collection	  of	  service	  use	  data	  only	  started	  at	  the	  follow-­‐up	  point	  and	  only	  on	  a	  sub-­‐sample	  of	  users.	  	  I	  standardised	  all	  costs	  to	  2007/08	  prices	  as	  data	  collection	  included	  all	  the	  costs	  associated	  with	  the	  LB	  until	  the	  data	  collection	  point	  in	  the	  evaluation	  study,	  which	  ended	  in	  2008.	  
a.	  Medication	  costs	  associated	  with	  exposure	  to	  the	  London	  bombings	  The	  British	  National	  Formulary	  (BNF)	  was	  the	  main	  source	  of	  information	  on	  medication	  unit	  costs	  as	  it	  provides	  the	  most	  complete	  source	  of	  information	  on	  “selection,	  prescribing	  and	  dispensing	  of	  medication”	  (BNF,	  2010,	  p.6).	  	  It	  aims	  to	  present	  the	  best	  evidence	  drawn	  from	  multiple	  sources	  such	  as	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“manufacturers'	  product	  literature,	  medical	  and	  pharmaceutical	  literature,	  UK	  health	  departments,	  regulatory	  authorities,	  and	  professional	  bodies	  (BNF,	  2010).	  	  I	  used	  the	  60th	  Edition,	  available	  online	  at	  http://bnf.org/bnf/	  (accessed	  between	  20	  and	  25	  October	  2011)	  and	  adjusted	  2010	  prices	  accordingly	  to	  2005,	  2006,	  2007,	  2008	  values.	  	  	   During	  the	  interview,	  participants	  were	  asked	  the	  name	  of	  the	  medication	  used,	  dosage,	  frequency	  and	  the	  duration	  of	  the	  medication	  intake.	  	  However,	  due	  to	  the	  long	  recall	  period,	  between	  13	  and	  22	  months	  after	  the	  London	  bombings,	  information	  on	  dosage	  and	  frequency	  was	  often	  missing	  while	  in	  some	  cases	  the	  only	  available	  data	  was	  a	  description	  of	  the	  medication	  or	  the	  main	  reason	  for	  intake.	  	  If	  dosage	  and	  frequency	  of	  medication	  were	  missing,	  I	  either	  used	  the	  group	  median	  value	  or,	  if	  that	  was	  not	  available,	  I	  used	  data	  on	  recommended	  dosages	  and	  frequency	  from	  the	  BNF.	  	  When	  participants	  stated	  they	  have	  used	  the	  medication	  ‘as	  needed’	  or	  ‘occasionally’	  I	  used	  group	  median	  values	  as	  the	  best	  available	  estimate.	  	  Where	  the	  medication	  name	  was	  missing	  or	  just	  a	  reason	  for	  intake	  was	  given	  I	  randomly	  chose	  a	  medication	  from	  a	  list	  recommended	  by	  BNF	  for	  the	  specific	  condition	  taking	  into	  account	  the	  available	  information	  on	  injuries	  or	  reason	  for	  hospitalisation.	  	  I	  applied	  the	  same	  principle	  in	  cases	  where	  a	  generic	  name	  was	  reported:	  I	  randomly	  allocated	  a	  branded	  drug.	  	  	   The	  costs	  of	  medication	  are	  calculated	  as	  per-­‐tablet	  cost2	  and	  have	  been	  multiplied	  by	  the	  daily	  dosage	  and	  the	  total	  number	  of	  medication	  intake	  days	  for	  each	  participant.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Drawn from the British National Formulary 2010. Number 61, March 2011. Joint publication of the 
British Medical Association and Royal Society of Great Britain. 
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Medication name Dosage and Price
Amitriptyline 10 mg 3.85p; 25 mg 3.9p; 50 mg 4.32p
Amoxicillin 250 mg 6.14p; 500 mg 7.76 p
Antihistamine (Promethazine) 10 mg 5.09p
Betahistine 8 mg 3.29p; 1.71p; 16 mg 2.86p
Blood-thinning injection (Heparin-sodium) 5000 units/mL, 5-mL amp 506p
Chloramphenicol  5% 10 ml 509 p
Citalopram 10 mg 4.39p; 20 mg 4.96p; 40 mg 5.6p
Co-codamol 500 mg 4.33p
Codeine 500 mg 4.33p
Cortisone injections (Kenalog) 1-mL vial 149p
Diazepam 2 mg 3.67p; 5 mg 3.71p; 10 mg 3.755p
Diclofenac 25 mg 1.59p; 50 mg 1.7p
Dihydrocodeine 30 mg  5.67p
Doxepin 25 mg 13.46p; 50 mg 20.39p
Escitalopran (Cipralex) 5 mg 32.03p; 10 mg 53.25p; 20 mg 90p
Fluoxetine 20 mg  8.36p;  60 mg 228.93p
Gallstone tablets (Urdox) 300 mg 44.16p
Gaviscon 500 mg 5.11p
Hepatitis injections (Havrix) 1-mL prefilled syringe, 2214p
Ibuprofen 200 mg 2.11p; 400 mg  2.11p; 600 mg 4.96p
Liquid paraffin 150ml 169p
Loprazolam 10 mg  64.28 p
Lorazepam (Benzodiazepin) 1 mg 23.57p; 2.5 mg 36.32p
Maxidex 142p per 5 ml
Morphine (Tramadol Hydrochloride) 50 mg 5.86p; 2.75p
Optrex solution for eyes 10 ml 400p
Paracetamol 500 mg 1.06p; 1.62p
Paroxetine (Seroxat) 10 mg 42.28p; 20 mg 42.3p; 30 mg 74.26p
Prednisolone 1 mg 3.82p; 5 mg 4.28p; 25 mg 53.57p
Propranolol 10 mg 3.71p; 40 mg 3.82p; 80 mg 3.03p; 160 mg 6.21p
Prozac 20 mg 16.66p
Salbutamol inhaler 200-dose unit 352p 
Sertraline 50 mg  5.17p; 100 mg 6.07p
Symmetrel 100 mg 28.96p
Syprolex (Cipralex) 5 mg 32.03p; 10 mg 53.25p; 20 mg 90p
Tranquilisers (Buspirone) 5 mg 50.66p; 10 mg 56.16p
Valerian tablets 150 mg 20.4p
Vancomycin 125 mg 473p; 250mg 473p
Voltarol 25 mg 3.5p; 50 mg 5.44p
Warfarin 500 mg 5.92p; 1 mg 3.89p; 3 mg 4.03p; 5 mg 4.21p
Xanax (Alprazolam) 250 mg 4.95p; 500 mg 9.48p
Zopiclone 3.75 mg 5.6p; 7.5 mg 5.42p 	  
b.	  Hospitalisation	  costs	  associated	  with	  exposure	  to	  the	  London	  bombings	  Unit	  costs	  for	  hospitalisation	  episodes	  were	  taken	  from	  the	  NHS	  Reference	  Costs	  compilation	  for	  2006/07.	  	  Although	  all	  hospitalisations	  occurred	  in	  2005	  and	  2006,	  I	  chose	  the	  2006/07	  compilation	  due	  to	  its	  comprehensiveness	  and	  completeness,	  and	  have	  adjusted	  costs	  accordingly	  to	  2007/08	  values.	  	  The	  unit	  costs	  are	  grouped	  into	  two	  categories	  depending	  on	  the	  length	  of	  hospitalisation:	  one	  to	  four	  days	  and	  more	  than	  four	  days.	  	  For	  the	  hospital	  stays	  from	  one	  up	  to	  four	  days	  for	  first	  hospitalisation,	  I	  used	  the	  ‘Accident	  and	  Emergency	  Services:	  Leading	  to	  Admitted’	  section	  as	  I	  assumed	  all	  participants	  used	  Accident	  and	  Emergency	  to	  reach	  health	  care	  services	  after	  the	  incident.	  	  Depending	  on	  the	  severity	  of	  the	  injury,	  I	  used	  Category	  1	  investigation	  with	  Category	  3-­‐4	  treatment	  costs	  of	  £123,	  or	  Category	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2	  investigation	  with	  Category	  3	  treatment	  costs	  of	  £158.	  	  However,	  in	  the	  case	  of	  second	  and	  third	  hospitalisation	  I	  used	  the	  ‘Non-­‐elective	  Inpatient	  HRG’	  section	  and	  multiplied	  it	  by	  the	  total	  days	  of	  hospitalisation.	  	  For	  stays	  longer	  than	  four	  days	  I	  used	  relevant	  treatment	  categories	  under	  the	  ‘Non-­‐elective	  Inpatient	  HRG’	  section	  and	  multiplied	  by	  the	  number	  of	  days	  hospitalised.	  	  In	  the	  cases	  where	  reason	  for	  admission	  was	  missing	  or	  the	  participant	  did	  not	  want	  to	  disclose	  it	  I	  used	  the	  ‘General	  Trauma	  and	  Blast	  Injuries’	  category.	  	  The	  NHS	  Reference	  category	  used	  is	  given	  in	  brackets	  next	  to	  the	  reported	  reason	  for	  admission.	  	  The	  costs	  of	  hospitalisation	  are	  calculated	  as	  cost	  per	  attendance	  and	  have	  been	  multiplied	  by	  the	  total	  days	  of	  hospitalisation	  for	  each	  participant.	  	  
c.	  Statutory	  service	  use	  costs	  associated	  with	  exposure	  to	  the	  London	  bombings	  	  This	  section	  outlines	  NHS-­‐provided	  services	  used	  by	  the	  individuals	  involved	  in	  the	  London	  bombings	  and	  their	  unit	  costs.	  	  The	  costs	  are	  reported	  from	  the	  two	  national	  compilations	  of	  costs	  for	  health	  and	  social	  care	  published	  annually:	  Unit	  Costs	  of	  Health	  and	  Social	  Care	  (UCHSC)	  and	  NHS	  Reference	  Costs	  (NHSRC).	  	  For	  costing	  community	  and	  hospital-­‐based	  health	  and	  social	  care	  services,	  I	  used	  UCHSC,	  while	  for	  costing	  specialised	  hospital-­‐based	  services	  I	  consulted	  NHSRC.	  	  Data	  on	  service	  usage	  covers	  different	  points	  of	  service	  use,	  ranging	  from	  hours,	  to	  up	  to	  three	  years	  after	  the	  London	  bombings.	  	  Therefore	  the	  service	  costs	  are	  calculated	  on	  the	  basis	  of	  the	  average	  service	  costs	  listed	  in	  the	  appropriate	  costing	  publications	  for	  the	  years	  2005,	  2006,	  2007	  and	  2008	  and	  adjusted	  for	  inflation,	  in	  order	  to	  cover	  the	  timeframe	  of	  ST	  and	  evaluation	  projects.	  	  Particulars	  and	  assumptions	  behind	  the	  costing	  for	  each	  source	  of	  information	  are	  described	  in	  greater	  detail	  below.	  	  	  
Unit	  Costs	  of	  Health	  and	  Social	  Care	  (UCHSC)	  	   The	  services	  costs	  used	  do	  not	  reflect	  London	  wages,	  as	  many	  participants	  were	  not	  London	  residents.	  	  Costs	  include	  direct	  care	  staff	  with	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qualifications	  and	  are	  expressed	  as	  costs	  per	  hour	  or	  per	  surgery	  consultation	  in	  pounds	  sterling.	  Where	  appropriate,	  the	  costs	  are	  broken	  down	  to	  first	  and	  subsequent	  appointments	  in	  order	  to	  take	  into	  account	  the	  difference	  in	  the	  costs.	  	  If	  cost	  information	  was	  not	  available	  for	  the	  appropriate	  year,	  data	  from	  the	  next	  available	  year	  was	  included	  and	  adjusted	  for	  inflation	  by	  using	  the	  relevant	  year	  Pay	  and	  Price	  Index	  for	  Hospital	  &	  Community	  Health	  Services3.	  	  	  
Type of service Unit cost (£ per time unit)
A&E 109.00 per hour
Care support worker 15.33 per hour 
Community nurse 30.67 per hour
Dietitician 24.00 per hour
General Practitioner 31.66 per surgery consultation lasting 11.7 minutes
Hospital check-up 109.00 per hour
Mental health nurse 25.66 per hour
NHS Counsellor 39.25 per hour
NHS Psychiatrist 111.33 per hour
NHS Psychologist 39.33 per hour
Other nurse 26.66 per hour
Paramedic 108.00 per hour
Physiotherapist 25.33 per hour
Podiatrist 23.00 per hour
Rehabilitation specialist 25.33 per hour
Social worker 27.00 per hour
Surgeon 108.67 per hour
Home care worker 15.33 per hour 	  
NHS	  Reference	  Costs	  (NHSRC)	  	   In	  order	  to	  cost	  specialist	  services	  I	  used	  consultant-­‐led	  first	  and	  follow-­‐up	  attendance	  outpatient	  face-­‐to-­‐face	  contact	  categories	  in	  the	  NHS	  reference	  costs	  manual.	  	  Due	  to	  changes	  in	  reporting	  format,	  data	  for	  2005,	  2006	  2007	  and	  2008	  were	  not	  directly	  comparable	  and	  so	  I	  used	  the	  2007/08	  dataset	  as	  it	  provided	  the	  most	  complete	  data,	  and	  then	  adjusted	  for	  inflation	  accordingly	  by	  using	  the	  Pay	  and	  Price	  Index	  for	  Hospital	  &	  Community	  Health	  Services	  for	  2005/06	  and	  2006/07	  values	  (DH,	  2011).	  	  Total	  cost	  is	  the	  mean	  value	  of	  the	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  Drawn	  from	  Pay	  and	  Price	  Index	  for	  Hospital	  &	  Community	  Health	  Services	  http://www.healthcaresupply.org.uk/health-­‐service-­‐cost-­‐index/	  accessed	  on	  
October	  27	  2011. 
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2005/06,	  2006/07	  and	  2007/08	  unit	  costs.	  	  When	  cost	  information	  was	  not	  available	  for	  the	  relevant	  year,	  data	  from	  the	  next	  available	  year	  was	  included	  and	  adjusted	  for	  inflation	  by	  using	  the	  relevant	  year	  Pay	  and	  Price	  Index	  for	  Hospital	  &	  Community	  Health	  Services4.	  	  	   All	  costs	  are	  expressed	  in	  pounds	  sterling	  per	  time	  unit,	  for	  first	  and	  follow-­‐up	  appointments.	  	  	  
Type of service Unit cost (£ per time unit)
Audiologist *169.75, **169.34  per hour
Back specialist *120.12, **77.70 per hour
Blood test 2.98 per test
Cardiologist *158.83, **104.59 per hour
Ear specialist *169.75, **169.34  per hour
ENT specialist *105.23, **68.73 hour
Maxillofacial specialist *125.8, **83.67 per hour
Neurologist *195.56, **127.50 per hour
Ophthalmologist *105.23, **64.75 per hour
Optician *105.23, **64.75 per hour
Pain specialist *163.80, **98.61 per hour
Plastic surgeon *117.14, **77.70 per hour
* First appointment
** Follow-up appointment 	  
d.	  Private	  Sector	  Provided	  Services	  	  Private	  sector	  services	  costs	  were	  obtained	  from	  various	  sources	  such	  as	  average	  market	  prices,	  direct	  out-­‐of-­‐pocket	  payments	  made	  by	  the	  participants,	  estimations	  based	  on	  previous	  research	  in	  the	  area,	  or	  from	  information	  found	  in	  the	  literature,	  participants’	  records,	  direct	  communication	  with	  service	  providers	  or	  the	  media.	  	  	   Unit	  costs	  for	  the	  private	  sector	  services	  are	  based	  on	  2008	  market	  prices	  adjusted	  for	  inflation	  to	  reflect	  2005,	  2006,	  and	  2007	  prices.	  	  Other	  therapies’	  prices	  are	  based	  on	  average	  donations	  estimates	  from	  the	  National	  Survey	  of	  Volunteering	  and	  Charitable	  Giving	  (Institute	  of	  Volunteering,	  2008).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 Drawn from Pay	  and	  Price	  Index	  for	  Hospital	  &	  Community	  Health	  Services	  
http://www.healthcaresupply.org.uk/health-service-cost-index/	  accessed	  on	  October	  
27	  2011. 
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The	  unit	  cost	  is	  expressed	  as	  an	  average	  price	  based	  on	  three	  randomly	  selected	  London	  and	  non-­‐London	  based	  service	  providers.	  	  	  
Type of service Unit cost (£ per time unit)
Acupuncture 57.68 per session
Counselling 62.33 per session
Counsellor provided by work 62.33 per session
Grief counsellor 38.83 per session
Herbalist 64.31 per session
Homeopathy 59.37 per session 
Hypnotherapist 69.26 per session
Massage 39.58 per session
Pilates 29.68 per session
Psychiatrist 125.66 per session
Psychological assessment 94.00 per session
Psychologist 59.37 per session 
Psychotherapy 94.00 per session
Yoga 9.89 per session 	  
Other therapies
Healer 4.94 per session
Spiritualist 4.94 per session 	  
e.	  Voluntary	  sector	  service	  use	  costs	  associated	  with	  exposure	  to	  the	  London	  
bombings	  	  Costing	  of	  not-­‐for-­‐profit	  organisations	  proved	  to	  be	  challenging	  on	  many	  levels.	  	  I	  based	  my	  calculations	  on	  records	  in	  the	  published	  and	  unpublished	  (grey)	  literature,	  personal	  records	  or	  available	  information	  found	  in	  the	  electronic	  media.	  	  Firstly,	  most	  of	  the	  organisations	  involved	  have	  no	  data	  available	  on	  the	  prices	  for	  their	  services	  per	  hour.	  	  Therefore	  where	  available	  I	  based	  the	  costing	  of	  the	  services	  on	  their	  annual	  financial	  reports	  comparing	  total	  number	  of	  service	  users	  with	  total	  year	  expenditure	  on	  the	  services	  in	  question.	  	  This	  approach	  was	  used	  for	  costing	  St.	  John’s	  Ambulance,	  Cruse	  Bereavement	  and	  Red	  Cross	  service	  units.	  	  In	  estimating	  service	  unit	  costs	  for	  7th	  of	  July	  Assistance	  Centre	  art	  therapy,	  counselling	  and	  massage	  services	  I	  used	  market	  prices	  of	  the	  activities	  as	  proxies.	  	  In	  addition	  to	  those	  services,	  7th	  of	  July	  provided	  other	  services	  that	  included	  information	  letters,	  running	  service	  users	  support	  groups,	  sharing	  information	  on	  other	  available	  services	  and	  support	  groups	  as	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well	  as	  information	  and	  assistance	  on	  legal	  and	  financial	  matters	  associated	  with	  the	  bombings.	  	  I	  used	  the	  unit	  costs	  of	  the	  Citizens	  Advice	  Bureau	  (CAB),	  based	  on	  the	  total	  number	  of	  clients	  divided	  by	  the	  total	  income	  spent	  on	  service	  provision	  and	  education	  for	  2009.	  	  Data	  on	  Alcoholics	  Anonymous	  (AA)	  UK	  branch	  unit	  costs	  is	  based	  on	  the	  organisation’s	  costing	  policies	  published	  on	  the	  Internet.	  	  AA	  funding	  is	  based	  on	  limited	  individual	  and	  member	  donations	  and	  after	  each	  session,	  participants	  donate	  voluntary	  contributions	  to	  cover	  for	  the	  running	  of	  the	  session.	  	  However,	  as	  the	  number	  of	  members	  was	  not	  available,	  I	  used	  £5	  as	  a	  proxy	  for	  voluntary	  donations	  based	  on	  the	  findings	  from	  National	  Survey	  of	  Volunteering	  and	  Charitable	  Giving	  on	  the	  average	  amount	  people	  donate	  per	  week	  to	  charity	  (IOV,	  2008).	  	  Due	  to	  the	  lack	  of	  available	  data	  on	  Disaster	  Action	  and	  Victim	  Support	  service	  unit	  costs,	  I	  used	  the	  unit	  cost	  for	  the	  CAB	  as	  a	  proxy.	  	  
Type of service Unit cost (£ per time unit)
7th of July Assistance Centre:
 art therapy 59.37 per session 
 counselling 62.33 per session
massage 39.58 per session
other services 39.58 per session
AA 4.94 per session
Cruse bereavement 106.20 per session
Disaster action 39.58 per session
Flexi care 16.33 per session
Priest 0 per session
Red Cross 128.34 per emergency response
St. John's Ambulance 85.09 per emergency response
Victim support 39.58 per session 	  	   Participants	  reported	  using	  two	  support	  groups	  set	  up	  by	  the	  London	  bombings	  survivors:	  King’s	  Cross	  United	  and	  Tavistock	  Square	  Help	  Group.	  	  Both	  were	  informal	  support	  groups,	  set	  up	  and	  run	  by	  survivors	  and	  both	  provided	  a	  platform	  for	  provision	  of	  support	  and	  information	  sharing.	  	  The	  groups	  run	  Internet	  forums	  and	  organised	  regular	  meetings	  in	  local	  informal	  settings,	  such	  as	  pubs.	  	  Appropriate	  unit	  cost	  allocation	  for	  support	  groups	  would	  mean	  establishing	  the	  opportunity	  cost	  for	  survivors	  behind	  the	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organisation	  and	  group	  users,	  but	  the	  data	  on	  both	  is	  unavailable	  and	  hence	  zero	  costs	  were	  allocated.	  
Type of service Unit cost (£ per time unit)
Informal 0 per session
Internet 0 per session
King's Cross United 0 per session
Tavistock Sq help group 0 per session 	  
4.2.4	   Occupation	  and	  earnings	  costs	  –	  productivity	  loss	  	  The	  following	  data	  are	  taken	  from	  the	  2005	  Annual	  Survey	  of	  Hours	  and	  Earnings	  (ASHE)	  analysis	  by	  occupation.	  	  For	  simplicity,	  the	  table	  below	  lists	  only	  the	  main	  employment	  categories	  and	  median,	  weekly	  and	  hourly	  gross	  annual	  earnings	  followed	  by	  median	  weekly	  hours.	  	  I	  allocated	  a	  4-­‐digit	  Standard	  Occupational	  Code	  for	  each	  participant	  based	  on	  the	  job	  title	  they	  provided	  and	  the	  corresponding	  median	  weekly	  earnings.	  	  Where	  a	  4-­‐digit	  code	  was	  not	  available	  I	  used	  the	  corresponding	  3	  or	  2-­‐digit	  code	  instead.	  	  Total	  productivity	  loss	  from	  absenteeism	  was	  calculated	  as	  a	  sum	  of	  daily	  productivity	  loss	  due	  to	  sickness	  leave,	  the	  total	  number	  of	  reduced	  hours	  of	  work,	  and	  the	  daily	  productivity	  loss	  due	  to	  unemployment	  as	  a	  consequence	  of	  involvement	  in	  the	  London	  bombings.	  	  The	  daily	  productivity	  loss	  represented	  one	  fifth	  of	  the	  median	  weekly	  wage	  (a	  daily	  wage)	  and	  was	  multiplied	  by	  the	  number	  of	  days	  on	  sick	  leave	  due	  to	  the	  London	  bombings.	  	  In	  order	  to	  calculate	  the	  productivity	  loss	  from	  reduced	  hours,	  I	  have	  multiplied	  the	  total	  number	  of	  hours	  reduced	  by	  the	  median	  hourly	  earnings	  for	  each	  employment	  category.	  	  Productivity	  loss	  from	  unemployment	  was	  estimated	  as	  a	  total	  number	  of	  days	  unemployed	  due	  to	  the	  London	  bombings	  and	  multiplied	  by	  the	  median	  daily	  earnings	  for	  the	  employment	  category	  (Table	  4.3).	  	  Productivity	  loss	  costs	  are	  based	  on	  2008	  market	  prices	  adjusted	  for	  inflation	  to	  reflect	  2005,	  2006,	  and	  2007	  prices.	  	  I	  have	  asked	  participants	  to	  recall	  how	  many	  days	  were	  they	  on	  the	  sick-­‐leave,	  if	  they	  had	  reduced	  hours	  at	  work	  or	  become	  unemployed	  due	  to	  exposure	  to	  the	  LB.	  	  As	  in	  some	  cases	  participants	  were	  interviewed	  up	  to	  two	  years	  after	  the	  LB,	  it	  is	  appropriate	  to	  question	  if	  and	  to	  what	  degree	  self-­‐recall	  is	  accurate.	  Such	  a	  long	  recall	  period	  can	  consequently	  result	  in	  under-­‐	  or	  overestimation	  of	  productivity	  costs.	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Table	  4.3	  Occupation	  and	  earnings	  categories	  (ASHE,	  2005)	  
Occupation	  group	  
Med.	  
gross	  
annual	  
earnings	  
Med.	  gross	  
weekly	  
earnings	  
Med.	  
Hourly	  
earnings	  	  
Med.	  
Weekly	  
hours	  Managers	  and	  senior	  officials	   32,216	   609,4	   16.25	   37.4	  Professional	  occupations	   30,783	   594.4	   18.13	   35.0	  Associate	  professional	  and	  technical	  occ.	   24,093	   456.9	   12.77	   37.0	  Administrative	  and	  secretarial	  occupations	   14,644	   279.4	   8.33	   35.0	  Skilled	  trades	  occupations	   20,708	   390.0	   9.47	   40.0	  Personal	  service	  occupations	   10,649	   209.6	   7.02	   30.3	  Sales	  and	  customer	  service	  occupations	   8,454	   161.2	   5.76	   27.9	  Process,	  plant	  and	  machine	  operatives	   18,790	   357.2	   8.19	   40.1	  Elementary	  occupations	   10,710	   195.3	   6.00	   34.4	  
4.3	  	   Costs	  of	  being	  involved	  in	  the	  London	  bombings	  	  This	  section	  will	  explore	  service	  use	  for	  a	  sample	  of	  people	  involved	  in	  the	  LB.	  	  I	  will	  present	  costs	  collected	  for	  a	  sub-­‐sample	  of	  230	  participants	  as	  a	  part	  of	  the	  evaluation	  of	  the	  ST	  programme	  undertaken	  between	  September	  2006	  and	  September	  2008.	  	  I	  have	  already	  described	  in	  Chapter	  3	  the	  participants,	  their	  socio-­‐demographic	  characteristics	  and	  occupation,	  alongside	  details	  about	  how	  they	  were	  affected	  by	  the	  bombings	  and,	  if	  they	  used	  the	  ST	  programme,	  the	  type,	  length	  and	  outcome	  of	  their	  treatment.	  	  The	  time	  frame	  for	  the	  estimates	  of	  costs	  varies	  significantly	  between	  the	  participants,	  as	  all	  participants	  were	  asked	  to	  recall	  their	  service	  use	  due	  to	  the	  LB	  from	  the	  exposure	  to	  the	  LB	  until	  their	  participation	  in	  the	  evaluation	  study.	  	  Due	  to	  the	  heterogeneity	  of	  the	  follow-­‐up	  timing,	  the	  estimated	  costs	  are	  more	  accurately	  portrayed	  as	  snapshots	  of	  the	  period	  post	  the	  LB	  up	  to	  the	  data	  collection	  point	  rather	  than	  total	  overall	  costs	  due	  to	  exposure	  to	  the	  LB,	  in	  particular	  for	  individuals	  with	  long-­‐term	  physical	  or	  mental	  health	  concerns.	  	  However,	  for	  participants	  with	  only	  short-­‐term	  consequences	  due	  to	  exposure,	  these	  estimates	  should	  reflect	  the	  overall	  effects	  of	  the	  exposure	  to	  the	  LB.	  Literature	  on	  costing	  or	  evaluation	  of	  health	  care	  very	  often	  categorises	  costs	  into	  direct,	  indirect,	  and	  intangible.	  	  Direct	  costs	  are	  often	  associated	  with	  measurable	  resources	  spent	  in	  the	  health	  care	  sector	  and	  could	  also	  refer	  to	  patient’s	  direct	  out-­‐of-­‐pocket	  spending.	  	  Indirect	  costs	  are	  commonly	  defined	  in	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the	  context	  of	  productivity	  loss	  in	  terms	  of	  days	  off	  work	  due	  to	  sickness,	  hours	  reduced,	  unemployment	  or	  presenteeism.	  Intangible	  costs	  refer	  to	  un-­‐measurable	  or	  difficult	  to	  measure	  constructs	  such	  as	  effects	  of	  pain	  and	  suffering	  or	  increased	  quality	  of	  life.	  	  Although	  Drummond	  (2005)	  has	  argued	  against	  this	  practice	  due	  to	  inconsistency	  of	  terminology	  use	  among	  different	  studies,	  I	  have	  adhered	  to	  it	  in	  the	  thesis	  as	  it	  has	  been	  frequently-­‐used.	  	  In	  order	  to	  ensure	  clarity	  and	  consistency	  of	  its	  use	  throughout	  the	  study,	  I	  will	  provide	  a	  detailed	  description	  and	  operationalise	  each	  cost	  category.	  	  The	  service	  costs	  category	  includes	  costs	  associated	  with	  all	  resources	  and	  services	  used	  by	  the	  participants	  as	  a	  result	  of	  their	  involvement	  in	  the	  2005	  London	  bombings.	  	  Direct	  costs	  are	  categorised	  as	  follows:	  the	  ST	  programme	  (screening	  and	  assessment,	  and	  treatment	  costs);	  NHS	  provided	  primary	  and	  secondary	  services;	  hospitalisation;	  medication;	  private	  sector	  services	  and	  voluntary	  sector	  services.	  	  	  	   Productivity	  loss	  costs	  include:	  workplace	  productivity	  loss	  due	  to	  sick	  leave,	  reduced	  work	  hours,	  and	  unemployment	  resulting	  from	  involvement	  in	  the	  London	  bombings.	  	  Fourteen	  participants	  reported	  diminished	  productivity	  at	  work	  (presenteeism)	  even	  though	  the	  CSRI	  did	  not	  ask	  specifically	  about	  it.	  	  At	  this	  point	  these	  costs	  are	  not	  included	  in	  the	  analysis.	  	  Table	  4.4	  presents	  total	  estimated	  costs	  reported	  by	  a	  sample	  of	  230	  individuals	  involved	  in	  the	  London	  bombings,	  with	  the	  total	  overall	  cost	  of	  £2,592,346	  at	  2007/08	  prices.	  	  Indirect	  costs	  represented	  62%	  of	  the	  total	  reported	  costs.	  	  All	  cost	  distributions	  are	  significantly	  different	  from	  a	  normal	  distribution	  due	  to	  a	  great	  variability	  and	  dispersion	  of	  costs	  reported	  by	  the	  service	  users	  (see	  the	  results	  of	  the	  Kolmogorov-­‐Smirnov	  test	  in	  Table	  4.4).	  	  A	  number	  of	  individuals	  did	  not	  use	  services;	  around	  12%	  reported	  zero	  costs	  for	  services	  and	  around	  40%	  for	  productivity	  costs.	  	  Four	  participants	  (1%)	  had	  total	  costs	  greater	  than	  £100,000,	  resulting	  in	  a	  long	  tail	  in	  the	  cost	  distribution	  and	  a	  large	  dispersion	  of	  the	  data.	  	  Around	  70%	  of	  participants	  reported	  total	  costs	  associated	  with	  the	  London	  bombings	  of	  between	  £1,000	  and	  £10,000	  per	  person.	  	  Table	  4.4	  Total	  costs	  associated	  with	  exposure	  to	  the	  London	  bombings	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   Service	  use	  
costs	  
Productivity	  
loss	  costs	  
Overall	  
costs	  
N	   230	   230	   230	  
M	  
Min	  
4362.45	  £0	   6026.62	  £0	   10389.22	  £0	  
Max	   £156480.81	   £167089.6	   £178842.5	  
SD	   £12702.6	   £19798.92	   £24875.25	  
N	  (%)	  of	  participants	  with	  
zero	  costs	  
28	  (12.2)	   93	  (40.3)	   21	  (9.1)	  
Total	  	  
%	  of	  overall	  costs	  
£1003364.03	  	  37.78	   £1386156.22	  	  62.22	   £2389520.45	  
Normality	  of	  distribution	  
test	  
Z=5.632,	  p<0.001	   Z=5.775,	  p<0.001	   Z=5.169,	  p<0.001	  
	  
4.3.1	  Service	  Costs	  	  The	  following	  categories	  are	  included	  in	  direct	  costs:	  the	  ST	  programme	  screening	  and	  assessment,	  the	  ST	  programme	  treatment,	  health	  services,	  hospitalisation,	  medication,	  private	  and	  voluntary	  sector	  services.	  Table	  4.5	  Service	  costs	  categories:	  screening	  and	  assessment,	  treatment,	  health	  services	  and	  hospitalisation	  costs	  
	  	   Screening	  and	  Assessment	  	   Treatment	   Health	  services	   Hospitalisation	  
N	  	   149	   97	   175	   24	  
M	   488.5	   1439.75	   £439.09	   £15623.33	  
Min	   £439	   £262	   £27	   £123	  
Max	   £878	   £16742	   £10692	   £153993	  
SD	   £198	   £3025	   £953	   £12256	  
Total	  
costs	   £112356.3	   £331185.60	   £113642.06	   £374960.00	  
%	  of	  
direct	  
costs	   11.20	   33.01	   11.33	   37.37	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Table	  4.6	  Service	  costs	  categories:	  medication,	  private	  and	  voluntary	  sector	  costs	  
	  	   Medication	   Private	  sector	   Voluntary	  sector	  
N	  	   68	   82	   39	  
M	   £22.03	   £228.71	   £384.74	  
Min	   £0	   £10	   £40	  
Max	   £931	   £3518	   £3428	  
SD	   £98	   £563	   £320	  
Total	  costs	   £4296.23	   £51919.00	   £15004.84	  
%	  of	  direct	  costs	   0.43	   5.17	   1.50	  	  Tables	  4.5	  and	  4.6	  show	  the	  variation	  in	  costs	  between	  participants	  per	  service	  categories.	  	  Costs	  are	  not	  normally	  distributed	  and	  this	  needs	  to	  be	  taken	  into	  account	  in	  data	  analysis	  and	  interpretation.	  	  The	  most	  frequently-­‐used	  services	  were	  health	  services	  followed	  by	  screening	  and	  assessment,	  with	  around	  65%	  of	  participants	  reporting	  using	  one	  of	  these	  services.	  	  However,	  although	  they	  were	  the	  most	  frequently-­‐used,	  each	  service	  only	  contributes	  up	  to	  11%	  of	  all	  service	  costs.	  	  It	  is	  the	  opposite	  with	  hospitalisation	  costs,	  where	  a	  relatively	  small	  number	  of	  users	  reported	  high	  costs:	  10%	  hospitalised	  participants	  accounted	  for	  37%	  of	  all	  direct	  costs.	  	  This	  was	  followed	  by	  treatment	  under	  the	  ST	  programme,	  33%	  of	  the	  service	  costs.	  	  Medication,	  voluntary	  sector	  and	  private	  costs	  accounted	  for	  only	  up	  to	  7%	  of	  total	  service	  costs.	  	  
a.	  Screening	  and	  Assessment	  In	  total,	  149	  participants	  were	  screened	  and	  assessed	  with	  a	  total	  cost	  of	  £112,356.30	  at	  2007/08	  prices.	  Participants	  were	  screened	  from	  one	  up	  to	  five	  times,	  with	  73%	  of	  participants	  screened	  once.	  	  	  
b.	  Treatment	  The	  cost	  of	  treatment	  was	  £331,185.60	  at	  2007/08	  prices	  and	  this	  was	  the	  second	  highest	  service	  cost	  (Table	  4.8).	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c.	  Health	  care	  services	  Although	  health	  care	  costs	  represent	  a	  very	  small	  percentage	  of	  reported	  direct	  costs	  (around	  7%),	  they	  are	  the	  most	  frequently-­‐used	  services	  after	  assessment	  and	  screening,	  with	  around	  63%	  of	  participants	  reporting	  using	  one	  of	  the	  associated	  NHS	  services.	  	  For	  simplicity	  of	  presentation	  I	  have	  grouped	  the	  following	  services	  within	  hospital	  outpatient	  services:	  ear	  specialist,	  eye	  specialist,	  podiatrist,	  knee	  specialist,	  leg	  injury	  specialist,	  neurologist,	  maxofacillo	  specialist,	  cardiologist,	  ENT	  specialist,	  rehabilitation	  specialist,	  pain	  specialist	  and	  plastic	  surgeon.	  	  NHS	  psychiatrist,	  psychologist	  and	  counsellor	  are	  grouped	  under	  NHS	  mental	  health	  services.	  	  As	  Table	  4.7	  shows,	  more	  commonly	  used	  services	  included	  GPs,	  followed	  by	  A&E,	  and	  NHS-­‐provided	  mental	  health	  services	  (in	  particular,	  psychologist	  and	  counsellor).	  	  A	  small	  number	  of	  participants	  used	  more	  specialised	  health	  care	  services	  depending	  on	  the	  type	  of	  health	  problem	  they	  experienced.	  Use	  of	  GP	  services	  varied	  from	  1-­‐150	  contacts.	  	  Table	  4.7	  Use	  of	  health	  care	  services	  	  
Health	  care	  services	   N	  	  of	  users	   %	  of	  users	  
%	  of	  total	  
costs	  GP	   155	   67.39	   29.53	  A&E	   68	   29.57	   7.77	  NHS	  mental	  health	   100	   43.57	   34.42	  Audiologist	   8	   3.48	   3.68	  Physiotherapist	   8	   3.48	   3.57	  Surgeon	   6	   2.61	   2.58	  Other	  nurse	   6	   2.61	   0.45	  Blood	  test	   3	   1.30	   0.00	  Hospital	  outpatients	   2	   6.88	   10.37	  Mental	  health	  nurse	   2	   0.87	   0.05	  
Health	  care	  services	   N	  	  of	  users	   %	  of	  users	   %	  of	  total	  costs	  Dietician	   1	   0.43	   0.06	  Social	  worker	   1	   0.43	   0.17	  Care	  support	  worker	   1	   0.43	   0.01	  Paramedic	   1	   0.43	   0.16	  Hospital	  check	  visit	   1	   0.43	   0.29	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d.	  Private	  sector	  services	  Fewer	  participants	  reported	  using	  private	  sector	  services	  in	  comparison	  to	  NHS	  provided	  services.	  	  	  The	  cost	  of	  private	  services	  was	  £51,919.00.	  	  Formal	  mental	  health	  services	  included	  the	  following	  service	  categories:	  counselling	  provided	  by	  employers,	  other	  counselling,	  psychotherapist,	  psychiatrist,	  psychologist,	  psychological	  assessment.	  	  Among	  formal	  mental	  health	  services,	  counselling	  and	  psychotherapy	  were	  the	  most	  commonly	  used	  services.	  Alternative	  or	  complementary	  services	  included	  acupuncture,	  massage,	  herbalist,	  osteopath,	  homeopathy,	  hypnotherapy,	  yoga	  and	  spiritualist	  services.	  	  Table	  4.8	  Use	  of	  private	  sector	  services	  	  
Type	  of	  service	  	   N	  of	  users	  
%	  of	  
participants	  
%	  of	  total	  
costs	  Formal	  mental	  health	  services	   63	   27.30	   71.25	  Alternative	  or	  complementary	  services	  	   29	   13.58	   28.75	  
	  
e.	  Voluntary	  sector	  services	  In	  total,	  costs	  for	  voluntary	  sector	  services	  absorbed	  only	  1.5%	  of	  total	  direct	  costs,	  and	  only	  43	  participants	  reported	  using	  voluntary	  sector	  services,	  with	  a	  total	  cost	  of	  £	  15,004.84	  (Table	  4.9).	  	  Voluntary	  sector	  services	  used	  were	  most	  frequently	  provided	  by	  organisations	  set	  up	  specifically	  to	  address	  the	  needs	  of	  individuals	  involved	  in	  the	  London	  bombings.	  	  Table	  4.9	  shows	  that	  the	  majority	  of	  respondents	  used	  7th	  July	  Assistance	  centre,	  followed-­‐by	  King’s	  Cross	  United,	  Cruse	  Bereavement	  and	  Victim	  Support.	  	  Table	  4.9	  Use	  of	  voluntary	  sector	  services	  	  
Type	  of	  service	  
N	  of	  
users	  
%	  of	  
participants	  
%	  of	  
total	  
costs	  7/7	  Assistance	  centre	  -­‐	  other	   21	   9.13	   30.86	  7/7	  Assistance	  centre	  -­‐	  counselling	   14	   6.09	   41.98	  7/7	  Assistance	  centre	  -­‐	  massage	   6	   2.61	   9.50	  Kings	  Cross	  United	   5	   2.17	   0.00	  Cruse	   3	   1.30	   3.43	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Victim	  Support	   3	   1.30	   1.32	  Home	  help	   1	   0.43	   1.43	  Flexicare	   1	   0.43	   16.97	  Red	  Cross	   1	   0.43	   0.86	  St.	  Johns'	  Ambulance	   1	   0.43	   0.57	  7/7	  Assistance	  centre	  -­‐	  art	  therapy	   1	   0.43	   2.38	  AA	   1	   0.43	   6.58	  Disaster	  Action	   1	   0.43	   0.26	  Tavistock	  Square	  group	   1	   0.43	   0.00	  Priest	   1	   0.43	   0.00	  
	  
f.	  Hospitalisation	  –	  types	  of	  services	  used	  In	  total,	  24	  respondents	  reported	  being	  hospitalised,	  the	  maximum	  number	  being	  three	  times.	  	  Length	  of	  stay	  averaged	  five	  days	  for	  first	  hospitalisation,	  19	  for	  the	  second	  and	  seven	  for	  the	  third.	  	  The	  most	  frequent	  reasons	  that	  participants	  were	  hospitalised	  were	  the	  trauma	  and	  blast	  injuries,	  followed	  by	  amputations	  and	  eye	  injuries	  (table	  4.10).	  	  The	  cost	  of	  hospitalisation	  was	  very	  high,	  37%	  of	  total	  direct	  costs	  being	  attributed	  to	  hospitalisation	  costs.	  	  In	  particular,	  the	  cost	  of	  interventions	  for	  MRSA	  infection,	  skin	  graft	  surgery	  and	  amputations	  was	  very	  high,	  accounting	  for	  almost	  78%	  of	  total	  hospitalisation	  costs.	  	  Table	  4.10	  Use	  of	  hospital	  services	  
Hospitalisation	  reason	  
N	  of	  
service	  
users	   %	  
%	  of	  the	  
total	  costs	  General	  trauma	  and	  blast	  injuries	   7	   3.04	   	  1.44	  Eye	  injury	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	   1.30 	  0.19	  Traumatic	  Amputations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	   1.30	   12.22	  Back	  injuries	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2 0.87	   	  0.09Burns	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	   0.87 	  1.98	  Knee	  injury	  and	  operation	   2	   0.87	   	  0.03	  Operations	  to	  face	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1 0.43	   	  0.04Leg	  surgery	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   0.43	   	  1.97	  Head	  injury	  and	  cuts	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   0.43	   	  0.03	  Wrist	  surgery	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   0.43	   0.17	  Chest	  pain	   1	   0.43	   	  0.42	  Right	  eardrum	  graft	  skin	  repair	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   0.43	   1.84	  Shock	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   0.43	   	  0.03	  Broken	  arm	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   0.43	   	  0.03	  Skin	  graft	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   1	   0.43	   25.44	  Head,	  neck,	  shoulder	  injuries	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	   0.43	   	  1.35	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Overdose	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  1	   0.43	   	  0.03	  Irregular	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  1 0.43	   	  1.34Depression	   1	   0.43	   	  0.96	  MRSA	  infection	   1	   0.43	   41.03	  
	  
g.	  Medication	  	  63	  participants	  reported	  using	  medications,	  on	  average	  two	  medications	  per	  person.	  	  Twenty-­‐one	  out	  of	  the	  50	  medications	  reported	  by	  the	  participants	  were	  mental	  health	  medications,	  and	  other	  medications	  covered	  physical	  health	  problems	  mostly	  related	  to	  the	  injuries	  received	  during	  the	  London	  bombings.	  	  Table	  4.11	  shows	  that	  the	  most	  frequently-­‐used	  medications	  were	  pain-­‐killers	  followed	  by	  mental	  health	  medications	  such	  as	  antidepressants,	  insomnia	  treatment	  and	  anxiolytic	  medication.	  	  Table	  4.11	  List	  of	  prescribed	  medications	  
Medication	   N	  of	  users	   %	  Painkillers	  (Ibuprofen)	   17	   7.39	  Antidepressant	  (Amitriptyline)	   17	   7.96	  Sleeping	  pills	  (Zopiclone)	   13	   5.65	  Diazepam	   11	   4.78	  Citalopram	  	   8	   3.48	  Antibiotics	  (Amoxicillin)	   7	   3.04	  Relaxation	  remedy	  (Valerian	  tablets)	   4	   1.74	  Anti-­‐inflammatories	  (Ibuprofen)	   3	   1.30	  Paracetamol	  	   3	   1.30	  Antihistamine	  (Promethazine)	   2	   0.87	  Codeine	   2	   0.87	  Ear	  drops	  (Chloramphenicol	  	  5%)	   2	   0.87	  Eye	  drops	  (Maxidex)	   2	   0.87	  Fluoxetine	  	   2	   0.87	  Psychotropic	  medicine	  (Prozac)	   2	   0.87	  Tranquilisers	  (Buspirone)	   3	   1.5	  Voltarol	   2	   0.87	  Antibiotics	  for	  MRSA	  (Vancomycin)	   1	   0.43	  Betahistine	   1	   0.43	  Blood-­‐thinning	  injection	  (Heparin-­‐sodium)	   1	   0.43	  Co-­‐codamol	   1	   0.43	  Cortisone	  injections	  (Kenalog)	   1	   0.43	  Diclofenac	   2	   0.43	  Dihydrocodeine	   1	   0.43	  Escitalopran	  (Cipralex)	   1	   0.43	  For	  heart	  flutter	  (Warfarin)	   1	   0.43	  Gallstone	  tablets	  (Urdox)	   1	   0.43	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Gaviscon	   1	   0.43	  Heart	  medicine	  (Warfarin)	   1	   0.43	  Hepatitis	  injections	  (Havrix)	   1	   0.43	  Herbal	  medicine	  for	  sleeping	  (Valerian	  capsules)	   1	   0.43	  Inhailers	  (Salbutamol)	   2	   0.43	  Liquid	  paraffin	   1	   0.43	  Lorazepam	  (Benzodiazepin)	   2	   0.86	  Optrex	  solution	  for	  eyes	   1	   0.43	  Paroxetine	  (Seroxat)	   2	   0.43	  Propranolol	   1	   0.43	  Prozac	   1	   0.43	  Sertraline	   1	   0.43	  Steroid	  tablets	  (Prednisolone)	   1	   0.43	  Symmetrel	  	   1	   0.43	  Syprolex	  (Cipralex)	   1	   0.43	  Xanax	  (Alprazolam)	   1	   0.43	  
	  
4.3.2	  Productivity	  loss	  costs	  The	  productivity	  costs	  category	  includes	  costs	  associated	  with	  productivity	  loss	  due	  to	  hours	  of	  work	  being	  reduced,	  sick	  leave	  and	  unemployment	  caused	  by	  exposure	  to	  the	  London	  bombings.	  	  Productivity	  costs	  make	  up	  around	  60%	  of	  total	  costs,	  and	  the	  biggest	  average	  reported	  cost	  was	  due	  to	  unemployment.	  	  Productivity	  costs	  by	  type	  of	  absence	  from	  work	  are	  presented	  in	  Table	  4.12.	  	  Only	  28	  participants	  reported	  being	  unemployed,	  although	  the	  total	  cost	  of	  unemployment	  of	  £544,627.12	  at	  2007/08	  prices	  accounted	  for	  almost	  45%	  of	  productivity	  costs.	  	  Length	  of	  unemployment	  ranged	  from	  3	  to	  320	  weeks,	  with	  a	  median	  of	  eight	  weeks.	  	  The	  most	  frequently	  reported	  productivity	  costs	  were	  associated	  with	  sick	  leave,	  with	  56%	  of	  participants	  reporting	  taking	  sick	  leave	  in	  duration	  of	  between	  1	  and	  1112	  days.	  	  A	  relatively	  small	  number	  of	  participants	  (N=29)	  reported	  reducing	  their	  hours	  of	  work,	  ranging	  from	  7	  to	  780	  with	  the	  total	  cost	  of	  £63,932.16	  at	  2007/08	  prices.	  	  Data	  on	  occupation	  were	  missing	  for	  20	  participants.	  I	  performed	  multiple	  imputation	  to	  impute	  weekly	  median	  wages	  based	  on	  the	  sample.	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Table	  4.12	  Productivity	  loss	  costs	  by	  type	  of	  absence	  from	  work	  
	   Productivity	  loss	  (£)	  	   Hours	  reduced	   Sick	  leave	  	   Unemployment	  N	   29	   124	   28	  M	   277.96	   3380.83	   2367.94	  Min	   54	   50	   1253.70	  Max	   17573.20	   155591.04	   124066.80	  SD	   3646.05	   17135.50	   30978.79	  Total	  costs	   63932.16	   777596.26	   544627.12	  %	  of	  work	  related	  costs	   4.01	   51.73	   44.29	  	   In	  addition	  to	  data	  on	  productivity	  loss,	  as	  a	  part	  of	  the	  evaluation,	  participants	  were	  asked	  about	  the	  effects	  of	  the	  LB	  on	  their	  work	  and	  leisure	  activities.	  	  In	  total,	  24	  participants	  who	  received	  treatment	  reported	  that	  the	  bombings	  had	  affected	  their	  work.	  	  Eight	  participants	  reported	  career	  effects	  such	  as:	  abandoning	  their	  current	  career	  due	  to	  injuries,	  loss	  of	  career	  opportunities	  such	  as	  promotions,	  missing	  job	  interviews	  or	  underperformance	  at	  job	  interviews,	  and	  loss	  of	  job	  opportunities	  that	  required	  travel	  to	  London.	  	  Nine	  participants	  stopped	  working	  or	  reported	  job/income	  losses	  due	  to	  the	  bombings,	  one	  participant	  retired	  early	  and	  five	  reported	  diminished	  work	  productivity.	  	  Seventeen	  participants	  reported	  difficulties	  with	  travelling	  and/or	  using	  public	  transport.	  	  Furthermore,	  participants	  reported	  effects	  on	  social	  life	  and	  educational	  opportunities.	  	  These	  effects,	  usually	  grouped	  into	  intangible	  costs	  (Drummond,	  2005),	  are	  difficult	  to	  cost	  and	  are	  consequently	  more	  often	  than	  not	  omitted	  from	  costing	  studies.	  	  Nevertheless,	  these	  effects	  are	  imposing	  a	  significant	  burden	  on	  individuals,	  their	  families	  and	  economy	  as	  a	  whole	  and	  should	  not	  be	  overlooked.	  	  In	  the	  evaluation	  study,	  24	  participants	  reported	  effects	  on	  social	  life	  that	  prevented	  them	  from	  “from	  going	  out,	  enjoying	  their	  leisure	  activities,	  and	  seeing	  their	  friends”,	  resulting	  in	  diminished	  social	  activities.	  	  Six	  participants	  reported	  strain	  on	  their	  family	  life,	  resulting	  in	  ending	  relationships/divorcing,	  or	  being	  overprotective	  of	  their	  children.	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4.4	   Comparisons	  with	  other	  studies	  It	  is	  interesting	  to	  investigate	  how	  the	  ST	  programme	  treatment	  costs	  compare	  to	  other	  reported	  PTSD	  CBT	  treatment	  costs.	  In	  their	  paper,	  Layard	  et	  al	  (2006)	  reported	  a	  cost	  of	  £750	  for	  a	  course	  of	  CBT	  therapy	  and	  the	  IAPT	  study	  reported	  average	  cost	  of	  £4.33	  per	  minute	  over	  the	  2	  years	  with	  the	  average	  contact	  time	  per	  patient	  of	  129	  min	  over	  an	  average	  of	  3	  sessions,	  giving	  an	  average	  cost	  per	  patient	  of	  £559.	  	  NICE	  guidelines	  estimate	  treatment	  cost	  to	  the	  NHS	  as	  £825	  for	  ten	  treatment	  sessions	  (1–	  1.5	  h	  in	  duration;	  NICE,	  2005).	  	  	  However,	  the	  validity	  of	  this	  comparison	  is	  questionable	  due	  to	  different	  methods	  of	  data	  collection	  used	  in	  studies	  (top-­‐down	  vs.	  bottom-­‐up),	  who	  delivered	  the	  therapy	  (clinical	  psychologist,	  computer	  administered	  therapy	  or	  nurse),	  type	  of	  disorder	  (depression,	  PTSD,	  travel	  phobia),	  and	  whether	  both	  direct	  and	  non-­‐direct	  therapist	  time	  were	  included	  in	  the	  cost.	  	  Some	  of	  these	  elements	  are	  not	  clear	  from	  the	  data	  presented	  in	  the	  published	  papers,	  which	  further	  complicates	  the	  comparison.	  	  What	  is	  observable	  though	  is	  that	  the	  ST	  programme	  reported	  higher	  average	  treatment	  session	  costs	  alongside	  a	  higher	  average	  number	  of	  sessions	  per	  patient	  when	  compared	  to	  numbers	  reported	  both	  by	  Layard	  and	  NICE	  guidelines.	  	  However,	  when	  comparing	  the	  ST	  programme	  and	  IAPT,	  the	  ST	  programme’s	  costs	  are	  well	  under,	  at	  on	  average	  £3	  per	  minute	  in	  comparison	  to	  £4.33	  in	  2008/09	  prices.	  	  It	  is	  also	  interesting	  to	  compare	  these	  results	  with	  the	  economic	  impact	  of	  PTSD	  in	  a	  Northern	  Ireland	  (NI)	  study,	  although	  due	  to	  sampling	  size	  and	  differences,	  the	  nature	  of	  the	  traumatic	  event,	  data	  collection	  instruments,	  timeline	  and	  cultural	  factors	  there	  are	  many	  limitations	  to	  this	  comparison.	  	  It	  is	  still	  worthwhile	  as	  this	  is	  the	  only	  other	  study	  looking	  into	  the	  economic	  impact	  of	  PTSD	  I	  have	  found.	  	  The	  NI	  cost-­‐of-­‐illness	  study	  interviewed	  1,986	  participants	  as	  a	  part	  of	  a	  representative	  household	  survey	  of	  English	  speakers	  in	  NI	  and	  included	  screening	  and	  assessment	  for	  depression	  and	  general	  anxiety,	  and	  PTSD	  in	  a	  face-­‐to-­‐face	  interview	  format	  (Ferry	  et	  al	  2008).	  	  The	  study	  assessed	  direct	  service	  costs	  including	  health	  service	  use	  and	  medication,	  alongside	  indirect	  costs	  including	  costs	  of	  lost	  work	  productivity	  and	  presenteeism	  costs	  for	  a	  one-­‐year	  period	  in	  2008	  for	  all	  individuals	  with	  PTSD.	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In	  total,	  1,095	  individuals	  completed	  the	  section	  on	  PTSD	  in	  the	  study	  and	  were	  included	  in	  the	  analysis.	  Apart	  from	  methodological	  and	  potential	  cultural	  differences	  between	  studies,	  another	  possible	  impediment	  to	  this	  comparison	  lies	  in	  the	  fact	  that	  data	  from	  the	  LB	  study	  includes	  participants	  with	  PTSD	  alongside	  a	  number	  of	  participants	  without	  a	  PTSD	  diagnosis,	  while	  the	  NI	  study	  looks	  at	  PTSD-­‐related	  costs	  only.	  	  However	  in	  the	  NI	  study,	  PTSD	  was	  not	  assessed	  by	  clinicians	  using	  standard	  clinical	  instruments	  such	  as	  SCID,	  and	  the	  study	  reports	  using	  “further	  questions	  on	  re-­‐experiencing,	  avoidance	  and	  hyper-­‐vigilance	  symptoms	  on	  random	  event	  and	  worst	  event”	  on	  participants	  who	  endorsed	  traumatic	  event(s)	  (Ferry	  et	  al,	  2008,	  p.7).	  	  In	  addition,	  the	  NI	  study	  sample	  included	  a	  sub-­‐sample	  comprised	  of	  individuals	  who	  “screened	  into	  the	  core	  disorder,	  a	  random	  sample	  of	  25%	  of	  individuals	  who	  did	  not	  screen	  into	  the	  core	  disorders	  and	  50%	  of	  individuals	  who	  are	  sub-­‐threshold	  core	  disorder	  cases”	  (Ferry	  et	  al,	  2008,	  p.9).	  	  Therefore	  in	  my	  view	  the	  NI	  study	  sample	  resembles	  the	  LB	  study	  sampling	  criteria	  and	  I	  have	  decided	  to	  proceed	  with	  comparison	  of	  the	  results.	  Both	  studies	  reported	  high	  indirect	  costs,	  in	  both	  cases	  related	  to	  work	  productivity	  loss.	  	  The	  NI	  study	  reported	  a	  higher	  percentage	  of	  indirect	  costs	  (81%)	  in	  comparison	  to	  the	  LB	  study	  (62%).	  	  Most	  cost-­‐of-­‐illness	  studies	  in	  the	  mental	  health	  domain	  report	  a	  similarly	  high	  contribution	  of	  indirect	  costs	  (Thomas	  &	  Morris,	  2003;	  Knapp,	  2003;	  Knapp	  et	  al.,	  1999).	  	  In	  the	  NI	  study,	  productivity	  losses	  represented	  66%	  of	  total	  costs	  among	  individuals	  with	  PTSD	  in	  2008,	  while	  presenteeism	  accounted	  for	  15%	  of	  total	  costs	  (Ferry	  et	  al.,	  2008).	  	  Sick	  leave	  (52%)	  and	  unemployment	  (44%)	  accounted	  for	  most	  of	  the	  productivity	  costs	  in	  the	  LB	  study,	  but	  presenteeism	  was	  not	  measured,	  although	  some	  of	  the	  interviewed	  individuals	  did	  report	  it.	  When	  I	  compare	  direct	  costs	  reported	  by	  the	  NI	  and	  LB	  studies,	  treatment/mental	  health	  services	  and	  hospitalisation	  costs	  accounted	  for	  the	  highest	  percentage	  of	  the	  direct	  costs:	  41%	  in	  the	  NI	  study	  and	  33%	  in	  the	  LB	  study	  for	  treatment,	  and	  around	  30%	  for	  hospitalisation	  costs	  in	  both	  studies.	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Anti-­‐depressants,	  hypnotics	  and	  anxiolytics	  were	  the	  most	  prominently	  reported	  medications	  in	  both	  studies.	  	  In	  the	  NI	  study,	  anti-­‐depressants	  represented	  57%	  of	  total	  medication	  costs,	  followed	  by	  psychoses	  and	  related	  disorders	  drugs	  (17%),	  and	  hypnotics	  and	  anxiolytics	  (16%;	  Ferry	  et	  al.,	  2008).	  	  In	  the	  LB	  study	  anti-­‐depressants	  (7%)	  were	  the	  most	  frequently	  reported	  medications,	  followed-­‐by	  hypnotics	  and	  anxiolytics	  (6%)	  and	  painkillers	  (6%).	  	  
4.5	   Summary	  Data	  presented	  in	  this	  chapter	  describes	  both	  the	  direct	  and	  indirect	  costs	  reported	  by	  individuals	  who	  were	  exposed	  to	  the	  bombings.	  	  At	  the	  time	  of	  data	  collection,	  this	  was	  the	  first	  time	  individuals	  exposed	  to	  such	  an	  event	  have	  reported	  services	  they	  used	  as	  a	  direct	  consequence	  of	  their	  exposure.	  	  Furthermore,	  to	  my	  knowledge,	  this	  is	  the	  only	  attempt	  to	  measure	  productivity-­‐related	  costs	  associated	  with	  exposure	  to	  the	  LB.	  	  The	  presented	  costs	  highlight	  productivity	  costs	  as	  the	  largest	  cost	  category	  (62%),	  almost	  twice	  as	  big	  as	  the	  reported	  direct	  (service	  use)	  costs	  (38%).	  	  In	  the	  direct	  (service	  use)	  cost	  category	  the	  most	  costly	  services	  when	  looking	  at	  the	  total	  costs	  were	  hospitalisation	  (38%)	  and	  treatment	  (32%).	  The	  time	  frame	  for	  the	  estimates	  of	  costs	  varies	  significantly	  between	  the	  participants,	  and	  due	  to	  the	  heterogeneity	  of	  the	  follow-­‐up	  timing	  the	  estimated	  costs	  are	  more	  accurately	  portrayed	  as	  snapshots	  of	  the	  period	  post	  the	  LB	  up	  to	  the	  data	  collection	  point,	  rather	  than	  total	  overall	  costs	  due	  to	  exposure	  to	  the	  LB.	  	  	   The	  LB	  study	  sample	  is	  only	  indicative	  of	  individuals	  exposed	  to	  the	  LB,	  and	  it	  is	  very	  likely	  that	  self-­‐selection	  affected	  the	  evaluation	  follow-­‐up	  sample	  as	  only	  a	  part	  of	  the	  contacted	  participants	  agreed	  to	  participate	  in	  the	  evaluation	  study;	  some	  participants	  refusing	  to	  take	  a	  part	  and	  a	  number	  of	  participants	  who	  it	  was	  not	  possible	  to	  contact.	  	  Furthermore,	  it	  is	  a	  valid	  question	  if	  the	  ST	  programme	  users	  were	  representative	  of	  the	  population	  of	  individuals	  exposed	  to	  the	  LB.	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  Although	  there	  is	  a	  limit	  to	  the	  generalisability	  of	  these	  findings	  due	  to	  possible	  self-­‐selection	  of	  the	  sample	  and	  the	  size	  of	  the	  sample,	  this	  study	  provides	  a	  unique	  opportunity	  for	  insight	  into	  the	  effects	  of	  a	  traumatic	  event	  of	  a	  relatively	  large	  scale	  on	  individuals	  and	  their	  health,	  social	  and	  work	  domains.	  	  This	  study	  provides	  an	  insight	  and	  documents	  all	  the	  challenges	  of	  measuring	  the	  effects	  of	  interventions	  applied	  in	  a	  real-­‐world	  context.	  	  This	  chapter	  serves	  as	  a	  foundation	  for	  the	  cost	  variation	  analyses	  presented	  in	  Chapter	  5	  and	  the	  economic	  evaluation	  of	  the	  ST	  programme	  explored	  in	  Chapters	  6	  and	  7.	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Chapter	  5	   Exploring	  variations	  in	  the	  costs	  of	  involvement	  in	  	  	  	  	  	  
the	  London	  bombings	  “No	  single	  model	  is	  best	  under	  all	  circumstances.”	  (Basu	  et	  al.,	  2004,	  p.	  751)	  
	  
5.1	   Introduction	  The	  investigation	  of	  the	  relationship	  between	  cost	  and	  its	  potential	  determinants	  while	  controlling	  for	  other	  covariates	  is	  of	  importance	  to	  decision-­‐makers	  (Knapp	  &	  Beecham,	  2001).	  	  Analysis	  of	  cost	  variations	  enables	  the	  researchers	  and	  policy-­‐makers	  to	  explore	  how	  participants	  with	  different	  needs	  and	  characteristics	  differ	  in	  their	  costs	  (and	  in	  the	  underlying	  patterns	  of	  services	  use).	  	  In	  the	  example	  of	  the	  ST	  programme,	  this	  approach	  aids	  in	  answering	  the	  following	  question:	  how	  costs	  for	  individuals	  sent	  to	  treatment	  compare	  to	  costs	  for	  individuals	  who	  either	  did	  not	  use	  the	  programme	  or	  were	  considered	  to	  be	  coping	  well	  without	  any	  need	  for	  treatment,	  having	  taken	  into	  account	  the	  characteristics	  of	  those	  individuals.	  
	  The	  aim	  of	  this	  chapter	  is	  to	  explore	  by	  using	  multivariate	  analysis	  the	  impact	  on	  health,	  social,	  and	  economic	  activity	  for	  those	  affected.	  	  Applied	  to	  the	  costs	  associated	  with	  the	  LB,	  multivariate	  analysis	  will	  give	  us	  information	  on	  which	  participant,	  exposure	  and	  service	  characteristics	  appear	  to	  have	  an	  effect	  on	  cost	  and	  on	  the	  nature	  of	  these	  relationships.	  	  In	  addition,	  Chapter	  5	  will	  lay	  a	  foundation	  for	  the	  analysis	  presented	  in	  Chapters	  6	  and	  7.	  	  	  I	  will	  start	  by	  briefly	  recapitulating	  challenges	  with	  the	  analysis	  of	  health	  service	  data	  and	  ways	  around	  them	  before	  proceeding	  with	  a	  description	  of	  the	  data	  analysis	  and	  interpretation	  of	  the	  results.	  	  Having	  estimated	  the	  cost	  of	  exposure	  to	  the	  LB	  in	  Chapter	  4,	  this	  chapter	  will	  explore	  the	  following	  questions:	  a. How	  do	  costs	  relate	  to	  the	  characteristics	  of	  the	  participants,	  exposure	  factors	  and	  service	  type?	  b. 	  Which	  factors	  are	  associated	  with	  being	  diagnosed	  with	  PTSD?	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c. 	  What	  is	  the	  cost	  of	  being	  diagnosed	  with	  PTSD?	  	  
5.2	   Exploring	  cost	  variations	  	  Understanding	  factors	  that	  explain	  differences	  in	  costs	  is	  crucial	  for	  any	  informed	  decision	  based	  on	  the	  costing	  study.	  	  Differences	  in	  costs	  might	  be	  attributed	  to	  systematic	  factors	  such	  as	  a	  participant’s	  characteristics	  and	  needs,	  and	  the	  broad	  approach	  to	  treatment	  response,	  as	  well	  as	  non-­‐systematic	  factors	  otherwise	  known	  as	  random	  or	  stochastic	  variation	  (Knapp	  et	  al.,	  1995).	  	  The	  cause	  of	  the	  latter	  could	  include	  random	  fluctuations	  in	  data	  recording,	  participants’	  responses	  to	  research	  questions	  and	  measurement	  errors.	  	  a.	  Cost	  variation	  –	  Two-­‐stage	  model	  In	  a	  cost	  variation	  analysis,	  both	  OLS	  and	  GLM	  will	  only	  include	  participants	  with	  cost	  data.	  	  However,	  information	  on	  whether	  participants	  used	  services	  alongside	  information	  on	  their	  characteristics	  should	  be	  reflected	  in	  the	  analysis.	  	  This	  information	  loss	  is	  avoided	  by	  use	  of	  two-­‐stage	  model	  analysis,	  which	  combines	  the	  odds	  of	  incurring	  costs	  with	  information	  on	  cost	  variations.	  It	  does	  so	  by	  combining	  binary	  regression	  analysis	  with	  GLM.	  Binary	  regression/multiple	  logistic	  regression	  analysis	  (Dunn,	  2003)	  explores	  differences	  between	  participants	  who	  did	  and	  did	  not	  use	  services,	  and	  estimates	  odds	  ratios	  of	  incurring	  a	  cost	  for	  each	  explanatory	  variable	  and	  statistical	  significance.	  	  The	  first	  step	  predicts	  which	  participants	  will	  incur	  costs	  and	  the	  second	  stage	  models	  incurred	  costs	  and	  participants’	  characteristics	  (Dunn,	  2003).	  	  The	  total	  cost	  per	  person	  is	  a	  product	  of	  a	  probability	  of	  being	  in	  the	  group	  that	  incurs	  costs,	  multiplied	  by	  modelled	  cost	  for	  the	  group	  (Dunn	  et	  al.,	  2003).	  	  	  Some	  authors	  have	  used	  OLS	  with	  untransformed	  cost	  data	  and	  compared	  results	  with	  OLS	  with	  bootstrapping,	  and	  GLM.	  	  Their	  conclusion	  was	  that	  all	  three	  models	  produced	  similar	  results	  (Byford	  et	  al.,	  2003)	  or	  they	  preferred	  log	  transformed	  OLS	  model	  (Knapp	  et	  al.,	  2002).	  	  However,	  this	  approach	  has	  been	  criticised	  (Dunn	  et	  al.,	  2003)	  and	  statistical	  techniques	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appropriate	  to	  handling	  skewed	  distributions	  in	  such	  cases	  are	  recommended	  (O’Hagan	  &	  Stevens,	  2003).	  	  As	  costs	  were	  measured	  at	  different	  time	  points	  for	  different	  participants,	  depending	  on	  the	  timing	  of	  the	  evaluation	  follow-­‐up	  interview,	  I	  have	  expressed	  all	  costs	  in	  a	  cost-­‐per-­‐month	  format	  to	  enable	  comparison.	  	  The	  choice	  of	  data	  analysis	  method	  depends	  on	  data	  characteristics.	  	  Therefore,	  my	  first	  step	  will	  be	  to	  conduct	  descriptive	  analysis	  of	  the	  dataset	  and	  test	  normality	  of	  distributions	  of	  dependent	  variables.	  	  In	  light	  of	  the	  recommendations	  from	  the	  literature	  discussed	  above,	  for	  non-­‐normally	  distributed	  dependent	  variables	  I	  used	  the	  GLM	  approach.	  	  I	  preferred	  the	  GLM	  approach	  to	  the	  alternatives	  discussed	  above	  due	  to	  the	  simplicity	  of	  the	  analysis	  that	  avoids	  all	  caveats	  of	  re-­‐transformation.	  	  For	  normally	  distributed	  variables	  I	  will	  employ	  OLS.	  In	  cases	  where	  participants	  reported	  zero	  costs	  I	  will	  use	  a	  two-­‐stage	  model.	  	  b.	  Handling	  missing	  data	  Missing	  data	  is	  a	  problem	  many	  studies	  face,	  and	  the	  literature	  suggests	  a	  number	  of	  approaches	  for	  dealing	  with	  this	  and	  prevent	  sample	  reduction.	  	  One	  way	  to	  approach	  this	  problem	  is	  to	  exclude	  cases	  with	  missing	  data	  from	  the	  analysis.	  	  However,	  this	  will	  cause	  a	  significant	  sample	  reduction	  and	  is	  a	  problem	  especially	  with	  small	  samples	  (Sterne	  et	  al.,	  2009).	  	  Another	  potential	  strategy	  is	  to	  calculate	  a	  group	  mean	  or	  mode	  for	  the	  whole	  variable	  or	  to	  use	  the	  last	  recorded	  value,	  depending	  on	  the	  variable	  distribution,	  and	  replace	  missing	  values	  (Carpenter	  &	  Kenward,	  2008).	  	  This	  strategy	  is	  problematic	  as	  it	  does	  not	  account	  for	  uncertainty	  and	  affects	  standard	  errors	  (Sterne	  et	  al.,	  2009).	  	  Another	  option	  is	  to	  conduct	  multiple	  imputation	  (MI).	  	  In	  brief,	  in	  order	  to	  account	  for	  the	  estimation	  uncertainties,	  MI	  creates	  a	  number	  of	  simulated	  versions	  of	  the	  dataset	  (usually	  5-­‐10)	  and	  predicts	  the	  missing	  values	  and	  confidence	  intervals	  for	  each	  predicted	  set	  and	  pools	  the	  results	  (Schafer,	  1999).	  	  This	  approach	  reflects	  the	  relationships	  between	  variables	  and	  does	  not	  alter	  their	  influence	  on	  the	  predicted	  values	  (Rubin,	  1987;	  Little	  &	  Rubin,	  2002),	  and	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preserves	  characteristics	  of	  the	  joint	  distribution	  in	  the	  imputed	  values	  (Schaffer	  &	  Graham,	  2002).	  	  However,	  the	  robustness	  and	  validity	  of	  the	  MI	  approach	  depend	  on	  the	  reason	  behind	  the	  missing	  data.	  Following	  Little	  and	  Rubin	  (2002),	  for	  the	  purposes	  of	  MI,	  data	  are	  classified	  as:	  missing	  completely	  at	  random	  (MCAR)	  where	  missing	  values	  are	  independent	  of	  other	  values,	  missing	  at	  random	  (MAR)	  in	  cases	  where	  missing	  data	  depends	  on	  observed	  data	  only,	  and	  missing	  not	  at	  random	  (MNAR).	  	  MI	  only	  delivers	  unbiased	  estimation	  in	  the	  case	  of	  MCAR,	  while	  in	  the	  case	  of	  MAR	  it	  is	  necessary	  to	  conduct	  a	  sensitivity	  analysis	  to	  explore	  the	  differences	  in	  assumptions	  behind	  missing	  data	  (Sterne	  et	  al,	  2009).	  	  Collins	  et	  al	  (2001)	  demonstrated	  that	  although	  a	  wrong	  assumption	  of	  MAR	  did	  affect	  the	  results,	  it	  did	  not	  seriously	  distort	  estimates	  and	  standard	  errors	  (Schaffer	  &	  Graham,	  2002;	  Schaffer	  &	  Olsen,	  1998).	  	  Schaffer	  (1999)	  has	  advised	  cautious	  use	  of	  this	  MI	  approach	  and	  identifies	  the	  effects	  of	  its	  misuse	  on	  “estimates,	  standard	  errors	  and	  hypothesis	  tests”	  (p.4).	  	  He	  advises	  further	  on	  the	  importance	  of	  compatibility	  of	  methods	  used	  to	  impute	  datasets	  and	  those	  used	  for	  subsequent	  data	  analysis,	  and	  a	  preference	  for	  a	  more	  general	  imputer’s	  model	  that	  contains	  a	  large	  number	  of	  associations	  (Schaffer,	  1999).	  	  This	  should	  ensure	  that	  distributional	  characteristics	  that	  are	  explored	  in	  future	  analysis	  are	  reflected	  in	  the	  MI	  in	  order	  to	  obtain	  valid	  inferences	  (Schaffer	  &	  Olsen,	  1998;	  Schaffer,	  2003).	  	  Another	  important	  issue	  in	  MI	  is	  including	  all	  relevant	  variables	  that	  carry	  information	  on	  missing	  data	  and	  are	  linked	  with	  missing	  variables,	  including	  outcome	  (dependent)	  variables	  (Sterne	  et	  al.,	  2009).	  	  Caution	  is	  also	  advised	  when	  conducting	  MI	  on	  skewed	  distributions,	  outliers	  and	  fifth	  or	  95th	  percentile	  values	  (Schaffer,	  1999).	  	  If	  the	  MI	  procedure	  assumes	  data	  are	  normally	  distributed,	  it	  is	  important	  to	  transform	  non-­‐normally	  distributed	  data	  before	  imputation	  by	  using	  logarithmic	  or	  other	  power	  transformations	  (Sterne	  et	  al.,	  2009,	  Schaffer	  and	  Graham,	  2002).	  I	  decided	  to	  employ	  MI	  for	  all	  socio-­‐economic	  and	  exposure	  variables	  with	  missing	  values	  (presented	  in	  Table	  5.2)	  by	  using	  SPSS	  17-­‐automated	  MI	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model	  based	  on	  the	  scan	  of	  the	  data	  set.	  	  For	  non-­‐normally	  distributed	  variables	  I	  used	  a	  logarithmic	  transformation	  prior	  to	  imputation	  to	  approximate	  normal	  distribution.	  	  As	  previously	  discussed,	  in	  such	  cases	  transformed	  variables	  need	  to	  be	  re-­‐transformed	  again	  after	  MI	  to	  their	  original	  values	  by	  using	  Duan’s	  smearing	  estimator,	  which	  is	  equal	  to	  the	  mean	  of	  the	  anti-­‐log	  of	  the	  residuals	  (Duan,	  1983).	  	  This	  step	  is	  necessary	  to	  avoid	  retransformation	  bias	  (Mullahy,	  1998),	  which	  will	  result	  in	  underestimated	  values	  (Dunn	  et	  al.,	  2003;	  Duan,	  1983).	  	  	   c.	  Data	  analysis	  protocol	  The	  first	  part	  of	  the	  analysis	  will	  look	  into	  the	  effects	  of	  socio-­‐demographic	  variables	  such	  as	  age,	  gender	  and	  ethnicity	  on	  costs.	  	  Secondly,	  I	  will	  look	  at	  the	  effects	  of	  exposure	  characteristics	  on	  costs.	  	  I	  will	  firstly	  explore	  unadjusted	  costs	  per	  service	  and	  participant	  group	  category.	  	  Following	  this,	  I	  will	  conduct	  analysis	  in	  the	  form	  of	  several	  two-­‐stage	  GLM	  or	  OLS	  models	  depending	  on	  the	  type	  of	  data	  distribution	  in	  order	  to	  predict	  costs.	  	  I	  will	  conduct	  the	  analysis	  on	  the	  sample	  as	  a	  whole	  (N=230)	  and	  for	  each	  participant	  group	  per	  each	  cost	  category.	  Finally,	  in	  a	  set	  of	  models	  I	  will	  explore	  the	  factors	  associated	  with	  being	  diagnosed	  with	  PTSD	  by	  using	  ICD-­‐10	  classification	  criteria.	  	  I	  chose	  this	  particular	  criterion	  instead	  of	  DSM-­‐IV	  due	  to	  its	  wider	  scope,	  which	  will	  enhance	  the	  number	  of	  participants	  included	  in	  the	  analysis.	  	  I	  will	  use	  the	  same	  criteria	  of	  model	  allocation	  as	  in	  the	  previous	  two	  analyses.	  	  	  
5.3	   Effects	  of	  socio-­‐demographic	  and	  exposure	  characteristics	  on	  costs	  In	  an	  attempt	  to	  identify	  and	  describe	  cost	  drivers	  I	  will	  start	  by	  exploring	  the	  effects	  of	  socio-­‐demographic	  and	  exposure	  characteristics	  by	  looking	  at	  the	  sample	  as	  a	  whole.	  	  Due	  to	  the	  design	  of	  the	  study	  (discussed	  in	  Chapter	  3),	  analysis	  involving	  the	  whole	  sample	  was	  limited	  in	  its	  scope	  as	  different	  participant	  sub-­‐groups	  were	  followed-­‐up	  with	  different	  outcome	  measures.	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As	  shown	  in	  Table	  5.1,	  costs	  were	  not	  normally	  distributed	  due	  to	  a	  number	  of	  participants	  reporting	  zero	  costs	  and	  a	  few	  participants	  reporting	  very	  high	  costs,	  resulting	  in	  an	  asymmetric	  cost	  distribution.	  	  Variables	  and	  missing	  values	  used	  in	  the	  model	  are	  listed	  in	  Table	  5.2.	  	  Table	  5.1	  One-­‐sample	  Kolmogorov-­‐Smirnov	  tests	  for	  normality	  of	  the	  cost	  per	  month	  distributions	  
Variable	   Z	   p	  Total	  cost	  per	  month	   5.336	   0.00	  Direct	  costs	  per	  month	   5.75	   0.00	  Work	  costs	  per	  month	   5.92	   0.00	  	  Table	  5.2	  Number	  of	  missing	  values	  per	  variables	  
Variable	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Overall	  sample	  size	  N=230	   N	  missing	   %	  missing	  
Age	   7	   3	  Gender	   0	   0	  White	  British	  ethnicity	   36	   15.7	  Median	  week	  salary	   13	   5.7	  Months	  since	  LB	   0	   0	  Q1.	  Injured	  in	  LB	  	   21	   9.1	  Q2.	  You	  felt	  you	  might	  be	  injured	  or	  killed?	   23	   10	  Q3.	  You	  saw	  someone	  who	  was	  injured	  or	  killed?	   26	   11.3	  Q4.	  A	  family	  member	  or	  a	  close	  friend	  was	  killed?	   26	   11.3	  	  Q5.	  A	  family	  member	  or	  a	  close	  friend	  was	  injured?	   25	   10.9	  	  Q6.	  You	  felt	  a	  family	  member	  might	  be	  injured	  or	  killed?	  	   25	   10.9	  Q7.	  You	  personally	  witnessed	  effects	  of	  LB?	   24	   10.4	  Total	  cost	  per	  month	   0	   0	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A	  comprehensive	  imputation	  model,	  as	  advised	  by	  STATA	  analysis	  manual	  (2010),	  “must	  include	  all	  predictors	  relevant	  to	  the	  missing-­‐data	  mechanism,	  and	  it	  must	  preserve	  all	  data	  characteristics	  likely	  to	  be	  explored	  at	  the	  analysis	  stage”	  (STATA	  MI	  help	  guideline,	  2010,	  p.	  8).	  	  I	  have	  therefore	  included	  all	  variables	  that	  I	  thought	  had	  a	  relevant	  relationship	  with	  the	  prediction	  of	  the	  missing	  values,	  as	  listed	  in	  Table	  5.2,	  even	  though	  by	  doing	  so	  there	  is	  a	  risk	  of	  arriving	  at	  artificially-­‐inflated	  regression	  coefficients	  due	  to	  ‘double-­‐counting’	  of	  the	  variables,	  by	  using	  them	  both	  in	  the	  imputation	  and	  prediction	  model.	  	  Although	  the	  percentage	  of	  missing	  values	  is	  not	  very	  high,	  as	  Table	  5.2	  shows,	  it	  is	  still	  important	  to	  interpret	  weak	  statistically	  significant	  coefficients	  cautiously.	  	  Two	  variables,	  total	  monthly	  cost	  and	  days	  since	  the	  LB,	  were	  not	  normally	  distributed	  and	  as	  MI	  uses	  logistical	  regression,	  which	  relies	  on	  the	  normal	  distribution	  inferences,	  I	  used	  logarithmic	  transformations	  of	  both	  variables	  in	  order	  to	  approximate	  a	  normal	  distribution.	  	  Both	  variables	  were	  re-­‐transformed	  again	  after	  IM	  to	  their	  original	  values	  by	  using	  Duan’s	  smearing	  estimator	  that	  equals	  the	  mean	  of	  the	  anti-­‐log	  of	  the	  residuals	  (Duan,	  1983).	  I	  have	  expressed	  costs	  in	  a	  costs-­‐per-­‐month	  form,	  estimated	  in	  order	  to	  account	  for	  different	  time	  points	  of	  data	  collection	  as	  evaluation	  interviews	  took	  place	  over	  a	  period	  ranging	  from	  13	  to	  38	  weeks	  since	  the	  LB.	  	  Prior	  to	  the	  data	  analysis,	   I	   explored	   the	   relationship	  between	   independent	   variables	   and	   costs	  by	  using	  correlation	  for	  scale	  variables	  and	  analysis	  of	  variance	  for	  categorical	  variables.	   	   The	   only	   significant	   relationship	  was	   found	   between	   being	   injured	  and	   total	   costs	   per	   month,	   with	   on	   average	   statistically	   higher	   costs	   for	  participants	  who	  have	  been	  injured	  (F=5.27,	  df=1,	  p<0.05).	  	  As	  the	  distribution	  of	  total	  cost	  per	  month	  is	  significantly	  different	  from	  normal,	  Z(209)=4.978,	  P<0.001,	  I	  applied	  the	  two-­‐stage	  model	  with	  logarithmic	  transformation	   and	   gamma	   distribution	   family.	   	   The	   results	   of	   the	   two-­‐stage	  model	  are	  reported	  in	  Table	  5.3.	   	  A	  significance	  level	  of	  around	  10%	  was	  used.	  	  Analysis	   was	   conducted	   on	   230	   individuals	   followed-­‐up	   as	   a	   part	   of	   the	  evaluation	  of	  the	  ST	  programme.	   	  Analysis	  of	  cost	  variations	  offers	  a	  relatively	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narrow	   view	   into	   factors	   that	   may	   be	   associated	   with	   the	   costs	   of	   the	   LB	  exposure,	   as	   only	   data	   on	   service	   use,	   socio-­‐demographic	   characteristics	   and	  exposure	   details	   were	   available	   for	   the	   whole	   sample.	   	   This	   was	   due	   to	   the	  nature	  of	  the	  sampling	  and	  data	  collection	  protocol	  in	  the	  evaluation,	  described	  in	  greater	  detail	   in	  Chapter	  3.	   	  However,	  this	  analysis	  still	  offers	  an	  interesting	  insight	   into	  how	  costs	  were	  distributed	  between	  participant	   categories	  before	  focusing	  the	  analysis	  on	  the	  particular	  participant	  sub-­‐groups.	  The	  Park	  test	  confirmed	  that	  this	  was	  the	  appropriate	  choice	  of	  family	  distribution	  and	  transformation,	  as	  Lambda=1.94	  (1.71-­‐2.1).	  	  The	  model	  suggests	  that,	  after	  controlling	  for	  other	  factors,	  age,	  female	  gender,	  ethnicity	  group,	  injury,	  and	  feeling	  the	  threat	  of	  being	  killed	  or	  injured	  are	  factors	  associated	  with	  higher	  costs.	  	  In	  order	  to	  calculate	  predicted	  monthly	  costs	  I	  multiplied	  the	  regression	  coefficients	  for	  people	  who	  generated	  costs	  with	  the	  probabilities	  of	  having	  a	  non-­‐zero	  cost.	  	  On	  average,	  injured	  participants	  reported	  three	  times	  higher	  costs	  than	  those	  who	  did	  not	  report	  injuries	  (£717.80	  vs.	  £206.91).	  	  Women	  reported	  on	  average	  double	  costs	  in	  comparison	  to	  men	  (£432.85	  vs.	  £208.17),	  and	  participants	  who	  were	  not	  white	  British	  had	  double	  the	  costs	  of	  those	  who	  were	  (£480.85	  vs.	  £249.07).	  	  Table	  5.3	  Two-­‐part	  model	  of	  factors	  associated	  with	  (i)	  reporting	  costs	  and	  (ii)	  total	  costs	  per	  month	  among	  those	  who	  used	  services	  in	  connection	  to	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  of	  
total	  costs	  per	  month	  due	  
to	  the	  LB	  
N=230	  observations	  
GLM	  of	  total	  costs	  per	  
month	  due	  to	  the	  LB	  
N=209	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
	  interval)	  Age	  	   0.98	  (0.92,	  1.02)	   0.03***	  (0.01,	  0.04)	  Males	  relative	  to	  females	   0.38	  (0.26,	  0.66)	   -­‐0.83***	  (-­‐1.17,	  -­‐0.58)	  White	  British	  relative	  to	  other	  ethnic	  categories	   0.26*	  (0.14,	  1.23)	   -­‐0.63*	  (-­‐1.36,	  0.10)	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Q1.	  Being	  injured	  relative	  to	  not	  being	  injured	   	  6.23	  (0.61,	  9.71)	   0.92***	  (0.62,	  1.68)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   3.85	  (1.85,	  30.33)	   0.58***	  (0.32,0.84)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   2.42	  (1.22,	  9.48)	   0.24	  (-­‐0.67,	  0.67)	  Months	  since	  LB	   1.13**	  (0.02,2.20)	   0.00	  (-­‐0.01,	  0.02)	  Constant	   -­‐	   4.59***	  (3.90,	  5.29)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.99	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.76	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   90.87%	   	  	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  These	  cost	  predictions	  must	  be	  interpreted	  with	  caution.	  	  The	  first	  potential	  problem	  lies	  in	  the	  skewed	  distribution	  of	  costs	  and	  the	  fact	  that	  cost	  outliers	  might	  affect	  prediction,	  which	  is	  reflected	  in	  large	  residuals,	  even	  though	  I	  have	  employed	  an	  appropriate	  family	  distribution	  and	  transformation.	  	  Although	  the	  data	  were	  analysed	  in	  line	  with	  the	  theoretical	  background,	  there	  are	  potentially	  many	  factors	  contributing	  to	  the	  variation	  for	  which	  data	  were	  not	  collected	  for	  the	  whole	  sample,	  and	  therefore	  cannot	  be	  controlled	  for	  in	  this	  analysis.	  	  Thus	  this	  model	  risks	  offering	  a	  ‘narrow’	  view	  of	  the	  pattern	  of	  cost	  variation.	  Heterogeneity	  in	  the	  participant	  sample	  is	  another	  feature	  of	  this	  study.	  	  Heterogeneity	  is	  present	  partially	  due	  to	  the	  bombings	  being	  a	  random	  traumatic	  event,	  with	  involvement	  in	  the	  bombings	  potentially	  being	  the	  only	  common	  characteristic	  of	  the	  individuals	  involved.	  	  Secondly,	  heterogeneity	  of	  the	  sample	  is	  introduced	  by	  the	  study	  sampling	  procedure,	  as	  the	  sample	  comprises	  individuals	  who	  for	  different	  reasons	  used	  or	  did	  not	  use	  the	  ST	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programme.	  	  There	  is	  a	  distinction	  even	  among	  the	  ST	  programme	  users,	  as	  only	  a	  part	  of	  this	  group	  received	  treatment	  after	  screening	  and	  assessment,	  while	  others	  were	  screened	  and	  assessed	  only.	  	  Finally,	  for	  evaluation	  purposes,	  a	  third	  group	  of	  participants	  was	  introduced	  based	  on	  the	  convenience	  sample	  of	  people	  who	  did	  not	  use	  the	  programme	  for	  various	  reasons.	  	  As	  a	  consequence,	  the	  study	  sample	  resembles	  a	  ‘patchwork’	  of	  participants	  with	  different	  needs	  and	  service	  experiences	  after	  the	  LB,	  with	  the	  common	  underlying	  factor	  being	  that	  they	  experienced	  the	  bombings.	  	  Therefore,	  I	  wanted	  to	  explore	  heterogeneity	  and	  control	  for	  differences	  between	  participants	  in	  further	  analysis	  and	  so	  divided	  participants	  into	  three	  groups	  that	  represented	  their	  role	  in	  the	  ST	  programme,	  linking	  the	  analysis	  with	  the	  evaluation	  sampling	  strategy.	  	  I	  will	  start	  with	  looking	  at	  the	  unadjusted	  costs	  and	  proceed	  to	  the	  cost	  model	  analysis.	  	  I	  explored	  differences	  between	  participants’	  groups	  per	  cost	  category	  in	  a	  series	  of	  two-­‐stage	  GLM	  models	  for	  each	  service	  type,	  as	  costs	  distributions	  were	  not	  normally	  distributed,	  as	  shown	  in	  Table	  5.1.	  	  	  	   As	  illustrated	  in	  Figure	  5.1,	  participants	  with	  the	  highest	  unadjusted	  total	  average	  costs,	  including	  productivity	  loss	  and	  service	  use	  costs,	  are	  the	  ones	  who	  received	  treatment	  within	  the	  ST	  programme,	  when	  compared	  to	  those	  who	  did	  not	  use	  the	  programme	  or	  were	  only	  screened	  and	  assessed.	  	  Programme	  non-­‐users	  reported	  double	  unadjusted	  average	  service	  use	  costs	  when	  compared	  to	  the	  screen	  and	  assessed	  group,	  while	  both	  groups	  reported	  similar	  average	  productivity	  loss	  and	  total	  costs.	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Figure	  5.1	  Unadjusted	  average	  costs	  by	  cost	  type	  and	  participant	  group	  
	  Table	  5.4	  presents	  a	  two-­‐stage	  GLM	  model	  for	  service	  costs.	  	  Factors	  associated	  with	  having	  a	  higher	  odds	  of	  reporting	  costs	  were	  being	  of	  non-­‐white	  British	  ethnic	  origin,	  feeling	  one	  might	  be	  injured	  or	  killed,	  and	  seeing	  someone	  being	  injured	  or	  killed.	  	  Being	  injured	  in	  the	  bombings	  and	  receiving	  treatment	  within	  the	  ST	  programme	  were	  significant	  predictors	  of	  reporting	  service	  use	  costs.	  	  Although	  participants	  who	  did	  use	  the	  ST	  programme	  appeared	  to	  report	  higher	  costs	  than	  those	  who	  did	  not	  use	  the	  programme	  (453.87	  vs.	  136.33)	  the	  difference	  was	  not	  statistically	  significant.	  	  However,	  participants	  who	  received	  treatment	  under	  the	  ST	  programme,	  while	  controlling	  for	  other	  factors,	  reported	  significantly	  higher	  costs	  than	  the	  rest	  of	  the	  participants.	  	  On	  average,	  treated	  participants	  reported	  up	  to	  four	  times	  higher	  costs	  in	  comparison	  to	  other	  participants	  (£680.98	  per	  month	  in	  comparison	  to	  £148.78	  per	  month	  at	  2007-­‐08	  prices).	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Table	  5.4	  Two-­‐stage	  GLM	  model	  for	  service	  use	  costs	  associated	  with	  the	  LB	  exposure	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  
of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=230	  observations	  
GLM	  of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=209	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  	  
interval)	  Age	  	   0.99	  (0.92,	  1.02)	   0.02	  (-­‐0.004,	  0.061)	  Males	  relative	  to	  Females	   0.52	  (0.11,	  1.17)	   -­‐0.58*	  (-­‐1.47,	  -­‐0.18)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.26*	  (0.14,	  1.23)	   -­‐0.13	  (-­‐1.36,	  0.10)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   	  3.80	  (0.61,	  9.71)	   1.53***	  (0.62,	  1.68)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   9.30**	  (1.85,	  30.33)	   -­‐0.20	  (-­‐0.22,	  1.08)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   3.20**	  (1.22,	  9.48)	   -­‐0.50	  (-­‐0.67,	  0.67)	  Did	  not	  use	  ST	  programme	   -­‐	   -­‐0.00	  (-­‐1.16,	  0.88)	  Treated	   -­‐	   	  0.63***	  (0.19,	  1.85)	  Months	  since	  LB	   1.13**	  (1.01,	  1.30)	   0.94	  (2.93,	  6.66)	  Constant	   -­‐	   4.01***	  (2.48,	  5.75)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.99	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.42	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   74.65%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  In	  the	  next	  step	  I	  wanted	  to	  compare	  the	  use	  of	  services	  between	  the	  groups	  excluding	  the	  cost	  of	  the	  ST	  programme.	  	  As	  a	  result,	  the	  difference	  in	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service	  costs	  between	  programme	  users	  and	  non-­‐users	  was	  no	  longer	  found.	  	  Furthermore,	  this	  analysis	  showed	  that	  gender,	  ethnicity,	  injury,	  helplessness	  and	  horror	  are	  significant	  predictors	  of	  costs.	  	  In	  more	  detail:	  women	  were	  twice	  as	  likely	  to	  report	  service	  use	  costs,	  and	  so	  were	  people	  from	  non-­‐white	  British	  ethnic	  backgrounds.	  	  Being	  injured	  in	  the	  bombings	  and	  being	  of	  female	  gender	  were	  significant	  predictors	  for	  service	  use,	  as	  presented	  in	  Table	  5.5.	  Table	  5.5	  Two-­‐stage	  GLM	  model	  for	  service	  use	  costs	  excluding	  the	  ST	  programme	  costs	  associated	  with	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  of	  
costs	  per	  month	  due	  
to	  the	  LB	  
N=230	  observations	  
GLM	  of	  costs	  per	  
month	  due	  to	  the	  LB	  
N=182	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
	  interval)	  Age	  	   1.00	  (0.97,	  1.04)	   0.01	  (-­‐0.004,	  0.061)	  Males	  relative	  to	  Females	   0.46**	  (0.21,	  1.01)	   -­‐0.44*	  (-­‐1.47,	  -­‐0.18)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.46*	  (0.19,	  1.10)	   -­‐0.00	  (-­‐1.36,	  0.10)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   8.17***	  (1.85,36.14)	   2.02***	  (0.62,	  1.68)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   2.30*	  (0.85,	  6.310)	   -­‐0.10	  (-­‐0.22,	  1.08)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   0.91	  (0.32,	  2.23)	   -­‐0.43	  (-­‐0.67,	  0.67)	  Median	  weekly	  wage	   0.99	  (0.99,	  1.00)	   0.00	  (-­‐0.00,	  0.002)	  Did	  not	  use	  ST	  programme	   -­‐	   -­‐0.29	  (-­‐1.16,	  0.88)	  Treated	   -­‐	   -­‐0.11(0.19,	  1.85)	  Months	  since	  LB	   1.04	  (0.99,	  1.11)	   -­‐0.00	  (2.93,	  6.66)	  Constant	   -­‐	   3.63***	  (2.48,	  5.75)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.96	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Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.41	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   84.65%	   	  	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  	  Figure	  5.2	  presents	  the	  percentages	  of	  participants	  for	  the	  most	  frequently-­‐used	  health	  service	  categories,	  presented	  separately	  for	  each	  participant	  group.	  	  The	  treated	  group	  has	  the	  highest	  percentage	  usage	  for	  most	  health	  care	  categories,	  although	  for	  the	  GP	  and	  A&E	  categories	  all	  three	  groups	  reported	  similar	  patterns.	  	  Figure	  5.2	  Percentages	  of	  participants	  using	  health	  care	  services	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Table	  5.6	  Two-­‐stage	  GLM	  model	  for	  the	  health	  care	  service	  costs	  associated	  with	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  
of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=230	  observations	  
GLM	  of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=175	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
interval)	  Age	  	   1.01	  (0.98,	  1.05)	   -­‐0.01	  (-­‐0.04,	  0.01)	  Males	  relative	  to	  Females	   0.47*	  (0.22,	  1.03)	   -­‐0.18*	  (-­‐0.64,	  0.28)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.36**	  (0.15,	  0.87)	   -­‐0.40	  (-­‐0.89,	  0.08)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   7.57***	  (2.07,27.70)	   1.14***	  (0.65,	  1.63)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   2.45*	  (0.95,	  6.33)	   0.15	  (-­‐0.42,	  0.70)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   1.06	  (0.45,	  2.49)	   -­‐0.22	  (-­‐0.77,	  0.34)	  Median	  weekly	  wage	   0.99	  (0.99,	  1.00)	   -­‐0.00	  (-­‐0.00,	  0.00)	  Did	  not	  use	  ST	  programme	   -­‐	   -­‐0.01	  (-­‐0.06,	  0.02)	  Treated	   -­‐	   1.19***(0.60,	  1.75)	  Months	  since	  LB	   1.06**	  (1.00	  1.13)	   -­‐0.01	  (-­‐0.03,	  0.26)	  Constant	   -­‐	   3.03***	  (1.57,	  4.45)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.92	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.47	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   80.35%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  As	  shown	  in	  Table	  5.6,	  health	  care	  costs	  were	  associated	  with	  being	  injured	  and	  with	  receipt	  of	  treatment	  within	  the	  ST	  programme.	  	  Being	  injured	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was	  associated	  with	  seven	  times	  higher	  odds	  of	  reporting	  costs.	  	  White	  British	  participants	  were	  less	  likely	  than	  participants	  from	  other	  ethnic	  backgrounds	  to	  report	  health	  care	  service	  costs.	  Table	  5.7	  Two-­‐stage	  GLM	  model	  for	  medication	  costs	  associated	  with	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  of	  
costs	  per	  month	  due	  
to	  the	  LB	  
N=230	  observations	  
GLM	  of	  costs	  per	  
month	  due	  to	  the	  LB	  
N=68	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
interval)	  Age	  	   1.02	  (0.99,	  1.05)	   0.04	  (-­‐0.04,	  0.01)	  Males	  relative	  to	  Females	   0.34**	  (0.16,	  0.74)	   -­‐0.40	  (-­‐1.90,	  1.09)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.71	  (0.29,	  1.73)	   -­‐1.28*	  (-­‐2.70,	  0.13)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   5.70***	  (2.65,12.26)	   0.01	  (-­‐1.28,	  1.30)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   5.24***	  (2.26,12.11)	   -­‐0.19	  (-­‐1.82,	  1.45)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   0.50	  (0.22,	  1.15)	   0.12	  (-­‐1.47,	  1.74)	  Median	  weekly	  wage	   0.99	  (0.99,	  1.00)	   0.00	  (-­‐0.00,	  0.00)	  Did	  not	  use	  ST	  programme	   -­‐	   0.74	  (-­‐1.83,	  3.02)	  Treated	   -­‐	   0.11	  (-­‐1.29,	  1.55)	  Months	  since	  LB	   1.05*	  (0.99	  1.11)	   0.01	  (-­‐0.06,	  0.76)	  Constant	   -­‐	   	  	  -­‐1.39	  (5.59,	  1.81)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.86	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.58	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	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Per	  cent	  correctly	  classified	   87.81%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  The	  results	  presented	  in	  Table	  5.7	  show	  that	  white	  British	  participants	  reported	  lower	  medication	  costs	  than	  participants	  from	  other	  ethnic	  groups.	  	  Again,	  being	  of	  female	  gender,	  being	  injured,	  witnessing	  someone’s	  death	  or	  injury	  were	  characteristics	  associated	  with	  higher	  odds	  of	  reporting	  medication	  costs.	  	  Figure	  5.3	  Percentages	  of	  participants	  using	  voluntary	  sector	  services	  	  
	  Costs	  associated	  with	  use	  of	  voluntary	  sector	  services	  were	  predicted	  by	  witnessing	  death	  or	  injury,	  with	  injured	  participants	  being	  up	  to	  three	  times	  more	  likely	  to	  use	  voluntary	  sector	  services.	  	  The	  estimated	  model	  is	  shown	  in	  Table	  5.8.	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  Table	  5.8	  Two-­‐stage	  GLM	  model	  for	  voluntary	  services	  costs	  associated	  with	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  of	  
costs	  per	  month	  due	  to	  
the	  LB	  
N=230	  observations	  
GLM	  of	  costs	  per	  
month	  due	  to	  the	  LB	  
N=39	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
interval)	  Age	  	   0.98	  (0.95,	  1.02)	   -­‐0.01	  (-­‐0.06,	  0.03)	  Males	  relative	  to	  Females	   0.63	  (0.29,	  1.37)	   0.61	  (-­‐0.42,	  1.65)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   1.18	  (0.48,	  2.93)	   0.02	  (-­‐1.25,	  1.29)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   3.56***	  (1.57,8.07)	   -­‐0.31	  (-­‐1.97,	  1.35)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   0.77	  (0.32,1.85)	   1.18***	  (0.57,	  3.05)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   0.63	  (0.25,	  1.51)	   -­‐0.70	  (-­‐2.61,	  1.19)	  Median	  weekly	  wage	   0.99	  (0.99,	  1.00)	   -­‐0.00	  (-­‐0.00,	  0.00)	  Did	  not	  use	  ST	  programme	   -­‐	   -­‐0.80	  (-­‐2.38,	  2.82)	  Treated	   -­‐	   -­‐0.88	  (-­‐2.29,	  0.91)	  Months	  since	  LB	   1.07**	  (1.00	  1.14)	   -­‐0.07**	  (-­‐0.13,	  0.00)	  Constant	   -­‐	   	  	  	  	  	  	  	  5.30	  (2.79,	  7.81)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.79	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.59	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   89.52%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	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  Figure	  5.4	  Percentage	  of	  participants	  using	  private	  sector	  services	  	  
	  Figure	  5.4	  shows	  the	  most	  frequently-­‐used	  services	  provided	  by	  the	  private	  sector.	  	  Mental	  health	  services	  are	  prominently	  represented,	  with	  counselling	  being	  used	  by	  the	  largest	  number	  of	  participants.	  	  Again,	  treatment	  group	  participants	  used	  more	  services	  in	  comparison	  to	  other	  participants.	  	  The	  costs	  of	  private	  sector	  services	  were	  also	  predicted	  by	  being	  injured,	  with	  women	  being	  three	  times	  more	  likely	  and	  injured	  participants	  two	  times	  more	  likely	  to	  report	  such	  costs	  (Table	  5.9).	  	  	  Table	  5.9	  Two-­‐stage	  GLM	  model	  for	  private	  sector	  services	  costs	  associated	  with	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  
of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=230	  observations	  
GLM	  of	  costs	  per	  
month	  due	  to	  the	  
LB	  
N=82	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
interval)	  Age	  	   0.99	  (0.96,	  1.02)	   0.00	  (-­‐0.2,	  0.03)	  Males	  relative	  to	  Females	   0.39**	  (0.21,	  0.73)	   -­‐0.45	  (-­‐1.02,	  0.11)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.82	  (0.44,	  1.53)	   0.13	  (-­‐0.40,	  0.66)	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Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   2.00**	  (1.02,3.90)	   0.47*	  (-­‐0.07,	  1.01)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   1.41	  (0.72,2.73)	   0.30(-­‐0.47,	  3.05)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   0.75	  (0.35,	  1.61)	   0.13	  (-­‐0.45,	  0.70)	  Median	  weekly	  wage	   1.00	  (0.99,	  1.00)	   0.00	  (-­‐0.00,	  0.00)	  Did	  not	  use	  ST	  programme	   -­‐	   0.96**	  (0.13,	  1.78)	  Treated	   -­‐	   0.30	  (-­‐0.50,	  1.12)	  Months	  since	  LB	   1.01**	  (0.95	  1.04)	   -­‐0.03	  (-­‐0.06,	  0.02)	  Constant	   -­‐	   2.59***	  (0.88,	  4.16)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.83	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.62	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   84.52%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  	  Table	  5.10	  Two-­‐stage	  GLM	  model	  for	  hospitalisation	  costs	  associated	  with	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  of	  
costs	  per	  month	  due	  
to	  the	  LB	  
N=230	  observations	  
GLM	  of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=24	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
interval)	  Age	  	   1.00	  (0.96,	  1.05)	   0.06	  (-­‐0.2,	  0.03)	  Males	  relative	  to	  Females	   0.72	  (0.21,	  2.73)	   0.89	  (-­‐1.02,	  0.11)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.74	  (0.24,	  2.53)	   0.69	  (-­‐0.40,	  0.66)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   16.56***(4.02,55.90)	   0.82	  (-­‐0.07,	  1.01)	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Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   1.24	  (0.37,4.07)	   -­‐1.40(-­‐0.47,	  3.05)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   0.75	  (0.18,	  3.06)	   -­‐0.79	  (-­‐0.45,	  0.70)	  Median	  weekly	  wage	   0.99	  (0.99,	  1.00)	   -­‐0.00	  (-­‐0.00,	  0.00)	  Did	  not	  use	  ST	  programme	   -­‐	   0.85	  (0.13,	  1.78)	  Treated	   -­‐	   0.48	  (-­‐0.50,	  1.12)	  Months	  since	  LB	   1.01	  (0.93	  1.09)	   -­‐0.01	  (-­‐0.06,	  0.02)	  Constant	   -­‐	   	  	  	  	  	  	  	  3.19	  (0.88,	  4.16)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.73	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.65	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   81.42%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Unsurprisingly,	  hospitalisation	  costs	  are	  associated	  with	  being	  injured,	  and	  those	  participants	  were	  up	  to	  16	  times	  more	  likely	  to	  report	  hospitalisation	  costs	  (Table	  5.10).	  	  Table	  5.11	  Two-­‐stage	  GLM	  model	  for	  productivity	  loss	  costs	  associated	  with	  exposure	  to	  the	  LB	  
	  
Potentially	  associated	  factors	  
Logistic	  regression	  
of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=230	  
observations	  
GLM	  of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=137	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
interval)	  Age	  	   1.00	  (0.97,	  1.05)	   0.03*	  (-­‐0.00,	  0.06)	  Males	  relative	  to	  Females	   0.54**	  (0.36,	  0.97)	   -­‐0.75	  **(-­‐1.52,-­‐	  0.00)	  White	  British	  relative	  to	  Other	  ethnic	   0.92	  (0.47,	  1.53)	   -­‐0.77*	  (-­‐1.56,	  0.02)	  
	   153	  
categories	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   1.56*(0.98,3.90)	   0.39	  (-­‐0.47,	  1.27)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   1.54	  (0.78,2.92)	   0.13(-­‐0.97,	  1.19)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   0.85	  (0.41,	  1.71)	   0.39	  (-­‐0.41,	  1.21)	  Median	  weekly	  wage	   1.00*	  (0.99,	  1.00)	   0.00	  (-­‐0.00,	  0.00)	  Did	  not	  use	  ST	  programme	   -­‐	   0.17	  (-­‐0.91,	  1.28)	  Treated	   -­‐	   0.90*	  (-­‐0.04,	  1.85)	  Months	  since	  LB	   0.99	  (0.95,	  1.03)	   -­‐0.00	  (-­‐0.05,	  0.03)	  Constant	   -­‐	   	  	  	  	  	  	  	  3.79***	  (1.92,	  5.66)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.69	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.61	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   84.25%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  As	  presented	  in	  Table	  5.11,	  higher	  productivity	  loss	  costs	  are	  predicted	  by	  being	  of	  female	  gender.	  	  Moreover,	  women	  were	  more	  likely	  to	  report	  costs	  in	  comparison	  to	  men.	  	  The	  results	  presented	  in	  this	  section	  are	  not	  unexpected	  or	  surprising.	  	  High	  costs	  of	  service	  use	  and	  productivity	  loss	  associated	  with	  mental	  health	  problems	  in	  general,	  and	  more	  particularly	  with	  anxiety	  disorders	  due	  to	  trauma	  exposure,	  have	  been	  reported	  in	  previous	  studies,	  as	  discussed	  in	  Chapter	  2.	  	  Nor	  it	  is	  surprising	  that	  a	  larger	  proportion	  of	  the	  costs	  is	  associated	  with	  productivity	  loss	  in	  comparison	  to	  service	  use	  cost.	  	  Factors	  associated	  with	  higher	  service	  use,	  and	  consequently	  costs	  highlighted	  by	  the	  models	  shown	  above	  are	  being	  of	  female	  gender,	  having	  a	  non-­‐white	  British	  background,	  experiencing	  injury,	  and	  fear	  and	  hopelessness.	  	  These	  are	  well-­‐known	  risk	  factors	  for	  developing	  PTSD	  identified	  by	  the	  literature,	  as	  reviewed	  in	  Chapter	  2.	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Analysis	  suggests	  that	  participants	  with	  the	  highest	  overall	  monthly	  costs	  are	  those	  with	  mental	  health	  needs	  identified	  by	  the	  ST	  programme.	  	  Health	  services	  costs	  have	  the	  same	  pattern.	  	  However,	  when	  the	  costs	  of	  the	  ST	  programme	  are	  excluded,	  there	  is	  no	  longer	  a	  statistical	  difference	  in	  service	  costs	  between	  programme	  users	  and	  non-­‐users	  while	  holding	  other	  factors	  constant.	  	  In	  fact,	  when	  looking	  at	  the	  services	  provided	  by	  the	  private	  sector	  solely,	  participants	  who	  did	  not	  use	  the	  ST	  programme	  reported	  statistically	  higher	  costs	  compared	  to	  programme	  users.	  	  This	  suggests	  that	  (some)	  individuals	  who	  did	  not	  use	  the	  ST	  programme	  may	  have	  sought	  treatment	  privately.	  	  
5.4	   Factors	  associated	  with	  being	  diagnosed	  with	  PTSD	  	  As	  found	  from	  the	  Literature	  Review,	  PTSD	  is	  a	  common	  mental	  health	  disorder	  following	  exposure	  to	  traumatic	  events	  with	  a	  significant	  impact	  on	  individuals	  and	  society	  as	  a	  whole.	  	  Evaluation	  of	  the	  LB	  mental	  health	  response	  is	  an	  opportunity	  to	  describe	  and	  measure	  the	  impact	  of	  PTSD	  in	  terms	  of	  costs,	  and	  cost	  function	  analysis	  provides	  a	  useful	  tool.	  	  This	  section	  will	  explore	  links	  between	  PTSD	  and	  costs	  in	  two	  separate	  analyses	  on	  a	  sub-­‐sample	  of	  participants	  who	  were	  assessed	  within	  the	  ST	  programme.	  	  The	  first	  model	  will	  assess	  potential	  risk	  factors	  associated	  with	  being	  diagnosed	  with	  PTSD	  by	  using	  PTSD	  ICD-­‐10	  criteria,	  while	  the	  second	  one	  will	  examine	  cost	  predictors.	  	  PTSD	  is	  the	  predominant	  primary	  diagnosis	  within	  the	  sub-­‐sample	  used	  in	  this	  PhD	  study,	  as	  well	  as	  among	  the	  original	  sample	  of	  ST	  programme	  users.	  	  In	  total,	  77	  participants	  were	  diagnosed	  with	  PTSD;	  67	  were	  diagnosed	  under	  both	  DSM-­‐IV	  and	  ICD-­‐10	  criteria	  (64%)	  and	  a	  further	  10	  (10%)	  participants	  received	  PTSD	  diagnosis	  based	  on	  ICD-­‐10	  criteria	  only.	  	  Other	  reported	  diagnoses	  were	  travel	  phobia	  (6%),	  adjustment	  disorder	  (6%),	  complicated	  grief	  (5%)	  and	  depression	  (2%).	  	  Table	  5.12	  lists	  all	  variables	  explored	  in	  the	  prediction	  model,	  with	  the	  number	  and	  percentage	  of	  missing	  values.	  	  I	  used	  MI	  to	  estimate	  missing	  values	  in	  the	  same	  manner	  as	  described	  in	  the	  previous	  section	  by	  using	  SPSS	  17’s	  automatic	  MI	  option	  that	  accommodates	  the	  imputation	  model	  to	  the	  pattern	  of	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the	  missing	  data.	  	  In	  the	  imputation	  model	  I	  included	  all	  variables	  that	  I	  will	  later	  use	  in	  the	  analysis	  including	  the	  outcome	  variables	  used	  only	  as	  a	  predictor.	  Table	  5.12	  Variables	  with	  missing	  values	  
Variable	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Overall	  sample	  size	  
N=117	  
N	  missing	   %	  missing	  
Age	   0	   0	  Gender	   0	   0	  White	  British	  ethnicity	   11	   9.4	  Median	  week	  salary	   6	   5.1	  Months	  since	  LB	   3	   2.6	  Q1.	  Injured	  in	  LB	  	   14	   12	  Q2.	  You	  felt	  you	  might	  be	  injured	  or	  killed?	   15	   12.8	  Q3.	  You	  saw	  someone	  who	  was	  injured	  or	  killed?	   17	   11.3	  
Variable	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Overall	  sample	  size	  
N=117	  
N	  missing	   %	  missing	  
N	  of	  previous	  trauma	   14	   11.3	  PDS	   13	   10.9	  BDI	   13	   10.9	  EQ5D	   37	   10.4	  Total	  cost	  per	  month	   0	   0	  Screened	  positive	  at	  1st	  screener	  N	  of	  screeners	   0	  0	   0	  0	  PTSD	  ICD-­‐10	   0	   0	  	   The	  model	  explores	  predictors	  of	  being	  diagnosed	  with	  PTSD	  ICD-­‐10	  primary	  diagnosis	  and	  the	  analysis	  included	  all	  117	  participants	  who	  were	  assessed	  during	  a	  structured	  clinical	  interview	  for	  DSM-­‐IV	  Axis	  I	  Disorders	  (SCID),	  which	  is	  commonly	  used	  to	  diagnose	  PTSD	  (First	  et	  al,	  1996).	  	  Statistically	  significant	  factors	  identified	  by	  the	  model	  are	  witnessing	  death	  or	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injury	  and	  feeling	  one	  will	  die	  or	  sustain	  injury.	  	  Participants	  with	  those	  experiences	  were	  four	  to	  five	  times	  more	  likely	  to	  have	  primary	  diagnosis	  of	  PTSD	  ICD-­‐10	  in	  comparison	  to	  the	  other	  participants.	  	  This	  finding	  is	  not	  surprising	  as	  witnessing	  injury	  and	  death,	  and	  experiencing	  helplessness	  and	  horror	  are	  components	  of	  criterion	  A	  as	  defined	  by	  DSM-­‐IV	  (APA,	  1994).	  	  Two	  further	  statistically	  significant	  factors	  were	  the	  number	  of	  screeners	  and	  being	  screened	  positive	  on	  the	  first	  screen.	  	  The	  more	  screeners	  an	  individual	  had,	  the	  less	  likely	  they	  were	  to	  receive	  a	  diagnosis,	  which	  can	  be	  interpreted	  as	  showing	  that	  the	  screening	  process	  was	  sensitive	  and	  discriminated	  well	  between	  participants	  with	  mental	  health	  needs	  and	  those	  without,	  as	  on	  average	  participants	  were	  sent	  to	  assessment	  and	  treatment	  on	  their	  first	  screener.	  	  Participants	  who	  screened	  positive	  at	  the	  first	  screener	  were	  five	  times	  more	  likely	  to	  receive	  the	  PTSD	  diagnosis	  in	  comparison	  to	  other	  participants.	  	  However,	  this	  effect	  is	  probably	  due	  to	  collinearity	  between	  screening	  positive	  and	  assessment,	  and	  consequently	  contributes	  little	  to	  the	  interpretation	  of	  the	  equation.	  	  Interestingly,	  	  two	  variables	  I	  expected	  to	  have	  an	  association	  with	  receiving	  a	  PTSD	  ICD-­‐10	  primary	  diagnosis,	  that	  is,	  having	  a	  premorbid	  condition	  and	  the	  number	  of	  previous	  trauma	  experiences,	  were	  not	  significant.	  	  Nor	  were	  demographic	  variables	  such	  as	  gender	  or	  ethnic	  background.	  	  Table	   5.13	   Potential	   risk	   factors	   associated	   with	   being	   diagnosed	   with	   PTSD	  ICD-­‐10	  criteria	  on	  a	  sample	  of	  the	  ST	  programme	  users	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Odds	  ratio	  
Logistic	  regression	  N=117	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Age	  	   1.00	  (0.92,	  1.06)	  Males…relative	  to	  females	   0.72	  (0.08,	  1.23)	  White	  British…relative	  to	  other	  ethnic	  categories	   0.89	  (0.37,	  5.34)	  Q1.	  Being	  injured…relative	  to	  not	  being	  injured	   	  1.55	  (0.26,	  5.71)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   4.00**	  (0.09,	  15.45)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   5.61***	  (0.12,	  49.48)	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Median	  weekly	  wage	   1.00	  (0.99,	  1.00)	  Assessment	  date	   1.06	  (0.99,	  1.20)	  N	  of	  previous	  trauma	   0.95	  (0.41,	  1.70)	  Premorbid	  condition…relative	  to	  No	  premorbid	  condition	   1.5	  (0.29,	  8.06)	  N	  of	  screeners	   0.21***(0.07.	  0.58)	  Screened	  positive	  at	  1st	  screener	   5.11*(0.80.	  32.54)	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.41	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p	  value	   0.51	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	  Per	  cent	  correctly	  classified	   82.91%	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  The	  next	  model,	  presented	  in	  Table	  5.14,	  examines	  the	  impact	  on	  costs	  of	  participant	  and	  exposure	  characteristics	  measured	  at	  the	  screening	  and	  assessment	  point.	  	  I	  used	  a	  GLM	  model	  with	  a	  	  gamma	  distribution	  and	  log	  transformation	  due	  to	  the	  skewed	  distribution.	  	  There	  was	  no	  need	  for	  a	  two-­‐stage	  model	  as	  all	  participants	  had	  non-­‐zero	  costs.	  	  Younger	  age,	  PTSD	  ICD-­‐10	  primary	  diagnosis,	  earlier	  assessment	  date	  and	  non-­‐white	  British	  background	  were	  predictors	  of	  higher	  average	  monthly	  costs	  at	  the	  follow-­‐up	  point.	  	  Translated	  to	  actual	  costs,	  participants	  with	  PTSD	  ICD-­‐10	  primary	  diagnosis	  reported	  up	  to	  three	  times	  higher	  costs	  than	  other	  participants	  (£628	  vs.	  £252),	  and	  non-­‐white	  British	  participants	  reported	  double	  monthly	  costs	  in	  comparison	  to	  the	  rest	  of	  the	  sample	  (£692	  vs.	  £392).	  	  Table	  5.14	  Generalised	  linear	  model	  of	  factors	  potentially	  associated	  with	  reporting	  costs	  in	  connection	  to	  exposure	  to	  the	  LB	  on	  a	  sample	  of	  the	  ST	  programme	  users	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  GLM,	  N=117	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  
interval)	  Age	  	   0.02*	  (0.01,	  0.04)	  Males…relative	  to	  females	   -­‐0.14	  (-­‐0.27,	  0.23)	  White	  British…relative	  to	  other	  ethnic	  categories	   -­‐0.45*	  (-­‐0.54,	  -­‐0.04)	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Q1.	  Being	  injured…relative	  to	  not	  being	  injured	   0.17	  (-­‐0.14,	  0.18)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   -­‐0.05	  (-­‐0.21,	  0.31)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   0.57**	  (0.18,	  0.73)	  Median	  weekly	  wage	   0.00	  (-­‐0.00,	  0.00)	  Assessment	  date	   -­‐0.00**	  (-­‐0.001,	  0.00)	  N	  of	  previous	  trauma	   0.19	  (-­‐0.27,	  0.24)	  Premorbid	  condition	   -­‐0.72	  (-­‐0.93,	  0.17)	  Months	  since	  LB	   -­‐0.02	  (-­‐0.23,	  0.37)	  PTSD	  ICD-­‐10	   0.62**	  (0.28,	  0.87)	  Constant	   5.62***	  (1.44,	  6.18)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Interpretation	  of	  the	  model	  is	  challenged	  by	  intercorrelations	  between	  some	  of	  the	  independent	  variables,	  namely	  PTSD	  and	  potential	  risk	  factors	  such	  as	  exposure	  variables	  (Q2	  and	  Q3),	  though,	  interestingly,	  the	  model	  on	  risk	  factors	  for	  PTSD	  presented	  in	  Table	  5.13	  did	  not	  show	  a	  link	  bethween	  ethnicity	  and	  PTSD	  as	  expected.	  	  Although	  intercorrelations	  do	  not	  affect	  the	  predictive	  power	  of	  the	  model	  as	  a	  whole	  (Knapp	  et	  al.,	  1995)	  it	  is	  difficult	  to	  separate	  the	  effects	  of	  those	  individual	  variables.	  	  It	  appears,	  however,	  that	  costs	  were	  higher	  for	  individuals	  who	  were	  assessed	  earlier	  in	  the	  programme,	  individuals	  with	  PTSD	  ICD-­‐10	  diagnosis	  and	  participants	  who	  saw	  someone	  being	  injured	  or	  killed.	  	  The	  reasons	  behind	  why	  participants	  who	  were	  assessed	  eariler	  in	  the	  programme	  reported	  higher	  costs	  are	  discussed	  in	  greater	  detail	  in	  Chapters	  6	  and	  7.	  	  Finding	  a	  link	  between	  reporting	  costs	  and	  PTSD	  diagnosis	  was	  expected	  as	  the	  Literature	  Review	  documented	  that	  PTSD	  diagnosis	  is	  associated	  with	  increased	  service	  use,	  various	  physical	  and	  mental	  health	  comorbidities	  and	  productivity	  loss	  costs.	  	  Seeing	  someone	  being	  injured	  or	  killed	  is	  a	  risk	  factor	  for	  PTSD,	  and	  the	  model	  presented	  in	  Table	  5.13	  confirmed	  expected	  significant	  association	  between	  PTSD	  diagnosis	  and	  this	  variable,	  hence	  association	  between	  reporting	  	  costs	  and	  witnessing	  death	  and/or	  injury	  is	  explained	  by	  intercorrelations.	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5.5	   Summary	  In	  this	  chapter	  I	  explored	  relationships	  between	  costs	  and	  the	  following	  variables:	  participants’	  characteristics,	  exposure	  factors	  and	  the	  type	  of	  the	  services	  they	  have	  used.	  	  The	  cost	  function	  approach	  is	  a	  very	  useful	  tool	  in	  this	  kind	  of	  exploration,	  as	  it	  enables	  the	  analysis	  to	  show	  the	  relationship	  between	  variables	  of	  interest	  while	  keeping	  other	  variables	  constant.	  	  The	  main	  cost	  drivers	  identified	  in	  the	  analysis	  on	  the	  whole	  sample	  of	  individuals	  exposed	  to	  the	  LB	  were	  female	  gender,	  being	  in	  a	  non-­‐white	  British	  ethnicity	  group,	  experiencing	  injury,	  age	  and	  feeling	  one	  might	  be	  killed	  and/or	  injured.	  	  Participants	  who	  had	  received	  treatment	  within	  the	  programme	  reported	  on	  average	  three	  times	  higher	  costs	  in	  comparison	  to	  the	  rest	  of	  participants,	  while	  women	  and	  participants	  of	  non-­‐white	  British	  origin	  reported	  on	  average	  double	  costs	  compared	  to	  men	  and	  the	  white	  ethnic	  group,	  respectively.	  	  When	  comparing	  health	  service	  use	  between	  programme	  users	  and	  non-­‐users,	  and	  excluding	  the	  ST	  programme	  costs,	  the	  difference	  in	  overall	  reported	  costs	  was	  no	  longer	  evident	  between	  the	  groups.	  	  Again,	  the	  analysis	  confirmed	  gender,	  ethnicity,	  injury	  and	  experiencing	  helplessness	  and	  horror	  as	  significant	  cost	  predictors.	  	  These	  results	  were	  consistent	  for	  health	  care	  costs	  and	  medication	  costs,	  while	  for	  private	  sector-­‐provided	  services,	  females	  and	  people	  who	  had	  been	  injured	  were	  twice	  as	  likely	  to	  report	  costs	  compared	  to	  other	  people.	  	  Lastly,	  models	  using	  data	  only	  for	  the	  ST	  subsample	  looked	  first	  at	  factors	  associated	  with	  being	  diagnosed	  with	  PTSD	  ICD-­‐10,	  and	  identified	  that	  witnessing	  death	  or	  injury,	  and	  feeling	  one	  might	  be	  injured	  or	  killed	  as	  significant,	  with	  those	  participants	  being	  four	  times	  more	  likely	  to	  receive	  the	  diagnosis.	  	  Participants	  with	  PTSD	  ICD-­‐10	  diagnosis	  reported	  up	  to	  three	  times	  higher	  costs	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  A	  second	  model	  for	  the	  ST	  group	  found	  that	  two	  well-­‐known	  risk	  factors	  for	  PTSD,	  younger	  age	  and	  non-­‐white	  British	  background,	  were	  significantly	  associated	  with	  higher	  costs.	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This	  analysis	  has	  been	  constrained	  by	  the	  study	  design	  (including	  the	  observational	  nature	  of	  the	  study,	  alongside	  the	  sampling	  strategy	  and	  size),	  but	  suggests	  one	  observation	  and	  a	  possible	  conclusion.	  	  First,	  the	  identified	  factors	  associated	  with	  higher	  mental	  health	  needs	  and	  service	  use	  are	  well	  known	  from	  the	  literature	  as	  predictors	  of	  PTSD.	  	  Second,	  this	  data	  possibly	  suggests	  that	  the	  ST	  programme	  was	  successful	  in	  identifying	  participants	  with	  higher	  mental	  health	  needs	  and	  providing	  them	  with	  treatment.	  	  This	  is	  supported	  by	  the	  finding	  that	  the	  more	  screeners	  an	  individual	  had	  the	  less	  likely	  they	  were	  to	  be	  diagnosed	  with	  PTSD,	  which	  indicates	  that	  the	  screening	  process	  was	  sensitive,	  and	  under	  the	  assumption	  that	  higher	  costs	  are	  positively	  associated	  with	  higher	  mental	  health	  needs,	  that	  individuals	  treated	  within	  the	  programme	  experienced	  higher	  mental	  health	  needs	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  The	  increased	  total	  cost	  of	  treated	  individuals	  possibly	  suggests	  that	  they	  were	  more	  severely	  affected	  than	  the	  programme	  non-­‐users	  and	  individuals	  who	  were	  screened	  only.	  	  However	  it	  is	  difficult	  to	  know	  from	  the	  available	  data	  how	  and	  if	  the	  ST	  programme	  made	  any	  economic	  difference	  to	  this	  group,	  such	  as	  averted	  high	  future	  costs	  associated	  with	  chronic	  PTSD	  and	  possible	  comorbid	  disorders,	  or	  if	  it	  had	  reduced	  productivity	  and	  unemployment.	  	  	  In	  my	  view,	  the	  biggest	  contribution	  of	  this	  chapter	  is	  not	  in	  producing	  robust	  cost	  predictions	  and	  models,	  but	  in	  describing	  challenges	  encountered	  in	  analysing	  cost	  data	  in	  the	  context	  of	  an	  observational	  study	  conducted	  as	  a	  part	  of	  the	  wider	  evaluation.	  	  Nevertheless,	  while	  acknowledging	  the	  methodological	  difficulties,	  this	  is	  an	  exciting	  and	  unique	  dataset	  and	  the	  findings	  offer	  a	  perfect	  learning	  opportunity	  for	  future	  studies.	  Costs	  described	  in	  this	  chapter	  will	  serve	  as	  a	  foundation	  for	  a	  cost-­‐effectiveness	  analysis	  of	  the	  ST	  programme	  described	  in	  Chapters	  6	  and	  7.	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Chapter	  6	   Comparing	  costs	  and	  outcomes	  of	  the	  ST	  programme	  	  
6.1	   Introduction	  The	  ST	  programme	  was	  an	  innovative	  mental	  health	  approach	  after	  a	  major	  traumatic	  event	  on	  a	  large	  scale	  and	  was	  a	  rare	  example	  of	  the	  direct	  translation	  of	  evidence-­‐based	  recommendations	  from	  previous	  literature	  on	  putting	  a	  mental	  health	  response	  policy	  into	  practice.	  	  In	  order	  to	  inform	  policies	  on	  mental	  health	  responses	  after	  major	  traumatic	  events	  as	  well	  as	  usual	  practice	  on	  treating	  PTSD,	  it	  was	  of	  importance	  to	  conduct	  an	  economic	  evaluation	  of	  the	  ST	  programme.	  	  However,	  as	  this	  chapter	  will	  demonstrate,	  it	  is	  a	  challenging	  task	  to	  conduct	  a	  robust	  economic	  evaluation	  given	  the	  real-­‐world	  context	  in	  which	  the	  ST	  programme	  was	  delivered.	  This	  chapter	  brings	  together	  work	  conducted	  in	  the	  previous	  two	  chapters	  into	  a	  new	  and	  integrated	  approach	  which,	  to	  cite	  a	  familiar	  Gestalt	  principle,	  is	  greater	  than	  the	  sum	  of	  its	  parts	  (Hothersall,	  2004).	  	  	  To	  elaborate,	  Chapters	  4	  and	  5	  have	  set	  the	  scene	  for	  the	  economic	  evaluation,	  which	  is	  the	  main	  subject	  of	  this	  and	  the	  subsequent	  chapter.	  	  In	  Chapter	  4,	  I	  identified	  all	  the	  services	  used	  by	  the	  sample	  of	  individuals	  affected	  by	  the	  LB	  and	  associated	  costs	  to	  the	  individuals	  and	  society	  as	  a	  whole.	  	  Following	  on	  from	  that,	  in	  Chapter	  5	  I	  explored	  costs	  and	  outcomes	  variations,	  linked	  to	  individuals’	  socio-­‐demographic	  characteristics,	  the	  nature	  of	  their	  involvement	  in	  the	  LB	  and	  the	  extent	  of	  their	  use	  of	  the	  ST	  programme.	  	  The	  aim	  of	  this	  chapter	  is	  to	  report	  the	  economic	  evaluation	  in	  the	  context	  of	  the	  mental	  health	  response,	  within	  the	  framework	  of	  an	  observational	  study,	  and	  from	  a	  societal	  perspective.	  	  The	  chapter	  will	  also	  discuss	  a	  number	  of	  methodological	  and	  econometric	  challenges	  and	  the	  ways	  I	  sought	  to	  address	  them.	  	  As	  discussed	  in	  Chapter	  3,	  I	  identified	  three	  potential	  comparator	  groups	  for	  the	  economic	  evaluation.	  	  I	  will	  present	  the	  economic	  evaluation	  of	  the	  ST	  programme	  in	  two	  chapters.	  	  Chapter	  6	  will	  present	  analysis	  comparing	  ST	  users	  with	  participants	  who	  did	  not	  use	  the	  programme.	  	  In	  addition,	  I	  will	  compare	  people	  who	  were	  treated	  within	  the	  programme	  to	  those	  who	  were	  screened	  and	  assessed	  only.	  	  Following	  on	  from	  these	  analyses,	  Chapter	  7	  will	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compare	  early	  and	  late	  treatment	  groups	  within	  the	  ST	  programme,	  using	  cost-­‐effectiveness	  analysis.	  The	  guiding	  idea	  behind	  this	  chapter	  is	  to	  discuss	  and	  explore	  all	  available	  avenues	  and	  approaches	  in	  this	  challenging	  context	  and	  to	  demonstrate	  the	  difficulties	  encountered	  and	  potential	  ways	  around	  them.	  	  The	  aim	  is	  not	  to	  provide	  an	  ultimate	  answer	  in	  how	  to	  approach	  evaluation	  of	  mental	  health	  interventions,	  but	  to	  explore	  and	  discuss	  available	  choices	  within	  the	  framework	  of	  applied	  clinical	  psychology	  research	  in	  the	  real	  world	  context,	  and	  provide	  practical	  lessons	  and	  insights	  for	  future	  evaluations	  in	  this	  field.	  	  
6.2	  	   Methods	  summary	  Economic	  evaluation	  is	  a	  relatively	  young	  yet	  potentially	  very	  useful	  and	  increasingly	  sought-­‐after	  tool	  for	  evidence-­‐based	  decision-­‐making	  in	  relation	  to	  mental	  health	  and	  other	  interventions.	  	  The	  outcome	  information	  that	  is	  available	  will	  determine	  the	  type	  of	  the	  economic	  evaluation	  that	  is	  possible.	  	  Within	  the	  context	  of	  the	  ST	  programme,	  the	  suitable	  economic	  evaluation	  tools	  were	  cost-­‐effectiveness	  and	  cost-­‐utility	  analyses.	  	  One	  of	  the	  major	  evaluation	  challenges	  was	  to	  identify	  appropriate	  comparator	  groups.	  	  As	  I	  described	  in	  Chapter	  3,	  I	  identified	  three	  ways	  to	  approach	  the	  evaluation	  of	  the	  ST	  programme,	  each	  with	  its	  own	  merits	  and	  limitations.	  	  The	  comparisons	  on	  which	  I	  focussed	  were:	  (a)	  early	  treatment	  versus	  later	  treatment	  group;	  (b)	  ST	  programme	  users	  versus	  participants	  who	  did	  not	  use	  the	  programme;	  and	  (c)	  participants	  who	  received	  treatment	  under	  the	  ST	  programme	  versus	  participants	  who	  were	  screened	  and	  assessed	  only.	  	  In	  order	  to	  minimise	  and	  adjust	  for	  observable	  biases	  introduced	  by	  the	  observational	  study	  design,	  I	  used	  multivariate	  regression	  to	  adjust	  both	  costs	  and	  outcomes	  for	  the	  same	  group	  of	  covariates	  based	  on	  theoretical	  and	  statistical	  criteria.	  	  In	  practice,	  this	  translates	  to	  running	  a	  set	  of	  GLM	  models	  for	  prediction	  of	  both	  costs	  and	  outcomes.	  	  The	  model	  protocol	  is	  outlined	  in	  Table	  6.1.	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Table	  6.1	  Costs	  and	  effects	  model	  protocol	  
GLM	  model	  protocol	  	  
**	  Step	  A1:	  GLM	  model	  for	  COSTS**	  glm	  COST	  i.group	  $covariates	  if	  COST>0,	  fam(gamma)	  link(log)	  	  predict	  yhat1	  if	  e(sample),	  mu	  
**Step	  A2:	  estimate	  person-­‐specific	  COSTS	  **	  gen	  yhat1c=phat1*yhat1	   	  
**	  Step	  A3:	  GLM	  model	  for	  EFFECTS	  (e.g.	  BDI	  score	  follow	  up)**	  glm	  BDI	  i.group	  $covariates,	  fam(gamma)	  link(log)	  
**Step	  A4:	  estimate	  person-­‐specific	  EFFECTS	  **	  predict	  yhat2	  if	  e(sample),	  mu	  
**Step	  B1:	  obtain	  mean	  predicted	  costs	  for	  group	  0	  and	  1,	  	  then	  subtract	  to	  get	  difference	  in	  group	  mean**	  margins	  COSTS	  treatment	  timing	  =(0	  1)	  atmeans	  
*	  *Step	  B2:	  obtain	  mean	  predicted	  BDI	  for	  group	  0	  and	  1,	  	  then	  subtract	  to	  get	  difference	  in	  group	  mean**	  margins	  EFFECTS	  (treatment	  timing	  =(0	  1)	  margins	  I	  used	  SPSS	  12	  and	  STATA	  11	  statistical	  packages	  to	  analyse	  costs	  and	  outcomes.	  	  I	  will	  start	  the	  analysis	  with	  adescriptive	  analysis	  of	  participants’	  sociodemographic	  characteristics,	  exposure	  and	  clinical	  characteristics.	  For	  costs	  and	  outcome	  categories	  for	  each	  participant	  group,	  I	  will	  present	  unadjusted	  mean	  values	  before	  presenting	  the	  models	  and	  adjusted	  estimates.	  	  Due	  to	  time	  and	  word	  constraints	  I	  will	  focus	  on	  three	  cost	  categories:	  	  a.	  ST	  programme	  costs	  	  b.	  direct	  costs:	  aggregate	  consisting	  of	  statutory	  provided	  health	  care	  services,	  hospitalisation,	  medication,	  voluntary	  and	  private	  sector	  services,	  and	  	  c.	  total	  costs:	  aggregate	  consisting	  of	  the	  ST	  programme,	  direct	  costs	  and	  work-­‐related	  costs	  due	  to	  sick	  leave,	  unemployment	  and	  reduced	  work	  hours.	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I	  adjusted	  all	  costs	  and	  effects	  models	  for	  the	  following	  covariates:	  age;	  gender;	  ethnicity;	  if	  the	  person	  was	  injured	  (Q1);	  if	  the	  person	  thought	  they	  will	  be	  injured	  or	  killed	  (Q2);	  if	  the	  person	  saw	  someone	  who	  was	  injured	  or	  killed	  (Q3);	  and	  follow-­‐up	  timing	  (days	  since	  LB).	  	  Although	  Q1,	  Q2	  and	  Q3	  are	  correlated	  I	  decided	  to	  include	  them	  in	  the	  analysis	  as	  Q1	  reflected	  the	  type	  of	  exposure	  while	  Q2	  and	  Q3	  are	  predictors	  for	  PTSD.	  	  I	  firstly	  present	  results	  of	  model	  evaluation,	  followed	  by	  assessment	  of	  the	  model	  fit	  by	  running	  a	  Park	  test,	  a	  link	  test	  to	  check	  linearity	  of	  the	  response	  and	  checking	  the	  distribution	  of	  the	  residuals	  to	  test	  for	  heteroscedasticity.	  	  In	  this	  chapter	  I	  cover	  comparisons:	  (b)	  ST	  programme	  users	  versus	  participants	  who	  did	  not	  use	  the	  programme;	  and	  (c)	  participants	  who	  received	  treatment	  under	  the	  ST	  programme	  versus	  participants	  who	  were	  screened	  and	  assessed	  only.	  	  The	  type	  of	  data	  available	  for	  those	  two	  comparisons	  and	  perspective	  offered	  by	  the	  analysis	  allows	  only	  for	  a	  partial	  economic	  evaluation	  (Drummond,	  2005)	  involving	  costs	  and	  outcomes	  description.	  	  Analyses	  of	  comparisons	  (b)	  and	  (c)	  offers	  an	  insight	  into	  the	  process	  and	  outcomes	  of	  the	  ST	  programme	  as	  they	  compare	  groups	  of	  participants	  with	  different	  mental	  health	  needs	  and	  status	  determined	  by	  the	  screening	  process.	  	  However,	  this	  is	  more	  of	  a	  descriptive	  analysis	  with	  insufficient	  scope	  for	  a	  comprehensive	  cost-­‐effectiveness	  analysis.	  	  
6.3	  	   Comparison	  between	  the	  ST	  programme	  users	  and	  non-­‐users	  Comparison	  of	  costs	  and	  outcomes	  between	  individuals	  who	  used	  the	  ST	  programme	  and	  those	  who	  did	  not	  provides	  an	  interesting	  and	  useful	  insight	  into	  the	  effectiveness	  of	  the	  programme.	  	  As	  mentioned	  in	  Chapter	  3,	  the	  ST	  programme	  evaluation	  study	  followed	  up	  103	  individuals	  who	  used	  the	  ST	  programme	  and	  77	  individuals	  who	  did	  not.	  	  Followed-­‐up	  individuals	  were	  asked	  to	  report	  all	  services	  they	  used	  due	  to	  involvement	  in	  the	  LB,	  and	  the	  impact	  of	  the	  LB	  on	  work	  performance	  in	  terms	  of	  sick	  leave,	  unemployment	  or	  reduced	  hours.	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In	  terms	  of	  the	  outcome	  measures,	  the	  ST	  users	  were	  followed-­‐up	  with	  TSQ	  questionnaire	  if	  they	  were	  screened	  only,	  and	  with	  BDI	  and	  PDS	  outcome	  measures	  if	  they	  were	  assessed	  and	  treated	  within	  the	  programme.	  	  Use	  of	  different	  instruments	  for	  different	  participant	  groups	  introduced	  a	  challenge	  in	  comparing	  their	  outcomes,	  and	  a	  solution	  to	  this	  problem	  was	  to	  compare	  TSQ	  items	  with	  items	  on	  PDS	  that	  correspond	  to	  the	  same	  symptoms.	  	  In	  Appendix	  D,	  I	  have	  highlighted	  items	  on	  PDS	  that	  correspond	  to	  TSQ	  items:	  there	  are	  slight	  differences	  in	  wording	  but	  in	  general	  the	  matched	  questions	  address	  the	  same	  symptoms.	  	  	  	  The	  TSQ	  consists	  of	  10	  questions	  that	  address	  frequency	  of	  five	  re-­‐experiencing	  and	  five	  arousal	  symptoms	  in	  the	  past	  week	  (Brewin	  et	  al.,	  2002),	  while	  PDS	  consists	  of	  49	  items	  that	  cover	  all	  DSM-­‐IV	  criteria	  for	  PTSD	  (A	  to	  F)	  including	  re-­‐experiencing	  and	  arousal	  symptoms	  within	  a	  time	  frame	  of	  the	  past	  month	  (McCarthy,	  2008).	  	  In	  order	  to	  be	  able	  to	  compare	  users	  with	  non-­‐users	  I	  have	  used	  10	  questions	  from	  PDS	  that	  address	  arousal	  and	  re-­‐experiencing	  symptoms	  and	  that	  correspond	  to	  the	  questions	  in	  TSQ.	  	  The	  TSQ	  items	  and	  corresponding	  PDS	  items	  are	  listed	  in	  Appendix	  D.	  	  A	  score	  of	  two	  or	  higher	  on	  items	  1,	  2,	  3,	  4,	  5,	  13,	  14,	  15,	  16	  and	  17	  of	  PDS	  counted	  as	  a	  yes	  on	  the	  equivalent	  question	  in	  TSQ.	  	  This	  approach	  only	  offers	  a	  crude	  approximation	  of	  the	  TSQ	  scores	  translated	  from	  PDS	  due	  to	  different	  psychometric	  properties	  of	  the	  questionnaires.	  	  Furthermore,	  as	  the	  questionnaires	  address	  different	  time	  periods	  (past	  week	  for	  TSQ;	  past	  month	  for	  PDS),	  interpretation	  of	  the	  results	  should	  be	  approached	  with	  caution.	  	  Before	  comparing	  costs	  and	  outcomes	  of	  participants	  who	  used	  the	  ST	  programme	  to	  those	  who	  did	  not,	  I	  wanted	  to	  compare	  their	  socio-­‐demographic	  and	  exposure	  characteristics	  (see	  Table	  6.2).	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Table	  6.2	  Comparison	  of	  socio-­‐demographic	  and	  exposure	  characteristics	  between	  participants	  who	  used	  the	  ST	  and	  those	  who	  did	  not	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ST	  non-­‐users	  N=77	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ST	  users	   	  
	   N	   %	   N	   %	   p	  Female	   28	   36	   61	   59	   0.54	  Ethnicity	  –	  white	  British	   57	   74	   64	   62	   0.05	  Employment	  category	   	   	  >£500	  median	  weekly	  salary	   31	   40	   42	   41	   0.25	  <£500	  median	  weekly	  salary	   36	   46	   53	   52	   0.42	  Student	   3	   4	   7	   5	   0.43	  Retired	   2	   3	   2	   1	   0.32	  Unemployed	   1	   1	   0	   0	   0.65	  Exposure	   	   	  Q1.	  Injured?	   19	   25	   52	   34	   0.71	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   26	   34	   92	   60	   0.00	  Q3.	  Witnessed	  injury	  or	  death?	   71	   92	   108	   70	   0.00	  Q4.	  Family	  member/	  close	  friend	  killed?	   1	   1	   16	   11	   0.00	  Q5.	  Family	  member/	  close	  friend	  injured?	   0	   0	   4	   3	   0.74	  Q6.	  You	  felt	  family	  member	  or	  a	  close	  friend	  might	  be	  injured/killed?	   1	   1	   15	   10	   0.07	  Q7.	  Personally	  witnessed	  effects	  of	  the	  bombings?	   74	   96	   131	   86	   0.00	  Screened	  positive	  at	  follow-­‐up	   31	   40	   31	   20	   0.00	  Age	  (mean)	   42.55	  (11.52)	   41.27	  (11.47)	   0.31	  	   There	  are	  several	  differences	  in	  socio-­‐demographic	  and	  exposure	  characteristics	  of	  people	  who	  did	  and	  did	  not	  use	  the	  ST	  programme.	  	  Significant	  differences	  are	  the	  larger	  proportion	  of	  white	  British	  participants	  and	  participants	  who	  were	  directly	  involved	  in	  the	  LB	  for	  programme	  non-­‐users.	  	  In	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addition,	  a	  higher	  percentage	  of	  participants	  who	  used	  the	  ST	  programme	  reported	  being	  more	  affected	  by	  the	  bombings	  in	  terms	  of	  witnessing	  injury	  and	  death,	  bereavement,	  fear	  for	  their	  own	  or	  a	  life	  of	  a	  close	  person.	  	  Most	  interestingly,	  a	  significantly	  higher	  proportion	  of	  participants	  who	  did	  not	  use	  the	  ST	  programme	  screened	  positive	  at	  the	  follow-­‐up:	  40%	  in	  comparison	  to	  20%	  of	  programme	  users.	  	  	  Before	  proceeding	  with	  prediction	  cost	  and	  outcome	  models	  in	  which	  I	  will	  be	  adjusting	  for	  the	  same	  group	  of	  baseline	  covariates,	  I	  will	  present	  unadjusted	  costs	  and	  outcomes	  for	  both	  groups.	  
6.3.1	  Outcomes	  –	  TSQ	  score	  at	  the	  follow-­‐up	  TSQ	  score	  at	  follow-­‐up	  was	  the	  only	  available	  outcome	  measure	  for	  both	  ST	  users	  and	  the	  non-­‐user	  group.	  	  In	  the	  first	  model	  I	  compared	  individuals	  who	  used	  the	  ST	  programme	  with	  those	  who	  did	  not	  by	  using	  a	  GLM	  model	  with	  Gauss	  family	  and	  identity	  link	  function,	  as	  confirmed	  by	  the	  Park	  test.	  	  After	  adjusting	  for	  socio-­‐demographic	  and	  exposure	  characteristics,	  there	  is	  no	  difference	  in	  the	  follow-­‐up	  TSQ	  score	  between	  the	  two	  groups:	  2.05	  for	  non-­‐users	  and	  2.35	  for	  ST	  users.	  	  Women	  and	  non-­‐white	  British	  respondents	  had	  significantly	  higher	  predicted	  TSQ	  end	  scores	  (3)	  in	  comparison	  to	  male	  and	  participants	  from	  other	  ethnic	  groups	  (2).	  	  However,	  this	  result	  is	  below	  the	  threshold	  of	  screening	  positive	  at	  TSQ,	  which	  was	  set	  at	  endorsing	  six	  symptoms	  or	  more	  (Brewin	  et	  al.,	  2002).	  Table	  6.3	  OLS	  on	  TSQ	  between	  participants	  who	  used	  the	  ST	  programme	  and	  those	  who	  did	  not	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=220	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.01	  (-­‐0.06,	  0.05)	  Males	  relative	  to	  females	   -­‐0.87***	  (-­‐1.57,	  -­‐0.24)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐1.21***	  (-­‐2.06,	  -­‐0.06)	  Q1.	  Injured?	   1.50***	  (0.75,	  2.27)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.03	  (-­‐1.44,	  0.86)	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Q3.	  Witnessed	  injury	  or	  death?	   0.75	  (-­‐3.19,	  1.65)	  Q7.	  You	  personally	  witnessed	  effects	  of	  the	  LB?	   -­‐0.50	  (-­‐1.81,	  0.87)	  ST	  users	  vs.	  non	  users	   0.30	  (-­‐0.49,	  1.04)	  Constant	  	  	  	   1.98***	  (4.26,	  11.63)	  Link	  function	   Identity	  Distributional	  family	   Gauss	  
6.3.2	  Costs	  For	  descriptive	  purposes,	  I	  start	  this	  section	  by	  presenting	  unadjusted	  costs	  for	  both	  programme	  users	  and	  non-­‐users.	  	  The	  ST	  programme	  users	  reported	  on	  average	  higher	  costs	  in	  all	  categories	  when	  compared	  with	  non-­‐users.	  	  However,	  the	  only	  significant	  difference	  between	  unadjusted	  average	  costs	  is	  for	  NHS	  services,	  voluntary	  sector	  services	  and	  medication	  in	  the	  direct	  cost	  category,	  overall	  work-­‐related	  costs	  and,	  more	  specifically,	  costs	  associated	  with	  productivity	  loss	  (table	  6.4).	  	  None	  of	  the	  costs	  are	  normally	  distributed.	  Table	  6.4	  Unadjusted	  average	  costs	  per	  cost	  category	  for	  ST	  users	  and	  non-­‐users	  
	  
ST	  users	  (N=153)	  
	  	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  
ST	  non-­‐users	  (N=77)	  
	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  	  	  	  	  	  
	  
p	  NHS	  health	  services	  	   654.28*	   164.95	   159.95*	   287.27	   0.00	  Private	  sector	  provided	  services	   272.42*	   100.42	   224.26*	   87.03	   0.58	  Voluntary	  sector	  provided	  services	   85.83*	   63.48	   22.37*	   52.07	   0.05	  Hospitalisation	   1361.27*	   342.75	   552.04*	   2164.01	   0.65	  Medication	   25.99*	   20.48	   5.52*	   6.13	   0.00	  Total	  direct	  costs	   2406.28*	   422.23	   2576.99*	   508.08	   0.93	  Productivity	  loss	   4185.96*	   3373.44	   1790.12*	   926.20	   0.09	  Hours	  reduced	   359.15*	   321.22	   115.27*	   22.67	   0.21	  Unemployment	   3427.33*	   3191.80	   262.66*	   1779.28	   0.04	  Total	  work	  costs	   9313.54*	   5021.07	   2159.31*	   2363.74	   0.01	  Total	  overall	  costs	  	   11719.68*	   5518.67	   4736.79*	   2532.54	   0.00	  *not	  normally	  distributed	  costs	  P<0.05	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Figure	  6.1	  Cost	  breakdown	  for	  ST	  users	  
	  	  Figure	  6.2	  Cost	  breakdown	  for	  participants	  who	  did	  not	  use	  the	  ST	  programme	  
	  In	  terms	  of	  the	  total	  contribution	  to	  overall	  costs,	  the	  dominant	  cost	  components	  for	  both	  ST	  users	  and	  non-­‐users	  were	  work-­‐related	  costs,	  followed	  by	  equal	  shares	  of	  hospitalisation	  and	  private	  sector	  costs	  for	  non-­‐users,	  while	  for	  ST-­‐users	  these	  were	  ST	  programme-­‐related	  costs	  followed	  by	  hospitalisation	  costs.	  	  Health	  care	  services	  costs,	  although	  the	  most	  frequently-­‐used,	  made	  a	  relatively	  small	  contribution	  to	  overall	  costs	  for	  both	  groups	  when	  compared	  with	  other	  cost	  components.	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Figure	  6.3	  Percentage	  of	  participants	  who	  reported	  costs	  per	  cost	  category	  
	  	  Figure	  6.4	  Percentage	  of	  participants	  who	  reported	  costs	  per	  cost	  type	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Table	  6.5	  GLM	  on	  direct	  costs	  between	  ST	  users	  and	  non-­‐users	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=206	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   -­‐0.00	  (-­‐0.06,	  0.05)	  Males	  relative	  to	  females	   -­‐1.13	  (-­‐0.57,	  1.54)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.48	  (-­‐1.06,	  0.06)	  Q1.	  Injured?	   1.42***	  (0.25,	  2.59)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.20	  (-­‐1.44,	  0.86)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.96	  (-­‐3.19,	  1.65)	  Non-­‐users	  vs.	  ST	  users	   -­‐1.58***	  (-­‐1.49,-­‐	  0.40)	  Constant	  	  	  	   7.17***	  (4.26,	  11.63)	  Link	  function	   Log	  Distributional	  family	   Gamma	  	   When	  comparing	  ST	  users	  with	  non-­‐users,	  the	  difference	  in	  mean	  predicted	  direct	  cost	  is	  statistically	  significant	  when	  controlling	  for	  socio-­‐demographic	  and	  exposure	  factors,	  with	  ST	  users	  reporting	  on	  average	  £1526	  in	  comparison	  to	  £484	  for	  non-­‐users.	  	  Again,	  injury	  was	  the	  only	  significant	  positive	  predictor	  of	  direct	  costs.	  Table	  6.6	  GLM	  on	  total	  costs	  between	  ST	  users	  and	  non-­‐users	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=206	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.01	  (-­‐0.06,	  0.05)	  Males	  relative	  to	  females	   -­‐0.83*	  (-­‐1.57,	  0.01)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.68	  (-­‐1.06,	  0.06)	  
Q1.	  Injured?	   1.29***	  (0.25,	  2.59)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.75*	  (-­‐1.44,	  0.86)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.96	  (-­‐3.19,	  1.65)	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ST	  Non-­‐users	  vs.	  Users	   -­‐1.22***	  (-­‐1.19,-­‐	  0.40)	  Constant	  	  	  	   8.27***	  (4.26,	  11.63)	  Link	  function	   Log	  Distributional	  family	   Gamma	  	   ST	  programme	  users	  had	  3.4	  times	  higher	  average	  total	  predicted	  costs,	  including	  work-­‐related	  costs	  and	  direct	  costs	  (£11454	  in	  comparison	  to	  £2380),	  when	  controlling	  for	  socio-­‐demographic	  and	  exposure	  characteristics.	  	  Injury	  was	  again	  a	  strong	  positive	  predictor	  of	  total	  costs.	  	   Results	  presented	  in	  this	  section	  suggest	  that	  the	  ST	  programme	  users	  reported	  higher	  average	  total,	  work	  and	  direct	  costs	  as	  a	  result	  of	  their	  exposure	  to	  the	  LB	  when	  compared	  to	  participants	  who	  did	  not	  use	  ST	  services.	  	  This	  difference	  is	  even	  larger	  when	  ST	  users	  are	  compared	  to	  participants	  who	  chose	  not	  to	  use	  services	  for	  other	  reasons	  explored	  earlier	  in	  the	  chapter,	  and	  presumably	  due	  to	  the	  fact	  they	  were	  recovering	  naturally	  or	  received	  enough	  support	  from	  alternative	  sources	  such	  as	  social	  networks	  or	  other	  services	  used.	  	  An	  alternative	  explanation	  could	  lie	  in	  the	  fact	  that	  the	  ST	  programme	  resulted	  in	  increased	  costs	  by	  pathologising	  the	  recovery	  of	  the	  programme	  users.	  	  However	  it	  is	  impossible	  to	  assess	  this	  assumption	  further	  as	  it	  is	  not	  possible	  to	  determine	  exactly	  when	  the	  reported	  costs	  occurred	  –	  prior	  to	  entry,	  during	  or	  after	  being	  discharged	  from	  the	  ST	  programme.	  	  Furthermore,	  the	  treatment	  effect	  size	  on	  PDS	  for	  treated	  participants	  was	  1.74	  and	  1.17	  for	  BDI	  which	  both	  indicate	  large	  treatment	  effect	  size.	  	  There	  was	  no	  statistically	  significant	  difference	  for	  either	  BDI	  or	  PDS	  scores	  at	  the	  treatment	  end	  and	  follow-­‐up,	  indicating	  that	  the	  treatment	  gains	  have	  been	  well	  maintained	  over	  time	  (Brewin	  et	  al.,	  2009).	  
6.3.3	  Comparison	  between	  participants	  who	  did	  not	  know	  of	  the	  ST	  
programme	  and	  those	  who	  did	  not	  want	  to	  use	  it	  It	  was	  important	  to	  address	  the	  reasons	  behind	  not	  using	  the	  ST	  programme,	  as	  participants	  who	  knew	  of	  the	  programme	  and	  decided	  not	  to	  use	  it	  might	  differ	  in	  their	  characteristics,	  costs	  and	  outcomes	  from	  participants	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who	  did	  not	  know	  of	  the	  programme.	  	  Although	  dividing	  an	  already	  small	  sample	  of	  people	  who	  did	  not	  use	  the	  programme	  into	  two	  is	  a	  statistically	  risky	  endeavour,	  it	  could	  still	  be	  informative	  in	  the	  context	  of	  future	  mental	  health	  response	  programmes	  to	  explore	  and	  describe	  potential	  differences	  between	  two	  sub-­‐samples	  in	  terms	  of	  their	  experiences,	  costs	  and	  outcomes.	  	  	  I	  have	  compared	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  with	  those	  who	  did	  not	  want	  to	  use	  it	  on	  socio-­‐demographic	  and	  exposure	  characteristics	  by	  using	  Chi-­‐square	  test.	  	  The	  only	  significant	  difference	  was	  in	  relation	  to	  ethnicity,	  with	  a	  higher	  number	  of	  white	  British	  participants	  in	  the	  category	  of	  participants	  who	  chose	  not	  to	  use	  the	  ST	  programme.	  	  Nevertheless,	  one	  must	  be	  cautious	  with	  conclusions	  based	  on	  such	  a	  small	  sample	  even	  if	  this	  finding	  is	  in	  line	  with	  previous	  literature	  reporting	  ethnicity	  as	  one	  of	  the	  important	  predictors	  in	  mental	  health	  resource	  use	  (Clark,	  2011).	  	  Furthermore,	  power	  issues	  may	  explain	  the	  absence	  of	  statistically	  significant	  differences.	  Out	  of	  77	  ST	  non-­‐users,	  33%	  of	  individuals	  did	  not	  hear	  about	  the	  ST	  programme	  or	  had	  no	  time	  or	  opportunity	  to	  respond,	  while	  77%	  felt	  they	  did	  not	  need	  the	  services.	  	  Reasons	  for	  not	  using	  the	  ST	  programme	  were:	  not	  feeling	  entitled	  or	  affected	  (14	  participants),	  having	  used	  other	  resources	  or	  services	  (14	  participants),	  having	  negative	  initial	  contact	  with	  services	  (5	  participants),	  not	  being	  based	  in	  London	  (5	  participants),	  wanting	  to	  move	  on	  (2	  participants),	  finding	  out	  about	  services	  too	  late	  (2	  participants),	  thinking	  service	  use	  would	  bring	  additional	  stress	  (1	  participant),	  other	  coping	  mechanisms:	  engaged	  in	  ‘cathartic‘	  activities	  (1	  participant).	  
a.	  Outcomes	  Participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  had	  significantly	  higher	  unadjusted	  TSQ	  scores	  at	  follow-­‐up	  (Z=-­‐3.76,	  p<0.01).	  	  This	  result	  was	  confirmed	  by	  the	  GLM	  model	  controlling	  for	  participant	  and	  exposure	  characteristics:	  the	  predicted	  TSQ	  follow-­‐up	  score	  for	  participants	  who	  did	  not	  know	  of	  ST	  programme	  was	  3.50	  in	  comparison	  to	  1.56	  for	  those	  who	  chose	  not	  to	  use	  it.	  	  Similar	  to	  the	  previous	  model,	  women	  and	  non-­‐white	  British	  respondents	  had	  significantly	  higher	  predicted	  TSQ	  end	  scores,	  and	  being	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injured	  in	  the	  bombings	  was	  positively	  correlated	  with	  follow-­‐up	  TSQ	  score.	  	  70%	  of	  participants	  who	  did	  not	  know	  of	  the	  programme	  reported	  the	  following	  symptoms:	  feeling	  upset	  by	  reminders	  of	  the	  bombings,	  heightened	  awareness	  of	  potential	  dangers	  to	  yourself	  and	  others,	  and	  being	  jumpy	  or	  startled.	  	  Around	  40%	  of	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  reported	  having	  upsetting	  thoughts	  or	  memories	  about	  the	  bombings	  that	  come	  to	  mind	  against	  one’s	  will	  and	  having	  upsetting	  dreams	  about	  the	  bombings.	  Table	  6.7	  GLM	  on	  TSQ	  between	  users	  who	  did	  not	  know	  about	  the	  ST	  programme	  versus	  participants	  who	  chose	  not	  to	  use	  it	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=71	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   -­‐0.01	  (-­‐0.06,	  0.05)	  Males	  relative	  to	  females	   -­‐0.28	  (-­‐0.57,	  0.04)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐1.58***	  (-­‐2.06,	  -­‐0.06)	  Q1.	  Injured?	   0.95***	  (0.55,	  2.29)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.40	  (-­‐1.44,	  0.86)	  Q3.	  Witnessed	  injury	  or	  death?	   0.46	  (-­‐3.19,	  1.65)	  Q7.	  You	  personally	  witnessed	  effects	  of	  the	  LB?	   0.81	  (-­‐1.80,	  1.49)	  Didn’t	  need	  vs.	  Didn’t	  know	   -­‐1.93***	  (-­‐2.97,	  -­‐0.89)	  Constant	  	  	  	   4.73***	  (2.26,	  7.63)	  Link	  function	   Identity	  Distributional	  family	   Gauss	  This	  result	  suggests	  that	  on	  average	  ST	  non-­‐users	  reported	  a	  higher	  level	  of	  symptoms	  even	  almost	  two	  years	  after	  the	  exposure	  to	  the	  LB	  in	  comparison	  to	  the	  programme	  users.	  	  Individuals	  who	  did	  not	  know	  about	  the	  programme	  reported	  higher	  screening	  scores	  in	  comparison	  to	  the	  individuals	  who	  chose	  not	  to	  use	  it,	  however	  for	  both	  groups	  the	  screening	  score	  was	  below	  the	  positive	  screening	  threshold.	  	  One	  possible	  conclusion	  could	  be	  that	  the	  ST	  non-­‐users	  would	  potentially	  have	  benefitted	  from	  using	  the	  ST	  programme,	  especially	  the	  screening	  and	  monitoring	  aspect.	  	  This	  explanation	  is	  based	  on	  the	  assumption	  that	  from	  the	  clinical,	  social	  and	  ethical	  perspectives,	  screening	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would	  not	  harm	  individuals	  by	  pathologising	  the	  natural	  recovery	  and	  re-­‐traumatising	  individuals	  by	  reminding	  them	  of	  the	  effects	  of	  the	  bombings,	  but	  instead	  providing	  information	  on	  the	  natural	  recovery	  process,	  support	  and	  potential	  safety-­‐nets	  should	  individuals	  need	  it.	  	  From	  an	  economic	  perspective,	  screening	  would	  not	  incur	  additional	  costs	  to	  the	  programme	  as	  the	  clinicians’	  wages,	  the	  costs	  of	  the	  screening	  team	  and	  the	  costs	  of	  the	  premises	  were	  fixed.	  	  Actually,	  the	  larger	  number	  of	  the	  programme	  users	  would	  bring	  down	  the	  total	  average	  cost	  per	  user	  and	  ensure	  better	  use	  of	  resources.	  	  	  
b.	  Costs	  Table	  6.8	  Unadjusted	  average	  costs	  per	  cost	  category	  for	  participants	  who	  did	  not	  use	  the	  ST	  programme	  
	  
Did	  not	  need	  ST	  	  	  	  (N=51)	  
	  	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  
Did	  not	  know	  of	  ST	  
(N=26)	  
	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  	  	  	  	  	  
	  
p	  NHS	  health	  services	  	   175.28*	   537.95	   128.95*	   149.27	   0.01	  Private	  sector	  provided	  services	   102.42*	   478.42	   462.26*	   871.03	   0.00	  Voluntary	  sector	  provided	  services	   31.83*	   163.48	   6.37*	   18.07	   0.86	  Hospitalisation	   3131.27*	   21562.75	   267.04*	   1339.01	   0.50	  Medication	   6.99*	   43.48	   2.52*	   8.13	   0.57	  
Total	  direct	  costs	   3448.26*	   21898.23	   867.29*	   1773.08	   0.00	  Productivity	  loss	   1621.96*	   7807.44	   2123.12*	   5817.20	   0.61	  Hours	  reduced	   104.15*	   598.22	   136.27*	   592.67	   0.72	  Unemployment	   83.33*	   595.80	   612.66*	   3124.28	   0.04	  
Total	  work	  costs	   1808.54*	   8429.07	   2847.31*	   6896.74	   0.14	  
Total	  overall	  costs	  	   5256.79*	   24321.54	   3739.68*	   7032.58	   0.00	  *not	  normally	  distributed	  costs	  P<0.05	   	  Looking	  at	  unadjusted	  mean	  costs,	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  reported	  higher	  average	  costs	  associated	  with	  private	  sector-­‐provided	  health	  care	  services.	  	  For	  all	  other	  direct	  cost	  categories	  and	  total	  costs,	  participants	  who	  chose	  not	  to	  use	  ST	  reported	  unadjusted	  higher	  average	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costs	  (Table	  6.8).	  	  However,	  the	  presented	  unadjusted	  costs	  are	  purely	  for	  illustrative	  purposes,	  as	  all	  cost	  variables	  are	  skewed	  and	  therefore	  mean	  values	  are	  not	  representative	  of	  groups,	  and	  costs	  have	  not	  been	  adjusted	  for	  all	  differences	  in	  socio-­‐demographic	  and	  exposure	  factors.	  	  Participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  had	  a	  similar	  proportion	  of	  work-­‐related	  costs	  as	  the	  ST	  users	  (77%	  of	  total	  cost),	  followed	  by	  private	  sector	  services	  costs	  and	  hospitalisation	  (Figure	  6.5).	  	  However	  the	  absence	  of	  the	  statistically	  significant	  differences	  in	  costs	  between	  the	  two	  groups	  might	  be	  explained	  by	  the	  sample	  power	  issues	  in	  particular	  in	  the	  case	  of	  hospitalisation,	  productivity	  and	  total	  work	  costs.	  Figure	  6.5	  Cost	  breakdown	  for	  participants	  who	  did	  not	  know	  about	  the	  ST	  programme	  
	  On	  the	  other	  hand,	  for	  participants	  who	  did	  not	  want	  the	  ST	  services	  hospitalisation	  costs	  were	  the	  largest	  total	  cost	  component,	  covering	  more	  than	  60%	  of	  costs,	  followed	  by	  work-­‐related	  costs	  and	  smaller	  percentages	  of	  private	  sector	  and	  hospitalisation	  costs	  (Figure	  6.6).	  	  	  Figure	  6.6	  Cost	  breakdown	  for	  participants	  who	  did	  not	  want	  to	  use	  the	  ST	  programme	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   However,	  from	  Figure	  6.7	  it	  is	  clear	  that	  a	  very	  small	  percentage	  of	  participants	  reported	  very	  high	  hospitalisation	  costs.	  Figure	  6.7	  Percentage	  of	  participants	  who	  reported	  costs	  per	  cost	  category	  
	  The	  next	  step	  is	  to	  compare	  percentages	  of	  participants	  who	  reported	  using	  services	  in	  order	  to	  understand	  which	  services	  were	  most	  frequently	  reported.	  	  For	  both	  groups,	  the	  most	  frequently-­‐used	  services	  were	  health	  care	  followed	  by	  private	  sector	  services.	  	  Work-­‐related	  costs	  were	  also	  frequently	  reported	  for	  both	  groups.	  	  Participants	  who	  used	  the	  programme	  reported	  higher	  percentages	  of	  service	  use	  and	  consequently	  higher	  costs	  for	  all	  cost	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groups.	  	  Productivity	  loss-­‐related	  costs	  were	  reported	  by	  the	  largest	  percentage	  of	  participants	  in	  both	  groups,	  as	  shown	  in	  Figure	  6.8.	  There	  is	  not	  much	  difference	  in	  the	  percentage	  of	  participants	  reporting	  medication,	  voluntary	  sector	  services	  and	  hospitalisation	  between	  participants	  who	  did	  not	  know	  or	  chose	  not	  to	  use	  ST.	  	  However,	  significantly	  more	  participants	  who	  did	  not	  hear	  of	  the	  ST	  programme	  reported	  using	  private	  sector	  services	  (Pearson-­‐Chi	  square=32.8,	  p=0.02).	  	  There	  was	  no	  difference	  between	  the	  number	  of	  people	  who	  reported	  number	  of	  hours	  reduced	  (Pearson-­‐Chi	  square=5.49,	  p=0.36).	  	  For	  both	  groups,	  the	  largest	  percentage	  of	  participants	  (around	  50%)	  reported	  health	  care	  services,	  while	  around	  40%	  of	  participants	  reported	  work-­‐related	  costs.	  As	  shown	  in	  Figure	  6.8,	  in	  both	  groups,	  the	  largest	  percentage	  of	  participants	  reported	  productivity	  loss-­‐related	  costs.	  	  Participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  reported	  up	  to	  four	  times	  higher	  costs	  associated	  with	  reduced	  work	  hours	  in	  comparison	  to	  participants	  who	  did	  not	  want	  to	  use	  the	  programme,	  although	  the	  difference	  is	  not	  statistically	  significant.	  Figure	  6.8	  Percentage	  of	  participants	  who	  reported	  work-­‐related	  costs	  per	  cost	  category	  
	  When	  controlling	  for	  age,	  gender,	  ethnicity	  and	  exposure	  factors,	  individuals	  who	  did	  not	  use	  the	  programme	  because	  they	  did	  not	  know	  about	  it	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had	  4	  times	  higher	  statistically	  significant	  overall	  costs,	  on	  average	  £2430	  versus	  £655,	  in	  comparison	  with	  individuals	  who	  choose	  not	  to	  use	  it	  (Table	  6.9).	   	  	  	  	  	  	  	  	  	  	  	  	  	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Although	  average	  predicted	  direct	  costs	  were	  higher	  for	  participants	  who	  did	  not	  know	  of	  the	  ST	  -­‐	  £469	  versus	  £269	  for	  participants	  who	  choose	  not	  to	  use	  the	  programme	  -­‐	  this	  difference	  was	  not	  statistically	  significant.	  	  Injury	  was	  the	  only	  significant	  positive	  predictor	  of	  direct	  services	  costs	  (Table	  6.10).	  	  	  Table	  6.10	  GLM	  on	  direct	  costs	  for	  participants	  who	  did	  not	  need	  versus	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=71	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  
Table	  6.9	  GLM	  on	  total	  costs	  for	  participants	  who	  did	  not	  need	  versus	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=71	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   -­‐0.16	  (-­‐0.07,	  0.05)	  Males	  relative	  to	  females	   0.52	  (-­‐0.57,	  1.54)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐1.48**	  (-­‐4.06,-­‐	  0.06)	  Q1.	  Injured?	   2.17***	  (1.25,	  2.59)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.86	  (-­‐0.44,	  0.86)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.99	  (-­‐1.19,	  0.05)	  Didn’t	  need	  vs.	  Didn’t	  know	   -­‐1.38**	  (-­‐2.49,	  -­‐0.10)	  Constant	  	  	  	   13.17***	  (9.26,	  17.63)	  Link	  function	   Log	  Distributional	  family	   Gamma	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Age	   -­‐0.00	  (-­‐0.06,	  0.05)	  Males	  relative	  to	  females	   -­‐1.13	  (-­‐0.57,	  1.54)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.48	  (-­‐1.06,	  0.06)	  Q1.	  Injured?	   1.62**	  (0.25,	  2.59)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.20	  (-­‐1.44,	  0.86)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.96	  (-­‐3.19,	  1.65)	  Didn’t	  need	  vs.	  Didn’t	  know	   -­‐0.58	  (-­‐1.49,	  0.10)	  Constant	  	  	  	   7.17***	  (4.26,	  11.63)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  
6.3.4	  Discussion	  and	  conclusions	  My	  analyses	  suggest	  there	  is	  no	  significant	  difference	  in	  the	  adjusted	  follow-­‐up	  TSQ	  score	  between	  the	  ST	  programme	  users	  and	  participants	  who	  did	  not	  use	  it,	  and	  for	  both	  groups	  average	  reported	  TSQ	  scores	  are	  well	  below	  the	  positive	  screening	  threshold	  of	  endorsing	  six	  symptoms	  (Brewin	  et	  al.,	  2002).	  	  Average	  adjusted	  follow-­‐up	  TSQ	  score	  for	  participants	  who	  did	  not	  know	  of	  the	  ST	  was	  3.5,	  just	  below	  the	  screening	  positive	  threshold	  margin,	  in	  comparison	  to	  1.5	  for	  participants	  who	  did	  not	  need	  it.	  	  	  	   However,	  when	  adjusting	  for	  socio-­‐demographic	  and	  exposure	  factors,	  participants	  who	  used	  the	  programme	  reported	  significantly	  higher	  average	  direct	  and	  total	  costs.	  	  As	  the	  category	  of	  participants	  who	  did	  not	  use	  the	  ST	  services	  is	  not	  homogeneous,	  one	  third	  of	  participants	  reporting	  not	  knowing	  about	  the	  programme	  while	  others	  chose	  not	  to	  use	  it,	  it	  was	  important	  to	  explore	  differences	  in	  outcomes	  and	  costs	  between	  those	  two	  groups	  and	  ST	  users.	  	  In	  regard	  to	  the	  average	  predicted	  costs,	  participants	  who	  did	  not	  know	  about	  the	  ST	  reported	  four	  times	  higher	  average	  total	  costs	  due	  to	  large	  productivity	  loss,	  and	  while	  they	  reported	  numerically	  larger	  direct	  costs,	  the	  difference	  was	  not	  significant	  from	  participants	  who	  did	  not	  need	  the	  programme.	  	  Another	  frequently	  reported	  cost	  group	  for	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  were	  private	  sector	  services	  with	  50%	  of	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participants	  reporting	  using	  them	  in	  comparison	  to	  only	  12%	  of	  participants	  who	  did	  not	  need	  the	  programme,	  and	  when	  looking	  at	  unadjusted	  average	  costs	  the	  difference	  in	  average	  private	  sector	  services	  costs	  is	  significant	  between	  the	  two	  groups.	  	  Furthermore	  their	  cost	  breakdown	  was	  similar	  to	  the	  ST	  users,	  although	  average	  adjusted	  costs	  were	  five	  times	  smaller.	  	  	  Symptoms	  most	  frequently	  reported	  by	  this	  group	  even	  (on	  average)	  2.5	  years	  after	  LB	  were	  related	  to	  heightened	  awareness	  and	  alertness	  to	  the	  potential	  dangers	  and	  being	  upset	  by	  reminders	  of	  the	  LB	  event.	  	  	  The	  power	  issues	  may	  explain	  the	  absence	  of	  statistically	  significant	  differences	  between	  the	  two	  groups,	  as	  the	  samples	  were	  small,	  particularly	  when	  comparing	  individuals	  who	  chose	  not	  to	  use	  the	  programme	  with	  participants	  who	  did	  not	  know	  about	  the	  programme.	  	  Due	  to	  the	  small	  and	  unrepresentative	  sample	  of	  individuals	  who	  did	  not	  know	  of	  the	  ST	  any	  conclusions	  based	  on	  this	  analysis	  are	  not	  generalisable.	  	  Nevertheless,	  my	  results	  suggest	  that	  interviewed	  participants	  who	  did	  not	  know	  of	  the	  ST	  would	  have	  been	  a	  target	  population	  for	  the	  ST	  programme	  and	  would	  have	  potentially	  benefited	  from	  screening	  and	  assessment	  in	  order	  to	  possibly	  avoid	  or	  reduce	  costs	  associated	  with	  use	  of	  private	  sector	  provided	  services.	  	  	  	  
6.4	  	   Comparison	  between	  ST	  users	  who	  received	  treatment	  and	  ones	  
who	  were	  screened	  and	  assessed	  only	  Another	  perspective	  on	  the	  effectiveness	  of	  the	  ST	  programme	  to	  identify	  participants	  in	  need	  of	  treatment	  may	  come	  from	  comparing	  individuals	  who	  were	  screened	  and	  assessed	  but	  were	  not	  sent	  for	  treatment	  with	  those	  individuals	  who	  were	  screened,	  assessed	  and	  were	  then	  treated	  within	  the	  ST	  programme.	  	  In	  my	  view,	  comparing	  costs	  due	  to	  LB	  exposure,	  the	  outcomes	  at	  the	  entry	  point	  to	  the	  ST	  programme	  and	  at	  the	  follow-­‐up	  provide	  interesting	  information	  on	  which	  aspects	  these	  two	  groups	  differ	  prior	  to	  entry	  to	  the	  programme	  and	  on	  average	  two	  years	  later	  from	  the	  LB,	  and	  what	  are	  possible	  cost	  and	  outcome	  predictors	  for	  both	  groups.	  	  This	  information	  might	  be	  useful	  for	  the	  future	  mental	  health	  responses	  as	  they	  provide	  insight	  into	  which	  socio-­‐
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economic	  and	  exposure	  factors	  are	  associated	  with	  referral	  to	  treatment	  and	  natural	  recovery.	  	  As	  in	  the	  previous	  section,	  I	  present	  unadjusted	  costs	  and	  outcomes	  followed	  by	  cost	  and	  outcome	  prediction	  models.	  	  Participants	  who	  were	  screened	  and	  assessed	  only	  were	  less	  likely	  to	  be	  white	  British	  in	  comparison	  to	  the	  treated	  group.	  	  Differences	  are	  also	  observed	  on	  some	  of	  the	  exposure	  variables,	  with	  a	  higher	  percentage	  of	  screened	  and	  assessed	  only	  participants	  reporting	  bereavement	  and	  a	  lower	  percentage	  being	  directly	  involved	  in	  the	  bombings	  when	  compared	  with	  the	  treated	  group.	  	  	  In	  the	  treated	  group,	  on	  the	  other	  hand,	  a	  larger	  percentage	  of	  participants	  reported	  witnessing	  and	  fear	  of	  injury	  or	  death.	  	  There	  was	  no	  difference	  in	  the	  average	  age	  between	  the	  groups.	  	  Unsurprisingly,	  the	  screened	  and	  assessed	  group	  had	  on	  average	  a	  higher	  number	  of	  screeners	  when	  compared	  to	  the	  treated	  group	  who	  were	  on	  average	  referred	  to	  treatment	  after	  the	  first	  screener,	  while	  participants	  in	  the	  assessed	  group	  were	  screened	  up	  to	  five	  times,	  and	  on	  average	  twice.	  	  There	  was	  no	  observed	  difference	  in	  average	  unadjusted	  score	  on	  TSQ	  measure	  at	  the	  treatment	  follow-­‐up:	  2.08	  for	  screened	  and	  assessed	  only	  group	  versus	  2.14	  for	  treated	  group	  (Mann-­‐Whitney	  Z=1.14,	  p=0.25).	  	  Similarly,	  there	  was	  no	  difference	  in	  unadjusted	  EQ5D	  score	  at	  the	  follow-­‐up	  between	  two	  groups:	  0.86	  for	  screened	  and	  assessed	  only	  and	  0.80	  for	  the	  treated	  group	  (Z=-­‐1.5,	  p=0.13).	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Table	  6.11	  Socio-­‐demographic	  and	  exposure	  characteristics	  of	  screened	  and	  assessed	  only	  participants	  and	  participants	  treated	  within	  the	  ST	  programme	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Screened	  and	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Treated	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  assessed	  only	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (N=50)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (N=103)	   	  	   N	   %	   N	   %	   p	  Female	   38	   71	   61	   59	   0.54	  Ethnicity	  –	  white	  British	   15	   30	   64	   62	   0.05	  Employment	  category	   	   	  >500	  £	  median	  weekly	  salary	   18	   36	   42	   41	   0.25	  <500	  £	  median	  weekly	  salary	   23	   46	   53	   52	   0.42	  Student	   5	   8	   3	   3	   0.43	  Retired	   1	   2	   1	   0	   0.32	  Not	  stated	   2	   4	   2	   2	   0.65	  Exposure	   	   	  Q1.	  Injured?	   16	   32	   36	   35	   0.71	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   19	   38	   73	   71	   0.00	  Q3.	  Witnessed	  injury	  or	  death?	   25	   50	   83	   80	   0.00	  Q4.	  Family	  member/	  close	  friend	  killed?	   10	   20	   6	   6	   0.00	  Q5.	  Family	  member/	  close	  friend	  injured?	   1	   2	   3	   3	   0.74	  Q6.	  You	  felt	  family	  member	  or	  a	  close	  friend	  might	  be	  injured/killed?	   8	   16	   7	   7	   0.07	  Q7.	  Personally	  witnessed	  effects	  of	  the	  bombings?	   34	   68	   97	   92	   0.00	  Age	  (mean)	   42.86	  (14.32)	   40.52	  (9.52)	   0.31	  Number	  of	  screeners	  (mean)	   1.98	  (1.09)	   1.04	  (0.54)	   0.00	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6.4.1	  Outcome	  models	  –	  TSQ	  follow-­‐up	  score	   	  Table	  6.12	  Predictive	  GLM	  on	  follow-­‐up	  TSQ	  score	  between	  ST	  users:	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.02	  (-­‐0,00,	  0.04)	  Total	  score	  at	  first	  screener	   0.26***(0.12,	  0.39)	  Males	  relative	  to	  females	   -­‐0.63**	  (-­‐1.15,	  -­‐0.05)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.75***(-­‐1.26,	  -­‐0.11)	  Q1.	  Injured?	   0.77**(0.25,	  1.59)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   -­‐0.90**(-­‐1.23,	  0.06)	  Q3.	  Witnessed	  injury	  or	  death?	   0.78*(-­‐0.09,	  1.66)	  Q7.	  You	  personally	  witnessed	  effects	  of	  the	  LB?	   -­‐0.36(-­‐1.43,	  0.73)	  Total	  number	  of	  screeners	   -­‐0.46**(-­‐0.82,	  -­‐0.01)	  Treated	  vs.	  Screened	  and	  assessed	  only	   -­‐1.16***	  (-­‐0.82,-­‐	  0.01)	  Constant	  	  	  	   0.37**	  (-­‐1.05,	  1.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  The	  average	  predicted	  TSQ	  score	  for	  treated	  group	  was	  1.06	  (0.73,	  1.57),	  and	  3.39	  for	  not	  treated	  participants	  (1.2	  -­‐	  5.27).	  The	  treated	  group	  had	  a	  significantly	  lower	  average	  predicted	  TSQ	  score	  at	  follow-­‐up	  when	  adjusting	  for	  covariates	  in	  comparison	  to	  the	  screened	  and	  assessed	  only	  group:	  1	  versus	  3	  symptoms.	  	  Although	  average	  predicted	  TSQ	  follow-­‐up	  scores	  were	  lower	  than	  the	  screening	  threshold	  of	  endorsing	  six	  symptoms	  (Brewin	  et	  al.,	  2002),	  this	  indicates	  a	  higher	  number	  of	  reported	  symptoms	  for	  participants	  who	  were	  not	  treated.	  	  Again,	  due	  to	  the	  small	  sample	  and	  the	  nature	  of	  the	  data	  collection	  process,	  these	  findings	  need	  to	  be	  treated	  with	  caution.	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Table	  6.13	  Predictive	  GLM	  on	  EQ5D	  score	  at	  follow-­‐up	  between	  ST	  users:	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   -­‐0.00	  (-­‐0,00,	  0.04)	  Males	  relative	  to	  females	   0.02	  (-­‐0.08,	  1.05)	  White	  British	  relative	  to	  other	  ethnic	  categories	   0.08	  (-­‐0.62,	  0.23)	  Q1.	  Injured?	   -­‐0.21***(-­‐0.31,	  -­‐0.09)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.08	  (-­‐0.23,	  0.20)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.06(-­‐0.09,	  1.66)	  Q7.	  You	  personally	  witnessed	  effects	  of	  the	  LB?	   0.18*(-­‐0.00,	  0.01)	  Follow-­‐up	  timing	   0.00(-­‐0.82,	  0.42)	  Treated	  vs.	  Screened	  and	  assessed	  only	   -­‐0.10(-­‐0.82,-­‐0.01)	  Constant	  	  	  	   -­‐0.28***	  (-­‐0.63,	  0.05)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Another	  outcome	  measure	  available	  for	  comparison	  between	  screened	  and	  assessed	  only	  and	  participants	  who	  received	  treatment,	  was	  EQ5D	  score	  at	  treatment	  follow-­‐up.	  	  Average	  predicted	  EQ5D	  scores	  for	  the	  non-­‐treated	  group	  was	  0.89	  (0.79,	  1.00),	  and	  0.80	  (0.76,	  0.85)	  for	  treated	  participants.	  	  There	  was	  no	  difference	  between	  two	  groups	  after	  adjusting	  for	  covariates,	  both	  groups	  reporting,	  on	  average,	  high	  quality	  of	  life.	  	  Injury	  was	  a	  negative	  predictor	  of	  the	  total	  EQ5D	  score	  at	  follow-­‐up.	  
6.4.2	  Cost	  description	  and	  models	  With	  the	  exception	  of	  the	  unadjusted	  mean	  hospitalisation	  costs,	  for	  all	  cost	  categories	  the	  treated	  group	  reported	  higher	  average	  unadjusted	  costs	  when	  compared	  to	  the	  screened	  and	  treated	  only	  group	  (Table	  6.13).	  	  None	  of	  the	  costs	  were	  normally	  distributed,	  as	  tested	  by	  Kolmogorov-­‐Smirnov	  test.	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Participants	  who	  received	  treatment	  within	  the	  ST	  programme	  were	  less	  likely	  to	  screen	  positive	  at	  follow-­‐up	  (OR=0.29,	  p=0.00):	  36%	  individuals	  who	  were	  screened	  and	  assessed	  only	  within	  the	  programme	  screened	  positive	  at	  follow-­‐up	  in	  comparison	  to	  13%	  from	  the	  treated	  group	  (Chi	  square=8.68,	  p=0.00).	  	  Table	  6.14	  Average	  unadjusted	  costs	  per	  cost	  and	  participant	  category	  	  
	  
Screened	  and	  assessed	  (N=50)	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  
Treated	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (N=103)	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	   	  p	  NHS	  health	  services	  	   199.28*	   324.95	   874.95*	   1650.27	   0.00	  Private	  sector	  provided	  services	   86.42*	   180.42	   362.26*	   680.03	   0.01	  Voluntary	  sector	  provided	  services	   41.83*	   150.48	   106.37*	   441.07	   0.04	  Hospitalisation	   3130.97*	   14426.75	   502.04*	   2224.01	   0.20	  Medication	   20.99*	   20.48	   27.08*	   6.13	   0.02	  NHS	  costs	   3350.89	   14539.22	   1404.88	   3168.41	   0.01	  Total	  direct	  costs	   3479.28*	   14516.23	   1886.99*	   3322.08	   0.10	  Productivity	  loss	   1499.82*	   3667.99	   5489.05*	   17480.31	   0.03	  Hours	  reduced	   302.12*	   1173.95	   388.02*	   1991.33	   0.02	  Unemployment	   586.98*	   2772.00	   4806.78	   18017.82	   0.31	  Total	  work	  costs	   2388.84*	   5156.07	   6509.31*	   12674.74	   0.00	  Total	  overall	  costs	  	   5867.91*	   17011.36	   14560.47*	   29243.25	   0.02	  *not	  normally	  distributed	  costs	  P<0.01	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Figure	  6.9	  Cost	  breakdown	  for	  screened	  and	  assessed	  only	  participants	  
	  Hospitalisation	  costs	  account	  for	  up	  to	  50%	  of	  the	  reported	  costs	  for	  screened	  and	  assessed	  only	  group,	  followed	  by	  work	  costs	  and	  the	  ST	  programme	  costs	  (Figure	  6.9).	  	  Although	  hospitalisation	  costs	  were	  high,	  only	  a	  small	  percentage	  of	  participants	  (18%)	  reported	  high	  costs	  due	  to	  injuries	  in	  the	  bombings	  (Figure	  6.11).	  	  For	  participants	  who	  received	  treatment,	  68%	  of	  the	  total	  cost	  was	  work-­‐related,	  mainly	  productivity	  loss	  costs.	  	  The	  ST	  programme-­‐related	  costs	  represented	  20%	  of	  the	  total	  cost,	  followed	  by	  a	  small	  percentage	  of	  health	  service	  costs	  and	  hospitalisation	  costs	  (Figure	  6.10).	  	  70%	  of	  participants	  in	  both	  groups	  reported	  using	  health	  care	  services,	  followed	  by	  private	  sector	  services	  and	  medication,	  and	  these	  were	  the	  most	  frequently-­‐reported	  costs	  for	  both	  groups.	  	  The	  most	  frequently-­‐reported	  services	  by	  the	  screened	  and	  assessed	  only	  group	  were	  GP,	  accident	  and	  emergency	  services,	  followed-­‐by	  private	  sector	  services,	  medication	  and	  NHS	  mental	  health	  services.	  For	  all	  costs	  types	  except	  hospitalisation,	  a	  higher	  percentage	  of	  treated	  participants	  reported	  using	  services.	  	  Productivity	  loss-­‐associated	  costs	  are	  highest	  among	  all	  work-­‐related	  costs,	  with	  around	  50%	  of	  participants	  in	  both	  groups	  reporting	  costs	  (Figure	  6.12).	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Figure	  6.10	  Treated	  group	  costs	  
	  	  Figure	  6.11	  Percentage	  of	  participants	  who	  reported	  costs	  per	  cost	  category	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Figure	  6.12	  Percentage	  of	  participants	  who	  reported	  work	  related	  costs	  
	  Table	  6.15	  The	  most	  frequently-­‐used	  services	  reported	  by	  screened	  and	  assessed	  only	  group	   	  	  	  
Screened	  and	  
assessed	  only	  (N=50)	  
N	  	  	  	  	  	  	  	  	  %	  NHS	  physical	  health:	   	   	  	  	  	  	  GP	   31	   62	  	  	  	  	  Accident	  and	  Emergency	   20	   40	  	  	  	  	  Surgeon	   3	   6	  	  	  	  	  Other	  nurse	   2	   4	  NHS	  provided	  MH	  services*	   11	   22	  Privately	  provided	  MH	  services*	   9	   18	  Medication	   13	   26	  Hospitalisation	   11	   22	  Private	  sector	  services	   14	   28	  Voluntary	  sector	  services	   8	   16	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Table	  6.16	  Predictive	  GLM	  on	  direct	  costs	  between	  ST	  users:	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.02*	  (-­‐0,00,	  0.04)	  Total	  score	  at	  first	  screener	   0.28	  (0.12,	  0.39)	  Males	  relative	  to	  females	   0.28	  (-­‐0.15,	  1.05)	  White	  British	  relative	  to	  other	  ethnic	  categories	   0.05	  (-­‐0.62,	  0.23)	  Q1.	  Injured?	   1.21***(0.52,	  1.99)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   -­‐0.48(-­‐1.23,	  0.06)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.44(-­‐0.09,	  1.66)	  Q7.	  You	  personally	  witnessed	  effects	  of	  the	  LB?	   1.10*(-­‐0.43,	  2.27)	  Follow-­‐up	  timing	   0.40(-­‐0.82,	  0.42)	  Treated	  vs.	  Screened	  and	  assessed	  only	   0.44(-­‐0.82,-­‐	  0.01)	  Constant	  	  	  	   3.77***	  (2.05,	  5.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Average	  predicted	  direct	  costs	  for	  participants	  who	  did	  not	  receive	  treatment	  were	  £963.64	  (398.35	  -­‐	  1528.94)	  and	  £1496.92	  (985.23	  -­‐	  2008.60)	  for	  the	  treated	  group.	  	  Although	  numerically	  almost	  double,	  average	  predicted	  direct	  costs	  for	  the	  treated	  group	  are	  not	  statistically	  different	  from	  the	  screened	  and	  assessed	  only	  group.	  	  The	  only	  significant	  positive	  predictor	  of	  direct	  costs	  is	  injury.	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Table	  6.17	  Predictive	  GLM	  on	  total	  costs	  between	  ST	  users:	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.05***	  (0.01,	  0.08)	  Males	  relative	  to	  females	   -­‐0.56	  (-­‐0.15,	  1.05)	  White	  British	  relative	  to	  other	  ethnic	  categories	   0.19	  (-­‐0.62,	  0.23)	  Q1.	  Injured?	   1.26***(0.52,	  1.99)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.08(-­‐0.73,	  0.90)	  Q3.	  Witnessed	  injury	  or	  death?	   0.24(-­‐0.86,	  1.36)	  Q7.	  You	  personally	  witnessed	  effects	  of	  the	  LB?	   -­‐0.80(-­‐0.43,	  2.27)	  Follow-­‐up	  timing	   0.02(-­‐0.02,	  0.68)	  Treated	  vs.	  Screened	  and	  assessed	  only	   1.07**(0.18,	  1.97)	  Constant	  	  	  	   5.84***	  (4.05,	  7.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Predictive	  general	  linearised	  model	  on	  total	  costs	  between	  treated	  participants	  and	  participants	  who	  were	  screened	  and	  assessed	  only	  shows	  that	  after	  adjusting	  for	  covariates,	  the	  treated	  group	  reported	  on	  average	  three	  times	  larger	  total	  costs,	  £11052	  (6477.23-­‐15627.60)	  versus	  £3755	  (1048.35	  -­‐	  6462.94).	  	  Significant	  positive	  predictors	  of	  costs	  were	  injury	  and	  age.	  	  As	  there	  was	  no	  difference	  in	  reported	  direct	  costs	  (Table	  6.15)	  between	  the	  two	  groups,	  the	  difference	  in	  total	  costs	  is	  attributed	  to	  a	  difference	  in	  work-­‐related	  costs.	  Average	  predicted	  NHS	  costs	  for	  non-­‐treated	  participants	  were	  £732.35	  (284.35,	  1180.94),	  and	  £895.3	  (566.23,	  1225.60)	  for	  treated	  participants.	  	  This	  model	  focuses	  only	  on	  the	  NHS-­‐related	  costs,	  a	  category	  which	  includes	  medication,	  hospitalisation	  and	  NHS-­‐provided	  health	  services.	  	  No	  difference	  between	  two	  groups	  was	  found	  after	  adjusting	  for	  covariates.	  	  Timing	  of	  the	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follow-­‐up,	  age,	  direct	  involvement	  in	  bombings	  and	  injury	  were	  all	  significant	  positive	  predictors	  of	  NHS	  costs.	  	  Table	  6.18	  Predictive	  GLM	  on	  NHS	  costs	  between	  the	  ST	  users:	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.04***	  (0.01,	  0.08)	  Males	  relative	  to	  females	   0.18	  (-­‐0.52,	  0.05)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.07	  (-­‐0.62,	  0.23)	  Q1.	  Injured?	   1.17***(0.52,	  1.99)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   -­‐0.48(-­‐0.73,	  0.90)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.49(-­‐0.86,	  1.36)	  Q7.	  You	  personally	  witnessed	  effects	  of	  the	  LB?	   2.13***(0.93,	  3.27)	  Follow-­‐up	  timing	   0.07***(0.02,	  0.12)	  Treated	  vs.	  Screened	  and	  assessed	  only	   0.20(-­‐0.18,	  1.97)	  Constant	  	  	  	   1.22	  (-­‐0.85,	  3.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  
6.4.3	  Discussion	  and	  conclusions	  The	  analysis	  suggests	  that	  the	  treated	  group	  reported	  statistically	  higher	  total	  costs	  (excluding	  the	  ST	  programme	  costs)	  when	  controlling	  for	  exposure	  and	  socio-­‐demographic	  characteristics	  compared	  to	  participants	  who	  were	  not	  referred	  to	  treatment.	  	  Costs	  were	  up	  to	  two	  and	  half	  times	  higher.	  	  Apart	  from	  differences	  in	  total	  costs,	  there	  is	  an	  observable	  difference	  in	  the	  proportion	  of	  contribution	  of	  different	  cost	  types	  in	  the	  overall	  cost	  and	  amount	  of	  services	  used	  between	  the	  two	  groups.	  	  	  For	  the	  treated	  group,	  work-­‐related	  costs	  have	  the	  highest	  contribution	  to	  the	  total	  cost,	  followed	  by	  the	  ST	  programme	  and	  health	  care	  services.	  	  However,	  for	  participants	  who	  were	  screened	  and	  assessed	  only,	  hospitalisation	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costs	  had	  the	  largest	  contribution	  to	  the	  overall	  costs	  (50%),	  followed	  by	  work-­‐related	  costs	  (37%),	  the	  ST	  programme	  and	  health	  care	  services.	  	  This	  difference	  is	  due	  to	  there	  being	  more	  injured	  and	  hospitalised	  participants	  in	  the	  screened	  and	  assessed	  group.	  	  	  Service	  use	  pattern,	  although	  always	  higher	  for	  the	  treated	  group,	  is	  similar	  between	  the	  two	  groups,	  with	  the	  highest	  percentage	  of	  participants	  in	  both	  groups	  using	  health	  care	  services,	  followed	  by	  private	  sector	  services,	  medication	  and	  voluntary	  sector	  services	  and	  finally,	  hospitalisation.	  	  	  	   When	  costs	  are	  adjusted	  for	  socio-­‐demographic	  and	  exposure	  covariates	  there	  is	  no	  significant	  difference	  in	  direct	  costs	  between	  the	  two	  groups.	  	  There	  is	  a	  significant	  difference	  between	  the	  total	  costs	  (that	  include	  work-­‐related	  costs)	  between	  the	  two	  groups,	  with	  the	  treated	  group	  reporting	  up	  to	  three	  times	  higher	  total	  costs	  in	  comparison	  to	  screened	  and	  assessed	  only	  participants.	  	  	  	   The	  two	  groups	  differ	  significantly	  in	  reporting	  work-­‐related	  costs,	  in	  particular	  productivity	  loss-­‐related	  costs,	  which	  represent	  the	  largest	  proportion	  of	  reported	  costs.	  	  These	  costs	  would	  be	  probably	  be	  even	  higher	  if	  participants	  did	  not	  receive	  treatment.	  	  In	  support	  of	  this	  assumption,	  60%	  of	  treated	  participants	  reported	  that	  treatment	  helped	  them	  return	  to	  work	  or	  prevented	  time	  off	  work,	  while	  15%	  reported	  no	  difference	  and	  3%	  reported	  a	  negative	  effect	  on	  time	  off	  work.	  	  If	  larger	  costs	  are	  an	  indicator	  of	  higher	  mental	  health	  and	  physical	  health	  needs,	  then	  the	  analysis	  indicates	  that	  the	  treated	  group	  consists	  of	  individuals	  who	  were	  more	  severely	  affected	  by	  the	  LB	  when	  compared	  to	  the	  screened	  and	  assessed	  only	  group.	  	  Another	  potential	  conclusion	  is	  that	  the	  ST	  programme	  was	  effective	  in	  identifying	  participants	  with	  stronger	  mental	  health	  needs	  and	  referring	  them	  to	  treatment.	   	  In	  regard	  to	  differences	  in	  the	  outcome	  measure	  in	  the	  TSQ	  follow-­‐up	  score,	  the	  treated	  group	  had	  a	  significantly	  lower	  score	  and	  a	  lower	  probability	  of	  screening	  positive	  at	  the	  follow-­‐up.	  	  However,	  TSQ	  follow-­‐up	  scores,	  although	  significantly	  different,	  were	  still	  below	  the	  screening	  threshold	  of	  six	  symptoms.	  	  Nevertheless,	  the	  difference	  in	  the	  follow-­‐up	  TSQ	  score	  possibly	  indicates	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higher	  prevalence	  of	  LB-­‐related	  problems	  for	  non-­‐treated	  participants,	  even	  on	  average	  two	  and	  a	  half	  years	  after	  the	  bombings.	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Chapter	  7	   Comparing	  costs	  and	  outcomes	  of	  the	  ST	  programme	  	  
–	  economic	  evaluation	  of	  the	  ST	  programme	  
“One	  of	  the	  greatest	  attributes	  of	  economic	  analysis	  in	  any	  field	  is	  the	  ability	  to	  work	  with	  
imperfect	  data.”	  Drummond	  et	  al.	  (2005,	  p.	  56)	  
	  
7.1	   Introduction	  This	  chapter	  presents	  the	  cost-­‐effectiveness	  analysis	  of	  the	  ST	  programme.	  	  It	  covers	  the	  third	  comparison	  option:	  it	  compares	  individuals	  who	  received	  treatment	  early	  and	  those	  who	  were	  treated	  later	  in	  the	  programme.	  	  As	  this	  chapter	  will	  demonstrate,	  it	  is	  a	  challenging	  task	  to	  conduct	  a	  robust	  economic	  evaluation	  given	  the	  real-­‐world	  context	  in	  which	  the	  ST	  programme	  was	  delivered.	  	  I	  will	  begin	  with	  a	  brief	  recapitulation	  of	  the	  methods	  used	  in	  the	  economic	  evaluation,	  in	  particular	  in	  the	  context	  of	  mental	  health	  response	  and	  non-­‐experimental	  study	  design.	  	  Finally,	  I	  will	  present	  a	  cost-­‐effectiveness	  analysis	  of	  the	  ST	  programme	  and	  discuss	  my	  choice	  of	  methods	  as	  well	  as	  alternative	  approaches	  to	  economic	  evaluation	  in	  this	  context,	  alongside	  their	  interpretational	  and	  practical	  challenges.	  	  The	  guiding	  idea	  behind	  this	  chapter	  is	  to	  discuss	  and	  explore	  all	  available	  avenues	  and	  approaches	  and	  to	  demonstrate	  how	  the	  encountered	  challenges	  were	  addressed.	  	  This	  analysis	  will	  demonstrate	  that	  each	  economic	  evaluation	  rests	  on	  a	  unique	  set	  of	  assumptions	  shaped	  by	  the	  individual	  context	  of	  the	  intervention	  and	  therefore	  needs	  a	  specific	  and	  tailored	  approach.	  	  	  	  
7.2	   Methods	  summary	  Economic	  evaluation	  is	  a	  relatively	  young	  yet	  very	  useful	  and	  increasingly	  demanded	  tool	  for	  evidence-­‐based	  decision-­‐making	  in	  funding	  mental	  health	  interventions.	  	  Available	  outcome	  information	  will	  determine	  the	  type	  of	  the	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economic	  evaluation,	  although	  the	  main	  influence	  on	  choice	  of	  analysis	  method	  is	  the	  question	  to	  be	  addressed.	  	  Within	  the	  context	  of	  the	  ST	  programme,	  due	  to	  collected	  information	  on	  costs	  and	  PTSD,	  depression	  and	  QoL	  outcomes,	  available	  economic	  evaluation	  tools	  were	  cost-­‐effectiveness	  and	  cost-­‐utility	  analyses.	  The	  rationale	  for	  the	  analysis	  presented	  in	  Chapter	  7	  was	  to	  conduct	  an	  economic	  evaluation	  of	  the	  ST	  programme	  in	  the	  form	  of	  the	  cost-­‐effectiveness	  analysis	  by	  comparing	  costs	  and	  outcomes	  of	  the	  participants	  who	  received	  treatment	  early	  with	  those	  who	  received	  treatment	  later.	  	  The	  hypothesis	  was	  that	  the	  later	  treatment	  group	  could	  serve	  as	  a	  proxy	  for	  individuals	  on	  the	  NHS	  waiting	  list,	  which	  is	  a	  comparison	  group	  I	  was	  aiming	  for	  but	  for	  which	  I	  was	  unfortunately	  not	  able	  to	  obtain	  data.	  	  The	  choice	  of	  comparison	  groups	  was	  guided	  by	  the	  availability	  of	  the	  data.	  	  Based	  on	  the	  findings	  on	  significant	  health,	  social	  and	  economic	  effects	  of	  PTSD,	  my	  expectation	  was	  to	  find	  a	  positive	  correlation	  between	  reported	  costs	  and	  treatment	  start	  timing.	  	  I	  assumed	  that	  the	  longer	  individuals	  wait	  for	  the	  treatment,	  the	  more	  likely	  they	  were	  to	  develop	  chronic	  PTSD	  and	  experience	  more	  profound	  health,	  social	  and	  economic	  consequences	  due	  to	  PTSD	  and	  its	  comorbid	  conditions.	  	  In	  regard	  to	  the	  differences	  in	  outcome	  scores	  between	  the	  two	  groups,	  I	  expected	  the	  later	  treatment	  group	  to	  report	  more	  severe	  symptoms	  and	  consequently	  higher	  scores	  on	  both	  outcome	  measures,	  as	  they	  were	  more	  likely,	  all	  things	  being	  equal,	  to	  develop	  chronic	  PTSD.	  	  	   In	  regard	  to	  the	  differences	  likely	  controlled	  for	  by	  the	  indicators	  in	  the	  analysis,	  it	  is	  important	  to	  highlight	  that	  the	  choice	  of	  indicators	  was	  dictated	  by	  the	  available	  data	  and	  not	  the	  theoretical	  framework.	  	  Therefore,	  I	  could	  only	  control	  for	  socio-­‐demographic	  characteristics	  (gender	  and	  ethnicity),	  exposure	  characteristics,	  treatment	  and	  follow-­‐up	  timing,	  treatment	  type	  and	  psychiatric	  comorbidity.	  	  Although	  the	  indicators	  I	  have	  included	  in	  the	  analysis	  have	  a	  theoretical	  backing	  (the	  effect	  of	  ethnicity	  and	  gender	  on	  PTSD	  and	  service	  use,	  the	  effect	  of	  exposure	  and	  injury	  on	  costs	  and	  PTSD	  rates,	  and	  the	  effect	  of	  psychiatric	  comorbidity	  in	  PTSD	  diagnosis)	  ideally	  I	  would	  like	  to	  have	  controlled	  for	  all	  other	  potential	  factors,	  observed	  and	  unobserved,	  ensuring	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that	  the	  only	  difference	  between	  the	  two	  groups	  is	  the	  start	  of	  the	  treatment.	  	  Unfortunately,	  this	  was	  not	  possible	  in	  this	  study	  design	  and	  therefore	  I	  cannot	  conclude	  with	  certainty	  that	  there	  is	  a	  causal	  relationship	  between	  timing	  of	  the	  treatment	  and	  differences	  in	  costs	  and	  outcomes	  between	  the	  two	  comparator	  groups.	  	  Still,	  the	  design	  allowed	  controlling	  for	  observed	  indicators,	  which	  play	  an	  important	  role	  as	  risk	  factors	  in	  PTSD	  such	  as	  gender	  and	  ethnicity,	  trauma	  exposure	  characteristics	  and	  psychiatric	  comorbidity.	  	  In	  order	  to	  minimise	  and	  adjust	  for	  observable	  biases	  introduced	  by	  the	  observational	  study	  design,	  I	  have	  used	  multivariate	  regression	  to	  adjust	  both	  costs	  and	  outcomes	  for	  the	  same	  group	  of	  covariates	  based	  on	  theoretical	  and	  statistical	  criteria.	  	  In	  practice,	  this	  translates	  to	  running	  a	  set	  of	  GLM	  models	  for	  prediction	  of	  both	  costs	  and	  outcomes.	  	  The	  model	  protocol	  is	  outlined	  in	  Table	  7.1.	  Table	  7.1	  Costs	  and	  effects	  model	  protocol	  	  
**	  Step	  A1:	  GLM	  model	  for	  COSTS**	  glm	  COST	  i.group	  $covariates	  if	  COST>0,	  fam(gamma)	  link(log)	  	  predict	  yhat1	  if	  e(sample),	  mu	  **Step	  A2:	  estimate	  person-­‐specific	  COSTS	  **	  gen	  yhat1c=phat1*yhat1	   	  **	  Step	  A3:	  GLM	  model	  for	  EFFECTS	  (e.g.	  BDI	  score	  follow	  up)**	  glm	  BDI	  i.group	  $covariates,	  fam(gamma)	  link(log)	  **Step	  A4:	  estimate	  person-­‐specific	  EFFECTS	  **	  predict	  yhat2	  if	  e(sample),	  mu	  **Step	  B1:	  obtain	  mean	  predicted	  costs	  for	  group	  0	  and	  1,	  	  then	  subtract	  to	  get	  difference	  in	  group	  mean**	  margins	  COSTS	  treatment	  timing	  =(0	  1)	  atmeans	  *	  *Step	  B2:	  obtain	  mean	  predicted	  BDI	  for	  group	  0	  and	  1,	  	  then	  subtract	  to	  get	  difference	  in	  group	  mean**	  margins	  EFFECTS	  (treatment	  timing	  =(0	  1)	  margins	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I	  used	  SPSS	  12	  and	  STATA	  11	  statistical	  packages	  to	  analyse	  costs	  and	  outcomes.	  I	  will	  start	  the	  analysis	  with	  descriptive	  analysis	  of	  participants’	  socio-­‐demographic,	  exposure	  and	  clinical	  characteristics.	  	  For	  costs	  and	  outcome	  categories	  for	  each	  participant	  group,	  I	  will	  present	  unadjusted	  mean	  values	  before	  presenting	  models	  and	  adjusted	  estimates.	  	  I	  have	  used	  three	  cost	  categories:	  	  a.	  ST	  programme	  costs	  	  b.	  direct	  costs:	  aggregate	  consisting	  of	  statutory-­‐provided	  health	  care	  services,	  hospitalisation,	  medication,	  voluntary	  and	  private	  sector-­‐provided	  services,	  and	  	  c.	  total	  costs:	  aggregate	  consisting	  of	  the	  ST	  programme,	  direct	  costs	  and	  work	  related	  costs	  due	  to	  sick	  leave,	  unemployment	  and	  reduced	  work	  hours.	  	  I	  have	  adjusted	  all	  costs	  and	  effects	  models	  for	  the	  following	  covariates:	  age;	  gender;	  ethnicity,	  if	  the	  person	  was	  injured	  (Q1);	  if	  person	  thought	  they	  would	  be	  injured	  or	  killed	  (Q2);	  if	  the	  person	  saw	  someone	  who	  was	  injured	  or	  killed	  (Q3);	  existence	  of	  psychiatric	  comorbid	  conditions;	  treatment	  type;	  follow-­‐up	  timing	  (days	  since	  the	  LB)	  and	  total	  number	  of	  treatment	  sessions.	  	  I	  will	  firstly	  present	  results	  of	  the	  model	  evaluation,	  followed	  by	  assessment	  of	  the	  model	  fit	  by	  running	  a	  Park	  test,	  a	  link	  test	  to	  check	  linearity	  of	  the	  response	  and	  then	  checking	  the	  distribution	  of	  the	  residuals	  to	  test	  for	  heteroscedasticity.	  	  I	  will	  calculate	  average	  mean	  predicted	  costs	  and	  effects	  for	  all	  treatment	  and	  comparator	  groups,	  and	  subtract	  them	  to	  get	  differences	  in	  group	  means	  in	  order	  to	  calculate	  ICERs	  for	  each	  evaluation	  scenario.	  	  In	  order	  to	  explore	  uncertainties	  around	  the	  cost-­‐effectiveness	  analysis	  I	  have	  calculated	  a	  cost–effectiveness	  acceptability	  curve	  (CEAC)	  for	  each	  evaluation	  scenario	  and	  I	  have	  bootstrapped	  the	  ICERS.	  	  In	  order	  to	  obtain	  CEACS	  I	  have	  entered	  predicted	  costs	  and	  effects	  into	  the	  CLT	  EXCELL	  model	  provided	  by	  Nixon	  et	  al	  (2005b).	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7.3	   Participants’	  and	  the	  ST	  programme	  outcomes	  description	  Prior	  to	  the	  commencement	  of	  the	  analysis,	  it	  is	  important	  to	  set	  the	  scene	  with	  detailed	  information	  on	  participants,	  in	  this	  case	  the	  ST	  program	  users.	  	  As	  Table	  7.2	  shows,	  there	  is	  no	  difference	  in	  exposure,	  employment,	  ethnicity	  or	  age.	  	  However,	  the	  early	  treatment	  group	  had	  30%	  more	  women	  (hi	  sq=7.03;	  p<0.01).	  	  In	  both	  early	  and	  later	  treatment	  groups	  around	  60%	  of	  participants	  were	  white	  British,	  on	  average	  40	  years	  of	  age.	  90%	  of	  the	  sample	  were	  personally	  involved	  in	  the	  LB,	  around	  40%	  were	  injured,	  and	  70%	  witnessed	  injury	  and	  death	  and	  felt	  they	  might	  be	  injured	  or	  killed.	  	  Table	  7.2	  Participants’	  socio-­‐demographic	  characteristics,	  employment	  and	  exposure	  information	  
	   Earlier	  	  	  	  treatment	  group	  (N=53)	  	  	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  
Later	  	  treatment	  group	  (N=50)	  	  	  	  	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  
	  	  	  	  p	  	   	   	   	   	   	  Female	   38	   71	   23	   46	   0.01	  Ethnicity	  –	  white	  British	   30	   57	   34	   68	   0.47	  Employment	  category	   	   	  >500	  £	  median	  weekly	  salary	   27	   51	   24	   48	   0.25	  <500	  £	  median	  weekly	  salary	   23	   44	   21	   42	   0.42	  Student	   2	   4	   2	   4	   0.43	  Retired	   1	   2	   0	   0	   0.32	  Not	  stated	   2	   4	   2	   4	   0.65	  Exposure	   	   	  Q1.	  Injured?	   20	   40	   16	   32	   0.68	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   34	   64	   39	   78	   0.13	  Q3.	  Witnessed	  injury	  or	  death?	   43	   81	   40	   80	   0.85	  Q4.	  Family	  member/	  close	  friend	  killed?	   4	   8	   2	   4	   0.44	  Q5.	  Family	  member/	  close	  friend	  injured?	   2	   4	   1	   2	   0.59	  Q6.	  You	  felt	  family	  member	  or	  a	  close	  friend	  might	  be	  injured/killed?	   5	   10	   2	   4	   0.28	  Q7.	  Personally	  witnessed	  effects	  of	  the	  bombings?	   49	   93	   48	   96	   0.44	  Age	  (mean)	   40.73	   40.30	   0.74	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   Follow-­‐up	  evaluation	  interviews	  took	  place	  once	  individuals	  finished	  treatment	  when	  most	  of	  the	  participants	  were	  discharged	  from	  the	  ST	  programme.	  	  Participants	  in	  both	  groups	  were,	  on	  average,	  screened	  once,	  with	  on	  average	  more	  participants	  with	  more	  than	  one	  screener	  in	  the	  later	  treatment	  group.	  	  There	  are	  several	  possible	  explanations	  for	  on	  average	  larger	  number	  of	  screeners	  for	  people	  who	  were	  treated	  later.	  	  In	  the	  second	  year	  of	  the	  programme,	  the	  number	  of	  referrals	  had	  dropped	  and	  this	  could	  have	  led	  to	  those	  individuals	  being	  more	  likely	  to	  be	  referred	  for	  treatment	  (even	  if	  they	  had	  milder	  symptoms)	  simply	  because	  there	  was	  more	  availability	  of	  the	  treatment.	  	  Another	  possible	  explanation	  could	  be	  that	  a	  number	  of	  individuals	  coming	  later	  to	  the	  treatment	  had	  delayed	  onset	  PTSD.	  	  	  Table	  7.3	  Assessment	  and	  treatment	  information	  
	   Earlier	  Treatment	  group	  (N=53)	  	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  
Later	  treatment	  group	  (N=50)	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  SD	  
	  	  	  	  	  	  p	  Number	  of	  screeners	  	   0.92	   	  0.43	   1.16	   0.61	   0.03	  Referral	  to	  the	  ST	  programme	  -­‐	  N	  of	  days	  since	  LB	   118.03	   76.54	   314.68	   138.13	   <0.01	  Assessment	  date	  –	  N	  of	  days	  since	  LB	   149.94	   66.12	   404.21	   124.73	   <0.01	  Treatment	  start	  –	  N	  of	  days	  since	  LB	   182.90	   68.26	   453.52	   112.39	   <0.01	  Treatment	  -­‐	  total	  number	  of	  sessions	   15.43	   13.85	   11.22	   8.70	   0.07	  	   N	   %	   N	   %	   	  Participants	  who	  finished	  treatment	   41	   77	   40	   80	   0.40	  PTSD	  –	  DSM	  IV	   36	   68	   30	   60	   0.32	  PTSD	  –	  ICD-­‐10	   43	   81	   35	   70	   0.13	  	  In	  both	  groups,	  around	  80%	  of	  participants	  finished	  treatment.	  	  Around	  70%	  of	  participants	  in	  both	  groups	  were	  diagnosed	  with	  PTSD	  (DSM	  IV).	  	  There	  was	  no	  difference	  between	  participants	  with	  PTSD	  ICD-­‐10	  or	  PTSD-­‐DSM	  IV	  primary	  diagnosis	  between	  two	  groups	  (chi	  sq	  DSM-­‐IV=0.95,	  P>0.05;	  chi	  sq	  ICD-­‐10=2.28,	  p>0.05).	  	  	  Although	  the	  early	  treatment	  group	  had	  on	  average	  a	  higher	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number	  of	  total	  therapy	  sessions	  this	  difference	  is	  not	  statistically	  significant	  at	  p=0.05	  criteria	  (t=1.84,	  p>0.05)	  (table	  7.3).	  	  There	  is	  a	  strong	  positive	  correlation	  of	  0.70	  (p<0.001)	  between	  referral	  to	  treatment,	  assessment	  and	  treatment	  date	  and	  therefore,	  I	  have	  chosen	  to	  use	  treatment	  start	  only	  (expressed	  as	  number	  of	  days	  since	  the	  LB)	  in	  the	  analysis.	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7.4	   Cost	  analysis	  	  I	  will	  start	  with	  description	  of	  the	  costs	  and	  differences	  between	  comparator	  groups	  based	  on	  unadjusted	  costs	  and	  proceed	  with	  presenting	  cost	  models	  for	  each	  cost	  category.	  	  Due	  to	  skewed	  cost	  distribution	  I	  have	  used	  the	  Mann-­‐Whitney	  test	  to	  test	  for	  differences	  in	  unadjusted	  costs	  between	  early	  and	  later	  treatment	  groups.	  	  Test	  results	  showed	  statistically	  significant	  differences	  only	  on	  work	  (productivity)	  costs	  between	  two	  groups	  (table	  7.3,	  Z=2.65,	  p<0.02).	  
7.4.1	  Service	  use	  and	  cost	  information	  Cost	  estimates	  in	  health	  care	  are	  rarely	  normally	  distributed	  and	  this	  is	  true	  for	  both	  early	  and	  later	  treatment	  groups.	  	  Table	  7.4	  presents	  unadjusted	  mean	  costs	  for	  both	  participant	  groups	  per	  each	  cost	  category.	  	  I	  have	  used	  the	  one-­‐sample	  Kolmogorov-­‐Smirnov	  test	  to	  test	  the	  costs	  distribution.	  	  All	  cost	  distributions	  are	  statistically	  different	  from	  normal	  distribution	  at	  p>0.05	  level.	  	  Two	  suggested	  approaches	  in	  dealing	  with	  issues	  of	  skewed	  costs	  distributions	  are	  log	  transformations	  of	  cost	  variables	  (Kilian	  et	  al.,	  2002)	  or	  ordinary	  least	  square	  model	  followed-­‐by	  bootstrapping.	  	  The	  Mann-­‐Whitney	  test	  showed	  no	  difference	  in	  average	  unadjusted	  reported	  costs	  between	  early	  and	  later	  treatment	  groups	  except	  for	  costs	  due	  to	  productivity	  loss	  (sick	  leave)	  and	  hours	  reduced	  (Table	  7.4).	  	  On	  average,	  when	  looking	  at	  unadjusted	  mean	  costs,	  the	  early	  treatment	  group	  reported	  three	  times	  higher	  work-­‐related	  costs;	  this	  measure	  includes	  all	  costs	  due	  to	  sick	  leave,	  reduced	  hours	  and	  unemployment.	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Table	  7.4	  Average	  unadjusted	  costs	  per	  cost	  and	  participant	  category	  	  
	  
Early	  treatment	  
group	  (N=53)	  
	  
	  	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  
Later	  treatment	  
group	  (N=50)	  
	  
	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  	  	  	  	  	  
	  
	  
	  
p	  ST	  screening	  and	  assessment	  	   778.42*	   280.78	   790.02*	   266.01	   0.83	  ST	  treatment	  	   3489.64*	   497.85	   2924.68*	   322.16	   0.97	  ST	  total	  	   4268.07*	   493.92	   3714.70*	   319.35	   0.97	  	  NHS	  health	  services	  	   820.28*	   164.95	   957.95*	   287.27	   0.32	  Private	  sector	  provided	  services	   435.42*	   100.42	   285.26*	   87.03	   0.12	  Voluntary	  sector	  provided	  services	   122.83*	   63.48	   89.37*	   52.07	   0.60	  Hospitalisation	   455.97*	   342.75	   552.04*	   272.01	   0.65	  Medication	   39.99*	   20.48	   14.08*	   6.13	   0.32	  NHS	  costs	   1316.10	   3005.20	   1524.19	   3354.12	   0.42	  Total	  direct	  costs	   1874.28*	   422.23	   1898.99*	   508.08	   0.10	  Sick	  leave	   10694.96*	   3373.44	   2484.12*	   926.20	   0.00	  Hours	  reduced	   549.15*	   321.22	   38.27*	   22.67	   0.09	  Unemployment	   7202.33*	   3191.80	   3986.66*	   1779.28	   0.31	  Total	  productivity	  loss	  costs	   18490.54*	   5021.07	   6509.31*	   2363.74	   0.00	  Total	  overall	  costs	  	   24632.68*	   5518.67	   12122.79*	   2532.54	   0.01	  *not	  normally	  distributed	  costs	  P<0.05	   	  The	  early	  treatment	  group	  reported	  more	  than	  double	  overall	  costs	  in	  comparison	  to	  the	  late	  treatment	  group.	  	  This	  is	  an	  interesting	  finding	  as	  I	  expected	  the	  converse	  –	  that	  the	  costs	  would	  be	  positively	  correlated	  with	  timing	  of	  the	  treatment.	  	  My	  hypothesis	  was	  that	  the	  longer	  it	  took	  for	  participants	  to	  reach	  treatment	  the	  higher	  the	  costs	  they	  would	  generate	  through	  seeking	  help	  from	  other	  services.	  	  Both	  groups	  reported	  similar	  total	  direct	  costs,	  while	  ST	  programme	  costs	  associated	  with	  the	  early	  treatment	  group	  are	  20%	  higher.	  	  Although	  productivity-­‐related	  costs	  make	  the	  greatest	  contribution	  to	  the	  total	  cost	  in	  both	  groups,	  in	  the	  early	  treatment	  group	  productivity	  loss	  costs	  represent	  75%	  of	  the	  total	  costs,	  while	  in	  the	  later	  group	  productivity	  costs	  represent	  50%	  of	  the	  total	  costs.	  	  Most	  of	  the	  difference	  in	  terms	  of	  costs	  derives	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from	  productivity	  loss-­‐related	  costs	  and	  is	  not	  related	  to	  service	  use.	  	  One	  potential	  interpretation	  could	  be	  that	  the	  later	  treatment	  group	  was	  observed	  in	  a	  period	  in	  which	  they	  had	  already	  overcome	  some	  of	  the	  mental	  health	  problems	  due	  to	  PTSD.	  Figure	  7.1	  Total	  cost	  break-­‐down	  for	  early	  and	  later	  treatment	  group	  in	  ST	  programme	  in	  £1000	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Later	  treatment	  group	  
ST#programme#226.2#
Health#services#43.5#
Medica;on#2.1#
Voluntary#sector#services#6.4#
Private#sector#services#23#
Hospitaliza;on#24.1#
Produc;vity#loss#979.9# 	  
ST#programme#185.7#
Health#services#47.8#
Medica;on#0.7#
Voluntary#sector#services#4.4#
Private#sector#services#14.2#
Hospitaliza;on#27.6#
Produc;vity#loss#325.5# 	  	   The	  early	  and	  later	  treatment	  groups	  differ	  in	  the	  percentage	  of	  contribution	  of	  each	  cost	  type	  in	  overall	  costs,	  as	  shown	  in	  Table	  7.5	  and	  Figure	  7.1.	  	  Costs	  associated	  with	  the	  ST	  programme	  are	  the	  second	  largest	  cost	  in	  both	  groups.	  	  The	  situation	  is	  the	  same	  for	  direct	  costs,	  with	  a	  higher	  overall	  proportion	  of	  health	  services	  and	  hospitalisation	  costs	  in	  the	  later	  treatment	  group,	  although	  the	  difference	  was	  not	  found	  to	  be	  significant.	  	  The	  contribution	  of	  the	  voluntary	  and	  private	  sector	  cost	  to	  the	  overall	  cost	  is	  the	  same	  in	  both	  groups.	  	  When	  looking	  at	  direct	  costs	  between	  early	  and	  later	  treatment	  groups,	  reported	  total	  direct	  costs	  are	  almost	  identical.	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Table	  7.5	  Percentage	  contribution	  of	  each	  service	  cost	  to	  the	  overall	  costs	  per	  participant	  group	  
	  
Early	  treatment	  
group	  (N=53)	  
	  	  	  	  	  SUM	  	  	  	  	  	  	  	  	  	  	  %	  
Later	  treatment	  
group	  (N=50)	  
	  	  	  SUM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  ST	  screening	  and	  assessment	  	   41256.6	   14	   39501	   24	  ST	  treatment	  	   184951.2	   3	   146234.4	   7	  ST	  total	  	   226207.8	   17	   185735.4	   30	  Health	  services	  	   43475.1	   3	   47897.7	   8	  Private	  sector	  provided	  services	   23075.18	   2	   14273.85	   2	  Voluntary	  sector	  provided	  services	   6496.9	   -­‐b	   4454.7	   -­‐b	  Hospitalisation	   24159	   2	   27608	   5	  Medication	   2119.46	   -­‐b	   704.1	   -­‐b	  Direct	  costs	  	   99325.7	   8	   94938.3	   16	  Productivity	  loss	  due	  to	  sick	  leave*	   566782.5	   43	   124208.4	   20	  Hours	  reduced	   31498.2	   2	   1933.3	   -­‐b	  Unemployment	   381717.7	   29	   199324.2	   33	  Total	  work	  costs*	   979998.41	   75	   325465.9	   54	  Total	  overall	  costs	  *	   1305531.9	   	   606139.6	   	  a	  All	  percentages	  have	  been	  rounded	  to	  nearest	  whole	  number	  b	  Denotes	  contribution	  less	  than	  1%	  *Denotes	  statistically	  significant	  difference	  between	  two	  groups	  P<0.05	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Figure	  7.2	  Number	  of	  participants	  who	  reported	  costs	  per	  cost	  category	  
	  Figure	  7.2	  illustrates	  the	  most	  frequently-­‐used	  services	  for	  both	  groups	  (the	  ST	  programme	  and	  health	  care	  services).	  	  Medication,	  voluntary	  and	  private	  sector	  services,	  on	  the	  other	  hand,	  were	  less	  frequently-­‐used:	  in	  both	  groups	  less	  than	  50%	  of	  the	  participants	  reported	  using	  those	  services.	  	  Figure	  7.2	  confirms	  that	  the	  largest	  differences	  in	  number	  of	  participants	  per	  cost	  category	  between	  the	  early	  and	  late	  group	  were	  for	  private	  sector	  and	  work-­‐related	  cost	  categories.	  Below	  is	  a	  summary	  of	  the	  details	  on	  service	  use	  presented	  in	  Chapter	  4	  and	  in	  Table	  7.6.	  	  The	  most	  frequently	  reported	  services	  used	  at	  least	  once	  by	  participants	  in	  both	  groups	  were	  GP	  services	  followed	  by	  NHS	  and	  privately-­‐provided	  mental	  health	  services,	  and	  A&E	  services.	  	  The	  early	  treatment	  group	  used	  more	  of	  both	  private-­‐	  and	  NHS-­‐provided	  mental	  health	  services	  (p<0.05),	  while	  the	  later	  treatment	  group	  reported	  using	  more	  A&E	  services	  (P<0.05).	  	  	  Painkillers,	  antidepressants,	  sleeping	  tablets	  and	  antibiotics	  were	  the	  most	  commonly	  reported	  medications	  used	  by	  the	  participants	  in	  both	  groups.	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  Table	  7.6	  Service	  use:	  health,	  voluntary,	  private,	  medication	  and	  hospitalisation	  
	  
Early	  	  
treatment	  
group	  (N=53)	  
N	  	  	  	  	  	  	  	  	  %	  
Later	  
treatment	  
group	  (N=50)	  
	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  
	  
p	  
NHS	  physical	  health	   	   	   	   	   	  GP	   44	   83	   39	   78	   0.60	  Accident	  and	  Emergency	   14	   26	   22	   44	   0.02	  Audiologist	   1	   2	   4	   8	   0.54	  Physiotherapist	   3	   6	   3	   6	   0.43	  Ear	  specialist	   1	   2	   1	   2	   0.44	  Eyes	  specialist	   1	   2	   1	   2	   0.59	  Neurologist	   2	   4	   0	   0	   0.32	  Surgeon	   1	   2	   1	   2	   0.28	  Other	  nurse	   1	   2	   2	   4	   0.36	  NHS	  provided	  MH	  services*	   25	   47	   10	   20	   0.03	  Privately	  provided	  MH	  services*	   18	   34	   12	   24	   0.15	  Medication	   27	   51	   22	   44	   0.25	  Hospitalisation	   5	   9	   6	   12	   0.49	  Private	  sector	  services	   28	   53	   19	   38	   0.59	  Voluntary	  sector	  services	   12	   22	   14	   28	   0.43	  *MH	  services	  provided	  by	  counsellor,	  psychiatrist,	  psychologist	  
7.4.2	  Cost	  models	  In	  Chapter	  5	  I	  explored	  cost	  variations	  by	  using	  multivariate	  analysis,	  with	  the	  aim	  of	  establishing	  the	  relative	  contribution	  of	  each	  of	  the	  sources	  of	  variation,	  as	  I	  was	  interested	  in	  exploring	  cost	  drivers	  for	  each	  participant	  group	  and	  cost	  category.	  	  In	  the	  cost	  models	  presented	  below,	  my	  aim	  was	  to	  predict	  costs	  as	  robustly	  as	  possible	  by	  controlling	  for	  all	  measured	  covariates	  consistently	  across	  cost	  groups.	  	  I	  have	  employed	  this	  approach	  in	  the	  outcome	  prediction	  models	  with	  the	  same	  aim.	  In	  each	  cost	  model	  I	  have	  controlled	  for	  the	  following	  covariates:	  
-­‐ gender	  (males	  relative	  to	  females),	  	  
-­‐ ethnicity	  (white	  British	  relative	  to	  other	  ethnic	  categories),	  	  
-­‐ Q1.	  Experiencing	  injury,	  	  
-­‐ Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	  
-­‐ Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	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-­‐ treatment	  start	  date	  –	  time	  elapsed	  between	  the	  LB	  until	  the	  start	  of	  the	  treatment	  in	  days	  
-­‐ follow-­‐up	  timing	  -­‐	  time	  elapsed	  between	  the	  LB	  until	  the	  start	  of	  the	  evaluation	  study	  in	  days	  
-­‐ psychiatric	  comorbidity	  
-­‐ treatment	  type	  (CBT	  vs.	  EMDR)	  Start	  of	  treatment,	  end	  of	  treatment	  and	  follow-­‐up	  periods	  vary	  significantly	  across	  patients	  in	  the	  study	  as	  they	  reflect	  the	  particular	  time	  when	  individuals	  started	  and	  ended	  treatment,	  and	  a	  point	  when	  they	  were	  followed-­‐up	  as	  a	  part	  of	  the	  evaluation	  study	  (upon	  finishing	  the	  treatment).	  	  Upon	  the	  initial	  analysis	  I	  was	  reluctant	  to	  proceed	  with	  dividing	  the	  ST	  programme	  users	  in	  two	  separate	  groups	  by	  using	  a	  dummy	  variable	  in	  the	  analysis.	  	  Rather	  than	  artificially	  creating	  early	  and	  late	  treatment	  groups	  based	  on	  a	  very	  crude	  measure.	  I	  looked	  instead	  at	  the	  treated	  participant	  sample	  as	  a	  whole	  and	  investigated	  the	  effect	  of	  timing	  of	  the	  entry	  to	  treatment,	  follow-­‐up	  timing,	  socio-­‐demographic	  and	  exposure	  characteristics.	  	  After	  adjusting	  for	  baseline	  covariates,	  the	  only	  statistically	  significant	  difference	  between	  the	  two	  treatment	  groups	  was	  found	  for	  work	  (productivity)	  and	  the	  ST	  programme-­‐related	  costs.	  	  For	  all	  other	  cost	  categories,	  the	  analysis	  showed	  no	  differences	  in	  adjusted	  costs	  among	  early	  and	  later	  treatment	  group.	  	  GLM	  models	  for	  total,	  ST	  programme,	  direct	  and	  productivity	  loss	  cost	  categories	  are	  presented	  below.	  	  a.	  Total	  costs	  Table	  7.7	  GLM	  on	  total	  costs	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=101	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Males	  relative	  to	  females	   -­‐0.06	  (-­‐0.57,	  0.54)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.28	  (-­‐1.06,	  0.06)	  Q1.	  Injured?	   0.62	  (0.25,	  1.59)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.20*(-­‐0.44,	  0.86)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.39(-­‐1.19,	  0.05)	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Timing	  of	  follow-­‐up	   0.02	  (-­‐1.49,	  0.10)	  Treatment	  start	  date	   -­‐0.93**	  (-­‐1.77,	  -­‐0.10)	  Psychiatric	  comorbidity	   -­‐0.52	  (-­‐0.93,	  0.21)	  Treatment	  type	   0.26	  (0.13,	  1.05)	  Constant	  	  	  	   9.17***	  (7.26,	  10.63)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  I	  tried	  fitting	  Gamma,	  Poisson	  and	  Gauss	  distributions	  to	  identity	  and	  log	  links,	  however	  none	  provided	  for	  a	  good	  model	  fit.	  	  The	  residual	  scatter	  plot	  gave	  the	  best	  results	  for	  Gamma	  distribution	  with	  log	  link	  and	  I	  have	  kept	  it	  in	  the	  model.	  	  In	  the	  best-­‐fit	  exploratory	  model,	  experiencing	  injury,	  ethnicity,	  timing	  of	  the	  evaluation	  follow-­‐up	  and	  treatment	  timing	  were	  significant	  predictors	  of	  total	  costs	  (Appendix	  E,	  Table	  E1).	  	  However,	  in	  the	  cost	  prediction	  model	  presented	  in	  Table	  7.7,	  when	  keeping	  in	  all	  covariates	  irrespective	  of	  their	  significance,	  only	  treatment	  timing	  remains	  a	  significant	  predictor	  of	  the	  costs,	  indicating	  that	  the	  early	  treatment	  group	  reported	  higher	  overall	  costs.	  	  b.	  Direct	  costs	  Table	  7.8	  GLM	  on	  direct	  costs	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=101	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Males	  relative	  to	  females	   	  	  	  	  	  	  	  	  	  0.79**	  (-­‐0.01,	  1.59)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.37	  (-­‐1.38,	  0.26)	  Q1.	  Injured?	   0.64(-­‐0.13,	  1.43)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   -­‐0.38(-­‐1.26,	  0.49)	  Q3.	  Witnessed	  injury	  or	  death?	   0.20(-­‐0.63,	  1.04)	  Timing	  of	  follow-­‐up	   0.05	  (-­‐0.01,	  0.12)	  Treatment	  start	  date	   -­‐0.71	  (-­‐1.8,	  0.38)	  Psychiatric	  comorbidity	   -­‐1.09***(-­‐1.48,	  -­‐0.21)	  Treatment	  type	   5.14	  (4.24,	  7.35)	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Constant	  	  	  	   6.07***	  (4.57,	  7.07)	  Link	  function	   Log	  Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Direct	  costs	  model	  (Table	  7.8)	  with	  gamma	  distribution	  family	  and	  log	  link	  function	  produced	  a	  funnel-­‐shaped	  scatter	  plot.	  	  The	  results	  of	  the	  Park	  test	  suggested	  that	  the	  use	  of	  a	  gamma	  distribution	  was	  more	  appropriate.	  	  This	  model	  is	  very	  similar	  to	  the	  best-­‐fit	  model	  (Appendix	  E,	  Table	  E.3)	  where	  gender	  and	  injury	  were	  significant	  positive	  predictors	  of	  costs,	  while	  psychiatric	  comorbidity	  diagnosis	  was	  a	  significant	  negative	  predictor	  of	  costs.	  Average	  predicted	  direct	  costs	  for	  the	  early	  treatment	  group	  were	  £1965.83	  with	  95%	  CI	  ranging	  from	  £720.34	  -­‐	  £3211.09.	  	  For	  the	  later	  treatment	  group,	  average	  predicted	  costs	  were	  £965.36	  with	  95%	  CI	  ranging	  from	  £372.13-­‐£1557.98.	  c.	  The	  ST	  programme	  costs	  Table	  7.9	  GLM	  on	  the	  ST	  programme	  costs	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=101	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Males	  relative	  to	  females	   -­‐0.43	  (-­‐0.53,	  0.10)	  White	  British	  relative	  to	  other	  ethnic	  categories	   -­‐0.32**	  (-­‐0.58,	  -­‐0.06)	  Q1.	  Injured?	   0.48***(0.21,	  0.75)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.04	  (0.02,	  -­‐0.30)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.06	  (-­‐0.63,	  1.04)	  Treatment	  start	  date	   -­‐0.46**	  (-­‐0.77,	  -­‐0.11)	  Psychiatric	  comorbidity	   0.10	  (-­‐1.48,	  0.21)	  Treatment	  type	   0.04	  (0.04,	  0.05)	  Time	  of	  follow-­‐up	   0.03**(0.00,	  0.04)	  Constant	  	  	  	   7.92***	  (7.57,	  8.51)	  Link	  function	   Log	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Distributional	  family	   Gamma	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Residuals	  scatter	  plots,	  although	  showing	  several	  negative	  outliers	  for	  larger	  predicted	  means	  and	  positive	  outliers	  for	  smaller	  predicted	  means,	  presented	  best	  results	  when	  the	  model	  was	  fitted	  with	  gamma	  distribution	  and	  log	  link.	  	  This	  was	  confirmed	  by	  the	  Park	  test.	  	  Average	  predicted	  ST	  programme	  costs	  for	  the	  early	  treatment	  group	  were	  £4697.83	  with	  95%	  CI	  ranging	  from	  £3767.34	  -­‐	  £5626.09.	  	  For	  the	  later	  treatment	  group,	  average	  predicted	  costs	  were	  £3277.36	  with	  95%	  CI	  ranging	  from	  £2689.13-­‐£3935.98.	  d.	  Productivity	  loss	  associated	  costs	  Table	  7.10	  GLM	  on	  productivity	  loss	  costs	  
	  
Potentially	  associated	  factors	  
Logistic	  
regression	  of	  
reporting	  work	  
related	  costs	  N=	  103	  
observations	  
GLM	  of	  costs	  per	  month	  
due	  to	  the	  LB	  
N=	  68	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  interval)	  
Males	  relative	  to	  females	   0.76(0.25,	  2.12)	   0.04	  (-­‐0.07,	  0.08)	  White	  British	  relative	  to	  other	  ethnic	  categories	   1.43(0.49,	  4.19)	   -­‐0.47	  (-­‐1.50,	  0.42)	  Q1.	  Injured?	   5.01***(1.37,	  18.36)	   0.02	  (-­‐1.01,	  0.08)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   1.35(0.99,	  4.99)	   0.97*	  (-­‐0.04,	  2.19)	  Q3.	  Witnessed	  injury	  or	  death?	   0.36(0.09,	  1.32)	   -­‐0.33	  (-­‐1.79,	  0.07)	  Treatment	  timing	   0.99	  (0.91,	  1.07)	   -­‐0.00***(-­‐0.01,	  -­‐0.00)	  Timing	  of	  the	  follow-­‐up	   0.98(0.88,	  1.10)	   0.06	  (-­‐0.02,	  0.13)	  Psychiatric	  comorbidity	   0.60(0.18,	  1.99)	   -­‐0.47	  (-­‐1.83,	  0.88)	  Treatment	  type	   1.64(0.59,	  4.52)	   0.25	  (-­‐0.73,	  1.24)	  Constant	   	   4.50**	  (0.30,	  8.47)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	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Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.46	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.27	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Per	  cent	  correctly	  classified	   70.02%	   	  *	  p<0.10;	   **	  p<0.05;	   ***	  p<0.01	  Average	  predicted	  productivity	  loss	  costs	  for	  the	  early	  treatment	  group	  were	  £11463.82	  with	  95%	  CI	  ranging	  from	  £3907.93	  -­‐	  £190189.16.	  	  For	  the	  later	  treatment	  group	  average	  predicted	  costs	  were	  £3925.69	  with	  95%	  CI	  ranging	  from	  £1018.53-­‐£6832.23.	  	  The	  early	  treatment	  group	  reported	  significantly	  higher	  overall	  costs	  when	  work-­‐related	  costs	  were	  included,	  both	  for	  adjusted	  and	  unadjusted	  costs.	  	  When	  controlling	  for	  socio-­‐demographic	  factors,	  exposure	  and	  treatment	  characteristics,	  the	  early	  treatment	  group	  had	  on	  average	  2.5	  times	  higher	  costs	  overall	  due	  to	  exposure	  to	  the	  LB.	  	  Table	  7.11	  presents	  the	  average	  adjusted	  costs	  for	  all	  cost	  categories	  for	  both	  early	  and	  later	  treatment	  groups.	  e.	  Adjusted	  costs	  Table	  7.11	  Average	  adjusted	  costs	  per	  cost	  and	  participant	  category	  
	  
Early	  treatment	  group	  
(N=53)	  
	  
	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  CI)	  
Later	  treatment	  group	  
(N=50)	  
	  
	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  CI)	  	  	  
	  
	  
	  
p	  
ST	  total	  	   4697.8	   3167.3-­‐4826.0	   3277.3	   3200.1-­‐3835.9	   0.03	  
Direct	  costs	   1965.8	   720.2-­‐3211.4	   965.3	   373.1-­‐1557.2	   0.45	  
Total	  costs	   24530.8	  	  	   11933.5-­‐37127.4	   9606.3	  	   4814.16-­‐14398.4	   0.02	  
Productivity	  
costs	   11463.8	   3907.9-­‐19019.1	   3925.6	   1018.5-­‐6832.2	   0.00	  	   As	  discussed	  earlier,	  there	  are	  various	  approaches	  in	  estimating	  both	  costs	  and	  effects,	  each	  with	  its	  own	  merits	  and	  problems.	  	  Adjusting	  costs	  and	  outcomes	  for	  the	  same	  set	  of	  covariates	  seems	  a	  sensible	  approach	  in	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distinguishing	  between	  the	  effect	  of	  the	  intervention	  and	  the	  ‘background	  noise’	  inevitable	  with	  an	  observational	  study	  design.	  	  Furthermore,	  using	  the	  same	  set	  of	  covariates	  ensures	  consistency	  and	  allows	  for	  comparability	  of	  the	  models.	  	  However,	  as	  seen	  from	  the	  presented	  models,	  costs	  and	  effects	  are	  significantly	  associated	  with	  different	  sets	  of	  covariates,	  both	  between	  groups	  and	  within	  cost	  and	  outcome	  categories.	  	  Therefore,	  a	  fixed	  set	  of	  covariates,	  although	  theoretically	  sound	  in	  practice,	  results	  in	  poorly	  fitting	  models	  with	  lower	  explanatory	  power	  and	  reduced	  statistical	  power.	  	  
7.5	   Outcomes	  analysis	  Three	  main	  outcome	  measures	  were	  collected	  as	  a	  part	  of	  the	  ST	  programme	  (all	  outcome	  measures	  are	  described	  in	  greater	  detail	  in	  Chapters	  3	  and	  5):	  BDI,	  PDS	  and	  EQ5D.	  	  	  Each	  outcome	  measure	  can	  be	  presented	  in	  a	  different	  way,	  each	  portraying	  a	  slightly	  different	  perspective.	  	  For	  example,	  I	  could	  compare	  scores	  at	  the	  end	  of	  the	  treatment	  for	  two	  groups,	  I	  could	  compare	  differences	  in	  scores	  between	  end	  and	  start	  of	  treatment,	  and	  I	  could	  look	  at	  the	  number	  of	  PTSD-­‐free	  and/or	  depression-­‐free	  days	  for	  each	  group.	  	  Mirroring	  the	  costs	  models,	  I	  ran	  a	  GLM	  for	  differences	  between	  start	  and	  end	  scores	  for	  BDI,	  PDS	  and	  EQ5D	  measures	  and	  I	  have	  adjusted	  the	  models	  for	  identical	  covariates	  to	  control	  for	  all	  observed	  factors	  that	  could	  influence	  the	  treatment	  outcome.	  	  In	  each	  outcome	  model	  I	  controlled	  for	  the	  following	  covariates,	  guided	  by	  theoretical	  underpinning:	  
-­‐ 	  gender	  (males	  relative	  to	  females)	  	  
-­‐ ethnicity	  (white	  British	  relative	  to	  other	  ethnic	  categories)	  
-­‐ Q1.	  Experiencing	  injury	  
-­‐ Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	  
-­‐ Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	  
-­‐ treatment	  timing	  –	  time	  elapsed	  since	  LB	  in	  days	  
-­‐ follow-­‐up	  timing	  -­‐	  time	  elapsed	  since	  LB	  in	  days	  
-­‐ psychiatric	  comorbidity	  
-­‐ treatment	  type	  (CBT	  vs.	  EMDR)	  
-­‐ baseline	  outcome	  measure	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Table	  7.12	  BDI,	  PDS	  and	  EQ5D	  unadjusted	  scores	  	  
	   Early	  treatment	  (N=53)	  	  
M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  
Later	  treatment	  	  
	  (N=50)	  
	  
M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  SD	  
	  
	  
	  
p	  Outcome	  measure	   	   	   	  BDI	  assessment	  (N=101)	   23.90	   10.78	   18.03	   11.16	   0.01	  BDI	  start	  (N=101)	   25.19	   11.57	   17.58	   11.69	   0.00	  BDI	  end	  (N=101)	   11.20	   10.18	   8.12	   9.23	   0.11	  BDI	  follow-­‐up	  (N=83)	   12.38	   	  9.84	   	  7.61	   9.91	   0.02	  BDI	  end-­‐start	   -­‐13.35	   10.14	   -­‐9.54	   8.58	   0.05	  PDS	  assessment	  (N=101)	   33.13	   9.20	   25.38	   11.32	   0.00	  PDS	  start	  (N=101)	   31.83	   10.97	   25.04	   12.91	   0.00	  PDS	  end	  (N=101)	   12.54	   11.97	   9.91	   11.20	   0.26	  PDS	  follow-­‐up	  (N=83)	   15.67	   11.96	   9.84	   9.84	   0.02	  PDS	  end-­‐start	   -­‐18.62	   12.53	   -­‐14.96	   11.72	   0.19	  EQ5D	  assessment	  (N=95)	   0.59	   0.30	   0.69	   0.23	   0.03	  EQ5D	  follow-­‐up	  (N=103)	   0.75	   0.25	   0.86	   0.19	   0.19	  EQ5D	  end-­‐start	   0.14	   0.24	   0.17	   0.26	   0.35	  	  Unadjusted	  scores	  for	  BDI,	  PDS	  and	  EQ5D	  presented	  in	  Table	  7.12	  suggest	  that	  participants	  in	  the	  early	  treatment	  group	  started	  treatment	  with	  higher	  scores	  on	  average	  for	  all	  outcome	  measures.	  	  Differences	  in	  the	  start	  and	  end	  scores	  between	  the	  early	  and	  later	  treatment	  groups	  are	  statistically	  significant	  for	  the	  BDI	  (p<0.05)	  measure	  but	  not	  for	  PDS	  and	  EQ5D	  measures.	  	  Differences	  on	  the	  outcome	  measures	  between	  the	  early	  and	  later	  treatment	  groups	  are	  presented	  in	  Figures	  7.2-­‐7.4.	  	  BDI	  scores	  for	  both	  groups	  indicate	  moderate	  depression	  (Beck,	  1961),	  while	  scores	  for	  PDS	  indicate	  moderate	  to	  severe	  PTSD	  (Foa	  et	  al,	  1997;	  McCarthy,	  2008)5.	  	  For	  BDI	  and	  PDS,	  a	  higher	  score	  indicates	  worsening	  in	  symptoms,	  while	  for	  EQ5D	  a	  higher	  score	  is	  connected	  with	  improvement	  in	  health	  state.	  	  Although	  there	  was	  no	  significant	  difference	  for	  unadjusted	  mean	  scores	  at	  the	  end	  of	  the	  treatment,	  the	  early	  treatment	  group	  reported,	  on	  average,	  higher	  outcome	  scores.	  	  According	  to	  the	  PDS,	  the	  mean	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 PDS scores range from 0-51 and the cut offs for symptom severity ratings are as 
follows: 0 no rating, 1-10 mild, 11-20 moderate, 21-35 moderate to severe and >36 
severe (Foa et al., 1997). BDI scores range from 0-63, with following score cut offs: 
0-9 minimal depression, 10-18 mild depression, 19-29 moderate depression and 30-63 
severe depression (Beck et al, 1988). 
	   215	  
end	  score	  for	  the	  early	  treatment	  group	  would	  be	  considered	  to	  represent	  moderate	  PTSD,	  while	  for	  the	  later	  treatment	  group	  the	  average	  score	  indicates	  mild	  PTSD.	  	  There	  was	  no	  statistically	  significant	  difference	  between	  BDI	  (t=0.23,	  df=43,	  p>0.01)	  and	  PDS	  (t=-­‐0.41,	  df=43,	  p>0.01)	  scores	  measured	  at	  the	  end	  of	  treatment	  and	  at	  treatment	  follow-­‐up	  for	  both	  early	  and	  later	  treatment	  groups.	  	  I	  calculated	  Cohen’s	  d,	  indicator	  of	  treatment	  effect	  size.	  Cohen’s	  d	  divides	  the	  difference	  in	  the	  group	  means	  by	  their	  pooled	  standard	  deviation	  and	  is	  independent	  of	  sample	  size	  (Cohen,	  1988).	  	  Treatment	  effects	  up	  to	  0.2-­‐0.3	  are	  considered	  low,	  0.5	  is	  considered	  to	  be	  a	  medium	  effect	  and	  0.8	  is	  a	  large	  treatment	  effect	  (Cohen,	  1988).	  	  The	  treatment	  size	  effects	  for	  BDI	  are	  1.22	  (r=0.52)	  for	  the	  early	  treatment	  group	  and	  d=0.90	  (r=0.41)	  for	  the	  later	  treatment	  group,	  both	  of	  which	  are	  considered	  large	  treatment	  effects	  (Cohen,	  1988).	  	  For	  PDS,	  the	  early	  treatment	  group	  treatment	  size	  effect	  is	  1.64	  (r=0.62),	  while	  for	  the	  later	  treatment	  group	  it	  is	  d=1.14	  (r=0.49).	  	  The	  early	  treatment	  group	  had	  larger	  treatment	  effect	  sizes	  on	  both	  measures.	  	  Figure	  7.3	  Difference	  in	  PDS	  assessment,	  start,	  end	  and	  follow-­‐up	  scores	  between	  early	  and	  later	  treatment	  groups	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Figure	  7.4	  Difference	  in	  BDI	  assessment,	  start,	  end	  and	  follow-­‐up	  scores	  between	  early	  and	  later	  treatment	  group	  
	  	  Figure	  7.5	  Difference	  in	  EQ5D	  assessment	  and	  follow-­‐up	  scores	  between	  early	  and	  later	  treatment	  group	  
	  The	  average	  outcome	  measures	  reported	  in	  Table	  7.12	  again	  show	  differences	  between	  start,	  end	  and	  follow-­‐up	  scores,	  as	  well	  as	  between	  immediate	  and	  delayed	  treatment	  groups.	  	  Scores	  for	  all	  measures	  for	  both	  groups	  were	  normally	  distributed	  except	  PDS	  post-­‐treatment	  for	  the	  later	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treatment	  group	  (Z=1.6,	  p=0.00)	  and	  EQ5D	  at	  the	  end	  of	  the	  treatment	  for	  both	  groups	  (Z=2.14,	  p=0.00;	  Z=1.6,	  p=0.01).	  T-­‐test	  for	  independent	  samples	  confirmed	  a	  statistically	  significant	  difference	  between	  both	  BDI	  and	  PDS	  scores	  at	  the	  start	  of	  the	  treatment	  between	  early	  and	  later	  treatment	  groups	  (t(BDIs)=3.25,	  p<0.01;	  	  t(PDSs)=2.84,	  p<0.01).	  	  Participants	  treated	  early	  had,	  on	  average,	  higher	  scores	  on	  both	  measures.	  	  At	  the	  follow-­‐up	  stage	  for	  unadjusted	  BDI	  and	  PDS	  scores,	  there	  was	  a	  statistically	  significant	  difference	  in	  the	  Mann-­‐Whitney	  test	  for	  both	  BDI	  and	  PDS	  between	  the	  early	  and	  later	  treatment	  groups	  (Z_BDI=-­‐2.4,	  p=0.02;	  Z_PDS=-­‐2.5,	  p=0.02).	  Another	  method	  for	  assessing	  treatment	  outcomes	  is	  to	  look	  at	  reliable	  improvement	  on	  the	  treatment	  outcome	  measure	  and	  to	  assess	  how	  this	  result	  compares	  with	  clinically	  functional	  and	  dysfunctional	  populations	  for	  this	  particular	  mental	  health	  intervention	  and	  outcome	  (Evans	  et	  al.,	  1998).	  	  A	  method	  that	  combines	  both	  elements	  was	  introduced	  by	  Jacobson	  and	  Truax	  (1991)	  and	  is	  based	  on	  a	  calculation	  of	  reliable	  change	  index	  (RC)	  that	  assesses	  the	  improvement	  beyond	  expected	  by	  chance	  alone	  and	  a	  cut-­‐off	  score	  that	  determines	  likelihood	  of	  person	  being	  closer	  to	  the	  mean	  of	  a	  functional	  trauma-­‐exposed	  population	  than	  to	  the	  mean	  of	  a	  population	  with	  PTSD.	  	  	  Reliable	  change	  calculation	  is	  based	  on	  multiplying	  the	  standard	  error	  of	  the	  difference	  by	  1.96	  for	  assessing	  95%	  confidence	  level	  for	  the	  change	  between	  the	  start	  and	  end	  scores.	  	  “Change	  exceeding	  1.96	  times	  SEdiff	  is	  unlikely	  to	  occur	  more	  than	  5%	  of	  the	  time	  by	  unrealibility	  of	  the	  measure	  alone”	  (Evans	  et	  al.,	  1998,	  p.	  70).	  SEdiff	  =	  SD1*√2	  *√1-­‐r	  	  	  SD1	  is	  the	  standard	  deviation	  of	  the	  baseline	  observations,	  and	  r	  is	  the	  reliability	  of	  the	  measure	  (Jacobson	  and	  Thoreaux,	  1991).	  	  Thresholds	  for	  the	  PDS	  for	  functional	  and	  PTSD	  populations	  were	  calculated	  from	  the	  original	  validation	  data	  provided	  in	  Foa	  et	  al.	  (1997),	  yielding	  a	  cut-­‐off	  of	  22	  for	  the	  early	  group	  and	  18	  for	  the	  later	  treatment	  group	  needed	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for	  a	  clinical	  change.	  	  A	  fall	  of	  at	  least	  9.46	  on	  the	  PDS	  for	  the	  early	  treated	  group	  and	  8.04	  for	  the	  later	  treatment	  group	  was	  needed	  for	  a	  reliable	  change.	  	  	   Mean	  BDI	  scores	  for	  functional	  populations	  were	  taken	  from	  Seggar,	  Lambert	  and	  Hansen	  (2002),	  yielding	  a	  cut-­‐off	  of	  13	  for	  the	  early	  group,	  and	  11	  for	  the	  later	  treatment	  group.	  	  Corresponding	  thresholds	  for	  the	  reliable	  change	  on	  BDI	  are	  11.99	  for	  the	  early	  group	  and	  12.12	  for	  the	  later	  treatment	  group.	  	  Chi-­‐square	  tests	  did	  not	  show	  statistically	  significant	  change	  in	  achieving	  only	  clinical	  or	  both	  clinical	  and	  statistical	  change	  between	  the	  early	  and	  later	  treatment	  groups,	  as	  presented	  in	  Table	  7.13	  (Pearson	  chi	  (BDIcs)=0.30,	  p>0.05;	  Pearson	  chi	  (PDScs)=0.30,	  p>0.05;	  Pearson	  chi	  (BDIc)=1.82,	  p=0.05;	  Pearson	  chi	  (PDSc)=0.28,	  p>0.05).	  Table	  7.13	  Number	  of	  participants	  who	  achieved	  a	  clinical	  and	  statistically	  significant	  change	  on	  BDI	  and	  PDS	  measure	  after	  the	  treatment	  
	   Early	  treatment	  group	  (N=53)	  	  
	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  
Later	  treatment	  
group	  (N=50)	  
	  
	  	  	  	  	  	  	  N	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  	  	  	  	  	  	  	  	  	  
P	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  P	  BDI	  clinical	  and	  statistical	  change	   24	   45	   20	   40	   0.48	  PDS	  clinical	  and	  statistical	  change	   33	   62	   31	   62	   0.29	  BDI	  reliable	  clinical	  change	   30	   56	   20	   40	   0.05	  PDS	  reliable	  clinical	  change	   39	   74	   32	   64	   0.24	  	  
7.5.1	  BDI	  	  
a.	  Factors	  associated	  with	  achieving	  clinically	  significant	  change	  in	  BDI	  I	  ran	  a	  logistic	  binary	  regression	  in	  order	  to	  look	  into	  factors	  associated	  with	  achieving	  clinically	  significant	  change	  on	  end	  of	  treatment	  scores.	  	  The	  model	  presented	  in	  Table	  7.14	  identified	  ethnicity	  and	  finishing	  treatment	  as	  factors	  associated	  with	  achieving	  clinically	  significant	  change	  on	  BDI.	  White	  British	  participants	  and	  participants	  who	  finished	  treatment	  were	  around	  three	  times	  more	  likely	  to	  achieve	  clinically	  significant	  change	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  The	  second	  part	  of	  the	  analysis	  is	  a	  GLM	  model	  that	  explores	  factors	  associated	  with	  end	  of	  treatment	  outcome	  scores.	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Table	  7.14	  Logistic	  regression	  analysis	  of	  achieving	  clinically	  significant	  change	  on	  BDI	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  OR	  	  	  N=94	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   3.52**	  (1.34,	  9.27)	  Finished	  treatment	   3.24**	  (1.03,	  13.48)	  BDI	  score	  at	  start	  of	  the	  treatment	   0.98	  (0.94,	  1.02)	  Treatment	  timing	   1.01	  (0.94,	  1.10)	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.23	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.03	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	  Per	  cent	  correctly	  classified	   65.65%	  
	  
b.	  Factors	  associated	  with	  BDI	  end	  score	  Table	  7.15	  GLM	  model	  on	  the	  BDI	  end	  score	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=94	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Finished	  treatment	   -­‐8.41***	  (-­‐12.03,	  -­‐4.48)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   -­‐3.90***(-­‐7.16,	  -­‐0.63)	  BDI	  score	  at	  start	  of	  the	  treatment	   0.43***	  (0.03,	  0.66)	  Treatment	  timing	   -­‐0.00	  (-­‐0.01,	  0.00)	  Physical	  comorbidity	   7.39***	  (3.03,	  11.76)	  Constant	   10.87***(4.13,	  17.60)	  Family	   Gauss	  Link	  	  R	  squared	  =	  0.56	   Identity	  	  	   Average	  predicted	  BDI	  end	  scores	  for	  the	  early	  treatment	  group	  was	  10.69	  (9.09-­‐12.28),	  and	  8.62	  (7.05-­‐10.29)	  for	  the	  later	  treatment	  group.	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Factors	  associated	  with	  the	  lower	  end	  BDI	  score,	  as	  shown	  in	  Table	  7.15	  and	  identified	  by	  the	  GLM	  model,	  included	  finishing	  treatment	  and	  being	  in	  the	  white	  British	  ethnicity	  category.	  	  Physical	  comorbidity	  and	  a	  higher	  BDI	  score	  at	  the	  start	  of	  the	  treatment	  predicted	  a	  higher	  BDI	  end	  score.	  
c.	  Factors	  associated	  in	  pre	  and	  post	  treatment	  difference	  in	  BDI	  	  Table	  7.16	  GLM	  on	  pre	  and	  post	  treatment	  difference	  in	  BDI	  score	  –	  prediction	  model	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=93	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Males	  relative	  to	  females	   	  	  	  	  	  -­‐0.67	  (-­‐4.11,	  5.05)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.97	  (-­‐8.50,	  4.12)	  Q1.	  You	  were	  injured	   1.54	  (-­‐2.60,11.18)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   -­‐2.07(-­‐7.06,	  -­‐2.49)	  Q3.	  Witnessed	  injury	  or	  death?	   6.04***(1.14,	  10.04)	  Treatment	  timing	  Follow-­‐up	  timing	   4.16**	  (-­‐0.57,	  8.11)	  3.72	  (-­‐0.2,	  6.45)	  Psychiatric	  comorbidity	   2.13(-­‐4.48,	  5.2)	  Treatment	  type	   -­‐0.40(-­‐2.24,	  4.35)	  Constant	  	  	  	   -­‐18.43***	  (-­‐28.21,	  -­‐9.66)	  Link	  function	   Identity	  Distributional	  family	   Gauss	  	  Average	  predicted	  pre-­‐	  and	  post-­‐treatment	  difference	  in	  BDI	  score	  for	  the	  early	  treatment	  group	  was	  -­‐13.78	  (-­‐16.10,	  -­‐10.23),	  and	  -­‐9.58	  (-­‐12.10,	  -­‐6.22)	  for	  the	  later	  treatment	  group.	  If	  I	  control	  for	  the	  BDI	  score	  at	  the	  treatment	  start	  there	  is	  no	  difference	  between	  the	  early	  and	  later	  treatment	  groups	  in	  the	  BDI	  score	  difference	  between	  the	  early	  (-­‐11.55)	  and	  later	  treatment	  groups	  (-­‐11.32).	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7.5.2	  PDS	  	  
a.	  Factors	  associated	  with	  achieving	  clinically	  significant	  change	  in	  PDS	  	  Table	  7.17	  Logistic	  regression	  analysis	  of	  achieving	  clinically	  significant	  change	  on	  PDS	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  OR	  	  	  N=	  94	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   7.26**	  (1.45,	  58.45)	  Q1.	  You	  were	  injured?	   3.19***	  (0.28,	  6.17)	  Finished	  treatment	   32.89***	  (6.03,	  448.48)	  BDI	  score	  at	  start	  of	  the	  treatment	   0.96	  (0.94,	  1.02)	  Treatment	  timing	   1.00	  (0.99,	  1.00)	  Link	  test	  p-­‐value	   -­‐	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.01	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.05	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	  Per	  cent	  correctly	  classified	   70.60%	  	   The	  model	  presented	  in	  Table	  7.17	  identified	  ethnicity,	  injury	  and	  finishing	  treatment	  as	  factors	  associated	  with	  achieving	  clinically	  significant	  change	  on	  PDS.	  	  Again,	  people	  of	  white	  British	  background	  were	  around	  seven	  times	  more	  likely,	  and	  those	  who	  finished	  treatment	  were	  32	  times	  more	  likely	  to	  achieve	  clinically	  significant	  change	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  Interestingly,	  the	  model	  identified	  injured	  participants	  as	  being	  three	  times	  more	  likely	  to	  achieve	  clinically	  significant	  change	  on	  PDS	  as	  well.	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b.	  Factors	  associated	  with	  PDS	  end	  score	  Table	  7.18	  GLM	  model	  on	  the	  PDS	  end	  score	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=94	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   -­‐5.80***	  (-­‐7.96,	  -­‐0.15)	  Physical	  comorbidity	   10.68***	  (4.17,	  17.18)	  Finished	  treatment	   -­‐11.90***	  (-­‐13.03,	  -­‐0.48)	  PDS	  score	  at	  start	  of	  the	  treatment	   0.39***	  (0.03,	  0.56)	  Treatment	  timing	   0.00	  (-­‐0.01,	  0.00)	  Constant	   13.81***(5.45,	  22.17)	  Family	   Gauss	  Link	  R	  squared=	  0.43	   Identity	  	   Average	  predicted	  end	  PDS	  score	  for	  the	  early	  treatment	  group	  was	  11.08	  (9.65,	  13.47),	  and	  8.47	  (8.29,	  12.67)	  for	  the	  later	  treatment	  group.	  	  The	  model	  presented	  in	  Table	  7.18	  identifies	  that	  participants	  of	  white	  British	  background	  and	  those	  who	  finished	  treatment	  are	  associated	  with	  lower	  PDS	  end	  scores.	  Unsurprisingly,	  physical	  comorbidity	  and	  higher	  PDS	  start	  scores	  were	  associated	  with	  higher	  PDS	  end	  scores.	  The	  role	  of	  the	  finished	  treatment	  coefficient	  should	  be	  taken	  into	  account	  when	  assessing	  the	  significance	  of	  other	  indicators	  in	  models	  examining	  clinically	  significant	  change	  or	  improvements	  on	  BDI	  and	  PDS.	  	  Finishing	  treatment	  has	  a	  strong	  positive	  correlation	  with	  a	  person	  feeling	  better	  and	  this	  is	  in	  turn	  positively	  associated	  with	  achieving	  clinically	  significant	  change	  and	  improvements	  in	  the	  BDA	  score.	  	  Therefore,	  the	  inclusion	  of	  a	  finished	  treatment	  indicator	  might	  undermine	  the	  significance	  of	  other	  indicators	  in	  the	  model,	  such	  as	  the	  start	  of	  the	  treatment	  or	  the	  outcome	  measure	  score	  at	  the	  start	  of	  the	  treatment.	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c.	  Factors	  associated	  in	  difference	  between	  pre	  and	  post	  treatment	  PDS	  scores	  	  Table	  7.19	  GLM	  for	  pre	  and	  post	  treatment	  difference	  in	  PDS	  score	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=93	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Males	  relative	  to	  females	   -­‐0.43	  (-­‐6.11,	  5.05)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   -­‐0.67	  (-­‐8.50,	  4.12)	  Q1.	  You	  were	  injured?	   4.08	  **(0.60,11.18)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   -­‐7.07***(-­‐16.06,	  -­‐2.49)	  Q3.	  Witnessed	  injury	  or	  death?	   4.04(-­‐2.14,	  10.04)	  Treatment	  timing	  Follow-­‐up	  timing	   5.70**	  (0.10,	  10.11)	  2.76	  (-­‐1.34,	  7.12)	  Psychiatric	  comorbidity	   1.13(-­‐4.48,	  5.2)	  Treatment	  type	   0.40(-­‐2.24,	  4.35)	  Constant	  	  	  	   -­‐20.43***	  (-­‐27.21,	  -­‐13.66)	  Link	  function	   Identity	  Distributional	  family	   Gauss	  	  Average	  predicted	  pre-­‐	  and	  post-­‐treatment	  differences	  in	  the	  PDS	  score	  for	  the	  early	  treatment	  group	  was	  -­‐19.98	  (-­‐22.10,	  -­‐14.23),	  and	  -­‐14.73	  (-­‐19.10,	  -­‐12.22)	  for	  the	  later	  treatment	  group.	  Residuals	  were	  nicely	  dispersed	  and	  the	  Park	  test	  approved	  Gauss	  distribution.	  	  Treatment	  difference	  is	  calculated	  as	  the	  score	  at	  the	  start	  of	  the	  treatment	  minus	  the	  score	  at	  the	  end	  of	  the	  treatment.	  	  On	  BDI,	  six	  participants	  reported	  higher	  scores	  at	  the	  end	  of	  the	  treatment	  in	  comparison	  to	  the	  treatment	  start	  (three	  from	  the	  early	  treatment	  group	  and	  two	  from	  later	  treatment).	  	  Three	  of	  those	  participants	  finished	  treatment	  while	  three	  did	  not.	  On	  PDS,	  five	  individuals	  had	  a	  higher	  score	  at	  the	  end	  of	  the	  treatment	  (out	  of	  which	  three	  were	  from	  the	  later	  treatment	  group)	  and	  out	  of	  those,	  only	  two	  finished	  treatment.	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7.5.3	  Depression-­‐free	  and	  PTSD-­‐free	  days	  calculation	  There	  are	  several	  difficulties	  in	  relation	  to	  the	  calculation	  of	  both	  PTSD-­‐free	  and	  depression-­‐free	  days.	  	  The	  first	  is	  the	  different	  timing	  of	  the	  data	  collection	  for	  each	  participant	  depending	  on	  when	  they	  entered	  the	  ST	  programme,	  i.e.	  when	  they	  were	  assessed,	  treated	  and	  followed-­‐up,	  which	  consequently	  produced	  a	  great	  variation	  of	  data	  for	  each	  data	  collection	  point.	  	  Secondly,	  there	  is	  an	  issue	  with	  the	  lack	  of	  data	  on	  both	  measures	  for	  the	  period	  from	  the	  LB	  to	  the	  assessment	  point,	  and	  this	  is	  crucial	  for	  calculation	  of	  PTSD-­‐free	  and	  depression-­‐free	  days	  as	  the	  LB	  event	  is	  a	  reference	  point	  for	  the	  calculation.	  	  	  There	  are	  two	  ways	  of	  addressing	  this	  problem	  as	  each	  is	  built	  on	  a	  set	  of	  assumptions,	  hence	  caution	  is	  required	  when	  interpreting	  the	  results.	  	  One	  approach	  is	  to	  use	  multiple	  imputation	  that	  takes	  into	  account	  changes	  in	  the	  scores	  over	  time	  alongside	  other	  explanatory	  variables,	  such	  as	  socio-­‐demographic	  and	  exposure	  characteristics.	  	  The	  imputation	  model	  assumes	  a	  linear	  relationship	  of	  the	  predicted	  values,	  which	  is	  questionable	  in	  this	  case	  as	  results	  from	  an	  RCT	  on	  interventions	  for	  PTSD	  suggest	  a	  potential	  non-­‐linear	  relationship	  between	  outcome	  scores	  and	  time,	  with	  a	  smaller	  initial	  drop	  in	  symptoms,	  followed-­‐by	  a	  plateau	  and	  a	  larger	  drop	  in	  scores	  at	  9	  months	  after	  exposure	  to	  the	  traumatic	  event	  (Ehlers	  et	  al.,	  2003).	  	  Values	  obtained	  by	  multiple	  imputation	  are	  built	  on	  heavy	  assumptions.	  which	  undermines	  the	  validity	  and	  generalisability	  of	  the	  model.	  Another	  equally	  challenging	  approach	  is	  to	  base	  the	  calculations	  of	  scores	  for	  the	  period	  between	  the	  LB	  and	  the	  ST	  programme	  start	  on	  data	  from	  existing	  studies.	  	  There	  are	  numerous	  issues	  with	  this	  approach,	  starting	  with	  the	  comparability	  of	  the	  samples,	  particularly	  in	  regard	  to	  socio-­‐demographics,	  exposure,	  traumatic	  event	  type,	  study	  time	  frame	  and	  treatment	  characteristics.	  	  Another	  problem	  is	  the	  assumption	  about	  the	  nature	  of	  the	  relationship	  between	  time	  and	  changes	  in	  the	  PDS	  and	  BDI	  measures	  since	  exposure	  to	  the	  traumatic	  event,	  which	  can	  easily	  be	  explored	  in	  the	  sensitivity	  analysis.	  	  Although	  both	  approaches	  in	  estimating	  depression-­‐free	  and	  PTSD-­‐free	  days	  have	  challenges,	  I	  have	  decided	  to	  follow	  the	  second	  approach	  and	  base	  the	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calculation	  on	  the	  findings	  from	  published	  studies.	  	  One	  of	  the	  reasons	  for	  this	  is	  that	  this	  approach	  offers	  an	  insight	  into	  the	  changes	  in	  the	  BDI	  and	  PDS	  scores	  over	  time	  since	  exposure	  to	  the	  traumatic	  event.	  	  Moreover,	  the	  RCT	  by	  Ehlers	  et	  al.	  (2003)	  on	  effects	  of	  early	  intervention	  for	  PTSD	  provides	  a	  valuable	  insight	  into	  the	  recovery	  mechanisms	  after	  the	  traumatic	  event	  and	  development	  of	  PTSD.	  	  The	  study	  recruited	  A&E	  attendees	  for	  injuries	  after	  motor	  vehicle	  accidents	  around	  four	  weeks	  after	  the	  traumatic	  event	  and	  followed	  them	  up	  after	  a	  three	  week-­‐period	  of	  self-­‐monitoring.	  	  Participants	  who	  scored	  above	  15	  on	  PDS	  (Foa	  et	  al.,	  1997)	  were	  randomly	  allocated	  three	  types	  of	  treatment:	  CBT,	  a	  self-­‐help	  CBT-­‐based	  booklet	  and	  repeated	  assessments.	  	  The	  study	  measured	  both	  BDI	  and	  PDS	  scores	  for	  individuals	  who	  qualified	  on	  criteria	  for	  PTSD	  at	  several	  time	  points:	  at	  the	  study	  assessment	  point,	  after	  self-­‐assessment,	  at	  three	  months	  (post-­‐treatment)	  and	  9	  months	  (follow-­‐up).	  	  Whilst	  there	  are	  differences	  between	  the	  LB	  and	  Ehlers	  study	  namely	  in	  the	  type	  of	  the	  traumatic	  event	  (terrorist	  attack	  vs.	  motor	  vehicle	  accident),	  timeline	  of	  the	  intervention	  (7	  weeks	  after	  the	  accident	  in	  comparison	  to	  a	  range	  of	  between	  8	  months	  and	  two	  years	  after	  the	  LB),	  participant	  characteristics	  (the	  RCT	  sample	  was	  almost	  exclusively	  Caucasian,	  while	  the	  LB	  was	  mixed,	  and	  a	  third	  of	  the	  RCT	  sample	  was	  blue	  collar,	  while	  the	  LB	  study	  was	  predominantly	  white	  collar	  and	  professional),	  the	  Ehlers	  study	  offers	  to	  my	  knowledge	  the	  best	  available	  published	  data	  on	  BDI	  and	  PDS	  score	  changes	  during	  exposure	  to	  a	  traumatic	  event	  and	  treatment.	  	  For	  the	  calculation	  of	  the	  BDI	  and	  PDS	  scores	  for	  the	  period	  between	  the	  LB	  and	  assessment	  point,	  I	  used	  the	  percentage	  increase	  in	  each	  measure	  as	  reported	  by	  Ehlers	  and	  applied	  it	  to	  the	  LB	  data.	  	  I	  have	  allocated	  Ehlers’	  data	  to	  matching	  time	  points	  in	  the	  LB	  study	  i.e.	  8	  weeks,	  3	  months,	  9	  months,	  >9	  after	  the	  LB.	  	  For	  participants	  who	  entered	  the	  ST	  programme	  more	  than	  9	  months	  after	  the	  LB,	  I	  used	  the	  9	  months	  rate	  as	  this	  was	  the	  only	  available	  score	  estimate.	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   For	  the	  BDI	  threshold	  calculation	  I	  followed	  the	  protocol	  suggested	  by	  Lave	  et	  al.	  (1998).	  	  Suggested	  cut-­‐off	  scores	  on	  BDI	  were	  22	  for	  severe	  depression	  and	  8	  for	  no	  depression	  (Lave	  et	  al.,	  1998).	  	  If	  a	  participant	  scored	  22	  or	  higher	  on	  BDI	  no	  depression-­‐free	  days	  (DFD)	  were	  assumed,	  while	  if	  the	  score	  was	  8	  or	  below	  a	  full	  DFD	  was	  assumed.	  	  	  In	  order	  to	  calculate	  depression-­‐free	  days	  for	  scores	  between	  8	  and	  22,	  I	  have	  expressed	  these	  scores	  in	  fractions	  of	  14,	  with	  a	  score	  of	  8	  equalling	  14/14	  of	  a	  DFD,	  and	  a	  score	  of	  22	  equalling	  0/14	  of	  a	  DFD.	  For	  example,	  a	  score	  of	  10	  equals	  12/14	  of	  a	  DFD,	  i.e.	  0.86	  DFD.	  	  I	  have	  calculated	  the	  number	  of	  DFD	  days	  per	  person	  by	  adding	  the	  number	  of	  DFD	  for	  time	  periods	  between	  assessment,	  treatment	  start,	  treatment	  end	  and	  follow-­‐up.	  	  For	  each	  time	  period	  I	  had	  a	  
a.	  Depression-­‐free	  days	  Table	  7.20	  GLM	  on	  depression-­‐free	  days	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=94	  	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Males	  relative	  to	  females	   -­‐27.82(-­‐35.83,	  -­‐9.51)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   135.03***	  (66.1,	  225.05)	  Q1.	  Injured?	   -­‐48.03	  (-­‐61.50,	  82.12)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   -­‐24.08	  (-­‐30.80,	  44.00)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐27.26(-­‐140.06,	  176.49)	  Timing	  of	  follow-­‐up	   4.04(-­‐6.14,	  16.04)	  Treatment	  start	  date	   49.00	  (18.49,	  299.10)	  Psychiatric	  comorbidity	   -­‐74.70	  (-­‐254.77,	  7.11)	  CBT	   13.13(-­‐185.48,	  28.2)	  Constant	  	  	  	   120.04(-­‐62.24,	  174.35)	  Link	  function	   Log	  Distributional	  family	   Gauss	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recording	  of	  the	  BDI	  score	  that	  I	  have	  expressed	  in	  fractions	  of	  14,	  as	  stated	  above.	  	  The	  number	  of	  DFD	  for	  each	  period	  was	  calculated	  as	  the	  score	  expressed	  in	  fractions	  at	  the	  start	  of	  the	  period	  minus	  the	  score	  expressed	  in	  fractions	  for	  the	  end	  of	  the	  period,	  divided	  by	  2	  and	  multiplied	  by	  the	  number	  of	  days	  between	  the	  two	  data	  collection	  points.	  	  	  	  The	  Mann-­‐Whitney	  test	  for	  independent	  samples	  showed	  a	  statistically	  significant	  difference	  in	  depression-­‐free	  days	  between	  the	  two	  treatment	  groups	  (Z=-­‐3.28,	  p<0.01)	  with	  the	  early	  treatment	  group	  reporting	  a	  median	  of	  3.5	  depression-­‐free	  days,	  while	  the	  later	  treatment	  group	  reported	  1.65	  depression-­‐free	  days.	  	  The	  unadjusted	  mean	  depression-­‐free	  days	  for	  early	  treatment	  group	  is	  260.33,	  while	  for	  the	  later	  treatment	  group	  it	  was	  464.36	  days	  (Z=-­‐4.09,	  p<0.00).	  Models	  show	  residuals	  are	  nicely	  dispersed	  and	  the	  Park	  test	  approved	  the	  use	  of	  Gauss	  distribution	  with	  log	  link.	  	  Average	  predicted	  depression-­‐free	  days	  for	  the	  early	  treatment	  group	  is	  265.38	  (271.10,	  354.23)	  and	  314.58	  (201.10,	  347.22)	  for	  the	  later	  treatment	  group.	  If	  I	  control	  for	  the	  BDI	  score	  at	  the	  start	  of	  the	  treatment,	  a	  statistically	  significant	  difference	  between	  the	  two	  groups	  on	  depression-­‐free	  days	  is	  no	  longer	  observed	  (299	  days	  versus	  282	  days).	  	  As	  the	  model	  in	  Table	  7.19	  presents,	  the	  only	  significant	  predictor	  of	  depression-­‐free	  days	  is	  ethnicity,	  with	  white	  British	  participants	  reporting	  significantly	  more	  depression-­‐free	  days	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  Although	  the	  early	  treatment	  group	  on	  average	  reported	  fewer	  depression-­‐free	  days	  in	  comparison	  to	  the	  later	  treatment	  group	  (265	  vs.	  314),	  the	  difference	  is	  not	  statistically	  significant.	  b.	  PTSD-­‐free	  days	  In	  order	  to	  calculate	  the	  PDS	  threshold	  I	  used	  scoring	  suggested	  by	  McCarthy	  (2002)	  where	  scores	  0-­‐10	  are	  associated	  with	  no	  PTSD,	  scores	  between	  11	  and	  35	  with	  moderate	  PTSD,	  and	  scores	  >36	  with	  severe	  PTSD.	  I	  have	  used	  the	  same	  calculation	  protocol	  as	  for	  DFD.	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Unadjusted	  mean	  PTSD-­‐free	  days	  for	  early	  treatment	  group	  is	  359.44,	  while	  for	  later	  treatment	  group	  is	  574.45	  days	  (Z=-­‐3.35,	  p<0.00).	  Table	  7.21	  GLM	  on	  PTSD	  free	  days	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=93	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Males	  relative	  to	  females	   21.03	  (-­‐66.11,	  75.05)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   102.03**	  (8.50,	  196.12)	  Q1.	  Injured?	   -­‐98.08	  **(-­‐190.,	  0.18)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   14.07(-­‐96.06,	  126.49)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐-­‐50.04(-­‐142.14,	  26.04)	  Treatment	  start	  date	   80.70	  (-­‐32.77,	  90.11)	  Follow-­‐up	  date	   10.77**(1.98,	  19.0)	  Psychiatric	  comorbidity	   -­‐149.13***(-­‐185.4,	  -­‐28.2)	  CBT	   44.04(-­‐62.24,	  74.35)	  Constant	  	  	  	   126.58	  (-­‐97.21,	  350.66)	  Link	  function	   Identity	  Distributional	  family	   Gauss	  	   Residuals	  are	  nicely	  dispersed	  and	  the	  Park	  test	  approved	  the	  use	  of	  Gauss	  distribution.	  	  Average	  predicted	  PTSD-­‐free	  days	  for	  the	  early	  treatment	  group	  is	  430.38	  (358.10,	  539.23)	  and	  511.58	  (441.10,	  581.22)	  for	  the	  later	  treatment	  group.	  If	  I	  control	  for	  the	  PDS	  score	  at	  the	  start	  of	  the	  treatment,	  the	  statistical	  difference	  between	  the	  number	  of	  PTSD	  free	  days	  between	  the	  two	  groups	  does	  not	  change,	  with	  the	  early	  treatment	  group	  averaging	  485	  PTSD-­‐free	  days,	  in	  comparison	  to	  the	  later	  treatment	  group	  averaging	  469	  PTSD-­‐free	  days.	  	  	   The	  GLM	  model	  presented	  in	  Table	  7.20	  shows	  several	  factors	  associated	  with	  PTSD-­‐free	  days,	  such	  as	  ethnicity	  and	  follow-­‐up	  date,	  which	  are	  positively	  associated	  with	  PTSD-­‐free	  days,	  meaning	  that	  again	  white	  British	  participants	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and	  participants	  followed-­‐up	  at	  the	  later	  date	  reported	  a	  higher	  number	  of	  PTSD-­‐free	  days	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  Injured	  participants	  and	  ones	  with	  psychiatric	  comorbidity,	  on	  the	  other	  hand,	  had	  significantly	  fewer	  PTSD-­‐free	  days	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  
7.5.4	  EQ5D	  Table	  7.22	  GLM	  on	  EQ5D	  difference	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=101	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  EQ5D	  at	  treatment	  start	   -­‐0.67***(-­‐0.83,	  -­‐0.51)	  Males	  relative	  to	  females	   -­‐0.03	  (-­‐0.11,	  0.05)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   0.03	  (-­‐0.50,	  0.12)	  Q1.	  Injured?	   -­‐0.08*(-­‐0.17,	  0.00)	  Q2.	  Thought	  you	  might	  be	  injured/killed?	   0.07(-­‐0.06,	  0.49)	  Q3.	  Witnessed	  injury	  or	  death?	   -­‐0.04(-­‐0.14,	  0.04)	  Timing	  of	  follow-­‐up	   0.00	  (-­‐1.49,	  0.10)	  Treatment	  start	  date	   -­‐0.00	  (-­‐0.77,	  0.11)	  Psychiatric	  comorbidity	   -­‐0.13***(-­‐1.48,	  -­‐0.21)	  CBT	   0.04(-­‐0.24,	  0.35)	  Constant	  	  	  	   0.43***	  (0.21,	  0.66)	  Link	  function	   Identity	  Distributional	  family	   Gauss	  Park	  test	  approved	  Gauss	  distribution.	  The	  average	  predicted	  pre-­‐	  and	  post-­‐treatment	  difference	  in	  EQ5D	  score	  for	  the	  early	  treatment	  group	  is	  0.17	  (0.10-­‐0.23),	  and	  0.16	  for	  the	  later	  treatment	  group	  (0.10-­‐0.22).	  	  The	  GLM	  model	  presented	  in	  Table	  7.22	  shows	  two	  significant	  factors	  associated	  with	  the	  EQ5D	  score	  difference:	  the	  EQ5D	  score	  at	  treatment	  start	  and	  psychiatric	  comorbidity	  were	  both	  negatively	  associated	  with	  EQ5D	  score	  difference,	  meaning	  that	  participants	  with	  lower	  EQ5D	  at	  the	  start	  of	  the	  treatment	  achieved	  larger	  EQ5D	  score	  difference	  i.e.	  reported	  a	  greater	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improvement	  in	  quality	  of	  life,	  and	  the	  same	  is	  true	  for	  participants	  with	  psychiatric	  comorbidity.	  	  However,	  there	  was	  no	  statistically	  significant	  difference	  in	  a	  pre-­‐	  and	  post-­‐treatment	  EQ5D	  scores	  between	  the	  early	  and	  later	  treatment	  groups.	  From	  a	  theoretical	  point	  of	  view,	  the	  EQ5D	  is	  the	  most	  appropriate	  measure	  for	  the	  analysis,	  as	  it	  introduces	  information	  on	  societal	  willingness	  to	  pay	  for	  improvement.	  	  However,	  the	  decision	  not	  to	  use	  QALYs	  to	  calculate	  ICERs	  and	  CEACs	  was	  guided	  by	  concerns	  over	  the	  quality	  of	  QALY	  data,	  which	  was	  obtained	  by	  converting	  the	  SF-­‐12	  scores	  into	  EQ5D.	  	  Initially,	  the	  study	  used	  the	  EQ5D	  measure	  due	  it	  having	  a	  short	  and	  user-­‐friendly	  format,	  however,	  soon	  into	  the	  evaluation	  study	  we	  realised	  that	  this	  instrument	  was	  not	  discriminating	  between	  participants	  with	  different	  needs	  and	  scores	  on	  BDI	  and	  PDS	  questionnaires	  and	  decided	  to	  replace	  it	  with	  the	  SF-­‐12	  questionnaire.	  	  The	  algorithm	  developed	  by	  the	  HERC-­‐enabled	  transformation	  of	  the	  SF-­‐12	  scores	  back	  to	  the	  EQ5D	  in	  order	  to	  avoid	  sample	  size	  reduction.	  	  Finally,	  as	  I	  was	  reaching	  the	  thesis’	  word	  limit,	  in	  consultation	  with	  my	  supervisors,	  I	  decided	  only	  to	  include	  data	  on	  depression	  and	  PTSD	  outcome	  measures	  in	  the	  economic	  evaluation.	  
7.6	   ICER	  calculations	  Table	  7.23	  Adjusted	  outcomes	  and	  costs	  for	  early	  and	  later	  treatment	  groups	  based	  on	  the	  multivariate	  regression	  analyses	  presented	  in	  subchapters	  7.4	  
and	  7.5	  
	   Early	  treatment	  group	  (N=53)	  	  
	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  95%	  	  CI	  	  	  
Later	  treatment	  group	  
(N=50)	  
	  	  	  	  
M	  	  	  	  	  	  	  	  	  	  	  95%	  CI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
P	  	  	  	  	  
	  
	  
p	  
Outcome	  measures	  (treatment	  end	  scores)	   	   	   	  BDI	  end	   10.69	   1	  0.4-­‐13.9	   8.62	   5	  	  	  5.7-­‐7.9	   0.07	  PDS	  end	   11.08	   88.98-­‐14.78	   8.47	  	  	  	  	  	   5.3-­‐8.1	   0.91	  EQ5D	  fup	   	  	  	  0.82	   00.75-­‐0.88	   0.81	   0.75-­‐0.87	   0.89	  
Outcome	  measures	  (end-­‐start	  difference)	   	   	   	  BDIe-­‐s	   -­‐13.78	  	  1	  -­‐16.76,-­‐10.63	   -­‐9.58	  	   5	  	  	  -­‐12.10,-­‐6.22	   0.04	  PDSe-­‐s	   -­‐19.38	  	  1-­‐20.68,-­‐12.33	   -­‐14.73	   -­‐22.26,-­‐14.65	   0.04	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EQ5De-­‐s	   	  	  	  	  0.17	   0	  0.10	  –	  0.28	   	  	  	  0.16	   0.06	  –	  0.23	   0.52	  
Outcome	  measures	  (depression	  and	  PTSD	  free	  days)	   	   	  DFD(BDI)	   265.38	   1271.2-­‐354.9	   314.58	   201.8-­‐347.4	   0.67	  PTSDFD(PDS)	   430.38	  	  	  	  3430.2-­‐539.4	   511.58	   417.1-­‐521.3	   0.71	  
Costs	   	   	   	   	   	  Total	  cost	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  24530.8	   	  11448	  -­‐	  37086	   9606.3	  	   4924	  -­‐	  14653	   0.02	  Direct	  cost	   1966.1	   	  712.9	  -­‐	  3221.1	   965.9	   352	  -­‐	  1410	   0.45	  ST	  total	  cost	   4697.4	   	  3123	  -­‐	  3879	   3277.4	   3222	  -­‐	  3897	   0.03	  NHS	  costs	   1503.7	   	  456.0	  -­‐	  2521.50	   735.69	   203.4	  –	  1221.9	   0.23	  Voluntary	  sector	   526.4	   	  141.8	  –	  910.3	   122.6	   51.1	  –	  193.4	   0.53	  Private	  sector	   451.77	   348.2	  -­‐	  554.4	   287.12	   219.3	  –	  355.6	   0.49	  	   After	  adjusting	  for	  the	  same	  set	  of	  covariates,	  the	  only	  statistically	  significant	  change	  between	  the	  early	  and	  later	  treatment	  groups	  is	  for	  costs	  associated	  with	  the	  use	  of	  the	  ST	  programme	  and	  for	  the	  total	  cost	  category,	  as	  presented	  in	  Table	  7.23.	  	  The	  early	  treatment	  group	  has	  on	  average	  2.5	  times	  higher	  costs	  in	  comparison	  to	  the	  later	  treated	  group	  when	  adjusting	  for	  participant,	  exposure	  and	  treatment	  related	  factors.	  	  Although	  other	  adjusted	  average	  group	  costs	  are	  not	  statistically	  different,	  for	  all	  categories	  apart	  from	  the	  ST	  programme	  costs	  early	  treated	  participants	  reported	  higher	  average	  costs.	  	  There	  was	  no	  statistical	  difference	  between	  adjusted	  end	  treatment	  outcome	  scores,	  although	  again,	  the	  early	  treatment	  group	  reported	  on	  average	  higher	  BDI	  and	  PDS	  end	  scores	  indicating	  more	  symptoms.	  	  There	  was	  no	  difference	  in	  follow-­‐up	  EQ5D	  scores	  between	  groups,	  or	  in	  difference	  between	  score	  at	  start	  and	  treatment	  follow-­‐up.	  Both	  treatment	  groups	  achieved	  large	  treatment	  effects.	  	  Although	  there	  was	  no	  statistically	  significant	  difference	  between	  the	  early	  and	  later	  treatment	  groups	  between	  start	  and	  end	  treatment	  scores,	  the	  early	  treatment	  group	  reported,	  on	  average,	  larger	  adjusted	  score	  differences	  for	  both	  BDI	  and	  PDS	  measures.	  	  This	  is	  reflected	  in	  reliable	  and	  clinically	  significant	  changes	  calculations	  as	  well,	  and	  is	  due	  to	  the	  early	  treatment	  group	  reporting	  higher	  average	  treatment	  start	  scores	  and	  therefore	  more	  ‘leverage’	  for	  change.	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In	  both	  groups,	  around	  40%	  of	  participants	  achieved	  both	  clinically	  and	  statistically	  significant	  change	  on	  BDI,	  and	  60%	  of	  participants	  achieved	  the	  same	  on	  PDS.	  	  On	  the	  other	  hand,	  reliable	  clinical	  improvement	  was	  achieved	  by	  a	  larger	  number	  of	  participants	  in	  the	  early	  treatment	  group,	  56%	  for	  BDI	  and	  74%	  for	  PDS,	  in	  comparison	  to	  40%	  on	  BDI	  and	  65%	  on	  PDS	  for	  later	  treatment	  group.	  The	  early	  treatment	  group	  had,	  on	  average,	  lower	  number	  of	  both	  PTSD-­‐free	  and	  depression-­‐free	  days.	  	  Although	  the	  difference	  was	  not	  statistically	  significant	  it	  is	  numerically	  quite	  big:	  the	  later	  group	  averaged	  50	  depression-­‐free	  and	  81	  PTSD-­‐free	  days	  more	  than	  the	  early	  treatment	  group.	  	  Looking	  at	  total	  cost,	  including	  societal	  costs,	  it	  costs	  £304	  to	  achieve	  an	  additional	  depression-­‐free	  day	  and	  £184	  for	  an	  additional	  PTSD-­‐free	  day	  for	  participants	  treated	  early	  in	  comparison	  to	  those	  treated	  later.	  	  When	  only	  the	  ST	  programme	  costs	  are	  considered,	  there	  is	  a	  very	  small	  numerical	  difference	  between	  the	  groups	  that	  is	  going	  in	  the	  opposite	  direction	  –	  to	  achieve	  additional	  depression-­‐free	  days	  for	  the	  later	  treatment	  group	  in	  comparison	  to	  earlier	  costs	  £3,	  while	  an	  additional	  PTSD-­‐free	  day	  costs	  £1.8	  more.	  Table	  7.24	  ICER	  calculations	  	  
ICER	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Total	  costs	  95%	  CI	  	  	  BDI	  end-­‐start	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4639.4	  (3670,	  5608)	  PDS	  end-­‐start	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5725.6	  (2281,	  9619)	  	   I	  have	  calculated	  ICER	  as	  the	  difference	  between	  costs	  of	  the	  early	  treatment	  group	  minus	  the	  later	  treatment	  group,	  divided	  by	  the	  difference	  between	  early	  and	  later	  treatment	  groups	  on	  outcome	  measure.	  ICER=	  (Cost	  earlier	  treatment	  group	  -­‐	  Cost	  later	  treatment	  group)/(Outcome	  earlier	  treatment	  group	  -­‐	  Outcome	  later	  treatment	  group)	  ICER	  calculations	  translate	  adjusted	  cost	  and	  outcomes	  reported	  in	  Table	  7.24	  in	  the	  ratios	  reporting	  additional	  cost	  and	  effect	  of	  treating	  people	  early	  rather	  than	  later.	  	  As	  suggested	  by	  Fernandez	  et	  al.	  (2005)	  citing	  Briggs	  &	  Fenn	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(1998)	  I	  have	  sampled	  with	  replacement	  cost/effect	  pairs	  based	  on	  GLM	  cost	  and	  outcome	  models	  for	  both	  comparator	  groups,	  and	  calculated	  mean	  bootstrapped	  estimates	  for	  costs	  and	  effects.	  	  It	  was	  important	  to	  estimate	  cost/effectiveness	  pairs	  in	  order	  to	  preserve	  covariance	  or	  pair-­‐specific	  correlations	  between	  them	  and	  achieve	  more	  robust	  predictions	  (Gray	  et	  al.,	  2007).	  	  Following	  on	  from	  this,	  I	  have	  calculated	  1000	  bootstrap	  replications	  of	  the	  ICER,	  and	  plotted	  bootstrapped	  estimates	  in	  the	  cost-­‐effectiveness	  plane	  to	  present	  confidence	  surfaces	  for	  the	  ICER.	  	  I	  have	  based	  the	  ICER	  calculation	  on	  differences	  between	  start	  and	  end	  scores	  for	  BDI	  and	  PDS	  measures,	  as	  the	  models	  suggested	  significant	  differences	  between	  early	  and	  later	  treatment	  groups	  in	  treatment	  gains	  for	  both	  outcome	  measures.	  	  I	  have	  used	  the	  same	  perspective	  for	  both	  costs	  and	  outcomes.	  The	  X-­‐axis	  on	  Figures	  7.6	  and	  7.7	  shows	  differences	  between	  the	  groups	  in	  the	  outcome	  measures	  (BDI,	  PDS,	  EQ5D).	  	  These	  are	  calculated	  as	  difference	  on	  the	  start	  and	  end	  scores	  for	  the	  early	  group	  minus	  the	  difference	  between	  start	  and	  end	  scores	  for	  the	  later	  treatment	  group.	  The	  Y-­‐axis	  depicts	  the	  difference	  in	  costs	  between	  early	  and	  later	  treatment	  groups	  (i.e.	  cost	  early	  treatment	  group	  minus	  cost	  later	  treatment	  group).	  	  Looking	  at	  the	  scatterplots	  for	  differences	  on	  the	  BDI	  measure	  for	  total	  costs,	  the	  majority	  of	  the	  bootstrapped	  estimates	  are	  placed	  in	  the	  north-­‐west	  quadrant	  of	  the	  cost-­‐effectiveness	  plane,	  indicating	  that	  treating	  participants	  early	  is	  both	  costlier	  and	  more	  effective	  (Figure	  7.6).	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Figure	  7.6	  Scatterplot	  of	  differences	  on	  BDI	  measure	  for	  total	  costs	  between	  early	  and	  later	  treatment	  groups	  
	  Figure	  7.7	  Scatterplot	  of	  difference	  on	  PDS	  measure	  for	  total	  costs	  between	  early	  and	  later	  treatment	  groups	  
	  A	  potential	  conclusion	  from	  the	  ICER	  calculation	  is	  that	  it	  is	  both	  costlier	  and	  more	  effective	  to	  treat	  participants	  early	  when	  overall	  societal	  costs	  are	  taken	  into	  account,	  and	  by	  looking	  at	  the	  difference	  between	  the	  start	  and	  end	  outcome	  score.	  	  However,	  when	  looking	  at	  the	  difference	  in	  the	  outcome	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measure	  at	  the	  end	  of	  the	  treatment,	  there	  is	  no	  statistically	  significant	  difference	  between	  the	  groups	  and	  the	  conclusion	  is	  that	  it	  is	  less	  expensive	  to	  treat	  participants	  later.	  	  Another	  possible	  interpretation	  of	  the	  results	  could	  be	  that	  although	  there	  is	  no	  difference	  in	  the	  outcome	  measures	  at	  the	  end	  of	  treatment	  between	  the	  early	  and	  later	  treatment	  groups,	  by	  treating	  individuals	  early	  we	  are	  avoiding	  large	  societal	  costs	  due	  to	  productivity	  loss	  becoming	  even	  larger.	  	  The	  cost-­‐effectiveness	  acceptability	  curve	  (CEAC)	  helps	  in	  deciding	  whether	  additional	  units	  of	  improvement	  on	  an	  outcome	  measure	  justifies	  the	  associated	  cost.	  	  The	  CEAC	  shows	  the	  probability	  that	  an	  intervention	  is	  cost-­‐effective	  compared	  with	  the	  alternative,	  given	  the	  observed	  data,	  and	  for	  a	  range	  of	  values	  a	  decision-­‐maker	  is	  willing	  to	  pay	  (Fenwick	  &	  Byford,	  2005).	  Figures	  7.8	  and	  7.9	  present	  CEACs	  curves	  for	  the	  total	  cost	  category.	  	  WTP	  thresholds	  have	  been	  chosen	  purely	  as	  an	  example;	  they	  are	  not	  based	  on	  any	  theoretical	  or	  practical	  underpinning.	  	  The	  CEACs	  show	  that	  willingness	  to	  pay	  (WTP)	  £5000	  per	  unit	  of	  improvement	  probability	  of	  cost-­‐effectiveness	  of	  the	  intervention	  does	  not	  exceed	  50%	  for	  PDS	  and	  60%	  for	  BDI.	  	  	  Figure	  7.8	  CEAC	  for	  PDS	  score	  difference	  and	  total	  costs	  
	  Figure	  7.9	  CEAC	  for	  BDI	  score	  difference	  and	  total	  costs	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  Table	  7.25	  Cost	  per	  clinically	  significant	  change	  
	  	  
Early	  treatment	  group	  
	  (N=53)	  
	  	  BDI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  PDS	  
Later	  treatment	  group	  	  
(N=50)	  
	  	  	  BDI	  	  	  	  	  	  	  	  	  	  	  	  	  	  PDS	  	  
Costs	   	  	   	  	   	  	   	  	  Total	  cost	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  24530.8	   30696.8	   9606.3	  	   14181.3	  Direct	  cost	   1966.1	   2460.3	   965.9	   1425.9	  ST	  total	  cost	  	   3769.4	   4716.8	   3917.4	   5783.1	  NHS	  cost	   1503.7	   1881.67	   735.7	   1086.1	  	   The	  overall	  total	  cost	  for	  a	  clinically	  significant	  change	  (including	  costs	  to	  society)	  is	  higher	  for	  the	  early	  treatment	  group,	  around	  £24	  500	  for	  BDI	  and	  £30	  000	  for	  PDS	  (Table	  7.25).	  	  The	  total	  cost	  per	  clinically	  significant	  change	  is	  almost	  double	  for	  the	  early	  treatment	  group	  in	  comparison	  to	  the	  later	  treatment	  group.	  	  A	  similar	  pattern	  is	  found	  for	  direct	  and	  NHS	  costs.	  	  However,	  when	  looking	  specifically	  at	  the	  ST	  programme	  costs,	  the	  cost	  per	  clinically	  significant	  change	  is	  almost	  identical	  for	  both	  groups.	  	  When	  looking	  at	  treatment	  cost	  only,	  the	  difference	  between	  groups	  is	  minimal,	  with	  a	  higher	  cost	  per	  unit	  PDS	  change	  for	  both	  groups.	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7.7	   Discussion	  and	  conclusion	  Individuals	  treated	  within	  the	  first	  year	  of	  the	  ST	  programme	  reported	  overall	  higher	  costs	  (up	  to	  2.5	  times	  on	  average)	  than	  individuals	  treated	  later	  in	  the	  programme.	  The	  general	  linear	  model	  confirmed	  a	  statistically	  significant	  difference	  between	  early	  and	  later	  treatment	  groups	  in	  total	  cost	  when	  controlling	  for	  age,	  gender,	  ethnicity	  and	  psychiatric	  comorbidity.	  	  The	  difference	  in	  costs	  between	  the	  two	  groups	  is	  driven	  by	  productivity	  loss-­‐related	  costs,	  i.e.	  when	  the	  total	  cost	  variable	  is	  broken	  down	  into	  cost	  categories,	  early	  and	  later	  treatment	  groups	  statistically	  differ	  only	  in	  productivity	  loss	  costs.	  	  The	  general	  linear	  model	  shows	  that	  when	  controlling	  for	  treatment,	  exposure	  and	  socio-­‐demographic	  characteristics,	  the	  early	  treatment	  group	  reported,	  on	  average,	  higher	  productivity	  loss-­‐related	  costs	  in	  comparison	  to	  the	  later	  treatment	  group.	  	  	  For	  participants	  who	  received	  treatment	  early,	  productivity	  loss	  costs	  accounted	  for	  up	  to	  75%	  of	  all	  reported	  costs,	  while	  for	  participants	  who	  received	  treatment	  more	  than	  8	  months	  after	  the	  LB	  the	  contribution	  of	  productivity	  loss	  costs	  was	  50%.	  	  For	  the	  early	  treatment	  group,	  60%	  of	  costs	  are	  due	  to	  productivity	  loss,	  while	  in	  the	  late	  treatment	  group	  unemployment	  costs	  account	  for	  60%	  of	  work	  costs.	  	  Participants	  who	  received	  treatment	  later	  reported	  a	  small	  rise	  (18%)	  in	  unemployment	  costs	  when	  compared	  to	  the	  early	  treatment	  participants.	  	  The	  GLM	  model	  on	  work	  costs	  highlighted	  treatment	  timing	  as	  the	  only	  significant	  predictor.	  	  Finally,	  a	  possible	  explanation	  for	  the	  higher	  observed	  costs	  in	  the	  early	  treatment	  group	  is	  that	  people	  were	  allocated	  early	  or	  later	  to	  treatment	  purely	  by	  chance	  or	  some	  systematic	  or	  unsystematic	  factor	  that	  has	  not	  been	  observed	  in	  the	  course	  of	  the	  evaluation.	  	  	   The	  increased	  costs	  in	  the	  early	  treatment	  group	  are	  an	  important	  and	  unexpected	  finding	  as	  my	  hypothesis	  predicted	  the	  exact	  opposite	  finding.	  	  A	  possible	  reason	  for	  this	  could	  lie	  in	  a	  couple	  of	  observed	  and	  possibly	  unobserved	  factors.	  	  In	  order	  to	  investigate	  why	  the	  early	  treatment	  group	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reported	  higher	  productivity	  costs,	  I	  have	  explored	  the	  impact	  of	  other	  variables	  such	  as	  cost	  categories	  and	  participants’	  characteristics.	  	  The	  early	  treatment	  group	  reported	  more	  hospitalisations	  and	  injuries;	  eight	  out	  of	  nine	  participants	  who	  reported	  injuries	  and	  hospitalisations	  were	  in	  this	  group,	  and	  these	  turned	  out	  to	  be	  the	  main	  drivers	  behind	  high	  productivity	  costs.	  	  This	  comes	  as	  no	  surprise	  as	  the	  ST	  programme	  obtained	  information	  on	  participants	  through	  hospital	  and	  A&E	  injured	  and	  wounded	  lists	  quite	  early	  in	  the	  programme.	  	  The	  correlation	  between	  treatment	  timing	  and	  cost	  collection	  date	  is	  positive	  and	  statistically	  significant	  (r=0.504,	  p=0.001).	  	  The	  reason	  for	  this	  lies	  in	  the	  timing	  of	  the	  evaluation	  data	  collection,	  which	  took	  place	  upon	  participants’	  completion	  of	  the	  treatment	  in	  the	  ST	  programme.	  In	  terms	  of	  treatment	  effectiveness,	  results	  demonstrate	  no	  significant	  difference	  between	  early	  and	  later	  treatment	  groups	  on	  all	  outcome	  measures	  while	  controlling	  for	  other	  factors.	  	  However,	  individuals	  who	  received	  treatment	  earlier	  in	  the	  programme	  reported,	  on	  average,	  higher	  start	  and	  final	  scores	  on	  both	  BDI	  and	  PDS	  measures,	  indicating	  more	  symptoms	  at	  the	  start	  of	  the	  treatment	  and	  worse	  treatment	  outcome.	  However,	  they	  have	  also	  achieved	  a	  more	  substantial	  improvement	  in	  outcome	  scores	  in	  comparison	  to	  the	  later	  treatment	  group.	  	  The	  pattern	  of	  more	  severe	  cases	  achieving	  on	  average	  a	  larger	  treatment	  improvement	  has	  been	  reported	  by	  Gyani	  et	  al.	  (2013)	  in	  a	  study	  looking	  at	  lessons	  from	  the	  first	  year	  of	  IAPT	  programme’s	  implementation.	  	  Predictors	  of	  achieving	  a	  clinically	  significant	  change	  on	  both	  outcome	  measures,	  as	  defined	  by	  Jacobson	  et	  al.	  (1984),	  were	  being	  white	  British	  and	  completing	  the	  treatment.	  The	  quality	  of	  economic	  evaluation	  of	  the	  ST	  programme	  depends	  on	  appropriateness	  of	  the	  comparator	  group.	  	  There	  are	  a	  couple	  of	  concerns	  and	  pending	  questions	  around	  the	  choice	  of	  the	  comparator	  group	  in	  this	  analysis,	  such	  as	  whether	  participants	  who	  started	  treatment	  more	  than	  300	  days	  after	  the	  LB	  are	  a	  valid	  proxy	  for	  the	  NHS	  PTSD	  treatment	  as	  usual	  users.	  	  Theoretically,	  all	  being	  equal,	  starting	  treatment	  later	  seems	  to	  be	  a	  valid	  proxy	  for	  people	  on	  the	  NHS	  PTSD	  treatment	  waiting	  list.	  	  However,	  there	  is	  a	  valid	  question	  as	  to	  whether	  participants	  who	  started	  treatment	  early	  are	  different	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from	  participants	  who	  started	  treatment	  later	  in	  characteristics	  other	  than	  treatment	  start	  date.	  	  Therefore,	  it	  is	  important	  to	  understand	  the	  reasons	  why	  individuals	  received	  treatment	  later,	  whether	  it	  is	  possible	  to	  control	  for	  those	  factors	  and	  whether	  they	  were	  measured	  in	  the	  first	  place.	  	  It	  is	  difficult	  to	  say	  the	  reason	  behind	  late	  entry	  to	  the	  ST	  programme,	  as	  it	  was	  not	  recorded.	  	  It	  is	  uncertain	  whether	  people	  who	  entered	  treatment	  later	  did	  so	  intentionally	  as	  they	  were	  coping	  well	  on	  their	  own	  and	  at	  some	  point	  decided	  to	  seek	  help,	  or	  because	  this	  is	  caused	  by	  late	  onset	  PTSD,	  lack	  of	  knowledge	  about	  the	  programme,	  treatment	  avoidance	  or	  receipt	  of	  alternative	  treatment	  elsewhere.	  	  	  A	  descriptive	  analysis	  identified	  differences	  between	  participants’	  characteristics	  among	  the	  two	  groups	  –	  the	  early	  treatment	  group	  had	  significantly	  more	  women,	  while	  the	  later	  treatment	  group	  had	  on	  average	  a	  higher	  number	  of	  individuals	  who	  were	  screened	  more	  than	  once.	  	  Both	  factors	  could	  contribute	  to	  the	  fact	  that	  at	  the	  start	  of	  the	  treatment	  the	  early	  treatment	  group	  had	  on	  average	  significantly	  higher	  adjusted	  and	  unadjusted	  PTSD	  and	  depression	  scores,	  which	  could	  be	  explained	  by	  the	  fact	  that	  the	  effect	  of	  natural	  recovery	  was	  not	  yet	  fully	  established	  in	  the	  early	  treatment	  group.	  	  Spontaneous	  recovery	  with	  time	  is	  well	  documented,	  as	  shown	  in	  Ehlers’	  study	  (2003).	  	  It	  is	  noticeable	  that	  after	  a	  traumatic	  event,	  the	  average	  scores	  for	  the	  exposed	  population	  spontaneously	  drop	  to	  a	  certain	  level	  without	  treatment.	  	  In	  Ehlers’	  study,	  the	  spontaneous	  recovery	  curve	  had	  a	  reversed	  sigmoid	  shape,	  and	  in	  addition	  the	  literature	  points	  out	  that	  the	  bulk	  of	  natural	  recovery	  occurs	  within	  first	  6-­‐12	  months	  after	  the	  trauma	  (Helzer	  et	  al.,	  1987;	  Kessler	  et	  al.,	  1995)	  and	  could	  potentially	  provide	  an	  explanation	  for	  the	  lower	  average	  scores	  of	  individuals	  treated	  later.	  	  Interestingly,	  although	  there	  was	  no	  significant	  difference	  in	  the	  outcome	  scores	  at	  the	  end	  of	  the	  treatment	  between	  the	  groups,	  the	  difference	  in	  scores	  appeared	  again	  at	  the	  follow-­‐up	  stage.	  	  However,	  this	  effect	  could	  be	  due	  to	  a	  reduced	  follow-­‐up	  sample	  caused	  by	  missing	  data	  on	  PDS	  and	  BDI.	  	  A	  number	  of	  participants	  did	  not	  want	  to	  go	  through	  PDS	  and	  BDI	  at	  the	  interview	  session	  due	  to	  the	  length	  of	  the	  questionnaire.	  	  They	  agreed	  to	  (e)mail	  it	  back	  instead,	  which	  then	  rarely	  happened.	  	  This	  could	  be	  due	  to	  the	  content	  of	  the	  questionnaires,	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which	  reminded	  participants	  of	  the	  traumatic	  event	  and	  may	  potentially	  have	  been	  re-­‐traumatising.	  	  A	  similar	  problem	  was	  encountered	  in	  the	  data	  collection	  process	  as	  therapists	  reported	  participants	  often	  refused	  to	  go	  through	  BDI	  and	  PDS	  measures	  prior	  to	  the	  start	  of	  each	  therapy	  session,	  which	  resulted	  in	  limited	  treatment	  progress	  monitoring	  and	  consequently	  the	  focus	  on	  fewer	  data	  collection	  points	  (assessment,	  treatment	  start	  and	  treatment	  end).	  	  The	  early	  treatment	  group	  achieved	  larger	  treatment	  gains.	  	  One	  explanation	  for	  larger	  treatment	  gains	  with	  the	  early	  treatment	  group	  could	  lie	  in	  the	  natural	  recovery	  process.	  I	  calculated	  the	  correlation	  between	  the	  extent	  of	  improvement	  on	  BDI	  and	  PDS	  outcome	  measures	  and	  the	  time	  elapsed	  between	  the	  LB	  and	  the	  start	  of	  treatment.	  	  Both	  correlations	  were	  small	  and	  positive	  but	  not	  statistically	  significant	  for	  PDS	  r(103)	  =	  0.16	  p=0.09,	  and	  significant	  at	  95%	  for	  the	  BDI,	  r(103)	  =	  0.19	  p=0.05.	  Differences	  between	  participants	  in	  early	  and	  later	  treatment	  groups	  could	  potentially	  be	  explained	  by	  the	  structure	  and	  set-­‐up	  of	  the	  ST	  programme.	  	  As	  the	  programme’s	  aim	  was	  to	  screen	  people	  for	  mental	  health	  problems	  and	  refer	  them	  for	  treatment,	  the	  differences	  among	  early	  and	  later	  groups	  could	  be	  explained	  by	  the	  ST	  programme	  being	  effective	  in	  identifying	  participants	  with	  greater	  mental	  health	  needs	  and	  treating	  them	  early.	  	  Despite	  this,	  it	  is	  difficult	  to	  control	  for	  all	  the	  factors	  behind	  the	  programme’s	  referral	  system	  and	  for	  pathways	  into	  the	  programme	  as	  they	  include	  a	  wide	  array	  of	  variables,	  from	  effectiveness	  of	  the	  referral	  pathways	  into	  the	  programme	  (timing	  of	  receipt	  of	  the	  affected	  individuals’	  details,	  effectiveness	  of	  standard	  referral	  pathways	  into	  treatment	  such	  as	  GPs	  or	  self-­‐referral,	  and	  effectiveness	  of	  the	  awareness-­‐raising	  media	  campaign),	  to	  individual	  decisions	  to	  accept	  and	  respond	  to	  screeners,	  assessment	  and	  treatment.	  	  	  A	  large	  number	  (60%)	  of	  the	  referrals	  to	  the	  ST	  programme	  came	  through	  hospital	  and	  police	  witness	  lists.	  	  Around	  60%	  (500)	  of	  total	  referrals	  to	  the	  programme	  came	  in	  the	  first	  six	  months	  after	  the	  LB,	  at	  a	  time	  when	  hospitals	  and	  Metropolitan	  police	  released	  contact	  details	  of	  the	  affected	  individuals.	  	  However,	  only	  50%	  of	  people	  referred	  the	  to	  programme	  at	  that	  stage	  were	  in	  the	  end	  referred	  to	  treatment.	  	  This	  is	  probably	  due	  to	  many	  of	  those	  referred	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early	  already	  showing	  signs	  of	  spontaneous	  recovery,	  so	  it	  was	  not	  appropriate	  to	  refer	  them	  for	  treatment.	  	  In	  the	  second	  year	  of	  the	  ST	  programme,	  the	  total	  number	  of	  referrals	  dropped	  significantly,	  but	  most	  of	  them	  were	  referred	  to	  treatment.	  	  This	  could	  have	  been	  a	  consequence	  of	  individuals	  with	  milder	  symptoms	  being	  referred	  to	  treatment	  rather	  than	  into	  monitoring	  (as	  it	  was	  the	  practice	  in	  the	  first	  year)	  when	  there	  were	  many	  referrals.	  	  Alternatively,	  individuals	  coming	  later	  to	  the	  treatment	  could	  have	  delayed	  onset	  PTSD.	  	  Referral,	  assessment	  and	  treatment	  timings	  were	  all	  positively	  correlated.	  	  Also,	  the	  analysis	  showed	  a	  couple	  of	  outliers	  without	  a	  particular	  pattern	  due	  to	  a	  small	  number	  of	  individuals	  having	  larger	  gaps	  between	  referral	  to	  the	  programme,	  assessment	  and	  treatment	  timing.	  	   It	  is	  unclear	  whether	  the	  ST	  programme	  was	  effective	  in	  recruiting	  individuals	  with	  high	  symptomatology	  early	  in	  the	  programme,	  while	  individuals	  who	  came	  later	  were	  less	  affected	  by	  mental	  ill	  health	  due	  PTSD,	  depression	  and	  travel	  phobia,	  which	  would	  indicate	  a	  self-­‐selection	  in	  the	  sample	  composition.	  	  Moreover,	  the	  difference	  between	  outcome	  scores	  for	  the	  two	  groups	  could	  be	  a	  consequence	  of	  the	  natural	  recovery.	  	  	  One	  of	  the	  potential	  conclusions	  of	  the	  cost-­‐effectiveness	  analysis	  could	  be	  that	  it	  is	  more	  cost-­‐effective	  to	  delay	  screening	  and	  treat	  participants	  later.	  	  However,	  this	  conclusion	  is	  only	  valid	  if	  the	  only	  difference	  between	  the	  two	  groups	  was	  the	  start	  of	  the	  treatment	  (early	  vs.	  late).	  All	  the	  discussed	  differences	  between	  early	  and	  later	  treatment	  groups	  point	  out	  that	  early	  and	  later	  treatment	  groups	  differ	  in	  other	  characteristics	  rather	  just	  in	  terms	  of	  the	  start	  of	  the	  treatment.	  	  There	  is	  a	  valid	  question	  as	  to	  whether	  the	  participants	  who	  received	  treatment	  later	  can	  serve	  as	  a	  valid	  comparator	  in	  the	  cost-­‐effectiveness	  analysis,	  if	  they	  could	  be	  compared	  fairly	  and	  in	  a	  way	  that	  informs	  decision	  makers.	  	  	  Alternative	  comparator	  groups	  for	  evaluating	  the	  ST	  programme	  could	  include	  individuals	  involved	  in	  a	  similar	  traumatic	  event	  who	  have	  received	  treatment	  as	  a	  part	  of	  the	  mental	  health	  response.	  	  I	  looked	  into	  comparisons	  with	  the	  9/11	  sample	  and	  the	  people	  involved	  in	  the	  Madrid	  bombings.	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However,	  there	  are	  numerous	  difficulties	  associated	  with	  this	  route,	  stemming	  from	  differences	  in	  structure,	  provision	  and	  delivery	  of	  mental	  health	  response	  programmes,	  to	  discrepancies	  in	  reporting	  and	  recording	  of	  mental	  health	  response	  outcomes	  and	  costs.	  	  For	  example,	  the	  mental	  health	  response	  after	  9/11	  did	  not	  include	  a	  single	  intervention.	  	  Due	  to	  the	  scale	  of	  the	  event,	  health	  system	  funding	  and	  mental	  health	  delivery	  factors,	  it	  consisted	  of	  a	  multitude	  of	  small	  and	  often	  isolated	  and	  in	  general	  short-­‐term	  interventions	  that	  differed	  in	  the	  type	  of	  treatment	  provided	  and	  their	  target	  audiences.	  	  Therefore,	  to	  directly	  compare	  those	  interventions	  to	  the	  ST	  programme	  would	  be	  difficult	  at	  the	  very	  least.	  	  	  The	  Madrid	  mental	  health	  response	  was	  similar	  to	  the	  one	  provided	  in	  London	  in	  terms	  of	  the	  type	  of	  treatment,	  but	  their	  response	  did	  not	  include	  systematic	  screening	  and	  follow-­‐up	  (Buesa	  et	  al.,	  2006).	  	  Furthermore,	  there	  are	  few	  publications	  on	  outcomes	  of	  the	  response	  and	  no	  information	  on	  costs	  associated	  with	  the	  response,	  which	  again	  made	  comparison	  difficult.	  	  	  Another	  potential	  source	  for	  a	  comparator	  group	  was	  the	  intervention	  delivered	  in	  Northern	  Ireland	  in	  response	  to	  terrorist	  events	  during	  the	  ‘troubles’.	  	  An	  intervention	  was	  well	  documented	  and	  evaluated	  with	  an	  RCT	  that	  compared	  immediate	  cognitive	  therapy	  with	  a	  12-­‐week	  wait	  (Duffy	  et	  al.,	  2007).	  	  However,	  comparison	  with	  the	  LB	  intervention	  is	  difficult	  due	  to	  differences	  in	  the	  treatment	  provided	  –	  cognitive	  therapy	  in	  Ireland	  and	  trauma-­‐focused	  CBT	  in	  the	  ST	  programme.	  	  Another	  problem	  lies	  in	  the	  unavailability	  of	  cost	  information,	  as	  the	  study	  did	  not	  report	  treatment,	  health	  services	  or	  societal	  costs.	  	  Another	  prospective	  candidate	  was	  intervention	  following	  the	  Omagh	  bombings	  (Gillespie	  et	  al.,	  2002),	  however	  this	  study	  reported	  only	  on	  treatment	  effects.	  My	  hypothesis	  was	  that	  the	  ST	  programme	  costs	  would	  be	  offset	  by	  the	  long-­‐term	  PTSD	  costs	  averted,	  and	  that	  the	  sooner	  the	  treatment	  was	  offered	  the	  lower	  the	  costs	  to	  the	  individuals	  and	  society	  would	  be.	  	  However,	  one	  cannot	  exclude	  the	  other	  possibility	  of	  screening	  potentially	  interfering	  with	  natural	  coping	  mechanism	  and	  re-­‐traumatising	  individuals	  by	  reminding	  them	  of	  the	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traumatic	  event,	  or	  pathologising	  their	  experience	  by	  suggesting	  people	  should	  feel	  the	  consequences	  of	  the	  traumatic	  event	  even	  months	  or	  years	  afterwards.	  	  However,	  in	  my	  view,	  the	  research	  methods	  available	  in	  this	  study	  will	  not	  allow	  us	  to	  reach	  a	  definite	  answer.	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Chapter	  8	   Screening	  for	  PTSD	  –	  benefits	  and	  barriers	  	  
8.1	   Introduction	  	  Treating	  mental	  health	  disorders	  has	  multiple	  benefits	  both	  to	  individuals,	  in	  terms	  of	  reduced	  suffering	  and	  enhanced	  quality	  of	  life,	  and	  to	  society,	  in	  terms	  of	  increased	  employment	  and	  savings	  to	  health	  care	  costs	  (Layard	  et	  al.,	  2007;	  Knapp,	  2003).	  	  There	  are	  other	  benefits	  to	  the	  Exchequer,	  including	  savings	  on	  incapacity	  benefits	  and	  higher	  tax	  receipts.	  	  It	  has	  been	  estimated	  that,	  due	  to	  the	  loss	  of	  output,	  the	  cost	  of	  depression	  and	  anxiety	  is	  £17	  billion	  per	  year	  in	  the	  UK,	  while	  the	  cost	  of	  providing	  evidence-­‐based	  treatments	  is	  £0.6	  billion	  per	  year	  (Layard	  et	  al.,	  2007).	  	  These	  costs	  create	  an	  urgency	  to	  finding	  means	  of	  treating	  such	  disorders.	  	  	  	   Taking	  into	  account	  these	  and	  other	  considerations,	  in	  2006	  the	  Government	  introduced	  the	  Improving	  Access	  to	  Psychological	  Treatment	  (IAPT)	  programme,	  with	  the	  aim	  of	  supporting	  the	  implementation	  of	  guidelines	  from	  the	  National	  Institute	  for	  Clinical	  Excellence	  (NICE)	  for	  depression	  and	  anxiety	  disorders.	  	  The	  allocated	  funding	  of	  £173	  million	  was	  intended	  to	  enable	  the	  then	  34	  Primary	  Care	  Trusts	  to	  implement	  IAPT	  services.	  	  The	  objective	  was	  to	  produce	  an	  additional	  3600	  trained	  therapists	  and	  to	  enable	  900,000	  people	  to	  access	  treatment	  (IAPT,	  2008).	  One	  of	  the	  disorders	  covered	  by	  the	  IAPT	  programme	  was	  posttraumatic	  stress	  disorder	  (PTSD).	  	  As	  argued	  in	  earlier	  chapters,	  PTSD	  is	  a	  prevalent	  disorder	  with	  significant	  health,	  social	  and	  economic	  consequences,	  however,	  there	  are	  only	  limited	  economic	  data	  on	  its	  direct	  and	  indirect	  costs	  or	  on	  the	  costs	  of	  its	  treatment.	  	  General	  mental	  health	  or	  depression	  studies	  are	  usually	  used	  as	  proxies,	  with	  the	  consequent	  risk	  of	  misrepresenting	  –	  and	  probably	  underestimating	  –	  the	  relevant	  costs.	  PTSD	  is	  treatable	  using	  high-­‐intensity	  interventions,	  such	  as	  Eye	  Movement	  Desensitization	  and	  Reprocessing	  and	  Trauma	  Focused	  Cognitive	  Behaviour	  Therapy,	  but	  there	  is	  as	  yet	  no	  evidence	  base	  supporting	  low-­‐intensity	  interventions.	  	  Within	  the	  IAPT	  programme,	  patients	  diagnosed	  with	  PTSD	  are	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expected	  to	  be	  immediately	  referred	  for	  high	  intensity	  treatment.	  	  UK	  treatment	  guidelines	  produced	  by	  the	  National	  Institute	  for	  Clinical	  Excellence	  (NICE,	  2005)	  recommend	  trauma-­‐focused	  cognitive-­‐behavioural	  therapy	  as	  one	  of	  the	  first-­‐line	  treatments.	  	  	  The	  assumption	  that	  individuals	  with	  PTSD	  will	  be	  referred	  in	  this	  way	  can	  be	  questioned,	  however.	  	  There	  seems	  to	  be	  a	  lack	  of	  recognition	  of	  the	  nature,	  seriousness,	  and	  chronic	  nature	  of	  the	  disorder,	  both	  among	  sufferers	  themselves	  (Kessler,	  2000)	  and	  among	  UK	  general	  practitioners	  (Munro	  et	  al.,	  2003;	  Duxbury,	  2006)	  who,	  alongside	  self-­‐referral,	  are	  the	  main	  gateway	  to	  the	  IAPT	  programme.	  	  This	  finding	  was	  confirmed	  by	  the	  evaluation	  of	  the	  ST	  programme	  as	  only	  3%	  of	  the	  referrals	  to	  the	  study	  came	  from	  GPs.	  	  Surveys	  of	  professionals’	  awareness	  of	  the	  NICE	  guidelines	  for	  PTSD	  and,	  indeed,	  of	  the	  existence	  of	  PTSD	  in	  practice	  patients,	  have	  concluded	  that	  there	  is	  a	  failure	  to	  detect	  cases	  in	  both	  primary	  and	  secondary	  care.	  	  Ehlers’	  (2006)	  GP	  survey	  revealed	  that	  the	  majority	  of	  patients	  with	  PTSD	  did	  not	  receive	  or	  were	  not	  referred	  for	  psychological	  treatment,	  but	  were	  instead	  prescribed	  medication,	  usually	  SSRIs,	  contrary	  to	  the	  NICE	  guidelines.	  	  The	  impact	  of	  such	  untreated	  or	  inappropriately-­‐treated	  PTSD	  on	  the	  individuals	  and	  their	  families	  –	  and	  the	  associated	  economic	  costs	  –	  is	  unknown,	  as	  there	  has	  been	  no	  research.	  	  	  The	  difficulties	  for	  people	  with	  PTSD	  are	  likely	  to	  be	  exacerbated	  by	  factors	  associated	  with	  social	  exclusion,	  despite	  the	  fact	  that	  it	  is	  a	  key	  policy	  objective	  to	  address	  this	  issue.	  	  Adults	  with	  mental	  health	  problems,	  black	  and	  minority	  ethnic	  groups	  and	  young	  men,	  have	  been	  found	  to	  be	  among	  the	  most	  excluded	  groups	  in	  society	  (Social	  Exclusion	  Unit,	  2004).	  	  The	  stigma	  of	  mental	  health	  leads	  to	  isolation	  and	  delays	  in	  seeking	  help.	  	  Data	  from	  the	  U.S.	  (Wang	  et	  al.,	  2005)	  suggest	  that	  it	  is	  on	  average	  12	  years	  before	  a	  person	  suffering	  from	  PTSD	  receives	  any	  treatment	  for	  it,	  evidence-­‐based	  or	  not.	  	  It	  is	  possible	  that	  social	  exclusion	  may	  hinder	  people	  from	  accessing	  IAPT;	  and	  the	  programme	  may	  need	  to	  be	  adapted	  to	  take	  this	  into	  account.	  	  	  	  Due	  to	  the	  high	  prevalence	  of	  PTSD	  and	  its	  significant	  impact	  on	  individuals,	  their	  families,	  the	  health	  system	  and	  society	  as	  a	  whole,	  screening	  is	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suggested	  by	  numerous	  authors	  for	  the	  early	  detection	  and	  prevention	  of	  chronic	  PTSD	  (Liebschutz	  et	  al.,	  2007;	  Kimerling	  et	  al.,	  2006;	  Ouimette	  et	  al.,	  2007;	  Van	  Dam	  et	  al.,	  2013;	  Lang	  and	  Stein,	  2005;	  Foa	  et	  al.,	  2008;	  Breslau	  et	  al.,	  2003;	  Silove	  et	  al.,	  2009;	  Ivanov	  et	  al.,	  2012).	  	  Indeed,	  screening,	  particularly	  after	  disasters,	  is	  recommended	  by	  the	  NICE	  guidelines,	  but	  it	  has	  never	  been	  implemented	  within	  the	  primary	  care	  sector.	  	  	  Brief	  valid	  screening	  instruments	  exist	  to	  enable	  GPs	  to	  detect	  people	  with	  likely	  PTSD	  and	  refer	  them	  for	  assessment	  and	  treatment.	  	  However,	  there	  is	  insufficient	  evidence	  as	  to	  whether	  screening	  at	  the	  primary	  care	  level	  is	  a	  valid	  and	  cost-­‐effective	  pathway	  into	  treatment.	  	  The	  most	  commonly	  identified	  barriers	  to	  screening	  for	  PTSD	  in	  primary	  care	  are	  low	  awareness	  of	  the	  disorder	  among	  GPs,	  insufficient	  information	  on	  available	  screening	  tools,	  and	  GP	  concerns	  about	  doing	  harm	  and	  re-­‐traumatising	  their	  patients	  (BPS,	  2012).	  The	  main	  objective	  of	  this	  chapter	  is	  to	  consider	  the	  benefits	  from	  –	  and	  barriers	  to	  –	  introducing	  screening	  for	  PTSD	  at	  the	  level	  of	  general	  practice.	  	  This	  should	  then	  make	  it	  possible	  to	  address	  key	  questions	  about	  ensuring	  the	  successful	  implementation	  of	  the	  IAPT	  programme.	  	  The	  effects	  of	  screening	  in	  primary	  care	  will	  be	  addressed	  from	  the	  perspective	  of	  all	  potential	  stakeholders	  likely	  to	  be	  involved	  in	  establishing,	  implementing	  and	  funding	  a	  screening	  policy.	  	  Some	  qualitative	  research	  offers	  an	  important	  contribution	  to	  understanding	  the	  views	  and	  perspectives	  of	  key	  stakeholders	  on	  the	  benefits	  and	  practical	  implications	  of	  implementing	  a	  screening	  policy	  within	  the	  IAPT	  programme.	  	  	  
8.2	   Methods	  summary	  A	  small	  qualitative	  study	  was	  designed	  to	  explore	  the	  benefits	  and	  barriers	  of	  implementing	  screening	  for	  PTSD	  policy	  within	  primary	  care.	  	  Some	  potential	  stakeholders	  involved	  in	  policy	  development,	  planning,	  implementation	  and	  funding	  were	  invited	  to	  take	  part	  in	  short	  (30-­‐40	  minute)	  semi-­‐structured	  face-­‐to-­‐face	  or	  telephone	  interviews.	  	  These	  interviews	  were	  conducted	  between	  October	  2009	  and	  June	  2011.	  	  The	  questions,	  set	  out	  in	  Appendix	  C	  and	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summarised	  in	  Table	  7.1,	  explored	  the	  perspectives	  of	  each	  stakeholder,	  with	  the	  aim	  of	  providing	  a	  comprehensive	  view	  of	  the	  benefits	  and	  practicalities	  of	  introducing	  such	  policy.	  	  I	  have	  used	  directed	  qualitative	  content	  analysis	  (Hsieh	  &	  Shannon,	  2005).	  	  I	  started	  with	  a	  couple	  of	  themes	  identified	  in	  the	  Literature	  Review	  and	  added	  new	  themes	  as	  they	  emerged	  in	  the	  analysis.	  	  Validity	  of	  the	  emerging	  themes	  was	  tested	  by	  triangulation	  with	  data	  identified	  in	  the	  Literature	  Review,	  and	  exploration	  of	  participants’	  underlying	  views	  on	  the	  emerging	  themes	  and	  discussion	  of	  the	  themes.	  	  In	  total	  I	  have	  identified	  8	  themes	  in	  the	  interviews:	  
-­‐ PTSD	  prevalence	  and	  presentation,	  
-­‐ Screening	  for	  PTSD	  as	  a	  concept,	  
-­‐ General	  population	  screening	  vs.	  targeted	  screening,	  
-­‐ Screening	  setting,	  
-­‐ Screening	  protocol,	  
-­‐ PTSD	  in	  the	  context	  of	  the	  IAPT	  programme,	  
-­‐ GP	  education	  and	  training,	  
-­‐ Screening	  in	  the	  context	  of	  the	  IAPT	  programme.	  	  	  
8.3	   Improving	  Access	  to	  Psychological	  Therapies	  (IAPT)	  Programme	  The	  IAPT	  programme	  is	  an	  example	  of	  the	  direct	  translation	  of	  policy	  recommendations	  into	  practice	  (Clark,	  2011).	  	  Its	  foundations	  lie	  in	  a	  series	  of	  NICE	  guidelines	  with	  recommendations	  for	  effective	  treatments	  for	  depression	  and	  anxiety	  disorders,	  along	  with	  an	  economic	  case	  provided	  by	  a	  wide	  academic	  and	  clinical	  community,	  most	  notably	  by	  Layard	  (2006)	  and	  Layard	  et	  al.	  (2007).	  	  Layard	  and	  colleagues	  argued	  that	  the	  costs	  of	  treatment	  and	  prevention	  of	  depression	  and	  anxiety	  disorders	  would	  be	  offset	  by	  reducing	  or,	  in	  some	  cases,	  preventing	  the	  large	  costs	  associated	  with	  lost	  productivity	  and	  time	  off	  work,	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alongside	  medical	  and	  societal	  costs	  arising	  from	  the	  consequences	  of	  chronic	  disorders	  and	  their	  associated	  comorbidities.	  	  This,	  in	  itself,	  constitutes	  an	  interesting	  and,	  until	  recently,	  rare	  example	  of	  where	  health	  economics	  has	  directly	  influenced	  the	  adoption	  of	  a	  prevention-­‐oriented	  policy.	  The	  programme,	  started	  in	  late	  2008,	  is	  now	  in	  its	  last	  stage,	  outlined	  in	  two	  policy	  documents:	  No	  Health	  Without	  Mental	  Health	  (DH,	  2011a),	  and	  
Talking	  Therapies:	  Four	  Year	  Plan	  of	  Action	  (DH,	  2011b).	  	  The	  programme	  plans	  to	  expand	  from	  providing	  solely	  adult	  services	  to	  offering	  elderly	  and	  young	  people	  services	  during	  the	  final	  phase	  of	  the	  roll-­‐out,	  from	  2011	  to	  2015.	  	  Special	  attention	  is	  also	  given	  to	  chronic	  physical	  health	  problems,	  medically	  unexplained	  symptoms	  that	  often	  present	  alongside	  depression,	  and	  targeting	  people	  with	  severe	  mental	  illness	  (DH,	  2011).	  	  The	  main	  principle	  underpinning	  the	  programme,	  as	  outlined	  in	  the	  
Implementation	  Plan	  (DH,	  2008),	  is	  the	  introduction	  and	  implementation	  of	  a	  stepped	  care	  approach,	  which	  offers	  appropriate	  evidence-­‐based	  treatment	  to	  a	  range	  of	  anxiety	  disorders	  in	  a	  “most	  effective	  and	  least	  resource	  intensive”	  way	  (Davison,	  2000,	  p.	  583).	  	  	  The	  stepped-­‐care	  treatment	  approach	  offers	  a	  flexible	  therapy	  system	  in	  which	  individuals	  can	  be	  easily	  stepped-­‐up	  or	  down	  in	  terms	  of	  treatment	  intensity	  depending	  on	  their	  diagnosis	  and	  needs.	  	  Low-­‐intensity	  interventions,	  such	  as	  computerised	  CBT,	  guided	  self-­‐help,	  behavioural	  activation	  or	  psycho-­‐educational	  groups	  (NICE,	  2009)	  are	  recommended	  for	  mild	  and	  moderate	  depression	  and	  some	  anxiety	  disorders	  such	  as	  panic	  disorder,	  GAD,	  OCD.	  	  For	  moderate	  to	  severe	  depression	  and	  PTSD,	  the	  NICE	  guidelines	  and	  stepped-­‐care	  approach	  are	  recommended	  solely	  for	  high-­‐intensity	  treatment,	  which	  consists	  of	  face-­‐to-­‐face	  CBT	  and	  or	  EMDR.	  	  	  Another	  distinctive	  feature	  of	  the	  programme,	  introduced	  to	  improve	  access,	  is	  self-­‐referral,	  alongside	  the	  standard	  GP	  point	  of	  entry.	  	  In	  order	  to	  facilitate	  a	  pathway	  to	  recovery,	  some	  IAPT	  services	  are	  supported	  by	  employment	  advisers.	  	  Another	  important	  aspect	  of	  the	  programme	  is	  monitoring	  a	  client’s	  progress,	  as	  this	  enables	  evaluating	  the	  outcomes	  and	  progress	  of	  the	  treatment.	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Therefore,	  a	  session-­‐by-­‐session	  clinical	  outcome	  monitoring	  system	  is	  introduced	  by	  employing	  the	  following	  measures:	  PHQ-­‐9	  (Kroenke	  et	  al.,	  2001)	  for	  depression,	  GAD-­‐7	  (Spitzer	  et	  al.,	  2006)	  for	  anxiety	  disorders	  and	  a	  measure	  for	  a	  specific	  anxiety	  disorder	  like	  PTSD,	  OCD,	  social	  or	  travel	  phobia	  (Richards	  &	  Suckling,	  2009).	  	  All	  collected	  data	  is	  stored	  in	  the	  IAPT	  minimum	  dataset	  (DH,	  2011),	  an	  electronic	  dataset	  available	  for	  therapists	  and	  funding	  bodies	  to	  monitor	  patient	  progress	  and	  for	  evaluation	  purposes.	  	  Before	  a	  national	  roll-­‐out,	  the	  programme	  was	  piloted	  in	  two	  demonstration	  sites	  based	  in	  PCTs	  within	  Newham	  and	  Doncaster.	  	  The	  sites	  differed	  in	  their	  approach	  and	  the	  audience	  they	  attracted.	  	  The	  Newham	  site	  focused	  predominantly	  on	  high-­‐intensity	  CBT,	  following	  the	  stepped-­‐care	  model	  where	  appropriate,	  which	  included	  low-­‐intensity	  treatments	  such	  as	  computerised	  CBT,	  guided	  self-­‐help,	  and	  psycho-­‐educational	  groups	  (Clark	  et	  al.,	  2009)	  and	  attracted	  a	  mixed	  ethnic	  community.	  	  In	  contrast,	  the	  Doncaster	  site	  focused	  on	  low-­‐intensity	  therapies,	  with	  a	  focus	  on	  guided	  self-­‐help;	  by	  adopting	  this	  approach,	  however,	  individuals	  with	  PTSD	  were	  excluded,	  as	  they	  require	  high-­‐intensity	  treatment.	  	  This	  allowed	  the	  site	  to	  manage	  a	  large	  number	  of	  cases.	   	  In	  total,	  both	  demonstration	  sites	  saw	  over	  3,500	  people	  in	  the	  first	  year.	  	  Both	  sites	  featured	  a	  session-­‐by-­‐session	  clinical	  outcome	  monitoring	  system	  as	  described	  previously	  and	  introduced	  self-­‐referral,	  with	  the	  aim	  of	  increasing	  equity	  of	  access,	  especially	  in	  the	  case	  of	  mixed	  ethnic	  communities.	  	  The	  evaluation	  of	  the	  demonstration	  sites	  was	  positive	  in	  terms	  of	  the	  number	  of	  people	  seen	  and	  the	  outcome	  monitoring,	  and	  high-­‐level	  of	  data	  completeness	  demonstrated	  large	  treatment	  effect	  sizes,	  which	  were	  maintained,	  although	  follow-­‐up	  data	  completeness	  was	  significantly	  lower	  than	  at	  post-­‐treatment	  (Clark,	  2011;	  Richards	  &	  Borglin,	  2011).	  	  	  At	  the	  end	  of	  the	  pilot	  phase,	  the	  programme	  was	  rolled	  out	  nationally	  in	  three	  waves	  of	  funding,	  the	  last	  one	  funded	  until	  2015	  when	  the	  programme	  was	  due	  to	  reach	  its	  initial	  goal	  of	  increasing	  the	  availability	  of	  evidence-­‐based	  therapies	  for	  depression	  and	  anxiety	  disorders	  throughout	  England.	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By	  2011,	  the	  UK	  Government	  had	  invested	  £309	  million	  in	  total	  to	  train	  up	  to	  3,660	  psychological	  therapists,	  60%	  providing	  high-­‐intensity	  treatment	  and	  40%	  providing	  low-­‐intensity	  treatment	  (Clark,	  2011).	  	  The	  projected	  savings	  to	  the	  public	  sector	  due	  to	  the	  roll-­‐out	  of	  the	  IAPT	  programme	  are	  over	  £700	  million,	  for	  £400	  million	  invested	  (DH,	  2011).	  	  It	  is	  expected	  that,	  as	  a	  result	  of	  the	  programme,	  50%	  of	  the	  individuals	  seen	  will	  recover	  and	  around	  25,000	  will	  move	  to	  employment	  from	  sick	  pay	  and	  state	  benefits	  (Clark,	  2011).	  	  In	  2011,	  the	  IAPT	  programme	  was	  present	  in	  around	  95%	  of	  PCTs,	  although	  there	  was	  a	  substantial	  variation	  in	  service	  provision	  between	  PCTs.	  	  Services	  were	  seeing	  310,000	  people	  each	  year	  and	  it	  was	  hoped	  to	  increase	  this	  number	  to	  900,000	  by	  2015	  (Clark,	  2011).	  	  In	  the	  next	  phase	  ending	  in	  2015,	  the	  government	  pledged	  to	  spend	  another	  £400	  million.	  	  By	  the	  end	  of	  the	  project,	  it	  is	  projected	  that	  3.2	  million	  people	  will	  have	  accessed	  the	  IAPT	  programme,	  2.6	  million	  will	  have	  completed	  a	  course	  of	  therapy	  treatment,	  of	  which	  up	  to	  1.3	  million	  will	  have	  moved	  to	  recovery	  and	  75,000	  will	  have	  returned	  to	  employment	  or	  education	  (DH,	  2011).	  The	  evaluation	  of	  the	  IAPT	  programme	  highlighted	  some	  implementation	  difficulties.	  	  These	  included	  under-­‐representation	  of	  people	  aged	  over	  65	  years	  and	  individuals	  from	  black	  and	  minority	  ethnic	  groups,	  attributed	  partially	  to	  the	  slow	  introduction	  of	  the	  self-­‐referral	  pathway.	  	  It	  was	  also	  found	  that	  there	  was	  under-­‐representation	  of	  patients	  with	  obsessive-­‐compulsive	  disorder	  (OCD),	  panic	  disorder,	  social	  phobia	  and	  agoraphobia	  and	  –	  most	  importantly	  for	  this	  study	  –	  PTSD.	  	  According	  to	  prevalence	  rates	  reported	  in	  the	  most	  recent	  Adult	  Psychiatric	  Morbidity	  Survey	  (McManus	  et	  al.,	  2007),	  it	  was	  expected	  that	  one	  third	  of	  patients	  would	  present	  with	  these	  diagnoses,	  including	  8%	  with	  PTSD.	  	  Yet	  records	  show	  that	  less	  than	  10%	  of	  patients	  actually	  presented	  with	  those	  diagnoses.	  	  The	  problem	  of	  under-­‐representation	  of	  PTSD	  patients	  was	  of	  a	  particular	  interest	  to	  this	  study.	  	  A	  part	  of	  the	  explanation	  could	  lie	  in	  the	  specific	  characteristics	  of	  PTSD	  as	  a	  diagnosis,	  such	  as	  avoidance	  of	  any	  stimuli	  that	  remind	  a	  person	  of	  their	  trauma	  or	  bring	  out	  the	  traumatic	  memory.	  	  This	  is	  a	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frequent	  coping	  mechanism	  for	  people	  suffering	  from	  PTSD,	  which	  makes	  them	  less	  likely	  to	  report	  any	  concerns	  to	  their	  GP.	  	  Moreover,	  people	  affected	  by	  PTSD	  are	  more	  likely	  to	  present	  with	  physical	  health	  issues	  or	  issues	  which	  are	  comorbid	  to	  PTSD,	  such	  as	  alcoholism	  or	  depression	  (Marciniak,	  2004).	  	  Another	  problem	  lies	  in	  a	  low	  recognition	  among	  GPs	  both	  of	  PTSD	  and	  of	  the	  available	  evidence-­‐based	  treatments	  recommended	  by	  NICE	  guidelines	  (Ehlers,	  2009).	  	  This	  is	  of	  a	  particular	  concern	  due	  to	  the	  key	  role	  of	  the	  GP	  as	  a	  gatekeeper	  to	  treatment,	  which	  is	  still	  a	  dominant	  pathway	  into	  treatment	  (even	  though	  the	  IAPT	  encourages	  self-­‐referral).	  	  This	  concern	  was	  reflected	  in	  the	  
Commissioning	  Talking	  Therapies	  2011/2012	  Toolkit	  (DH,	  2011	  c),	  a	  document	  published	  by	  DH	  that	  clearly	  outlined	  arguments	  of	  investing	  in	  evidence-­‐based	  treatments	  for	  depression	  and	  anxiety	  disorders.	  	   For	  all	  these	  reasons,	  exploring	  the	  pathways	  into	  treatment	  for	  people	  with	  PTSD	  seemed	  an	  important	  topic	  to	  be	  explored,	  particularly	  in	  the	  context	  of	  the	  IAPT	  programme.	  	  However,	  due	  to	  lack	  of	  funding,	  the	  study	  was	  not	  undertaken	  as	  originally	  planned	  and	  had	  to	  be	  replaced	  by	  a	  small	  qualitative	  study	  examining	  the	  benefits	  and	  barriers	  to	  screening	  for	  PTSD.	  	  The	  study	  methodology	  and	  findings	  are	  presented	  in	  the	  next	  section.	  	  
8.4	   Screening	  for	  PTSD:	  Benefits	  and	  Barriers	  –	  qualitative	  study	  findings	  
8.4.1	  PTSD	  prevalence	  and	  presentation	  	  Most	  of	  the	  GPs	  interviewed	  reported	  that	  they	  do	  not	  see	  PTSD	  cases	  very	  often,	  although	  the	  prevalence	  of	  PTSD	  was	  higher	  in	  those	  GP	  settings	  that	  see	  many	  refugees	  and	  asylum	  seekers;	  one	  suggested	  two	  to	  three	  times	  a	  year.	  The	  GPs	  in	  general	  acknowledged	  that	  PTSD	  is	  under-­‐diagnosed	  in	  general	  practice,	  some	  suggesting	  that	  this	  was	  due	  to	  being	  disguised	  by	  co-­‐morbidity	  or	  to	  low	  recognition	  of	  the	  disorder	  by	  GPs:	  PTSD	  is	  incredibly	  under	  diagnosed,	  really	  under	  diagnosed.	  (GP	  3)	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I	  do	  think	  that	  there	  is	  something	  distinctly	  and	  discretely	  different	  about	  PTSD	  in	  comparison	  to	  other	  anxiety	  disorders.	  	  It	  is	  often	  masked	  in	  presentation.	  (GP	  4)	  It	  is	  not	  really	  a	  condition	  high	  in	  the	  mind	  of	  a	  GP	  unless	  it	  is	  very	  obvious,	  such	  as	  person	  is	  very	  distressed.	  (GP	  5)	  	   Two	  GPs	  expressed	  scepticism	  about	  PTSD	  as	  a	  diagnostic	  category	  and	  a	  concern	  about	  the	  over-­‐medicalisation	  of	  a	  normal	  mechanism	  for	  coping	  with	  trauma:	  	  I	  have	  problems	  with	  a	  label	  like	  PTSD	  –	  I	  prefer	  to	  see	  it	  as	  a	  psychological	  distress,	  rather	  than	  saying	  this	  is	  the	  case	  of	  PTSD	  and	  it	  must	  be	  treated	  in	  following	  way.	  (GP	  6)	  My	  worry	  is	  about	  PTSD	  as	  a	  diagnosis,	  looking	  at	  Sommerfield’s	  scepticism	  about	  PTSD	  as	  an	  entity.	  	  I	  think	  I	  share	  some	  of	  that,	  it	  is	  rather	  reductionist	  seeing	  people	  as	  a	  tick-­‐box	  of	  things	  they	  have	  or	  haven’t	  got.	  Make	  them	  fill-­‐in	  a	  tick-­‐box	  might	  make	  them	  not	  come	  back.	  	  What	  they	  need	  is	  to	  share	  a	  story,	  develop	  a	  relationship.”	  (GP	  7)	  With	  regard	  to	  PTSD	  presentation,	  the	  GPs	  reported	  various	  cases	  of	  complex	  and	  single-­‐incident	  traumas,	  and	  different	  presentations	  varying	  from	  psychological	  to	  physical	  symptoms:	  	  The	  commonest	  way	  would	  be	  people	  coming	  in	  with	  anxiety,	  depression,	  mixed	  picture,	  who	  tell	  us	  about	  particular	  incident	  that	  trigger	  different	  feelings.	  (GP	  7)	  	   Access	  to	  services	  by	  high-­‐risk	  groups,	  such	  as	  veterans,	  refugees	  and	  asylum	  seekers	  were	  discussed,	  along	  with	  differentiation	  between	  single-­‐incident	  and	  multiple	  trauma	  exposure:	  	  Refugees	  and	  asylum	  seekers	  –	  I	  would	  almost	  assume	  they	  have	  PTSD	  if	  they	  have	  been	  through	  situations	  like	  that.	  	  Difficult	  because	  they	  often	  don’t	  speak	  English	  and	  are	  often	  transient,	  difficult	  to	  organise	  treatment	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for	  them,	  they	  might	  come	  to	  the	  practice	  one	  to	  two	  times	  and	  then	  they	  are	  off	  somewhere	  else.	  (GP	  1)	  Veterans	  access	  the	  services	  on	  average	  ten	  years	  later.	  We	  often	  see	  people	  who	  are	  abused	  in	  childhood	  for	  whom	  this	  is	  the	  first	  time	  they	  accessed	  the	  services.	  	  Two	  reasons	  –	  stigma	  and	  people	  avoid	  thinking	  or	  talking	  about	  it.	  Single	  incident	  people	  come	  up	  sooner,	  multiple	  traumas	  access	  the	  services	  later.	  (CL	  1)	  
8.4.2	  Screening	  for	  PTSD	  as	  a	  concept	  	   All	  interviewed	  clinicians	  agreed	  that	  screening	  for	  PTSD	  was	  an	  interesting	  proposition	  and	  ‘worth	  trying’	  despite	  practical	  difficulties:	  in	  their	  view,	  screening	  was	  a	  good	  way	  to	  reach	  individuals	  who	  would	  not	  otherwise	  access	  services,	  due	  to	  the	  low	  detection	  of	  the	  disorder	  by	  GPs,	  and	  also	  served	  to	  obtain	  information	  on	  the	  prevalence	  of	  PTSD	  and	  complex	  PTSD.	  	  [Screening	  will	  help	  in]	  having	  a	  clearer	  idea	  about	  prevalence	  of	  PTSD	  alongside	  a	  clearer	  idea	  on	  prevalence	  of	  complex	  trauma	  cases.	  (CL	  2)	  Most	  people	  who	  suffer	  from	  these	  types	  of	  disorders	  don’t	  come	  to	  the	  services	  –	  they	  suffer	  and	  very	  little	  attempt	  is	  made	  to	  find	  them	  and	  offer	  them	  treatment.	  (CL	  1)	  Good	  incentive	  to	  get	  people	  in	  the	  treatment	  early,	  because	  the	  consequences	  are	  not	  just	  for	  the	  patient	  and	  the	  family,	  but	  a	  burden	  to	  the	  health	  system	  as	  a	  whole.	  (PD	  2)	  	   Furthermore,	  screening	  would	  enable	  professionals	  to	  distinguish	  people	  suffering	  from	  PTSD	  from	  those	  suffering	  other	  co-­‐morbid	  conditions	  arising	  from	  exposure	  to	  traumatic	  events	  and	  ensure	  appropriate	  treatment	  is	  provided:	  	  I	  suspect	  a	  lot	  of	  PTSD	  patients	  are	  lumped	  in	  with	  depression	  and	  get	  antidepressants.	  (GP	  5)	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In	  contrast,	  most	  of	  the	  GPs	  expressed	  a	  more	  conservative	  approach	  towards	  screening.	  They	  argued	  the	  need	  for	  robust	  evidence	  on	  the	  effectiveness	  on	  benefits	  of	  screening:	  	  	  I	  think	  ‘screening’	  is	  probably	  not	  the	  right	  word	  to	  use.	  ‘Case	  finding’	  rather	  than	  ‘screening’	  is	  more	  appropriate.	  (GP	  3)	  There	  needs	  to	  be	  hard	  evidence	  to	  support	  this.	  (GP	  1,	  GP	  2,	  GP	  5)	  	  	  	   One	  GP	  actively	  opposed	  the	  concept	  of	  screening,	  along	  with	  a	  proactive	  outreach	  for	  PTSD	  cases	  within	  the	  general	  population,	  with	  the	  aim	  of	  providing	  evidence-­‐based	  treatment.	  	  He	  expressed	  a	  particular	  concern	  in	  regard	  to	  “over-­‐medicalisation	  of	  the	  normal	  human	  behaviour.”	  My	  default	  assumption	  is	  that	  screening	  will	  create	  more	  cases,	  you	  might	  be	  perversely	  doing	  harm.	  Let	  people	  come	  to	  their	  GP.	  	  Why	  should	  avoidance	  be	  a	  pathological	  response,	  maybe	  it	  is	  a	  natural	  coping	  response?....I	  am	  sure	  it	  is	  a	  good	  treatment	  but	  it	  is	  not	  a	  magical	  solution	  –	  you	  will	  be	  cured	  if	  only	  I	  can	  persuade	  you	  to	  have	  six	  sessions	  of	  CBT	  –	  it	  does	  not	  justify	  me	  to	  go	  out	  there	  and	  case	  find	  and	  offer	  treatment.	  (GP	  1,	  GP	  4)	  Some	  GPs	  drew	  a	  parallel	  with	  screening	  for	  depression,	  expressing	  scepticism	  about	  screening	  for	  a	  disorder	  with	  an	  even	  lower	  prevalence	  rate:	  Screening	  for	  depression,	  which	  is	  much	  more	  common,	  it	  is	  still	  not	  effective.	  (GP	  6)	  You	  would	  get	  a	  poor	  return	  if	  you	  try	  this	  kind	  of	  approach	  with	  PTSD.	  (GP	  6)	  
8.4.3	  General	  population	  screening	  vs.	  targeted	  screening	  	   On	  the	  issue	  of	  general	  population	  (‘blanket’)	  screening	  vs.	  targeted	  (‘high	  risk	  population’)	  screening,	  GPs	  were	  generally	  in	  favour	  of	  the	  latter:	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Certainly,	  if	  you	  can	  correctly	  identify	  who	  is	  high	  risk,	  then	  it	  would	  be	  more	  appropriate	  to	  screen	  within	  that	  high	  risk	  group.	  (GP	  3)	  For	  certain	  groups	  of	  people,	  we	  should	  automatically	  be	  asking	  about	  the	  possibility	  of	  PTSD,	  for	  instance	  people	  with	  alcohol	  presentations.	  	  Do	  you	  screen	  the	  population,	  only	  high	  risk	  groups,	  everyone	  whom	  casualty	  department,	  as	  a	  part	  of	  your	  patient	  medical?	  (GP	  4)	  	  The	  rule	  of	  thumb	  generally	  is	  that	  screening	  is	  often	  done	  in	  high	  risk	  groups,	  rather	  than	  blanket	  screening.	  	  People	  need	  to	  think	  who	  are	  the	  higher	  risk	  group	  who	  would	  benefit	  from	  intervention.	  (GP	  3)	  In	  contrast,	  one	  clinician	  pointed	  out	  that	  the	  advantage	  of	  screening	  the	  general	  population	  lies	  in	  “reaching	  a	  completely	  different	  group	  not	  otherwise	  identified	  as	  having	  treatable	  problems”.	  (CL	  2)	  	   A	  number	  of	  factors	  were	  identified	  as	  necessary	  for	  the	  successful	  implementation	  and	  delivery	  of	  PTSD	  screening,	  including	  sufficient	  resources	  for	  screening	  and	  referral	  training,	  good	  liaison	  with	  specialist	  services,	  a	  clear	  referral	  pathway	  and	  a	  well-­‐integrated	  assessment	  and	  treatment	  mechanism:	  It	  would	  not	  be	  acceptable	  to	  screen	  people	  and	  not	  provide	  them	  with	  feedback	  and	  move	  them	  on	  to	  the	  treatment.	  	  It	  is	  important	  to	  ensure	  resources	  are	  there	  to	  deal	  with	  any	  morbidity	  discovered	  within	  the	  process.	  (CL	  2)	  Work	  closely	  with	  services,	  with	  a	  clear	  message	  that	  if	  people	  did	  screen	  positive,	  there	  was	  a	  service	  they	  could	  get	  help	  from,	  and	  to	  very	  much	  encourage	  that	  pathway.	  (PD	  2)	  Another	  question	  is	  how	  practical	  this	  would	  be.	  It	  would	  need	  to	  be	  a	  very	  simple	  scheme	  or	  focused	  on	  particular	  populations.	  (GP	  1)	  	   In	  addition,	  the	  issues	  of	  specificity,	  sensitivity,	  and	  the	  potential	  to	  administer	  the	  screening	  questionnaires	  in	  multiple	  languages	  for	  non-­‐English	  speaking	  groups	  were	  regarded	  as	  essential	  elements	  of	  any	  screening	  exercise.	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Furthermore,	  a	  question	  was	  raised	  about	  the	  referral	  of	  identified	  cases	  and	  the	  capacity	  of	  the	  health	  system	  to	  provide	  treatment:	  You	  need	  to	  have	  a	  very	  clear	  pathway	  on	  what	  to	  do	  if	  you	  get	  a	  positive	  screen.	  	  The	  worst	  thing	  you	  could	  do	  is	  to	  set-­‐up	  screening	  and	  if	  people	  screened	  positive,	  not	  much	  is	  going	  to	  happen.	  (PD	  2)	  	   One	  recommendation	  from	  both	  GPs	  and	  policy	  developers	  was	  to	  combine	  screening	  for	  PTSD	  with	  screening	  for	  depression	  (either	  via	  a	  short	  additional	  questionnaire	  or	  as	  an	  additional	  item	  on	  the	  PTSD	  screen).	  	  Several	  GPs	  suggested	  that	  individuals	  with	  conditions	  co-­‐morbid	  with	  PTSD	  or	  in	  a	  high-­‐risk	  group	  for	  PTSD	  should	  be	  checked	  for	  symptoms	  of	  PTSD:	  If	  we	  are	  already	  handing	  out	  the	  PHQ9,	  we	  might	  also	  do	  a	  simple	  screen	  for	  PTSD,	  as	  long	  as	  it	  is	  simple	  to	  do.	  (GP	  1)	  For	  anyone	  who	  gets	  a	  new	  diagnosis	  of	  depression	  and	  anxiety	  (there)	  should	  be	  an	  automatic	  question	  about	  PTSD.	  	  A	  similar	  screen	  could	  be	  [developed]	  for	  people	  with	  alcohol	  or	  domestic	  violence	  problems.	  	  In	  other	  words,	  pick-­‐up	  groups	  who	  are	  already	  presenting	  in	  one	  way	  or	  another	  as	  having	  a	  functional	  problem	  and	  then	  look	  to	  screen	  more	  selectively	  for	  PTSD.	  (GP	  4)	  If	  it	  is	  a	  part	  of	  the	  questionnaire,	  which	  is	  a	  diagnostic	  screen	  such	  as	  PHQ9,	  it	  could	  be	  genuinely	  helpful	  if	  it	  was	  used	  as	  a	  diagnostic	  screen,	  if	  it	  was	  used	  to	  help	  GPs	  make	  a	  [diagnosis]	  perhaps	  they	  would	  not	  be	  competent	  in	  making	  otherwise.	  	  But	  I	  would	  be	  thrown	  re:	  how	  to	  pick	  a	  group	  of	  people	  to	  focus	  on.	  (GP	  8,	  GP	  5)	  What	  you	  would	  like	  to	  have	  for	  PTSD	  is	  some	  trigger	  on	  the	  generic	  tool	  that	  could	  take	  you	  to	  a	  place	  where	  you	  could	  use	  your	  specific	  screening	  tool…	  If	  you	  could	  get	  one	  tool	  for	  common	  mental	  health	  and	  PTSD	  problems,	  one	  size	  fits	  all	  for	  the	  whole	  population,	  with	  sensitivity	  within	  that	  to	  drill-­‐down	  to	  people	  with	  people	  who	  trigger	  the	  risk	  factors	  around	  your	  area.	  (PD	  3)	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Some	  respondents	  raised	  the	  question	  of	  appropriateness	  of	  screening	  for	  PTSD,	  in	  comparison	  to	  other	  mental	  health	  conditions.	  If	  we	  are	  not	  doing	  it	  for	  any	  other	  aspects	  of	  primary	  care	  mental	  health,	  why	  should	  we	  do	  it	  for	  PTSD?	  (GP	  6)	  	   A	  number	  of	  arguments	  were	  made	  for	  general	  PTSD	  screening,	  including	  the	  fact	  that	  it	  is	  poorly	  recognised	  in	  general	  practice,	  that	  there	  could	  be	  long	  delays	  in	  getting	  treatment	  and	  that	  ‘avoidance	  is	  a	  part	  of	  the	  symptoms’.	  	  It	  was	  felt	  that	  there	  were	  effective	  treatments	  and	  validated	  screening	  measures,	  so	  it	  made	  sense	  to	  use	  these.	  But	  some	  felt	  that	  screening	  was	  most	  appropriate	  where	  there	  were	  other	  triggers,	  such	  as	  major	  events	  in	  a	  person’s	  life.	  	  
8.4.4	  Screening	  setting	  Aside	  from	  the	  GP	  setting,	  other	  potential	  screening	  settings	  identified	  by	  participants	  were	  A&E	  departments	  (for	  people	  involved	  in	  accidents)	  or	  intensive	  care	  units,	  as	  these	  are	  “a	  specific	  setting	  where	  you	  are	  likely	  to	  pick-­‐up	  a	  large	  number	  of	  people	  who	  have	  been	  traumatised”.	  (CL	  2)	  	  	   Those	  participants	  who	  were	  in	  favour	  of	  screening	  generally	  agreed	  that	  the	  GP	  surgery	  was	  the	  most	  suitable	  setting.	  	  IAPT	  services	  could	  then	  see	  those	  who	  had	  been	  screened	  as	  well	  as	  self-­‐referred	  individuals,	  provide	  assessment	  and	  if	  necessary	  refer	  for	  treatment,	  as	  suggested	  by	  one	  of	  the	  interviewees.	  	  The	  (GP	  practice)	  [is]	  the	  only	  setting	  where	  people	  go	  routinely.	  It	  can	  be	  a	  good	  place	  to	  screen,	  just	  like	  for	  many	  other	  conditions	  like	  cervical	  cancer.	  	  An	  alternative	  could	  be	  the	  IAPT,	  but	  then,	  of	  course,	  people	  need	  to	  get	  to	  IAPT	  in	  the	  first	  place,	  so	  you	  would	  miss	  a	  lot	  of	  people	  if	  you	  start	  at	  IAPT.	  (GP	  5)	  One	  GP	  suggested	  focusing	  on	  the	  practices	  with	  a	  higher	  incidence	  of	  factors	  associated	  with	  the	  onset	  of	  PTSD.	  
8.4.5	  Screening	  protocol	  When	  discussing	  the	  screening	  protocol,	  it	  was	  widely	  felt	  that	  it	  would	  need	  to	  be	  short,	  simple	  and	  easily	  understood,	  with	  a	  simple	  response	  scale,	  as	  well	  as	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the	  usual	  characteristics	  of	  sensitivity	  and	  specificity.	  	  However,	  a	  few	  GPs	  questioned	  practical	  aspects	  of	  implementing	  such	  a	  policy	  and	  the	  feasibility	  of	  such	  practice	  across	  the	  country,	  as	  it	  would	  have	  the	  effect	  of	  “increasing	  the	  volume	  of	  work	  in	  the	  practice”	  (GP	  4).	  	  One	  potential	  solution	  was	  to	  make	  possible	  self-­‐referral	  to	  IAPT	  services,	  “already	  explored	  as	  a	  part	  of	  proactive	  targeting	  for	  depression	  that	  will	  prevent	  burdening	  the	  GP	  practice”	  (PD	  2).	  	  	   Piloting	  such	  a	  scheme	  was	  seen	  to	  be	  important	  to	  determine	  the	  feasibility	  of	  screening,	  to	  gain	  an	  insight	  into	  the	  process	  of	  screening	  and	  the	  complexity	  of	  cases,	  to	  investigate	  screening	  as	  a	  pathway	  into	  treatment	  and	  to	  explore	  all	  practical	  issues	  along	  the	  way.	  	  
8.4.6	  PTSD	  in	  the	  context	  of	  the	  IAPT	  programme	  In	  general,	  the	  GPs	  perceived	  IAPT	  positively	  and	  expressed	  a	  willingness	  to	  refer	  to	  the	  IAPT:	  IAPT	  –	  one	  of	  the	  good	  things	  is	  that	  there	  are	  more	  people	  to	  deliver	  CBT	  and	  identify	  people	  with	  PTSD.	  (GP	  3)	  A	  number	  of	  those	  interviewed	  discussed	  aspects	  of	  the	  IAPT	  programme.	  	  A	  key	  theme	  was	  under-­‐representation	  of	  individuals	  with	  anxiety	  disorders	  and	  PTSD	  within	  the	  programme,	  found	  to	  be	  much	  lower	  than	  the	  prevalence	  of	  the	  disorder	  within	  the	  general	  population:	  One	  would	  expect,	  based	  on	  the	  epidemiology,	  that	  around	  about	  a	  third	  of	  people	  in	  the	  IAPT	  services	  should	  have	  one	  of	  the	  anxiety	  disorders,	  other	  than	  GAD,	  PTSD,	  panic	  disorder,	  social	  phobia,	  OCD.	  Actually,	  there	  was	  only	  8.5%.	  	  So	  there	  is	  quite	  a	  serious	  overrepresentation	  of	  depression,	  relative	  to	  anxiety	  disorders.	  (CL	  3)	  Several	  potential	  causes	  were	  identified,	  including	  complications	  with	  the	  database	  and	  the	  allocation	  of	  a	  provisional	  diagnosis:	  Quite	  a	  lot	  of	  people	  were	  recorded	  as	  having	  mixed	  anxiety	  and	  depression.	  But	  a	  fair	  number	  of	  them	  may	  actually	  have	  had	  PTSD	  so	  the	  figure	  might	  be	  a	  bit	  higher.	  	  A	  lot	  of	  people	  with	  PTSD	  are	  also	  depressed	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and	  clinicians	  tend	  to	  think	  that	  mixed	  diagnosis	  of	  anxiety	  and	  PTSD	  –	  restricted	  for	  people	  who	  fit	  neither	  group.	  (CL	  3)	  Furthermore,	  it	  was	  said	  that	  both	  recovery	  rates	  and	  the	  number	  of	  treatment	  sessions	  were	  not	  calculated	  correctly	  in	  the	  initial	  IAPT	  report.	  	  	   Clinicians	  also	  noted	  problems	  in	  correctly	  identifying	  people	  with	  PTSD	  problems,	  arising	  perhaps	  from	  the	  sense	  of	  stigma	  around	  a	  PTSD	  diagnosis.	  	  Another	  identified	  issue	  was	  a	  referral	  bias	  of	  some	  GPs	  with	  a	  big	  interest	  in	  mental	  health.	  	  	  One	  commissioner	  discussed	  potential	  system	  problems	  in	  the	  early	  stages	  of	  the	  IAPT	  programme,	  such	  as	  the	  inadequate	  training	  of	  IAPT	  therapists,	  the	  GP	  referral	  pathway	  and	  around	  commissioning:	  There	  are	  lots	  of	  system	  problems	  not	  just	  about	  recognition	  but	  about	  training	  therapists,	  and	  making	  sure	  that	  commissioners	  are	  enabling	  that	  work	  goes	  to	  the	  right	  place,	  in	  the	  right	  time	  etc.	  (PD	  3)	  	   Another	  important	  finding	  was	  that	  the	  IAPT	  programme	  was	  picking	  up	  a	  higher	  number	  of	  complex	  PTSD	  cases	  than	  expected.	  	  As	  this	  was	  in	  the	  early	  phase,	  the	  programme	  was	  not	  geared	  to	  treating	  complex	  cases	  and	  providing	  high-­‐intensity	  treatment	  and	  such	  cases	  were	  consequently	  referred	  to	  specialised	  mental	  health	  services:	  IAPT	  doesn’t	  treat	  complex	  cases.	  	  It	  is	  designed	  to	  treat	  low	  intensity	  and	  actually	  struggles	  to	  find	  cases.	  	  A	  lot	  of	  individuals	  with	  chronic	  and	  complex	  problems	  are	  coming	  through	  and	  IAPT	  isn’t	  designed	  to	  deal	  with	  this.	  	  As	  a	  consequence,	  this	  increases	  pressure	  on	  other	  MH	  services	  and	  impacts	  on	  other	  services,	  which	  are	  under	  resourced.	  	  Resources	  need	  to	  be	  allocated	  accordingly.	  (CL	  1)	  (High-­‐intensity	  treatment)	  should	  be	  part	  of	  the	  core	  IAPT	  service,	  but	  I	  am	  acknowledging	  it	  is	  not	  happening	  now.	  (PD	  3)	  One	  clinician	  pointed	  out	  that	  this	  problem	  may	  stem	  from	  the	  fact	  that	  mental	  health	  services	  were	  not	  involved	  in	  planning	  the	  IAPT.	  	  He	  concluded	  that	  the	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IAPT	  programme	  only	  made	  sense	  if	  the	  resources	  were	  available	  because	  of	  the	  number	  of	  complex	  cases.	  	  
8.4.7	  GP	  education	  and	  training	  All	  those	  interviewed	  felt	  there	  was	  a	  need	  for	  improved	  GP	  education	  on	  the	  available	  treatment	  for	  people	  with	  PTSD.	  	  Many	  of	  the	  GPs	  interviewed	  agreed	  that	  the	  role	  of	  a	  GP	  should	  be	  to	  recognise	  and	  detect	  the	  symptoms	  and	  make	  a	  referral,	  rather	  than	  making	  a	  diagnosis:	  	  You	  are	  right	  about	  increasing	  awareness	  for	  GPs,	  but	  there	  is	  no	  point	  of	  having	  an	  incredibly	  complicated	  educational	  programme,	  it	  is	  just	  one	  of	  the	  diagnoses	  a	  GP	  has	  to	  consider.	  	  It	  is	  probably	  unreasonable	  for	  a	  GP	  to	  make	  a	  firm	  PTSD	  diagnosis.	  	  He/she	  can	  raise	  the	  question	  and	  make	  a	  referral	  to	  community	  mental	  health	  team	  or	  to	  IAPT.	  	  (GP	  3)	  Awareness	  can	  increase	  sensitivity	  of	  practitioners,	  education	  of	  practitioners	  and	  the	  population	  and	  is	  a	  relatively	  efficient	  tool	  to	  use	  in	  a	  primary	  care	  setting.	  	  And	  is	  probably	  a	  more	  implementable	  nationwide,	  rather	  than	  a	  blanket	  whole	  population	  screening.	  (GP	  4)	  The	  best	  channels	  of	  awareness-­‐raising	  and	  education	  about	  PTSD,	  GPs	  suggested,	  were	  online	  resources	  such	  as	  BMJ	  Learning,	  EAMIS,	  patient.co.uk,	  and	  numerous	  national	  portals	  focusing	  on	  general	  practice	  training	  in	  mental	  health.	  	  User-­‐friendly,	  readily-­‐available	  educational	  materials	  in	  the	  form	  of	  patient	  leaflets	  or	  information	  sheets	  that	  can	  be	  printed	  out,	  along	  with	  podcasts,	  were	  seen	  as	  particularly	  helpful:	  	  	  	  If	  there	  was	  a	  written	  piece	  on	  mental	  health	  and	  PTSD	  associated	  with	  a	  patient	  leaflet,	  even	  better.	  	  We	  are	  all	  getting	  used	  to	  clicking-­‐in	  and	  finding	  patient	  leaflets	  and	  giving	  patients	  information	  to	  back-­‐up	  information	  given	  out	  in	  the	  session.	  (GP	  8)	  	   As	  discussed	  with	  the	  IAPT	  director,	  mental	  health	  training	  for	  GPs	  was	  not	  obligatory	  at	  the	  time	  of	  the	  interviews.	  	  Consequently,	  training	  in	  that	  area	  falls	  to	  GPs	  having	  a	  personal	  interest	  –	  and	  there	  are	  no	  additional	  incentives	  or	  sanctions	  to	  nudge	  GPs	  into	  mental	  health	  education.	  	  However,	  with	  the	  current	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changes	  in	  the	  NHS	  and	  commissioning	  being	  passed	  from	  PCTs	  to	  GP	  consortia,	  this	  is	  likely	  to	  change:	  GPs	  are	  very	  variable.	  	  There	  are	  some	  GPs	  that	  are	  more	  trained	  and	  knowledgeable	  in	  mental	  health	  and	  others	  who	  are	  not	  interested,	  which	  is	  a	  bit	  worrying	  considering	  this	  is	  around	  a	  third	  of	  their	  work.	  (PD	  2)	  By	  and	  large,	  GPs	  still	  don’t	  do	  mental	  health	  very	  well,	  let	  alone	  common	  mental	  health.	  	  Their	  responsibilities	  around	  commissioning	  will	  come	  with	  greater	  responsibilities	  that	  will	  require	  training	  across	  GPs.	  (PD	  3)	  It	  will	  take	  some	  cultural	  change	  and	  leadership	  to	  make	  a	  new	  step.	  	  I	  am	  optimistic	  as	  a	  good	  handful	  of	  first	  wave	  GP	  commissioning	  consortia	  have	  expressed	  that	  their	  particular	  area	  of	  interest	  is	  IAPT	  and	  services	  we	  got.	  	  We	  have	  some	  champions	  coming	  forward,	  and	  that	  is	  much	  more	  powerful	  to	  hear	  from	  another	  GP	  consortium	  first	  than	  from	  some	  policy	  suit.	  (PD	  3)	  	   Lastly,	  issues	  of	  policy	  development,	  process	  and	  implementation	  were	  discussed.	  	  Clinicians,	  GPs	  and	  commissioners	  agreed	  about	  the	  importance	  of	  evidence	  in	  policy	  making,	  along	  with	  the	  availability	  of	  guidelines:	  	  Having	  NICE	  guidelines	  and	  a	  clear	  message	  on	  available	  evidence	  does	  make	  a	  very	  big	  difference.	  	  Commissioners	  won’t	  know	  the	  details	  and	  they	  are	  guided	  by	  that	  sort	  of	  thing.	  (PD	  2)	  Participants	  also	  agreed	  on	  the	  paramount	  role	  of	  developing	  an	  economic	  argument	  for	  policy	  funding	  and	  implementation:	  Economic	  argument	  changed	  it....	  the	  most	  testing	  moment	  in	  the	  whole	  policy	  development.	  (PD	  1)	  	  Layard	  built	  on	  the	  body	  of	  work	  that	  existed,	  putting	  an	  economic	  twist	  and	  presented	  it	  to	  the	  Chancellor.	  	  Interesting	  how	  policy	  is	  being	  made,	  not	  enough	  saying	  all	  these	  people	  are	  suffering	  –	  you	  need	  to	  make	  an	  economic	  case.	  	  (GP	  5)	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One	  interviewee	  who	  was	  involved	  in	  the	  development	  and	  implementation	  of	  early	  treatment	  of	  psychosis	  highlighted	  some	  key	  elements	  of	  policy	  development	  and	  change	  process:	  Right	  timing,	  channelling	  out	  dissatisfaction	  with	  services,	  a	  strong	  network	  which	  is	  responsive	  and	  inclusive	  of	  all	  important	  stakeholders	  (academics,	  policy	  makers,	  health	  economists,	  health	  care	  users).	  	  Another	  important	  thing	  –	  it	  is	  not	  sufficient	  just	  to	  complain.	  	  It	  is	  important	  to	  have	  a	  pathway	  audit	  along	  making	  a	  strong	  economic	  case	  to	  support	  the	  process.	  (PD	  1)	  	  Due	  to	  the	  pending	  NHS	  reform	  around	  commissioning	  of	  services,	  there	  was	  a	  lot	  of	  uncertainty	  about	  changes	  in	  the	  policy	  making	  process.	  	  One	  mental	  health	  commissioner	  noted:	  It	  would	  be	  that	  sort	  of	  thing	  the	  GP	  consortium	  would	  be	  interested	  in.	  In	  the	  old	  days,	  it	  would	  be	  discussed	  by	  the	  Primary	  Care	  Trust,	  it	  may	  go	  to	  professional	  executive	  commissioning	  within	  the	  PCT	  and	  clinical	  pathways	  group.	  You	  have	  to	  ensure	  that	  GPs	  are	  involved	  and	  linked	  in	  with	  commissioning	  groups.	  (PD	  2)	  
8.4.8	  Screening	  in	  the	  context	  of	  IAPT	  programme	  At	  the	  time	  of	  the	  interviews,	  the	  IAPT	  lead	  person	  acknowledged	  that	  there	  would	  be	  sufficient	  flexibility	  and	  resources	  within	  IAPT	  services	  to	  accommodate	  a	  pilot,	  and	  it	  would	  bring	  beneficial	  insights	  into	  the	  reasons	  behind	  the	  low	  referral	  rate	  of	  PTSD	  to	  the	  IAPT	  services:	  	   We	  have	  huge	  targets	  for	  the	  numbers	  of	  people	  we	  can	  see,	  which	  we	  need	  to	  meet.	  	  In	  principle,	  the	  numbers	  of	  PTSD	  are	  not	  that	  huge,	  this	  is	  the	  group	  we	  should	  be	  seeing	  and	  that	  is	  why	  we	  need	  a	  pilot.	  (PD	  2)	  
8.4.9	  Satisfaction	  with	  the	  ST	  programme	  
The	  presented	  information	  is	  cited	  from	  the	  Evaluation	  study	  report	  by	  Brewin	  et	  al	  (2009)	  and	  it	  was	  collected	  as	  a	  part	  of	  the	  Evaluation	  study.	  	  The	  vast	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majority	  of	  the	  230	  respondents	  interviewed	  (90%)	  had	  no	  objection	  to	  being	  contacted	  by	  the	  programme.	  	  There	  was	  a	  small	  preference	  in	  favour	  of	  being	  initially	  contacted	  by	  letter	  rather	  than	  by	  telephone.	  	  Moreover,	  25%	  of	  those	  who	  finished	  treatment	  said	  it	  was	  unlikely	  that	  they	  would	  have	  asked	  for	  help	  if	  they	  had	  not	  been	  approached	  by	  the	  programme.	  	  Of	  those	  who	  were	  screened	  or	  assessed	  but	  not	  offered	  treatment,	  around	  70%	  were	  satisfied	  with	  the	  programme.	  Reported	  levels	  of	  satisfaction	  were	  higher,	  80%,	  in	  those	  who	  were	  actually	  treated	  within	  the	  programme.	  	  
	  
8.5	   Conclusion	  and	  recommendations	  This	  chapter	  has	  discussed	  arguments	  for	  and	  against	  screening	  for	  PTSD	  from	  both	  an	  empirical	  and	  practical	  perspective.	  	  It	  has	  been	  shown	  that	  despite	  numerous	  potential	  benefits,	  there	  are	  also	  practical	  and	  theoretical	  problems	  in	  introducing	  screening,	  including	  the	  opportunity	  cost	  of	  implementation	  of	  such	  a	  policy.	  	  Before	  proceeding	  to	  the	  final	  conclusions	  about	  the	  screening	  programme,	  it	  is	  important	  to	  compare	  these	  findings	  against	  the	  UK	  National	  Screening	  Committee’s	  Criteria	  NSCC)	  to	  establish	  if	  they	  are	  met.	  	  The	  summary	  of	  the	  guidelines	  is	  presented	  in	  Chapter	  2,	  Table	  2.1.	  	  	  In	  my	  view,	  the	  National	  Screening	  Committee’s	  Criteria	  are	  met	  with	  regards	  to	  the	  condition	  and	  treatment.	  	  As	  outlined	  in	  Chapter	  2,	  PTSD	  is	  a	  prevalent	  disorder	  with	  quantifiable	  health,	  social	  and	  economic	  impact	  on	  individuals,	  their	  families	  and	  society	  as	  a	  whole.	  	  The	  impact	  of	  PTSD	  and	  the	  benefits	  of	  timely	  provision	  of	  evidence-­‐based	  treatment,	  both	  health	  and	  economic,	  have	  been	  recognised	  by	  the	  government,	  which	  funded	  the	  IAPT	  programme.	  	  The	  IAPT	  programme	  ensures	  availability	  of	  optimal	  clinical	  management	  of	  the	  condition	  and	  patient	  management	  and	  the	  provision	  of	  the	  best	  evidence-­‐based	  treatment	  throughout	  the	  country.	  	  Furthermore,	  evidence	  supports	  provision	  of	  the	  early	  treatment	  for	  PTSD.	  	  However,	  the	  evidence	  is	  not	  so	  clear	  with	  regard	  to	  the	  screening	  test	  and	  the	  screening	  programme	  itself.	  	  The	  NSCC	  asks	  for	  a	  simple,	  safe	  and	  valid	  instrument	  that	  is	  acceptable	  to	  the	  population	  with	  suitable	  cut-­‐off	  level	  defined	  and	  agreed.	  	  The	  TSQ	  ticks	  most	  of	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the	  boxes	  and	  has	  been	  used	  in	  several	  UK	  screening	  studies	  already.	  It	  has	  good	  psychometric	  properties,	  a	  short,	  user-­‐friendly	  format	  and	  agreed	  a	  well-­‐documented	  cut-­‐off	  level	  of	  six	  or	  above	  for	  the	  UK-­‐based	  population.	  	  However,	  as	  the	  TSQ	  is	  covering	  DSM-­‐IV	  and	  ICD-­‐10	  criteria,	  its	  diagnostic	  properties	  need	  to	  be	  further	  tested	  in	  order	  to	  reflect	  the	  changes	  introduced	  in	  the	  DSM-­‐V	  and	  ICD-­‐11	  diagnostic	  manuals.	  	  Therefore,	  it	  could	  be	  argued	  that	  its	  diagnostic	  properties	  could	  be	  affected	  with	  the	  diagnostic	  changes	  and	  its	  performance	  needs	  to	  be	  further	  tested	  and	  documented.	  	  	  With	  regards	  to	  the	  screening	  programme	  itself,	  the	  evidence	  is	  scarce	  for	  most	  of	  the	  criteria.	  	  To	  my	  knowledge,	  there	  are	  so	  far	  no	  RCTs	  supporting	  screening	  for	  PTSD	  in	  reducing	  morbidity	  and	  mortality	  in	  the	  general	  population.	  	  Existing	  evidence	  on	  screening	  for	  PTSD	  in	  military	  contexts	  and	  in	  hospital	  settings	  targeting	  victims	  of	  violent	  crime	  did	  not	  perform	  well	  as	  expected,	  resulting	  in	  low	  response	  rates	  and	  high	  costs	  of	  treatment	  (Bisson	  et	  al.,	  2010,	  Rona	  et	  al.,	  2004).	  	  In	  contrast,	  evaluation	  of	  the	  mental	  health	  response	  to	  the	  LB	  screened	  65%	  of	  individuals	  who	  came	  into	  contact	  with	  the	  programme,	  out	  of	  which	  30.5%	  were	  consequently	  referred	  to	  treatment.	  	  	  	  	  Evidence	  on	  screening	  being	  clinically,	  socially	  and	  ethically	  acceptable	  to	  both	  health	  professionals	  and	  to	  the	  public	  is	  divided,	  and	  the	  results	  of	  the	  qualitative	  study	  attest	  to	  that.	  	  An	  interesting	  finding	  from	  the	  evaluation	  study	  pointed	  out	  that	  screening	  was	  perceived	  positively	  by	  majority	  of	  people	  followed-­‐up	  in	  the	  evaluation	  study,	  who	  had	  no	  objections	  to	  being	  contacted.	  	  Participants	  reported	  screening	  was	  “an	  opportunity	  to	  check	  how	  they	  were	  doing”	  and	  it	  was	  “comforting	  to	  know	  there	  was	  available	  help	  should	  they	  need	  it”.	  	  Importantly,	  for	  the	  20%	  of	  participants	  who	  received	  treatment	  within	  the	  programme,	  screening	  served	  as	  a	  pathway	  into	  treatment.	  	  Evidence	  that	  screening	  benefits	  outweigh	  the	  potential	  harm	  from	  screening	  is	  not	  fully	  established,	  and	  there	  are	  numerous	  arguments	  for	  and	  against,	  involved	  in	  a	  debate	  around	  screening	  and	  PTSD	  as	  a	  diagnosis,	  as	  reflected	  by	  the	  qualitative	  study	  findings.	  	  Finally,	  opportunity	  cost	  involved	  in	  the	  screening	  should	  be	  considered.	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Following	  that,	  there	  should	  be	  capacity	  within	  the	  health	  system	  to	  accommodate	  all	  identified	  individuals	  who	  screened	  positive	  on	  the	  test	  and	  an	  agreed	  policy	  on	  how	  to	  address	  their	  needs.	  This	  should	  be	  ensured	  by	  available	  capacities	  within	  the	  IAPT	  programme,	  which	  receives	  relatively	  low	  numbers	  of	  PTSD	  cases	  based	  on	  their	  calculations	  from	  the	  UK	  national	  psychiatric	  morbidity	  rates	  for	  PTSD.	  	  On	  another	  note:	  not	  all	  screening	  contexts	  work	  equally	  well	  for	  PTSD.	  	  For	  example,	  while	  victims	  of	  the	  terrorist	  attacks	  might	  expect	  help	  and	  response	  from	  the	  health	  services,	  the	  situation	  might	  be	  different	  in	  the	  context	  of	  refugees/asylum	  seekers/illegal	  migrants	  or	  as	  accident	  and	  emergency	  services	  users	  (Bisson	  et	  al,	  2009).	  	  Possible	  stigmatisation,	  or	  legal	  issues	  around	  their	  status	  might	  prove	  to	  be	  an	  obstacle	  in	  screening	  for	  PTSD	  in	  this	  context.	  	  	  Furthermore,	  the	  possibility	  of	  further	  traumatisation	  or	  victimisation	  and	  interference	  with	  the	  recovery	  process	  need	  to	  be	  taken	  into	  account.	  	  However,	  these	  are	  difficult	  to	  measure	  and	  require	  a	  dedicated	  longitudinal	  study.	  	  	  The	  short	  qualitative	  study	  reported	  here	  has	  not	  made	  it	  possible	  to	  provide	  any	  definitive	  answers	  with	  regard	  to	  the	  introduction	  of	  a	  screening	  policy.	  	  What	  it	  has	  done	  is	  to	  highlight	  different	  views	  and	  perspectives.	  	  A	  number	  of	  participants	  identified	  benefits,	  which	  would	  accrue	  from	  introducing	  a	  pilot	  screening	  study	  in	  one	  or	  two	  GP	  practices,	  in	  particular	  ones	  whose	  main	  target	  population	  are	  refugees	  or	  asylum	  seekers.	  	  This	  would	  elicit	  valuable	  information	  on	  key	  elements	  of	  the	  screening	  process,	  the	  prevalence	  of	  PTSD	  cases	  in	  the	  population,	  the	  type	  of	  cases,	  and	  pathways	  into	  treatment;	  and	  shed	  light	  on	  the	  low	  number	  of	  PTSD	  referrals	  to	  IAPT	  services.	  	  In	  my	  opinion,	  it	  would	  be	  possible	  to	  implement	  a	  pilot	  study	  in	  the	  existing	  capacity	  within	  the	  NHS	  introduced	  by	  the	  IAPT	  programme,	  particularly	  when	  lower	  than	  expected	  rates	  of	  PTSD	  into	  the	  programme	  have	  been	  reported.	  	  The	  qualitative	  study	  identified	  and	  described	  a	  scenario	  for	  a	  screening	  pilot	  that	  would	  be	  implementable	  in	  general	  practice,	  which	  is	  discussed	  in	  greater	  detail	  in	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Chapter	  9.	  	  The	  pilot	  would	  enable	  researchers	  to	  collect	  data	  on	  the	  costs	  and	  effects	  of	  screening	  and	  analyse	  the	  costs	  and	  benefits	  of	  such	  an	  intervention,	  thereby	  allowing	  policy	  makers	  to	  make	  informed	  decisions	  grounded	  in	  evidence.	  	  Furthermore,	  such	  evidence	  would	  provide	  an	  insight	  into	  the	  low	  referral	  rates	  of	  individuals	  with	  PTSD	  to	  the	  IAPT	  programme,	  and	  perhaps	  improve	  access	  to	  the	  best	  evidence-­‐based	  treatment	  currently	  funded	  by	  the	  DH.	  	  Importantly,	  if	  appropriately	  designed,	  data	  collected	  by	  a	  pilot	  would	  enable	  researchers	  to	  undertake	  a	  cost-­‐effectiveness	  analysis	  of	  the	  introduction	  of	  such	  a	  policy.	  	  Most	  of	  the	  interviewed	  clinicians	  agreed	  that	  running	  a	  pilot	  PTSD	  screening	  in	  primary	  care	  could	  be	  a	  helpful	  way	  forward.	  	  However,	  some	  of	  the	  interviewed	  participants	  (mostly	  GPs)	  highlighted	  possible	  negative	  outcomes	  such	  as	  re-­‐traumatisation	  and	  interfering	  with	  the	  process	  of	  natural	  recovery.	  	  Alternative	  proposals	  to	  screening	  suggested	  by	  all	  participants	  in	  the	  study	  focused	  on	  GP	  awareness-­‐raising	  around	  PTSD	  and	  its	  symptoms,	  screening	  at	  A&E	  and	  intensive	  care	  units,	  or	  the	  inclusion	  of	  PTSD	  into	  screening	  for	  depression	  protocol.	  	  In	  the	  context	  of	  availability	  of	  the	  best-­‐evidence	  based	  treatment	  trough	  the	  IAPT	  services	  and	  the	  evidence	  on	  low	  rate	  of	  recognition	  of	  PTSD	  by	  the	  GPs,	  awareness-­‐raising	  was	  identified	  as	  a	  good	  alternative	  to	  screening	  in	  primary	  care.	  	  Participants	  highlighted	  the	  importance	  of	  educating	  GPs	  to	  recognise	  the	  symptoms	  and	  make	  a	  referral	  rather	  than	  make	  a	  diagnosis	  themselves.	  	  	  When	  discussing	  these	  findings,	  it	  is	  important	  to	  highlight	  their	  limitations.	  	  First,	  the	  findings	  from	  the	  qualitative	  study	  are	  affected	  by	  the	  small	  purposive	  sample	  of	  interviewed	  participants,	  and	  although	  the	  sample	  aimed	  to	  include	  all	  the	  important	  stakeholders	  in	  the	  decision-­‐making	  process	  of	  introducing	  PTSD	  screening	  policy,	  it	  omitted	  to	  include	  the	  views	  of	  the	  service	  users	  themselves.	  	  Instead	  I	  have	  included	  findings	  from	  the	  Evaluation	  study,	  which	  looked	  at	  satisfaction	  with	  screening.	  	  Secondly,	  it	  is	  difficult	  to	  know	  how	  representative	  the	  comments	  of	  the	  different	  participants	  in	  the	  qualitative	  study	  were	  and,	  indeed,	  if	  saturation	  of	  themes	  was	  achieved.	  	  A	  relatively	  small	  number	  of	  participants	  involved	  in	  the	  study	  affects	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generalisability	  of	  the	  findings.	  	  Furthermore,	  representativeness	  of	  the	  comments	  collected	  on	  such	  a	  small	  sample	  is	  a	  concern.	  	  However,	  the	  participants’	  sample	  was	  varied	  and	  reflected	  stakeholders	  likely	  involved	  in	  the	  decision-­‐making,	  policy	  implementation	  and	  funding	  behind	  introduction	  of	  the	  PTSD	  screening.	  	  Furthermore,	  the	  findings	  highlighted	  a	  range	  of	  the	  opinions	  in	  regards	  to	  the	  screening	  and	  reflected	  the	  current	  debate	  in	  the	  field,	  which	  possibly	  points	  out	  that	  although	  small,	  the	  sample	  reflected	  the	  main	  discourses	  in	  the	  field,	  arguing	  both	  pro-­‐	  and	  against	  screening,	  from	  the	  various	  stakeholders’	  perspectives.	  	  The	  main	  screening	  scenario	  was	  examined	  in	  the	  interviews;	  its	  strengths	  and	  weaknesses	  were	  discussed	  alongside	  implication	  of	  its	  use	  in	  the	  general	  practice	  setting.	  	  	  The	  generalisation	  of	  the	  study	  findings	  needs	  to	  be	  carefully	  assessed,	  as	  the	  number	  of	  the	  participants	  was	  small.	  	  This	  is	  particularly	  true	  for	  clinical	  research	  and	  policy	  development,	  funding	  and	  implementation	  subcategories	  where	  only	  three	  participants	  were	  interviewed	  from	  different	  backgrounds,	  so	  there	  is	  a	  possibility	  that	  the	  saturation	  of	  the	  theme	  was	  not	  achieved.	  	  However,	  I	  believe	  saturation	  of	  the	  themes	  was	  likely	  to	  have	  been	  reached	  in	  the	  GP	  participant	  category	  as	  the	  number	  of	  new	  themes	  and	  codes	  did	  not	  emerge	  after	  the	  first	  six	  interviews.	  	  	  Another	  important	  limitation	  of	  the	  study	  that	  has	  quite	  likely	  affected	  the	  overall	  saturation	  of	  themes	  is	  the	  failure	  to	  include	  PTSD	  sufferers,	  the	  general	  public	  and	  screening	  experts	  in	  particular.	  	  PTSD	  sufferers	  were	  not	  contacted	  as	  the	  evaluation	  study	  already	  collected	  data	  on	  the	  screening	  satisfaction	  from	  the	  perspective	  of	  the	  programme	  users	  and	  the	  views	  on	  the	  screening	  protocol	  from	  the	  participants	  who	  did	  not	  use	  the	  programme,	  the	  findings	  for	  which	  are	  presented	  as	  a	  part	  of	  the	  qualitative	  study	  in	  Section	  8.4.	  	  Looking	  at	  the	  study	  retrospectively,	  the	  study	  would	  have	  benefitted	  from	  the	  involvement	  of	  the	  general	  public	  and	  the	  screening	  experts.	  	  This	  omission	  affects	  the	  representativeness	  of	  the	  findings	  as	  not	  all	  the	  aspects	  of	  the	  decision	  making	  process	  were	  discussed.	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Chapter	  9	   Conclusion	  and	  recommendations	  	  
9.1	   Introduction	  The	  aim	  of	  the	  thesis	  was	  to	  assess	  the	  health,	  social,	  and	  economic	  impact	  of	  PTSD	  by	  focusing	  on	  the	  individuals	  exposed	  to	  the	  London	  bombings	  (LB).	  	  While	  both	  academic	  and	  non-­‐academic	  literature	  highlighted	  significant	  burdens	  of	  the	  disorder	  on	  individuals,	  their	  families	  and	  society,	  there	  is	  a	  lack	  of	  empirical	  data	  in	  relation	  to	  its	  economic	  impact	  on	  individuals,	  the	  health	  system	  and	  wider	  society,	  and	  in	  particular	  a	  lack	  of	  economic	  evaluations	  of	  PTSD	  interventions	  (NICE,	  2005).	  	  This	  study	  aimed	  to	  fill	  some	  of	  the	  gaps	  in	  the	  evidence	  by	  measuring	  the	  health	  and	  economic	  impact	  on	  individuals	  and	  society	  as	  a	  whole,	  and	  by	  applying	  a	  cost-­‐effectiveness	  analysis	  to	  evaluate	  the	  mental	  health	  response	  to	  the	  LB.	  	  The	  study	  aimed	  to	  answer	  questions	  such	  as	  what	  it	  meant	  for	  individuals	  to	  have	  been	  involved	  in	  the	  LB,	  both	  from	  a	  health	  and	  an	  economic	  perspective,	  what	  services	  they	  used,	  how	  participants’	  characteristics,	  patterns	  of	  exposure	  and	  service	  use	  related	  to	  reported	  costs,	  and	  which	  factors	  were	  associated	  with	  being	  diagnosed	  with	  PTSD.	  	  The	  application	  of	  economic	  evaluation	  tools	  allowed	  closer	  investigation	  of	  the	  costs	  and	  outcomes	  of	  the	  ST	  programme.	  	  Finally,	  a	  qualitative	  study	  explored	  the	  benefits	  of	  and	  barriers	  to	  PTSD	  screening	  in	  a	  primary	  care	  context.	  The	  aim	  of	  this	  chapter	  is	  to	  bring	  together	  themes	  explored	  in	  the	  empirical	  chapters,	  provide	  a	  summary	  of	  findings,	  discuss	  the	  study’s	  limitations	  and	  strengths	  in	  order	  to	  inform	  future	  research,	  and	  draw	  out	  some	  implications	  for	  practice	  and	  policy.	  	  
9.2	   Thesis	  summary	  and	  discussion	  	  This	  section	  will	  present	  the	  methods	  used	  and	  discuss	  the	  main	  findings	  of	  the	  study.	  	  For	  each	  section	  I	  will	  first	  present	  a	  summary	  of	  findings	  followed	  by	  a	  discussion	  of	  the	  main	  points	  and	  results.	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9.2.1	  Costs	  of	  involvement	  in	  the	  LB	  The	  total	  estimated	  costs	  reported	  by	  a	  sample	  of	  230	  individuals	  involved	  in	  the	  LB	  were	  £2,389,520.45	  at	  2007/08	  prices.	  	  This	  translates	  to	  an	  average	  of	  £4,362.45	  for	  service	  use	  costs	  and	  £60,266.62	  for	  indirect	  costs	  per	  person.	  	  Indirect	  costs	  represented	  58%	  of	  the	  total	  reported	  costs.	  	  Among	  indirect	  costs	  the	  most	  frequently	  reported	  ones	  were	  related	  to	  productivity,	  i.e.	  are	  associated	  with	  sick	  leave.	  	  Costs	  due	  to	  unemployment	  accounted	  for	  almost	  40%	  of	  the	  productivity	  costs.	  	  In	  the	  direct	  (service	  use)	  cost	  category	  the	  most	  costly	  services,	  when	  looking	  at	  totals,	  were	  hospitalisation	  (38%)	  and	  treatment	  costs	  (32%).	  	  Health	  services	  were	  the	  most	  frequently-­‐used	  services	  after	  assessment	  and	  screening,	  with	  around	  63%	  of	  participants	  reporting	  using	  one	  of	  the	  associated	  NHS	  services.	  	  Participants	  who	  received	  treatment	  within	  the	  ST	  programme	  reported	  the	  highest	  percentage	  of	  usage	  for	  all	  cost	  categories.	  	  The	  GP,	  A&E	  and	  the	  NHS	  mental	  health	  services	  were	  the	  most	  frequently	  used	  for	  all	  participants’	  groups.	  	  These	  results	  show	  that	  the	  burden	  of	  exposure	  to	  terrorist	  attack	  lies	  in	  providing	  statutory	  sector	  health	  services	  in	  a	  form	  of	  hospital	  treatments,	  general	  health	  services	  provision	  through	  A&E	  services	  and	  general	  practice.	  	  In	  the	  aftermath	  of	  terrorist	  attacks,	  health	  service	  use	  was	  mostly	  focused	  on	  treating	  the	  injured	  and	  the	  type	  of	  service	  used	  depended	  on	  the	  type	  of	  injuries.	  	  Higher	  private	  sector	  service	  use	  was	  evident	  for	  participants	  who	  did	  not	  use	  the	  ST	  programme	  because	  they	  did	  not	  know	  about	  it.	  	  Participants	  accessed	  services	  in	  the	  non-­‐statutory	  and	  private	  sector	  mainly	  for	  their	  mental	  health	  needs.	  	  Findings	  on	  the	  use	  of	  general	  practice	  services	  and	  mental	  health	  services	  (provided	  by	  both	  the	  statutory	  and	  private	  sectors)	  point	  out	  where	  capacity	  should	  be	  available	  in	  the	  aftermath	  of	  similar	  traumatic	  events.	  	  In	  this	  particular	  sample,	  twenty-­‐one	  out	  of	  fifty	  types	  of	  medication	  used	  by	  participants	  were	  mental	  health-­‐related	  medications.	  	  Other	  reported	  medications	  covered	  physical	  health	  problems,	  mostly	  related	  to	  the	  injuries	  received	  during	  the	  London	  bombings.	  	  This	  is	  an	  interesting	  finding,	  particularly	  in	  the	  context	  of	  medication	  not	  being	  recommended	  by	  the	  best-­‐evidence	  based	  practice	  in	  the	  UK	  as	  the	  first	  choice	  of	  treatment	  for	  PTSD.	  	  Still,	  38%	  of	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participants	  reported	  using	  at	  least	  one	  type	  of	  mental	  health-­‐related	  medication	  either	  for	  relaxation,	  sleeping,	  anxiety	  or	  managing	  panic	  attacks.	  	  These	  results	  indicate	  the	  underlying	  mental	  health	  needs	  among	  the	  participants.	  Costs	  were	  higher	  for	  individuals	  who	  were	  assessed	  earlier	  in	  the	  programme,	  individuals	  with	  PTSD	  ICD-­‐10	  diagnosis	  and	  participants	  who	  saw	  someone	  being	  injured	  or	  killed.	  	  In	  Section	  9.2.4,	  I	  will	  address	  in	  greater	  detail	  findings	  on	  higher	  costs	  reported	  earlier	  in	  the	  programme.	  	  Findings	  pointing	  out	  higher	  costs	  for	  participants	  with	  PTSD	  diagnosis	  in	  comparison	  to	  the	  rest	  of	  the	  sample	  were	  expected,	  and	  are	  in	  line	  with	  findings	  from	  the	  literature	  on	  the	  burden	  associated	  with	  PTSD	  discussed	  in	  Chapter	  2.	  	  Injury	  and	  witnessing	  death	  are	  both	  risk	  factors	  for	  PTSD	  and	  their	  role	  as	  cost	  predictors	  is	  not	  a	  surprise.	  	  In	  fact,	  inclusion	  of	  these	  two	  factors	  in	  the	  model	  possibly	  ‘diluted’	  the	  effect	  of	  PTSD	  variable	  on	  cost.	  	  For	  comparison,	  Ferry	  et	  al.	  (2009)	  reported	  £172.8	  million	  in	  2008	  as	  the	  total	  economic	  burden	  (direct	  and	  indirect	  costs)	  for	  individuals	  with	  PTSD	  in	  Northern	  Ireland	  (NI),	  of	  which	  an	  estimated	  £46.7	  million	  was	  attributed	  to	  the	  conflict	  in	  NI.	  	  Translated	  to	  the	  average	  cost	  per	  person,	  the	  NI	  study	  reported	  an	  average	  direct	  cost	  of	  £16,616	  and	  £22,268	  for	  indirect	  costs	  per	  person,	  which	  is	  around	  four	  times	  higher	  for	  both	  cost	  categories	  when	  compared	  to	  the	  costs	  from	  the	  LB	  study.	  	  	  When	  interpreting	  and	  comparing	  results	  from	  the	  two	  studies,	  it	  is	  important	  to	  take	  into	  account	  differences	  between	  study	  populations	  and	  designs;	  one	  is	  looking	  at	  the	  prevalence	  and	  costs	  of	  PTSD	  at	  the	  general	  population	  level,	  while	  the	  other	  is	  focusing	  on	  a	  particular	  sample	  of	  individuals	  involved	  in	  a	  terrorist	  attack	  in	  a	  major	  urban	  area.	  	  Both	  studies	  point	  out	  the	  high	  burden	  of	  PTSD,	  although	  it	  is	  likely	  that	  the	  LB	  study	  underestimated	  the	  economic	  burden	  of	  PTSD	  by	  not	  using	  any	  objective	  records	  of	  service	  use	  or	  productivity	  loss,	  by	  not	  measuring	  the	  effects	  of	  PTSD	  on	  formal	  carers	  such	  as	  family	  and	  friends,	  and	  by	  relying	  on	  participant	  recall	  of	  services	  used	  between	  six	  months	  and	  two	  years	  after	  the	  LB.	  	  The	  costs	  due	  to	  exposure	  to	  the	  LB	  and	  PTSD	  are	  likely	  to	  be	  conservative	  estimates,	  as	  the	  study	  did	  not	  measure	  costs	  of	  presenteeism,	  costs	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to	  caregivers/families,	  and	  effects	  on	  quality	  of	  life	  and	  effects	  on	  social	  and	  family	  life	  of	  participants.	  	  Furthermore,	  the	  study	  relied	  on	  participants’	  recollection	  for	  events	  up	  to	  two	  years	  prior	  to	  the	  time	  of	  data	  collection,	  which	  could	  have	  affected	  the	  accuracy	  of	  reported	  data.	  	  Another	  important	  point	  is	  that	  the	  presented	  costs	  represent	  the	  economic	  burden	  of	  being	  exposed	  to	  the	  LB	  and	  due	  to	  developing	  PTSD,	  rather	  than	  costs	  due	  to	  PTSD	  exclusively.	  	  Both	  studies	  report	  a	  high	  proportion	  of	  indirect	  costs	  in	  the	  total	  estimated	  cost;	  81%	  in	  the	  NI	  study	  and	  58%	  in	  the	  LB	  study.	  	  High	  indirect	  costs	  due	  to	  reduced	  or	  lost	  productivity	  are	  typical	  of	  mental	  health	  disorders	  and	  they	  “either	  match	  or	  outweigh	  direct	  costs	  for	  all	  mental	  health	  areas”	  (WHO,	  2003,	  p.	  17).	  	  Productivity	  loss-­‐related	  costs	  for	  the	  LB	  sub-­‐sample	  are	  characterised	  by	  high	  costs	  of	  unemployment	  and	  a	  large	  proportion	  of	  participants	  reporting	  taking	  sick-­‐leave	  due	  to	  the	  effects	  of	  the	  LB.	  	  Higher	  productivity	  loss	  costs	  were	  associated	  with	  the	  female	  gender,	  although	  gender	  was	  not	  a	  significant	  predictor	  of	  the	  PTSD	  ICD-­‐10	  diagnosis.	  	  	  Participants	  who	  received	  treatment	  under	  the	  ST	  programme	  reported	  the	  highest	  costs	  and	  the	  highest	  frequency	  of	  service	  use	  for	  all	  the	  service	  categories.	  	  This	  finding	  indicates	  that	  this	  group	  had	  the	  greatest	  needs.	  	  Moreover,	  this	  finding	  possibly	  suggests	  that	  the	  ST	  programme	  screening	  protocol	  was	  effective	  in	  identifying	  and	  triaging	  people	  with	  mental	  health	  needs	  and	  then	  referring	  them	  to	  treatment.	  	  However,	  without	  an	  appropriate	  comparison	  group	  this	  interpretation	  is	  speculative	  and	  remains	  unproven.	  	  Analysis	  of	  cost	  variations	  provides	  an	  insight	  into	  how	  participants	  differ	  in	  their	  costs	  and	  service	  use.	  	  This	  information	  is	  particularly	  useful	  for	  service	  providers	  and	  planners	  as	  it	  will	  inform	  them	  about	  specific	  needs	  as	  well	  as	  about	  service	  use	  pattern	  in	  the	  context	  of	  exposure	  to	  the	  LB.	  	  	  The	  analysis	  showed	  that	  groups	  such	  as	  women,	  participants	  of	  an	  older	  age	  and	  participants	  from	  minority	  ethnic	  groups	  were	  more	  likely	  to	  report	  costs	  or	  to	  use	  services	  associated	  with	  exposure	  to	  the	  LB	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  Women	  were	  twice	  as	  likely	  to	  report	  service	  use	  costs	  when	  compared	  to	  men.	  	  Women	  were	  more	  likely	  to	  report	  private	  sector	  and	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medication	  costs,	  service	  use	  costs	  (without	  the	  ST	  programme	  costs),	  and	  costs	  due	  to	  productivity	  loss.	  	  Unsurprisingly,	  injury	  was	  a	  significant	  predictor	  of	  use	  of	  services	  provided	  by	  the	  NHS,	  private	  and	  voluntary	  sectors,	  and	  of	  use	  of	  medication.	  	  These	  findings	  are	  not	  surprising	  and	  are	  in	  line	  with	  the	  literature	  on	  risk	  factors	  for	  PTSD	  and	  service	  use	  in	  the	  context	  of	  PTSD	  discussed	  in	  Chapter	  2.	  	  Minority	  ethnic	  status,	  being	  a	  woman	  and	  older	  age	  all	  contribute	  to	  vulnerability	  after	  trauma	  exposure	  and	  increase	  the	  odds	  of	  service	  use	  and	  associated	  costs.	  	  This	  is	  an	  important	  finding	  that	  calls	  for	  a	  specific	  attention	  to	  the	  needs	  of	  these	  particular	  groups	  and	  should	  inform	  planning	  and	  provision	  of	  mental	  health	  response	  and	  services.	  	  	  The	  study	  has	  identified	  two	  well-­‐known	  PTSD	  risk	  factors	  -­‐	  witnessing	  death	  or	  injury	  and	  feeling	  one	  will	  die	  or	  sustain	  injury	  as	  predictors	  of	  PTSD	  ICD-­‐10	  diagnosis.	  	  Participants	  who	  reported	  those	  factors	  were	  four	  to	  five	  times	  more	  likely	  to	  have	  a	  primary	  diagnosis	  of	  PTSD–ICD	  10	  in	  comparison	  to	  other	  participants.	  	  	  The	  study	  results	  confirmed	  my	  hypothesis	  on	  positive	  correlation	  between	  PTSD	  ICD-­‐10	  diagnosis	  and	  reporting	  high	  costs.	  	  Not	  surprisingly,	  two	  well-­‐known	  predictors	  of	  PTSD,	  witnessing	  death	  and	  injury,	  were	  identified	  as	  predictors	  of	  PTSD	  ICD-­‐10	  diagnosis.	  	  Lastly,	  early	  assessment	  was	  another	  predictor	  of	  high	  costs.	  This	  result	  could	  be	  explained	  by	  the	  differences	  between	  early	  and	  later	  treatment	  groups,	  which	  I	  will	  discuss	  in	  greater	  detail	  in	  Section	  9.2.4,	  rather	  than	  an	  association	  between	  the	  timing	  of	  the	  assessment	  and	  reporting	  costs.	  	  
9.2.3	  Comparing	  costs	  and	  outcomes	  of	  the	  ST	  programme	  In	  Chapter	  6,	  I	  was	  not	  able	  to	  conduct	  an	  economic	  evaluation	  due	  to	  the	  limited	  data	  on	  programme	  users	  and	  non-­‐users.	  	  Instead	  I	  have	  explored	  and	  compared	  costs	  and	  outcomes	  for	  programme	  users	  and	  people	  who	  did	  not	  use	  it,	  and	  between	  people	  who	  received	  treatment	  and	  participants	  who	  were	  only	  screened	  and	  assessed,	  in	  order	  to	  have	  a	  better	  understanding	  of	  the	  screening	  process	  and	  its	  outcomes.	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Service	  use	  patterns	  were	  similar	  between	  all	  participant	  sub-­‐groups.	  	  The	  highest	  percentage	  of	  participants	  in	  all	  groups	  reported	  using	  health	  care	  services,	  followed	  by	  private	  sector	  services,	  medication	  and	  voluntary	  sector	  services	  and	  finally	  hospitalisation.	  The	  treated	  group	  had	  a	  significantly	  lower	  screening	  score	  and	  lower	  probability	  of	  screening	  positive	  at	  follow-­‐up	  in	  comparison	  to	  participants	  who	  did	  not	  receive	  treatment.	  	  There	  was	  no	  statistically	  significant	  difference	  in	  adjusted	  follow-­‐up	  TSQ	  scores	  between	  the	  ST	  programme	  users	  and	  participants	  who	  did	  not	  use	  it.	  	  This	  means	  that	  participants	  who	  were	  treated	  maintained	  their	  treatment	  gains,	  and	  the	  screened	  only	  and	  assessed	  but	  not	  treated	  participants	  along	  participants	  who	  did	  not	  use	  the	  ST	  programme	  remained	  under	  the	  positive	  screening	  threshold.	  	  In	  terms	  of	  costs,	  the	  programme	  users	  reported	  significantly	  higher	  average	  direct	  and	  total	  costs	  in	  comparison	  to	  programme	  non-­‐users.	  	  	  As	  the	  group	  of	  participants	  who	  did	  not	  use	  the	  programme	  consisted	  of	  people	  who	  knew	  of	  the	  programme	  but	  decided	  not	  to	  use	  it,	  and	  others	  who	  did	  not	  know	  about	  the	  ST	  programme,	  it	  was	  interesting	  to	  compare	  their	  outcomes	  and	  costs.	  	  Participants	  who	  did	  not	  know	  about	  the	  programme	  reported	  four	  times	  higher	  average	  total	  costs	  due	  to	  high	  productivity	  loss.	  	  Although	  they	  reported	  numerically	  larger	  direct	  costs,	  the	  difference	  was	  not	  significant	  from	  participants	  who	  did	  not	  need	  the	  programme.	  	  50%	  of	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  reported	  using	  private	  sector	  services,	  in	  comparison	  to	  only	  12%	  of	  participants	  who	  did	  not	  need	  the	  programme.	  	  Although	  participants	  who	  did	  not	  know	  of	  the	  ST	  programme	  screened	  below	  the	  TSQ	  threshold	  at	  the	  evaluation	  follow-­‐up,	  they	  cited	  heightened	  awareness	  and	  alertness	  to	  potential	  dangers,	  and	  being	  upset	  by	  reminders	  of	  the	  LB	  event	  as	  their	  main	  concerns,	  even	  after	  significant	  time	  had	  elapsed	  since	  the	  LB.	  	  These	  findings	  potentially	  suggest	  that	  this	  sub-­‐group	  of	  participants	  would	  have	  benefited	  from	  the	  use	  of	  ST	  programme	  services,	  as	  their	  use	  of	  private	  sector	  services	  indicates	  their	  needs.	  	  This	  finding	  points	  out	  that	  the	  wide	  outreach	  strategy	  is	  an	  important	  aspect	  of	  mental	  health	  response	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after	  terrorist	  events.	  	  Moreover,	  this	  finding	  indicates	  how	  difficult	  it	  is	  to	  reach	  the	  targeted	  population	  of	  individuals	  affected	  by	  the	  traumatic	  event	  even	  when	  using	  an	  elaborate	  and	  long-­‐term	  outreach	  relying	  on	  regular	  information	  channels	  such	  as	  GPs	  and	  the	  media.	  	  	  	   Comparison	  between	  participants	  who	  received	  treatment	  and	  those	  who	  were	  screened	  and	  assessed	  only	  also	  highlighted	  some	  interesting	  findings.	  	  Participants	  who	  received	  treatment	  were	  more	  severely	  affected	  by	  the	  bombings	  in	  comparison	  to	  the	  individuals	  who	  were	  assessed	  and	  screened	  only.	  	  Apart	  from	  screening	  positive	  on	  TSQ	  and	  reporting	  high	  scores	  on	  BDI	  and	  PDS	  measures,	  they	  reported	  statistically	  higher	  costs.	  	  This	  finding	  suggests	  that	  the	  ST	  programme	  was	  successful	  in	  identifying	  people	  in	  need	  of	  treatment.	  	  Both	  participant	  groups	  reported	  similar	  service	  use	  patterns.	  	  They	  reported	  health	  services	  as	  the	  most	  heavily-­‐used	  service	  category	  followed	  by	  private	  sector	  services,	  medication,	  voluntary	  sector	  services	  and	  finally	  hospitalisation.	  	  The	  productivity	  loss-­‐related	  costs	  were	  the	  dominant	  cost	  category	  reported	  by	  people	  who	  received	  treatment,	  while	  for	  the	  screened	  and	  assessed-­‐only	  participants	  the	  dominant	  cost	  category	  was	  hospitalisation.	  The	  treated	  group	  reported	  a	  significantly	  smaller	  score	  on	  the	  screener	  and	  lower	  probability	  of	  screening	  positive	  at	  follow-­‐up,	  in	  comparison	  to	  participants	  who	  did	  not	  receive	  treatment.	  	  This	  finding	  suggests	  effectiveness	  of	  treatment,	  and	  supports	  the	  benefits	  of	  longer-­‐term	  screening	  and	  assessment	  alongside	  the	  availability	  of	  evidence-­‐based	  treatment.	  	  	  Finally,	  the	  analysis	  pointed	  out	  ethnicity	  as	  a	  significant	  predictor	  of	  worse	  outcomes	  for	  all	  participant	  groups.	  	  Non-­‐white	  British	  respondents	  had,	  in	  general,	  significantly	  higher	  predicted	  TSQ	  end	  scores	  across	  all	  the	  ST	  programme	  user	  groups.	  	  As	  highlighted	  by	  Brewin	  et	  al	  (2009),	  these	  findings	  suggest	  a	  careful	  consideration	  of	  the	  use	  of	  the	  TSQ	  with	  the	  members	  of	  black	  and	  minority	  ethnic	  groups.	  	  	  Results	  presented	  in	  this	  section	  need	  to	  be	  interpreted	  with	  caution	  due	  to	  several	  issues	  including	  small	  sample	  sizes,	  in	  particular	  for	  participants	  who	  were	  screened	  and	  assessed	  only,	  and	  convenience	  sampling.	  	  Different	  outcome	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measures	  for	  different	  participant	  groups	  complicated	  further	  group	  comparison	  and	  data	  analysis	  and	  required	  transformation	  of	  the	  PDS	  scale	  into	  TSQ	  for	  treated	  participants.	  	  This	  could	  possibly	  have	  affected	  the	  psychometric	  properties	  of	  the	  scales,	  particularly	  in	  regard	  to	  their	  reliability.	  	  	  
9.2.4	  Cost-­‐effectiveness	  of	  the	  ST	  programme	  The	  cost-­‐effectiveness	  analysis	  of	  the	  ST	  programme	  is	  the	  most	  interesting	  empirical	  chapter	  and	  in	  my	  view,	  represents	  the	  highlight	  of	  the	  thesis.	  	  It	  presents	  an	  innovative	  approach	  to	  conducting	  the	  economic	  evaluation	  of	  a	  mental	  health	  intervention	  delivered	  within	  the	  ST	  programme.	  	  Economic	  evaluations	  in	  the	  observational	  study	  context	  are	  quite	  a	  rare	  occurrence,	  possibly	  due	  to	  the	  many	  difficulties	  and	  methodological	  challenges	  introduced	  by	  observational	  study	  design.	  	  This	  analysis	  was	  challenged	  by	  a	  number	  of	  factors	  ranging	  from	  study	  design,	  issues	  with	  comparator	  groups,	  and	  missing	  data.	  	  The	  observational	  study	  design	  possibly	  led	  to	  self-­‐selection	  of	  different	  groups,	  which	  in	  turn	  renders	  comparison	  difficult	  and	  ultimately	  raises	  questions	  in	  regards	  to	  representativeness	  and	  generalisability	  of	  the	  findings.	  	  However,	  one	  of	  the	  major	  advantages	  of	  observational	  study	  design	  is	  high	  ecological	  validity,	  as	  the	  evaluation	  in	  this	  context,	  in	  comparison	  to	  the	  experimental	  study	  design,	  has	  the	  valuable	  opportunity	  to	  capture,	  can	  be	  generalised	  and	  reflects	  real	  life	  conditions.	  	  In	  the	  cost-­‐effectiveness	  analysis,	  I	  compared	  participants	  who	  received	  treatment	  early	  (<1	  year)	  with	  ones	  who	  received	  treatment	  more	  than	  a	  year	  after	  exposure	  to	  the	  LB	  (later	  treatment	  group)	  –	  which	  I	  used	  as	  a	  proxy	  for	  the	  people	  on	  the	  NHS	  waitlist	  for	  evidence-­‐based	  treatment	  for	  PTSD.	  	  	  Interestingly,	  participants	  who	  were	  treated	  early	  reported	  higher	  total	  costs	  in	  comparison	  to	  the	  participants	  treated	  later.	  	  This	  was	  a	  surprising	  finding,	  as	  I	  had	  expected	  exactly	  the	  opposite	  –	  participants	  who	  were	  treated	  later	  in	  the	  programme	  to	  report	  higher	  costs.	  	  My	  hypothesis	  was	  that	  by	  treating	  participants	  early,	  large	  societal	  costs	  could	  be	  avoided	  by	  preventing	  health	  service	  use	  costs	  and	  productivity	  loss	  becoming	  even	  greater.	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Although	  the	  groups	  differed	  statistically	  in	  reported	  costs,	  in	  both	  groups	  productivity	  loss	  were	  the	  highest	  reported	  costs.	  	  I	  compared	  the	  early	  and	  late	  treatment	  groups	  on	  several	  aspects	  of	  PTSD	  and	  depression	  outcome	  measures:	  the	  end	  score,	  the	  difference	  between	  start	  and	  end	  scores,	  the	  number	  of	  depression-­‐free	  and	  PTSD-­‐free	  days,	  and	  the	  percentage	  of	  people	  achieving	  clinically	  significant	  change.	  	  While	  controlling	  for	  other	  factors	  I	  found	  no	  difference	  between	  the	  two	  groups	  on	  outcome	  measures,	  except	  the	  start-­‐end	  score	  difference	  on	  PDS	  and	  BDI	  scales,	  with	  the	  early	  treatment	  group	  achieving	  greater	  treatment	  improvement.	  	  Differences	  in	  start	  and	  end	  of	  treatment	  outcome	  scores	  between	  early	  and	  later	  and	  outcomes	  could	  be	  attributed	  to	  the	  effect	  of	  natural	  recovery,	  which	  usually	  takes	  place	  between	  6-­‐12	  months	  after	  trauma	  exposure.	  Both	  groups	  achieved	  large	  treatment	  effects	  on	  both	  measures	  that	  were	  maintained	  at	  the	  point	  of	  evaluation	  follow	  up.	  	  In	  the	  early	  treatment	  group,	  56%	  of	  participants	  achieved	  a	  reliable	  clinical	  improvement	  on	  the	  BDI	  and	  74%	  on	  the	  PDS,	  in	  comparison	  to	  40%	  on	  the	  BDI	  and	  65%	  on	  the	  PDS	  for	  the	  later	  treatment	  group.	  	  For	  both	  groups,	  around	  40%	  of	  participants	  on	  the	  BDI	  and	  60%	  of	  participants	  on	  the	  PDS	  achieved	  both	  clinically	  and	  statistically	  significant	  change.	  Due	  to	  the	  absence	  of	  control	  waiting-­‐list	  group	  it	  is	  difficult	  to	  say	  with	  certainty	  if	  these	  effects	  are	  due	  to	  treatment	  or	  natural	  recovery.	  	  However,	  the	  results	  show	  that	  there	  is	  no	  significant	  difference	  between	  the	  early	  and	  later	  treatment	  groups	  in	  treatment	  outcomes,	  which	  is	  inconsistent	  with	  the	  idea	  that	  improvement	  could	  be	  accounted	  for	  by	  natural	  recovery.	  	  Ethnicity	  and	  completing	  treatment	  were	  the	  only	  significant	  predictors	  of	  achieving	  a	  clinically	  significant	  change,	  however	  this	  contribution	  of	  other	  factors	  could	  have	  been	  undermined	  by	  inclusion	  of	  the	  finished	  treatment	  variable	  in	  the	  model,	  which	  is	  a	  clear	  predictor	  of	  clinical	  improvement.	  	  Looking	  at	  the	  results	  of	  the	  cost-­‐effectiveness	  analysis	  without	  taking	  into	  account	  the	  differences	  between	  the	  early	  and	  later	  treatment	  groups,	  the	  results	  highlight	  that	  the	  early	  treatment	  group	  participants	  showed	  larger	  treatment	  gains	  but	  only	  when	  comparing	  the	  difference	  on	  the	  start	  and	  end	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score;	  this	  difference	  was	  not	  observed	  on	  BDI	  and	  PDS	  end	  scores	  between	  the	  two	  groups.	  	  In	  terms	  of	  the	  cost	  differences,	  the	  early	  treatment	  group	  reported	  significantly	  larger	  costs	  on	  all	  cost	  categories	  except	  direct	  costs.	  Taking	  a	  societal	  perspective,	  the	  cost-­‐effectiveness	  analysis	  showed	  that,	  when	  comparing	  costs	  and	  effects	  for	  early	  and	  later	  treatment	  groups	  for	  a	  willingness	  to	  pay	  above	  £5000	  per	  unit	  of	  improvement	  on	  the	  PDS	  and	  BDI	  measures,	  the	  early	  treatment	  had	  only	  around	  60%	  probability	  of	  being	  cost-­‐effective	  compared	  to	  the	  later	  treatment.	  	  By	  looking	  at	  the	  relatively	  modest	  probability	  and	  a	  very	  high	  cost	  for	  only	  one	  unit	  of	  improvement	  on	  each	  scale,	  it	  does	  not	  seem	  to	  be	  cost	  effective	  to	  treat	  participants	  early.	  	  	  Cost	  per	  clinically	  significant	  change	  provides	  an	  alternative	  way	  to	  look	  at	  the	  ST	  programme.	  	  The	  total	  cost	  of	  achieving	  clinically	  significant	  change	  for	  the	  early	  treatment	  group	  (including	  costs	  to	  society)	  was	  around	  £25,500	  for	  the	  BDI	  and	  £30,000	  for	  the	  PDS,	  while	  for	  the	  later	  treatment	  group	  the	  total	  cost	  was	  around	  50%	  lower	  for	  both	  outcome	  measures.	  	  When	  looking	  at	  treatment	  costs	  only,	  the	  difference	  between	  groups	  was	  minimal,	  with	  a	  higher	  cost	  per	  PDS	  change	  for	  both	  groups.	  	  	  When	  interpreting	  the	  findings	  of	  the	  cost-­‐effectiveness	  analysis,	  it	  is	  important	  to	  understand	  the	  differences	  between	  the	  two	  comparator	  groups	  that	  could	  have	  affected	  the	  analysis.	  	  The	  hypothesis	  I	  tested	  in	  the	  analysis	  relied	  on	  the	  assumption	  that	  both	  early	  and	  later	  treatment	  group	  are	  comparable,	  that	  the	  later	  treatment	  group	  can	  be	  used	  as	  a	  proxy	  for	  the	  NHS	  waiting-­‐list	  for	  PTSD	  treatment,	  and	  that	  the	  two	  groups	  differ	  only	  in	  the	  timing	  of	  the	  treatment.	  	  	  By	  looking	  more	  closely	  at	  the	  differences	  between	  the	  two	  groups	  other	  than	  treatment	  timing,	  it	  is	  questionable	  that	  those	  assumptions	  hold.	  	  Namely,	  the	  early	  treatment	  group	  had	  30%	  more	  women	  than	  the	  later	  treatment	  group,	  participants	  in	  the	  later	  treatment	  group	  had	  on	  average	  more	  screeners	  than	  in	  the	  early	  treatment	  group,	  and	  participants	  in	  the	  later	  treatment	  group	  were	  more	  likely	  to	  have	  a	  late	  onset	  PTSD	  (however,	  the	  study	  did	  not	  record	  this	  information).	  	  There	  are	  possibly	  other	  systematic	  and	  non-­‐systematic	  factors	  that	  could	  have	  contributed	  to	  the	  timing	  of	  the	  treatment	  and	  differences	  between	  the	  groups	  that	  were	  not	  measured	  and	  thus	  cannot	  be	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controlled	  for.	  	  Possible	  other	  interpretations	  of	  the	  larger	  costs	  reported	  early	  in	  the	  programme	  include:	  spontaneous	  recovery	  (Ehring	  &	  Ehlers,	  2014);	  high	  proportion	  of	  hospitalised	  participants	  who	  received	  treatment	  early,	  or	  larger	  costs	  for	  the	  early	  treatment	  group	  could	  possibly	  indicate	  that	  the	  ST	  programme	  identified	  individuals	  with	  great(er)	  mental	  health	  needs	  early	  in	  the	  programme.	  	  Lastly,	  the	  analysis	  presented	  in	  this	  chapter	  highlighted	  again	  the	  association	  between	  being	  in	  a	  non-­‐white	  British	  ethnicity	  group	  with	  higher	  costs	  and	  worse	  outcomes	  on	  mental	  health	  measures.	  	  Non-­‐white	  British	  respondents	  had	  significantly	  higher	  predicted	  ST	  programme-­‐related	  costs,	  while	  controlling	  for	  other	  factors,	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  Being	  in	  the	  non-­‐white	  British	  ethnicity	  category	  was	  associated	  with	  higher	  BDI	  and	  PDS	  end	  scores	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  Furthermore,	  non-­‐white	  British	  participants	  were	  around	  seven	  times	  less	  likely	  to	  achieve	  clinically	  significant	  change	  in	  comparison	  to	  the	  rest	  of	  the	  sample	  and	  they	  reported	  significantly	  fewer	  depression-­‐free	  and	  PTSD-­‐free	  days	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  An	  important	  finding	  is	  that	  ethnicity	  was	  a	  significant	  factor	  in	  predicting	  the	  number	  of	  depression-­‐free	  and	  PTSD-­‐free	  days,	  with	  white	  British	  participants	  reporting	  a	  larger	  number	  of	  depression-­‐free	  and	  PTSD-­‐free	  days	  in	  comparison	  to	  the	  rest	  of	  the	  sample.	  	  The	  finding	  that	  members	  of	  black	  and	  minority	  ethnic	  groups	  reported	  worse	  outcomes	  after	  exposure	  to	  disasters	  in	  comparison	  to	  members	  of	  the	  majority	  ethnic	  group,	  and	  that	  they	  have	  restricted	  access	  to	  the	  evidence-­‐based	  treatment	  is	  well	  documented	  in	  the	  literature	  (Norris	  &	  Allegria,	  2005;	  Clark,	  2011).	  	  This	  finding	  is	  of	  particular	  importance	  to	  service	  planners	  and	  providers,	  as	  it	  highlights	  yet	  again	  the	  vulnerability	  of	  these	  particular	  groups	  and	  the	  need	  to	  address	  it	  in	  mental	  health	  service	  planning	  and	  provision.	  In	  conclusion,	  although	  the	  economic	  evaluation	  of	  the	  ST	  programme	  suggested	  it	  is	  not	  cost-­‐effective	  to	  treat	  participants	  early	  (within	  the	  first	  year	  after	  the	  LB),	  it	  is	  questionable	  whether	  this	  finding	  is	  accurate	  and	  useful	  to	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policy	  planners	  and	  funders.	  	  To	  begin	  with,	  the	  division	  of	  the	  participants	  into	  the	  early	  and	  later	  treatment	  groups	  is	  based	  on	  the	  estimate	  of	  the	  8	  month	  waiting	  list	  for	  NHS	  treatment	  rather	  than	  a	  well-­‐	  and	  pre-­‐defined	  sampling	  frame.	  	  In	  addition,	  in	  order	  to	  get	  more	  balanced	  sample	  sizes	  for	  early	  and	  later	  treatment	  groups,	  I	  extended	  the	  8	  month	  timeframe	  to	  10	  months.	  Furthermore,	  due	  to	  the	  absence	  of	  experimental	  control	  conditions	  in	  treatment	  allocation,	  it	  is	  very	  likely	  that	  the	  differences	  between	  the	  early	  and	  later	  treatment	  sample	  could	  have	  accounted	  for	  the	  cost	  differences	  between	  the	  groups	  rather	  than	  the	  treatment	  timing	  itself;	  hence,	  it	  is	  difficult	  to	  establish	  with	  certainty	  whether	  it	  is	  cost-­‐effective	  to	  provide	  treatment	  early.	  	  
9.2.5	  Qualitative	  study	  on	  screening	  for	  PTSD	  The	  qualitative	  study	  aimed	  to	  complement	  findings	  from	  the	  cost-­‐effectiveness	  evaluation	  of	  the	  ST	  programme	  and	  to	  explore	  if	  and	  how	  it	  could	  be	  applied	  in	  a	  wider	  context.	  	  Semi-­‐structured	  interviews	  with	  experts	  from	  clinical,	  academic	  and	  policy	  backgrounds	  uncovered	  a	  number	  of	  arguments	  for	  and	  against	  screening	  for	  PTSD	  in	  primary	  care.	  	  Screening	  for	  PTSD	  proved	  to	  be	  a	  controversial	  topic	  with	  polarised	  views	  on	  many	  aspects:	  from	  the	  screening	  concept	  itself,	  to	  PTSD	  as	  a	  disorder	  and	  screening	  as	  a	  pathway	  into	  treatment.	  	  The	  consensus	  was	  only	  on	  the	  paucity	  of	  evidence	  on	  costs	  and	  benefits	  of	  screening	  for	  PTSD,	  and	  a	  lack	  of	  evidence	  from	  economic	  evaluations.	  	  There	  are	  a	  number	  of	  arguments	  in	  support	  of	  screening	  ranging	  from	  high	  prevalence	  of	  PTSD	  and	  its	  detrimental	  effects,	  poor	  recognition	  of	  the	  disorder	  in	  primary	  care,	  to	  compliance	  with	  most	  of	  the	  criteria	  set	  out	  by	  the	  UK	  National	  Screening	  Committee.	  	  However,	  from	  the	  available	  data	  there	  was	  still	  no	  evidence-­‐based	  economic	  argument	  for	  introducing	  such	  a	  policy.	  	  Next,	  the	  study	  interviewed	  the	  key	  stakeholders	  who	  would	  ideally	  be	  involved	  in	  the	  decision-­‐making	  process,	  funding	  and	  implementation	  of	  such	  policy	  in	  order	  to	  gain	  understanding	  into	  the	  feasibility	  of	  screening	  in	  general	  practice.	  	  Through	  the	  semi-­‐structured	  interviews,	  the	  qualitative	  study	  identified	  the	  key	  elements	  and	  proposed	  a	  design	  for	  a	  pilot	  PTSD	  screening	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study	  that	  in	  the	  view	  of	  many	  interviewees	  would	  be	  implementable	  in	  the	  context	  of	  the	  IAPT	  programme	  and	  would	  bring	  valuable	  insights	  into	  the	  actual	  benefits	  and	  barriers	  of	  implementing	  primary	  care	  screening	  for	  PTSD.	  	  These	  benefits	  range	  from	  prevalence	  of	  PTSD	  cases	  in	  the	  general	  population,	  description	  of	  types	  of	  cases,	  analysis	  of	  pathways	  into	  treatment,	  and	  shedding	  light	  on	  the	  low	  number	  of	  PTSD	  referrals	  to	  IAPT	  services.	  	  Although	  the	  study	  findings	  are	  limited	  by	  the	  small	  sample,	  purposive	  sampling,	  and	  by	  missing	  the	  opportunity	  to	  interview	  participants	  with	  PTSD	  (service	  users)	  on	  their	  views	  of	  screening	  for	  PTSD,	  it	  still	  brings	  together	  views	  and	  experiences	  of	  a	  number	  of	  professionals	  in	  the	  field	  and	  points	  out	  important	  aspects	  of	  decision	  making	  in	  this	  area,	  thus	  can	  serve	  as	  a	  framework	  for	  policymakers	  and	  future	  research.	  	  The	  qualitative	  study	  highlighted	  the	  major	  discourse	  in	  the	  area,	  has	  reflected	  on	  how	  PTSD	  has	  not	  ceased	  to	  be	  a	  controversial	  topic	  and	  how	  general	  practitioners,	  academics	  and	  policy	  makers	  perceive	  and	  approach	  it	  in	  their	  everyday	  practice.	  	  	  	  
9.3	   Limitations	  and	  strengths	  There	  were	  challenges	  associated	  with	  this	  study	  that	  leave	  it	  with	  some	  limitations,	  including	  design,	  sample	  size,	  data	  collection	  methods,	  timing	  and	  missing	  data,	  working	  with	  skewed	  distributions,	  and	  the	  lack	  of	  comparator	  groups.	  	  It	  could	  be	  argued	  that	  the	  ideal	  approach	  would	  be	  to	  use	  an	  RCT	  design,	  with	  a	  carefully	  calculated	  sample	  size	  based	  on	  a	  power	  calculation,	  and	  perfectly	  timed	  data	  collection	  points.	  	  This	  approach,	  while	  sensible	  methodologically,	  is	  very	  difficult	  to	  implement	  in	  real	  life	  and	  is	  one	  reason	  for	  the	  scarcity	  of	  economic	  evaluations	  of	  mental	  health	  interventions.	  	  If	  one	  wants	  to	  include	  and	  reflect	  the	  real-­‐life	  challenges	  of	  mental	  health	  interventions,	  particularly	  of	  mental	  health	  responses	  where	  the	  response	  needs	  to	  be	  set	  up	  and	  run	  quickly,	  this	  study	  offers	  a	  useful	  template.	  Working	  in	  this	  difficult	  context	  required	  me	  to	  identify	  ways	  to	  overcome	  the	  challenges	  and	  in	  my	  view	  this	  constitutes	  the	  study’s	  key	  strength	  and	  contribution	  to	  the	  evidence	  base.	  	  Moreover,	  even	  though	  the	  evaluation	  sample	  is	  not	  representative,	  the	  analysis	  yielded	  conclusions	  that	  are	  in	  line	  with	  existing	  evidence.	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9.3.1	  The	  study	  design	  	  The	  study	  design	  was	  determined	  by	  the	  set-­‐up	  of	  the	  evaluation	  of	  the	  ST	  programme,	  which	  allowed	  only	  for	  an	  observational	  study	  and	  a	  one-­‐point	  retrospective	  data	  collection	  on	  the	  economic	  effects	  of	  the	  LB.	  As	  previously	  discussed	  in	  Chapter	  3,	  the	  programme	  steering	  group	  saw	  the	  observational	  study	  design	  as	  the	  only	  available	  option	  for	  evaluating	  the	  NHS	  mental	  health	  response	  after	  the	  LB.	  	  Although	  the	  RCT	  design	  enables	  control	  of	  unobserved	  systematic	  variable	  factors	  by	  random	  allocation	  of	  participants	  in	  treatment	  and	  control	  groups,	  and	  (often)	  by	  blinding	  researchers	  and	  clinicians	  with	  regard	  to	  treatment	  allocation,	  its	  application	  in	  this	  context	  would	  have	  been	  inappropriate,	  both	  ethically	  and	  politically.	  	  Despite	  its	  methodological	  limitations,	  the	  main	  advantage	  of	  an	  observational	  study	  is	  the	  ability	  to	  evaluate	  real-­‐life	  situations,	  giving	  it	  high	  ecological	  validity.	  	  This	  is	  in	  my	  view	  the	  core	  strength	  of	  this	  study	  –	  to	  capture,	  measure	  and	  evaluate	  a	  clinical	  intervention	  in	  the	  real-­‐world	  context	  as	  experienced	  by	  individuals,	  health	  systems	  and	  societies,	  particularly	  to	  measure	  health,	  social	  and	  economic	  impact.	  	  Although	  this	  study	  aimed	  to	  capture	  a	  societal	  perspective	  of	  the	  costs	  of	  PTSD	  it	  failed	  to	  measure	  a	  couple	  of	  important	  aspects	  of	  indirect	  costs	  such	  as	  costs	  due	  to	  presenteeism,	  and	  the	  effects	  of	  PTSD	  on	  family	  and	  carers	  or	  to	  try	  and	  capture	  the	  burden	  to	  informal	  carers,	  families	  and	  friends.	  	  I	  tried	  to	  overcome	  the	  methodological	  limitations	  of	  the	  observational	  design	  by	  applying	  multivariate	  modelling	  in	  order	  to	  re-­‐create	  to	  some	  extent	  the	  conditions	  of	  experimental	  study	  design.	  	  Multivariate	  modelling	  was	  introduced	  to	  control	  for	  all	  observable	  factors	  that	  could	  have	  influenced	  costs	  and	  outcomes.	  	  In	  practice,	  this	  translates	  into	  controlling	  for	  the	  same	  set	  of	  factors	  within	  each	  cost	  and	  outcome	  model	  in	  the	  cost-­‐effectiveness	  analysis	  to	  simulate	  the	  same	  conditions.	  	  However,	  this	  approach	  was	  limited	  to	  control	  only	  for	  the	  variables	  measured	  in	  the	  study.	  It	  is	  unlikely	  to	  have	  captured	  the	  majority	  of	  the	  relevant	  need	  characteristics	  in	  order	  to	  standardise	  for	  all	  the	  differences	  in	  the	  case	  mix	  across	  the	  user	  groups	  used	  in	  the	  evaluation.	  	  Future	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studies	  in	  this	  area	  should	  aim	  for	  a	  more	  comprehensive	  inclusion	  of	  the	  measures	  based	  on	  the	  findings	  from	  the	  literature	  on	  risk	  factors,	  participant	  characteristics,	  exposure	  factors,	  social	  support,	  informal	  care,	  health	  and	  mental	  health	  needs,	  service	  use	  etc.	  	  The	  study	  objectives	  called	  for	  a	  mixed-­‐methods	  approach	  –	  a	  quantitative	  study	  that	  explored	  the	  costs	  and	  outcomes	  of	  the	  ST	  programme,	  and	  a	  qualitative	  study	  that	  looked	  into	  themes	  around	  screening	  for	  PTSD	  in	  primary	  care.	  	  The	  quantitative	  analysis	  involved	  multivariate	  regression	  methods	  that	  included	  GLM	  and	  OLS	  models	  (Chapters	  5,	  6	  and	  7)	  alongside	  cost-­‐effectiveness	  analysis	  (Chapter	  7).	  	  Inclusion	  of	  both	  quantitative	  and	  qualitative	  approaches	  allowed	  for	  a	  greater	  insight	  into	  the	  process	  of	  evaluating	  mental	  health	  intervention	  and	  to	  explore	  in	  greater	  depth	  the	  potential	  policy	  implications	  and	  recommendations.	  	  The	  mixed-­‐method	  approach	  was	  suitable	  as	  my	  study	  objectives	  addressed	  the	  wide	  scope	  of	  the	  effects	  of	  PTSD	  and	  enabled	  me	  to	  explore	  the	  implementation	  of	  the	  study	  findings	  in	  a	  broader	  context	  (primary	  care).	  	  The	  quantitative	  study	  explored	  costs	  and	  outcomes	  of	  the	  ST	  programme,	  while	  the	  qualitative	  study	  looked	  into	  themes	  around	  screening	  for	  PTSD	  in	  primary	  care.	  	  This	  approach	  was	  particularly	  informative	  in	  identifying	  the	  screening	  pilot	  scenario	  that	  would	  be	  readily	  implementable	  in	  a	  primary	  care	  setting.	  The	  quantitative	  study	  was	  designed	  specifically	  for	  the	  purpose	  of	  evaluating	  the	  ST	  programme,	  and	  included	  standardised	  instruments	  on	  mental	  health	  outcomes	  (BDI	  and	  PDS),	  quality	  of	  life	  (EQ5D	  and	  SF-­‐12)	  and	  service	  use	  (CSRI),	  alongside	  additional	  questions	  on	  experience	  and	  satisfaction	  with	  the	  ST	  programme,	  and	  on	  social	  effects	  of	  the	  bombings.	  	  Each	  participant	  group	  was	  followed	  up	  with	  a	  set	  of	  specific	  outcome	  measures	  used	  for	  that	  particular	  sub-­‐sample	  during	  the	  running	  of	  the	  ST	  programme.	  	  This	  approach,	  pre-­‐determined	  by	  the	  evaluation	  study	  design,	  was	  not	  ideal,	  as	  it	  resulted	  in	  different	  indicators	  for	  different	  groups	  and	  difficulties	  in	  comparing	  across	  groups,	  which	  required	  re-­‐transformation	  of	  the	  PDS	  scale	  into	  the	  TSQ	  for	  the	  treated	  participant	  group.	  	  Even	  though	  the	  PDS	  and	  the	  TSQ	  cover	  the	  same	  PTSD	  symptoms	  and	  there	  are	  only	  slight	  semantic	  differences	  in	  the	  wording	  of	  some	  of	  the	  ten	  items	  taken	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from	  the	  PDS,	  this	  practice	  is	  not	  ideal	  as	  it	  alters	  psychometric	  properties	  of	  the	  instruments	  and	  ideally	  requires	  a	  sensitivity	  analysis	  of	  the	  results.	  	  Furthermore,	  the	  evaluation	  study	  omitted	  to	  measure	  the	  role	  of	  social	  support	  and	  networks	  in	  the	  recovery	  process.	  	  Social	  networks	  have	  a	  very	  important	  role	  in	  preventing	  onset	  of	  chronic	  PTSD	  and	  it	  is	  important	  to	  reflect	  their	  role	  supporting	  individuals	  in	  the	  aftermath	  of	  trauma	  exposure	  (Bisson	  et	  al.,	  2009).	  I	  identified	  and	  used	  three	  comparator	  groups	  in	  the	  analysis	  of	  the	  costs	  and	  outcomes	  to	  reflect	  different	  aspects	  of	  the	  programme.	  	  Each	  analysis	  presented	  a	  slightly	  different	  outlook	  on	  the	  programme	  and	  the	  scope	  of	  the	  analysis	  depended	  on	  the	  availability	  of	  the	  data.	  	  The	  most	  comprehensive	  cost-­‐effectiveness	  analysis	  was	  only	  possible	  for	  the	  sub-­‐sample	  of	  participants	  who	  received	  treatment	  within	  the	  ST	  programme.	  	  Due	  to	  the	  lack	  of	  funding,	  I	  needed	  to	  adapt	  the	  original	  design	  of	  the	  qualitative	  study.	  	  Instead	  of	  a	  study	  looking	  into	  individuals	  with	  PTSD	  on	  the	  NHS	  waiting	  list	  for	  the	  CBT/EMDR	  treatment	  that	  would	  have	  constituted	  the	  best	  comparison	  group	  for	  the	  economic	  evaluation,	  I	  conducted	  a	  small	  qualitative	  study	  that	  looked	  into	  the	  barriers	  to	  and	  benefits	  of	  introducing	  screening	  for	  PTSD	  in	  primary	  care.	  	  	  
9.3.2	  Data	  collection	  methods	  The	  main	  limitation	  in	  the	  data	  collection	  methods	  lies	  in	  its	  retrospective	  nature,	  with	  a	  single	  data	  collection	  point	  that	  varied	  among	  interviewed	  participants	  and	  relied	  heavily	  on	  their	  recollection	  of	  the	  economic,	  health	  and	  social	  effects	  of	  the	  LB.	  	  Self-­‐reporting	  was	  used	  in	  this	  study	  for	  several	  reasons.	  	  It	  was	  not	  feasible	  to	  assess	  service	  records,	  and	  besides	  this	  the	  literature	  on	  participants’	  recall	  versus	  care	  records	  suggested	  not	  many	  systematic	  differences,	  concluded	  that	  self-­‐reporting	  is	  generally	  an	  accurate	  measure	  of	  service	  use	  (Patel	  et	  al.,	  2005)	  and	  thus	  can	  be	  used	  in	  economic	  evaluations	  (Byford	  et	  al.,	  2007).	  	  Another	  potential	  limitation	  lies	  in	  the	  retrospective	  nature	  of	  data	  collection;	  participants	  were	  asked	  to	  recall	  service	  use	  in	  some	  cases	  up	  to	  37	  months	  ago	  and	  it	  is	  justified	  to	  question	  the	  accuracy	  of	  the	  reported	  costs.	  Data	  on	  functioning	  of	  the	  memory	  in	  emotionally	  charged	  situations	  is	  not	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conclusive.	  	  There	  is	  plenty	  of	  evidence	  on	  people	  vividly	  remembering	  injuries	  they	  experienced,	  natural	  disasters	  or	  terrorist	  attacks,	  however	  the	  accuracy	  of	  those	  memories	  are	  questionable	  and	  often	  difficult	  to	  assess	  (Kensinger,	  2009).	  	  Furthermore,	  it	  is	  important	  to	  consider	  the	  validity	  of	  measured	  indicators	  of	  service	  use	  associated	  with	  the	  LB	  only,	  and	  if	  participants	  were	  able	  to	  distinguish	  between	  services	  and	  treatment	  specifically	  linked	  to	  the	  LB	  exposure	  and	  those	  that	  were	  not.	  	  This	  is	  a	  valid	  and	  important	  question,	  in	  particular	  in	  the	  context	  of	  the	  retrospective	  nature	  of	  data	  collection	  that	  involved	  remembering	  service	  use	  in	  some	  cases	  up	  to	  two	  years	  back	  from	  the	  data	  collection	  point.	  	  The	  study	  tried	  to	  ensure	  accurate	  reporting	  and	  recollection	  of	  service	  use	  by	  specifically	  asking	  participants	  to	  report	  service	  use	  due	  to	  the	  LB	  exposure	  only,	  relying	  on	  the	  participant’s	  subjective	  interpretation	  of	  the	  nature	  of	  their	  problems.	  	  Inclusion	  of	  the	  objective	  records	  of	  service	  use	  such	  as	  GP	  or	  hospital	  records	  would	  ensure	  more	  accurate	  estimate	  of	  service	  use	  in	  the	  future	  studies.	  Although	  a	  variety	  of	  data	  collection	  methods	  introduced	  even	  more	  variability	  into	  an	  already	  heterogeneous	  sample,	  at	  the	  same	  time	  such	  an	  approach	  offered	  flexibility	  that	  increased	  response	  rates.	  	  Moreover,	  when	  I	  checked,	  my	  analyses	  showed	  no	  difference	  between	  different	  data	  collection	  methods.	  Introducing	  an	  alternative	  QoL	  measure	  a	  couple	  of	  months	  after	  the	  start	  of	  the	  evaluation	  study	  added	  to	  the	  heterogeneity	  of	  the	  data	  by	  creating	  two	  sub-­‐groups	  of	  participants	  and	  limiting	  comparability	  between	  them.	  	  This	  limitation	  was	  partially	  addressed	  by	  using	  an	  algorithm	  to	  translate	  SF-­‐12	  into	  EQ5D	  scores,	  which	  prevented	  data	  loss	  and	  enabled	  comparison	  of	  the	  two	  sub-­‐groups.	  	  	   The	  use	  of	  standardised	  instruments	  in	  measurement	  of	  mental	  health	  outcomes	  (BDI	  and	  PDS)	  allowed	  for	  comparability	  with	  other	  studies.	  	  For	  collecting	  service	  use	  and	  costs	  I	  used	  the	  CSRI,	  a	  standardised	  measure	  of	  service	  use	  adapted	  for	  this	  study	  in	  consultation	  with	  a	  health	  economist.	  	  The	  changes	  involved	  revising	  the	  wording	  and	  order	  of	  questions,	  and	  introducing	  a	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number	  of	  study-­‐specific	  items	  such	  as	  effects	  on	  work	  and	  productivity,	  effects	  of	  the	  LB	  on	  social	  domain,	  and	  participants’	  experiences	  with	  the	  ST	  programme.	  	  The	  CSRI	  is	  well	  known	  for	  the	  versatility	  of	  its	  use	  and	  adaptability	  in	  different	  study	  settings.	  	  All	  study	  materials,	  such	  as	  interview	  schedules,	  information	  letters	  and	  consent	  forms	  were	  carefully	  developed	  and	  structured	  with	  input	  from	  clinicians	  and	  a	  health	  economist,	  approved	  by	  the	  ethics	  committee	  and	  piloted	  prior	  to	  the	  start	  of	  the	  evaluation	  study.	  	  Involvement	  of	  two	  interviewers	  could	  have	  introduced	  variability	  and	  affected	  the	  quality	  of	  the	  collected	  data.	  	  However,	  these	  effects	  were	  minimised	  by	  establishment	  of	  strict	  interviewing	  protocols	  and	  interviewer	  training.	  	  Although	  the	  clinical	  approach	  focused	  on	  delivery	  of	  CBT	  and	  EMDR,	  there	  was	  no	  specific	  treatment	  protocol	  that	  clinicians	  needed	  to	  adhere	  to,	  which	  again	  introduced	  potential	  heterogeneity	  into	  the	  treatment	  data	  (length	  of	  sessions,	  number	  of	  sessions,	  specific	  therapy	  protocol,	  and	  adherence	  to	  the	  use	  of	  follow-­‐up	  measures).	  	  Moreover,	  the	  ST	  programme	  database	  was	  compiled	  on	  the	  basis	  of	  data	  sent	  by	  three	  different	  clinics	  and	  a	  dozen	  clinicians.	  	  Missing	  responses,	  in	  particular	  for	  the	  clinical	  outcome	  measures,	  presented	  a	  problem	  in	  the	  data	  analysis.	  	  In	  order	  to	  address	  this	  problem	  and	  to	  avoid	  data	  loss	  I	  used	  multiple	  imputation.	  	  The	  fact	  that	  each	  participant’s	  sub-­‐group	  was	  followed-­‐up	  with	  a	  specific	  set	  of	  outcome	  measures,	  depending	  on	  the	  aspect	  of	  programme	  they	  had	  used,	  has	  limited	  the	  data	  analysis.	  	  Moreover,	  it	  affected	  comparison	  of	  the	  groups	  and	  introduced	  a	  need	  to	  conduct	  separate	  data	  analysis	  for	  each	  sub-­‐group.	  	  This	  was	  an	  unavoidable	  step	  that	  on	  the	  one	  hand	  resulted	  in	  the	  segmentation	  of	  the	  sample,	  but	  on	  the	  other	  hand	  enabled	  follow-­‐up	  of	  participants.	  For	  the	  qualitative	  study	  I	  conducted	  semi-­‐structured	  interviews	  with	  a	  purposive	  sample	  of	  participants	  that	  included	  policy	  makers,	  academics	  and	  clinicians	  involved	  in	  work	  in	  the	  PTSD	  area	  in	  the	  UK.	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9.3.3	  Study	  sample	  The	  evaluation	  study	  did	  not	  use	  a	  rigorous	  sampling	  technique	  or	  power	  calculation.	  	  The	  aim	  was	  to	  interview	  as	  many	  programme	  users	  and	  non-­‐users	  as	  possible.	  	  In	  the	  qualitative	  study	  I	  used	  a	  purposive	  sample	  of	  experts	  in	  clinical,	  academic	  and	  policy-­‐making	  domains.	  	  In	  addition,	  I	  employed	  snowballing	  sampling	  to	  ensure	  I	  included	  relevant	  experts,	  particularly	  in	  the	  policy-­‐making	  domain.	  	  The	  study	  sampling	  approach	  can	  be	  seen	  as	  a	  study	  limitation,	  and	  may	  affect	  representativeness,	  comparability	  and	  generalisability	  of	  the	  findings,	  although	  there	  was	  no	  statistical	  difference	  in	  any	  of	  the	  main	  socio-­‐demographic	  and	  exposure	  characteristics	  between	  the	  ST	  programme	  users	  and	  the	  evaluation	  sub-­‐sample.	  	  More	  generally,	  one	  can	  question	  the	  representativeness	  of	  the	  ST	  programme	  users	  in	  general,	  as	  the	  programme	  only	  included	  a	  fraction	  of	  the	  people	  involved	  in	  the	  bombings.	  	  We	  tried	  to	  address	  this	  and	  to	  contact	  people	  who	  did	  not	  want	  to	  participate	  in	  the	  programme	  or	  did	  not	  know	  of	  it.	  	  Another	  selection	  bias	  could	  have	  occurred	  in	  recruiting	  the	  evaluation	  follow-­‐up	  subsample,	  as	  only	  a	  number	  of	  individuals	  agreed	  to	  take	  part	  in	  the	  study,	  while	  some	  potential	  participants	  firmly	  refused	  or	  could	  not	  be	  reached.	  	  The	  evaluation	  strategy	  was	  to	  obtain	  an	  accurate	  representation	  of	  the	  sample	  recorded	  on	  the	  screening	  team	  database	  as	  well	  as	  people	  who	  did	  not	  use	  the	  programme.	  	  The	  sample	  sizes	  were	  mainly	  determined	  by	  the	  feasibility	  of	  identifying,	  contacting,	  and	  persuading	  these	  groups	  to	  participate,	  and	  as	  such	  samples	  should	  be	  regarded	  as	  indicative	  rather	  than	  representative	  (Brewin	  et	  al.,	  2009).	  	  Again,	  these	  limitations	  need	  to	  be	  assessed	  in	  the	  context	  of	  the	  real-­‐life	  nature	  of	  this	  study	  and,	  as	  imperfect	  as	  it	  is,	  the	  evaluation	  sub-­‐sample	  still	  offers	  an	  interesting	  insight	  into	  the	  programme’s	  effectiveness	  and	  the	  effects	  of	  the	  LB.	  	  
9.3.4	  Data	  analysis	  A	  mix	  of	  quantitative	  and	  qualitative	  methods	  was	  used	  to	  reflect	  the	  complexity	  of	  the	  subject	  and	  to	  address	  the	  study	  objectives.	  	  Both	  qualitative	  and	  quantitative	  methods	  were	  rigorously	  applied.	  I	  used	  multivariate	  methods	  to	  explore	  the	  effects	  of	  different	  factors	  on	  cost	  and	  outcome	  measures.	  	  The	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choice	  of	  factors	  I	  controlled	  for	  was	  determined	  by	  the	  availability	  of	  collected	  data	  as	  well	  as	  previous	  research	  findings	  found	  in	  the	  literature.	  	  In	  the	  qualitative	  study	  I	  used	  directed	  qualitative	  content	  analysis.	  The	  lack	  of	  a	  proper	  comparison	  group	  is	  the	  main	  limitation	  of	  the	  economic	  evaluation.	  	  Comparing	  the	  ST	  programme	  users	  to	  people	  on	  the	  NHS	  waiting	  list	  or	  no	  intervention	  group	  would	  possibly	  constitute	  the	  ideal	  comparison	  groups	  for	  the	  analysis.	  	  In	  the	  absence	  of	  alternative	  options	  I	  decided,	  in	  consultation	  with	  my	  supervisors,	  to	  focus	  on	  three	  different	  comparator	  groups,	  each	  with	  its	  own	  strengths	  and	  limitations,	  and	  each	  offering	  a	  different	  perspective	  on	  the	  intervention.	  	  This	  approach	  in	  my	  view	  offered	  an	  alternative	  insight	  into	  evaluating	  mental	  health	  interventions,	  and	  should	  be	  seen	  as	  a	  valuable	  contribution	  to	  existing	  knowledge.	  
9.4	   Research,	  policy	  and	  practice	  implications	  
9.4.1	  Research	  implications	  The	  Literature	  Review	  highlighted	  a	  need	  for	  comprehensive	  and	  transparent	  economic	  evaluation	  of	  mental	  health	  interventions	  for	  PTSD.	  	  At	  the	  same	  time	  the	  Literature	  Review	  demonstrated	  a	  paucity	  of	  such	  data	  for	  PTSD	  in	  particular,	  and	  a	  need	  for	  clarity	  (Barrett	  &	  Petkova,	  2013)	  and	  transparency	  (Graves	  et	  al.,	  2002)	  in	  the	  costing	  methodology.	  	  Furthermore,	  apart	  from	  the	  clarity	  behind	  the	  costing	  methodology,	  evaluations	  of	  mental	  health	  interventions	  should	  present	  incremental	  costs	  and	  benefits,	  include	  a	  comparison	  group	  and	  a	  sensitivity	  analysis.	  The	  literature	  on	  evaluating	  mental	  health	  interventions	  is	  unanimous	  in	  recommending	  that	  evaluation	  should,	  where	  possible,	  be	  introduced	  into	  an	  intervention	  at	  an	  early	  stage.	  	  Ideally,	  this	  would	  be	  done	  at	  the	  time	  of	  planning	  the	  intervention	  and	  not,	  as	  is	  commonly	  done,	  as	  a	  separate	  add-­‐on	  study	  at	  the	  end	  or	  half-­‐way	  into	  the	  intervention.	  	  Incorporating	  the	  evaluation	  into	  the	  intervention	  from	  the	  planning	  phase	  should	  ensure	  not	  only	  the	  collection	  of	  data	  on	  the	  intervention	  outcomes,	  but	  also	  monitor	  the	  process	  of	  the	  intervention,	  so	  there	  is	  timely	  data	  collection	  and	  the	  possibility	  for	  multiple	  points	  of	  data	  collection.	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The	  major	  contribution	  of	  the	  thesis	  is	  not	  in	  providing	  definitive	  answers	  but	  in	  exploring	  alternative	  approaches	  in	  evaluating	  mental	  health	  interventions	  in	  a	  real-­‐world	  context.	  	  It	  offers	  an	  insight	  into	  how	  to	  make	  the	  best	  use	  of	  data	  obtained	  in	  an	  observational	  study	  context	  with	  the	  help	  of	  econometric	  tools.	  	  I	  wanted	  to	  demonstrate	  how	  it	  is	  possible	  to	  use	  an	  alternative	  evaluation	  route	  to	  an	  RCT,	  and	  so	  I	  have	  explored	  the	  use	  of	  multivariate	  modelling	  to	  address	  methodological	  limitations	  stemming	  from	  the	  observational	  study	  design.	  	  In	  my	  view,	  wider	  application	  of	  such	  techniques	  should	  be	  encouraged	  and	  funded,	  as	  they	  can	  provide	  useful	  tools	  in	  addressing	  methodological	  limitations	  and	  enable	  the	  potential	  use	  of	  otherwise	  potentially	  unusable	  or	  ‘difficult’	  data.	  	  As	  part	  of	  the	  economic	  evaluation,	  I	  explored	  different	  techniques	  of	  exploring	  uncertainty	  of	  the	  analysis	  and	  decided	  to	  plot	  CEACs.	  	  I	  would	  recommend	  the	  use	  of	  this	  particular	  type	  of	  analysis	  due	  to	  the	  simplicity	  of	  its	  application	  and	  interpretation.	  The	  qualitative	  study	  identified	  and	  explored	  opposing	  views	  on	  screening	  for	  PTSD	  in	  primary	  care.	  	  The	  study	  discussed	  a	  pilot	  study	  scenario	  that	  would	  provide	  a	  comprehensive	  evaluation	  of	  such	  an	  intervention.	  	  Interviewed	  participants	  came	  with	  a	  specific	  set	  of	  recommendations	  for	  a	  pilot	  study	  scenario	  and	  set-­‐up,	  which	  in	  my	  view	  offers	  valuable	  input	  for	  future	  research	  in	  this	  controversial	  area,	  especially	  at	  a	  time	  of	  increasingly	  tight	  mental	  health	  budgets	  that	  increase	  the	  need	  for	  reliable	  evidence	  on	  best	  resource	  allocation.	  	  It	  is	  proposed	  that	  a	  pilot	  should	  include	  at	  least	  two	  GP	  practices,	  preferably	  in	  an	  ethnically	  mixed	  area.	  	  The	  GPs	  should	  write	  to	  all	  members	  of	  their	  practice,	  providing	  information	  on	  the	  study,	  along	  with	  the	  screening	  questionnaires.	  	  Letters	  should	  invite	  participants	  to	  fill	  out	  the	  questionnaire	  and	  send	  it	  free	  of	  charge	  to	  the	  local	  IAPT	  team.	  	  Participants	  would	  be	  encouraged	  to	  self-­‐refer	  to	  or	  contact	  their	  local	  IAPT	  team	  if	  they	  have	  any	  questions	  or	  concerns.	  	  Participants	  should	  be	  given	  an	  opportunity	  to	  opt	  out	  of	  the	  pilot	  at	  any	  stage.	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   The	  choice	  of	  screening	  instrument	  should	  be	  guided	  by	  the	  recommendations	  from	  the	  qualitative	  study.	  	  Although	  TSQ	  would	  make	  a	  logical	  choice	  due	  to	  its	  characteristics,	  alongside	  the	  fact	  it	  has	  already	  been	  used	  in	  a	  couple	  of	  UK	  studies,	  which	  would	  allow	  comparison	  of	  findings,	  the	  role	  of	  its	  use	  in	  light	  of	  the	  changes	  in	  the	  diagnostic	  criteria	  for	  PTSD	  introduced	  by	  DSM-­‐5	  and	  ICD-­‐11	  needs	  to	  be	  carefully	  reconsidered.	  	  Screening	  questionnaires	  would	  need	  to	  be	  translated	  into	  the	  languages	  spoken	  in	  the	  local	  catchment	  area,	  and	  each	  letter	  would	  need	  to	  contain	  an	  English	  version	  as	  well	  as	  a	  translated	  one,	  where	  appropriate.	  	  The	  local	  IAPT	  team	  would	  then	  need	  to	  follow	  up	  with	  people	  whose	  screening	  questionnaires	  suggest	  they	  might	  need	  help,	  offering	  further	  assessment	  and	  treatment	  if	  needed.	  	  This	  assessment	  could	  be	  conducted	  in	  the	  IAPT	  office	  face-­‐to-­‐face	  or,	  if	  more	  convenient,	  over	  the	  telephone.	  	  Those	  in	  need	  of	  treatment	  should	  be	  offered	  evidence-­‐based	  treatment	  by	  the	  IAPT	  team.	  	  In	  addition,	  the	  IAPT	  team,	  supported	  preferably	  by	  a	  researcher,	  should	  then	  collect	  data	  on	  the	  number	  of	  individuals	  screened,	  assessed	  and	  treated	  as	  well	  as	  the	  outcomes	  and	  duration	  of	  their	  treatment.	  	  The	  London	  bombings	  study	  would	  provide	  a	  good	  example	  in	  terms	  of	  study	  methodology	  and	  implementation.	  	  Similarly,	  it	  would	  be	  valuable	  to	  collect	  data	  on	  the	  nature	  of	  the	  traumatic	  event	  that	  triggered	  the	  symptoms	  and	  timing	  of	  the	  event.	  	  It	  would	  also	  be	  important	  to	  collect	  data	  on	  all	  associated	  costs,	  including	  the	  screening	  itself,	  assessment,	  treatment	  and	  the	  costs	  of	  other	  related	  services	  received	  by	  participants	  from	  the	  onset	  of	  the	  symptoms,	  including	  health	  services	  provided	  by	  statutory	  and	  non-­‐statutory	  organisations,	  sick	  leave,	  reduced	  hours	  or	  unemployment.	  It	  would	  be	  important	  to	  record	  the	  effects	  on	  participants’	  social	  and	  family	  lives	  following	  the	  onset	  of	  the	  symptoms	  or	  exposure	  to	  the	  traumatic	  event	  and	  the	  role	  of	  informal	  carers.	  	  This	  could	  be	  done	  retrospectively,	  by	  asking	  participants	  to	  recount	  the	  effects	  of	  the	  traumatic	  event	  and	  by	  accessing	  GP	  records.	  	  Such	  an	  approach	  would	  enable	  comparisons	  with	  existing	  data	  on	  the	  effects	  and	  costs	  of	  PTSD	  and	  ensure	  optimal	  use	  of	  information	  collected.	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The	  pilot	  would	  enable	  researchers	  to	  collect	  data	  on	  the	  costs	  and	  effects	  of	  screening	  and	  analyse	  the	  costs	  and	  benefits	  of	  such	  an	  intervention,	  thereby	  allowing	  policy	  makers	  to	  make	  informed	  decisions	  grounded	  in	  evidence.	  	  Furthermore,	  such	  evidence	  would	  provide	  an	  insight	  into	  the	  low	  referral	  rates	  of	  individuals	  with	  PTSD	  to	  the	  IAPT	  programme,	  and	  perhaps	  improve	  access	  to	  the	  best	  evidence-­‐based	  treatment	  currently	  funded	  by	  the	  DH.	  	  Importantly,	  if	  appropriately	  designed,	  data	  collected	  by	  a	  pilot	  would	  enable	  researchers	  to	  undertake	  a	  cost-­‐effectiveness	  analysis	  of	  the	  introduction	  of	  such	  a	  policy.	  	  
9.4.2	  Policy	  and	  practice	  implications	  	  In	  the	  context	  of	  “scarce	  high-­‐quality	  research	  evidence	  on	  post-­‐disaster	  psychosocial	  management”	  (Bisson	  et	  al,	  2010,	  b,	  p.71)	  this	  study	  offers	  a	  contribution	  in	  providing	  information	  on	  the	  effectiveness	  of	  the	  mental	  health	  response	  programme.	  	  Evidence	  on	  optimal	  psychosocial	  response	  following	  disasters	  and	  major	  incidents	  is	  very	  limited	  (Bisson,	  2014)	  and	  therefore	  this	  study	  offers	  insights	  into	  the	  effectiveness	  of	  an	  innovative	  mental	  health	  response	  based	  on	  the	  stepped-­‐care	  approach	  and	  screening.	  	  Information	  on	  programme	  set-­‐up,	  running,	  outcomes,	  costs	  and	  effectiveness	  are	  of	  value	  and	  offer	  a	  template	  for	  future	  responses	  and	  their	  evaluations.	  One	  contribution	  of	  the	  study	  lies	  in	  the	  evaluation	  of	  the	  innovative	  mental	  health	  response	  based	  on	  screening	  of	  individuals	  exposed	  to	  the	  LB.	  	  Although	  literature	  recommends	  early	  detection	  and	  referral	  for	  evidence-­‐based	  treatment	  of	  individuals	  with	  PTSD,	  there	  is	  an	  absence	  of	  evidence	  on	  the	  effectiveness	  of	  screening	  in	  the	  context	  of	  mental	  health	  responses	  after	  traumatic	  events	  (Bisson	  et	  al,	  2010	  b).	  	  Guidelines	  on	  psychosocial	  care	  following	  disasters	  and	  major	  incidents	  advise	  against	  formal	  screening	  of	  everyone	  involved.	  	  However,	  at	  the	  same	  time,	  they	  highlight	  the	  need	  to	  be	  “aware	  of	  the	  importance	  of	  identifying	  individuals	  with	  significant	  difficulties”	  (Bisson	  et	  al.,	  2010	  b,	  p.	  7).	  	  Similarly,	  although	  in	  the	  qualitative	  study	  GPs	  expressed	  mixed	  views	  on	  implementation	  of	  primary	  care	  screening	  for	  PTSD,	  they	  nevertheless	  agreed	  that	  a	  pilot/evaluation	  was	  needed.	  	  In	  this	  context	  of	  scarce	  evidence	  and	  conflicting	  recommendations,	  it	  is	  hoped	  that	  this	  study	  makes	  a	  helpful	  contribution.	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This	  study	  highlights	  the	  fact	  that	  providing	  the	  best	  evidence-­‐based	  treatment	  early,	  in	  the	  form	  of	  the	  ‘screen	  and	  treat’	  approach,	  does	  not	  seem	  to	  be	  cost-­‐effective,	  as	  there	  is	  no	  difference	  in	  treatment	  effectiveness	  between	  the	  early	  and	  later	  treatment	  groups	  while	  early	  treatment	  group	  reported	  significantly	  higher	  costs.	  	  I	  expected	  to	  find	  that	  the	  costs	  incurred	  for	  running	  the	  ST	  programme	  could	  be	  offset	  by	  the	  savings	  from	  avoiding	  chronic	  PTSD	  and	  large	  productivity-­‐related	  costs	  to	  become	  even	  larger.	  	  However,	  without	  having	  a	  proper	  waiting	  list	  comparison	  group,	  the	  questions	  on	  cost-­‐effectiveness	  of	  the	  ST	  programme	  are	  difficult	  to	  answer	  with	  certainty.	  	  It	  is	  difficult	  to	  determine	  whether	  the	  higher	  costs	  reported	  by	  the	  early	  treatment	  group	  are	  indeed	  associated	  with	  treating	  them	  early	  or	  are	  due	  to	  other	  observed	  or	  unobserved	  factors.	  	  For	  the	  same	  reason,	  it	  is	  difficult	  to	  establish	  with	  certainty	  if	  the	  treatment	  effects	  observed	  in	  the	  programme	  are	  due	  to	  treatment	  effectiveness	  or	  to	  natural	  recovery.	  	  However,	  results	  showing	  that	  74%	  in	  the	  early	  and	  65%	  in	  later	  treatment	  group	  achieved	  reliable	  clinical	  improvement,	  that	  the	  treatment	  effect	  was	  large	  and	  well	  maintained	  at	  the	  follow-­‐up,	  and	  results	  showing	  no	  differences	  in	  treatment	  effectiveness	  between	  early	  and	  later	  treatment	  group	  suggest	  that	  the	  provided	  treatment	  was	  indeed	  effective	  (Brewin	  et	  al,	  2009a).	  	  	  Another	  important	  point	  to	  consider	  is	  whether	  or	  not	  provision	  of	  treatment	  within	  the	  first	  years	  after	  the	  exposure	  to	  the	  LB	  can	  be	  classified	  as	  early	  treatment,	  as	  the	  NICE	  guidelines	  refer	  to	  treatment	  provided	  up	  to	  three	  months	  post	  trauma	  as	  ‘early’	  (NICE,	  2007).	  	  However,	  due	  to	  the	  logistics	  of	  obtaining	  the	  contact	  details	  of	  exposed	  participants,	  it	  took	  around	  two	  months	  to	  start	  receiving	  larger	  numbers	  of	  referrals	  to	  the	  programme	  with	  the	  majority	  of	  referrals	  only	  being	  received	  five	  months	  after	  the	  LB.	  	  This	  finding	  highlights	  the	  logistical	  challenges	  in	  setting	  up	  a	  mental	  health	  response,	  which	  can	  interfere	  with	  timely	  treatment	  provision	  and	  capture	  the	  real-­‐world	  context	  of	  the	  evaluation	  study.	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In	  examining	  the	  cost-­‐effectiveness	  of	  the	  ST	  programme	  it	  is	  important	  to	  look	  at	  the	  effectiveness	  of	  the	  screening	  process	  itself.	  	  By	  looking	  at	  the	  qualitative	  data	  from	  the	  evaluation	  study,	  the	  great	  majority	  of	  people	  did	  not	  object	  to	  being	  approached	  for	  screening	  purposes.	  	  In	  fact,	  25%	  of	  participants	  who	  finished	  treatment	  stated	  they	  would	  have	  not	  asked	  for	  help	  themselves,	  which	  indicates	  the	  important	  role	  of	  proactive	  outreach.	  	  In	  total,	  65%	  of	  participants	  identified	  by	  the	  programme	  were	  screened	  and	  30.5%	  of	  those	  were	  referred	  for	  treatment,	  which	  indicates	  a	  high	  response	  rate	  and	  a	  good	  screening	  uptake.	  	  Another	  finding	  that	  possibly	  points	  towards	  the	  effectiveness	  of	  screening	  to	  identify	  people	  in	  need	  of	  treatment	  was	  the	  negative	  correlation	  between	  the	  total	  number	  of	  screeners	  and	  PTSD	  ICD-­‐10	  diagnosis,	  meaning	  that	  the	  more	  screeners	  individuals	  received	  the	  less	  likely	  they	  were	  to	  be	  diagnosed	  with	  PTSD.	  	  Most	  of	  the	  participants	  were	  referred	  to	  treatment	  after	  the	  first	  screener.	  	  This	  finding	  may	  suggest	  a	  waste	  of	  resources	  on	  continuous	  screening.	  	  However,	  when	  looking	  at	  the	  percentage	  of	  people	  screening	  positive	  on	  TSQ,	  the	  data	  shows	  50%	  of	  participants	  screened	  positive	  at	  the	  first	  screener,	  30%	  of	  participants	  screened	  positive	  at	  the	  second	  screener,	  while	  17%	  and	  9%	  screened	  positive	  on	  the	  third	  and	  fourth	  screener	  respectively.	  	  This	  data	  may	  indicates	  the	  benefits	  of	  continued	  screening	  up	  to	  at	  least	  two	  consecutive	  screeners.	  	  Brewin	  et	  al	  (2010,	  p.	  397)	  concluded	  that	  “three	  screeners	  were	  the	  maximum	  that	  was	  worthwhile	  in	  terms	  of	  the	  response	  rate	  in	  the	  mental	  health	  response	  to	  the	  LB”.	  	  Furthermore,	  an	  additional	  benefit	  of	  continuous	  screening	  is	  the	  ability	  to	  detect	  late	  onset	  PTSD.	  An	  important	  question	  for	  the	  future	  is:	  how	  many	  screeners	  is	  a	  good	  use	  of	  resources?	  	  Most	  of	  the	  participants	  were	  referred	  to	  treatment	  after	  the	  first	  screener	  and	  there	  was	  a	  negative	  correlation	  between	  the	  number	  of	  people	  screened	  and	  the	  total	  number	  of	  screeners.	  	  As	  people	  were	  screened	  up	  to	  five	  times	  in	  the	  ST	  programme,	  it	  is	  questionable	  as	  to	  whether	  this	  is	  the	  best	  use	  of	  the	  resources	  considering	  the	  findings	  above.	  	  The	  evaluation	  study	  recommended	  a	  maximum	  number	  of	  three	  screeners	  as	  on	  the	  fourth	  screener	  the	  number	  of	  positively	  screened	  individuals	  dropped	  to	  only	  9%	  (Brewin	  et	  al,	  2010).	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The	  government	  in	  England	  is	  committed	  to	  investing	  more	  money	  in	  mental	  health,	  and	  long-­‐term	  funding	  programmes	  such	  as	  IAPT	  confirm	  their	  pledge.	  	  This	  evaluation	  suggests	  that	  the	  costs	  of	  treatment	  are	  offset	  by	  savings	  in	  indirect	  costs.	  	  Therefore,	  allocating	  more	  money	  to	  recognition	  and	  treatment	  of	  PTSD	  would	  be	  both	  effective	  for	  the	  individuals	  concerned	  and	  also	  economically	  attractive.	  	  Apart	  from	  investing	  in	  the	  treatment	  of	  PTSD,	  funding	  should	  be	  available	  for	  recognition	  of	  the	  disorder	  itself,	  especially	  in	  the	  context	  where	  usual	  pathways	  into	  treatment,	  such	  as	  GPs	  and	  self-­‐referrals,	  are	  shown	  not	  to	  be	  effective.	  	  This	  is	  particularly	  important	  in	  the	  case	  of	  PTSD,	  as	  IAPT	  reported	  lower	  rates	  of	  referrals	  for	  PTSD	  than	  expected	  from	  general	  population	  PTSD	  prevalence	  rates.	  	  The	  finding	  that	  only	  3%	  of	  all	  referrals	  to	  the	  ST	  programme	  came	  via	  GPs	  supports	  the	  need	  for	  improvement	  in	  PTSD	  recognition	  at	  the	  general	  practice	  level.	  	  Furthermore,	  this	  finding	  is	  in	  line	  with	  existing	  evidence	  on	  the	  need	  to	  increase	  GP	  awareness	  and	  recognition	  of	  PTSD,	  as	  well	  as	  knowledge	  around	  effective	  treatment.	  	  	  The	  next	  recommendation	  is	  around	  the	  importance	  of	  providing	  information	  and	  support	  to	  the	  families	  of	  the	  affected	  individuals	  as	  a	  part	  of	  the	  mental	  health	  response.	  	  The	  protective	  role	  of	  social	  support	  in	  preventing	  the	  onset	  of	  chronic	  PTSD	  has	  been	  highlighted	  by	  numerous	  studies	  (Bisson	  et	  al.,	  2009).	  	  Immediate	  family	  and	  social	  networks	  play	  a	  crucial	  role	  in	  supporting	  individuals	  affected	  by	  traumatic	  events,	  especially	  in	  the	  early	  days,	  and	  are	  an	  important	  element	  of	  the	  path	  to	  recovery.	  	  However,	  traumatic	  events	  often	  have	  a	  massive	  impact	  on	  the	  families	  of	  those	  directly	  involved.	  	  Therefore,	  it	  is	  important	  for	  families	  to	  understand	  the	  process	  of	  recovery,	  which	  will	  enable	  them	  to	  spot	  the	  symptoms	  of	  PTSD	  in	  the	  affected	  individual	  and	  refer	  him/her	  to	  specialist	  services.	  	  Secondly,	  such	  services	  would	  provide	  support	  for	  other	  family	  members.	  This	  study	  highlighted	  that	  there	  is	  a	  need	  not	  just	  for	  better	  recognition	  of	  PTSD	  but	  also	  for	  continued	  longer-­‐term	  monitoring	  of	  individuals	  affected	  by	  a	  traumatic	  event.	  	  With	  the	  introduction	  of	  IAPT	  services,	  this	  practice	  is	  indeed	  implementable	  and	  does	  not	  require	  allocation	  of	  additional	  resources.	  	  Yet,	  if	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effective,	  it	  can	  result	  in	  great	  economic	  benefits	  and	  savings	  by	  preventing	  the	  onset	  of	  chronic	  PTSD.	  This	  study	  confirmed	  findings	  from	  other	  studies	  on	  factors	  associated	  with	  service	  use	  and	  risk	  factors	  for	  PTSD.	  	  Importantly,	  the	  analysis	  identified	  vulnerable	  groups	  such	  as	  women,	  participants	  of	  an	  older	  age	  and	  participants	  from	  minority	  ethnic	  groups	  who	  were	  either	  more	  likely	  to	  report	  the	  costs	  or	  to	  use	  the	  services	  associated	  with	  exposure	  to	  the	  LB,	  and	  to	  report	  worse	  mental	  health	  outcomes.	  	  This	  study	  also	  highlighted	  being	  injured,	  witnessing	  death	  or	  injury,	  and	  feeling	  one	  will	  die	  or	  sustain	  injury	  as	  predictors	  of	  PTSD	  and	  higher	  costs.	  	  These	  findings	  are	  of	  relevance	  for	  mental	  health	  service	  planning	  and	  provision,	  and	  constitute	  an	  important	  element	  of	  effective	  psychosocial	  response	  as	  “the	  key	  to	  effective	  response	  is	  awareness	  of	  populations	  at	  risk	  and	  their	  particular	  needs”	  (DH,	  2009,	  p.	  27).	  	  Other	  populations	  at	  a	  higher	  risk	  of	  developing	  PTSD	  due	  to	  the	  nature	  of	  their	  work	  that	  involves	  exposure	  to	  traumatic	  events	  are	  first	  responders,	  A&E	  personnel,	  police	  officers	  and	  fire	  fighters.	  	  Recognising	  and	  addressing	  their	  psychosocial	  and	  mental	  health	  needs	  is	  an	  important	  element	  of	  every	  mental	  health	  response	  programme,	  as	  well	  as	  an	  essential	  part	  of	  the	  support	  services	  provided	  by	  their	  employers.	  	  This	  is	  particularly	  significant,	  as	  these	  professions	  have	  a	  tendency	  to	  create	  a	  work	  culture	  that	  stigmatises	  help-­‐seeking	  behaviour	  around	  mental	  health.	  More	  generally,	  when	  taking	  into	  account	  high	  indirect	  costs	  associated	  with	  PTSD	  due	  to	  reduced	  productivity,	  sick-­‐leave	  and	  presenteeism,	  there	  is	  a	  strong	  economic	  case	  from	  an	  employer’s	  perspective	  to	  recognise	  and	  address	  mental	  health	  needs	  associated	  with	  PTSD.	  	  Participants	  in	  this	  study	  used	  a	  wide	  range	  of	  services	  to	  support	  their	  physical	  and	  mental	  health	  needs.	  	  In	  particular,	  there	  is	  a	  need	  to	  develop	  a	  wider	  catchment	  network	  for	  the	  participants	  who	  are	  unlikely	  to	  be	  aware	  of	  mental	  health	  response	  or	  regular	  pathways	  into	  treatment.	  	  This	  can	  be	  established	  by	  better	  sharing	  of	  information	  between	  agencies	  such	  as	  the	  NHS	  (hospitals,	  A&E	  services	  and	  GPs),	  police	  and	  other	  first	  response	  agencies,	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councils,	  and	  others.	  	  Viable	  communication	  channels	  and	  data-­‐sharing	  agreements	  should	  be	  established	  for	  future	  emergencies.	  To	  state	  that	  evaluation	  is	  a	  crucial	  part	  of	  every	  intervention	  and	  should	  be	  much	  more	  than	  just	  a	  formal	  requirement	  by	  intervention	  commissioners	  and	  funders	  is	  not	  a	  finding	  or	  recommendation	  unique	  to	  this	  thesis.	  	  However,	  this	  is	  increasingly	  important	  in	  the	  context	  of	  constrained	  budgets	  and	  limited	  resources,	  as	  evaluations	  (particularly	  economic	  evaluations)	  can	  help	  guide	  the	  decisions	  behind	  resource	  allocation.	  	  More	  resources	  should	  be	  available	  for	  evaluating	  ways	  to	  recognise	  and	  treat	  PTSD.	  	  Moreover,	  it	  is	  important	  to	  recognise	  and	  investigate	  the	  potential	  role	  and	  contribution	  of	  a	  range	  of	  available	  evaluation	  designs.	  	  This	  recommendation	  translates	  into	  more	  available	  funding	  for	  non-­‐experimental	  evaluation	  study	  designs,	  which	  would	  boost	  the	  evidence	  base	  on	  interventions	  for	  PTSD.	  In	  conclusion,	  this	  thesis	  has	  approached	  the	  subject	  of	  PTSD	  from	  several	  angles.	  	  The	  study	  has	  confirmed,	  in	  line	  with	  evidence	  discussed	  in	  Chapter	  2,	  that	  the	  effects	  of	  trauma	  exposure	  and	  PTSD	  have	  a	  wide-­‐ranging	  and	  long-­‐term	  health-­‐related	  and	  economic	  impact	  on	  exposed	  individuals.	  	  Costs,	  particularly	  productivity	  loss,	  associated	  with	  trauma	  exposure	  and	  PTSD	  are	  significant.	  	  Long-­‐term	  health,	  social	  and	  economic	  effects	  of	  PTSD	  can	  be	  prevented	  or	  reduced	  by	  timely	  and	  appropriate	  treatment	  provision.	  	  This	  study	  has	  not	  shown	  that	  it	  is	  cost-­‐effective	  to	  implement	  an	  outreach	  programme	  following	  a	  large-­‐scale	  traumatic	  event	  that	  will	  identify,	  screen	  and	  treat	  individuals	  whose	  mental	  health	  needs	  would	  otherwise	  be	  likely	  to	  remain	  unmet.	  	  However,	  as	  discussed	  earlier	  in	  the	  chapter,	  I	  would	  strongly	  argue	  that	  due	  to	  the	  design	  of	  the	  study	  and	  with	  the	  available	  data,	  it	  is	  not	  possible	  to	  provide	  answers	  to	  the	  questions	  that	  economic	  evaluation	  addressed	  in	  the	  first	  place.	  	  This	  study	  has	  pointed	  out	  vulnerable	  groups	  such	  as	  minority	  ethnic	  groups	  and	  women	  who	  are	  likely	  to	  experience	  worse	  outcomes	  and	  generate	  higher	  direct	  and	  indirect	  costs.	  	  It	  is	  important	  that	  future	  trauma	  responses	  are	  aware	  of	  specific	  needs	  of	  these	  groups	  in	  order	  to	  ensure	  equal	  access	  to	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treatment	  and	  to	  prevent	  long-­‐term	  health	  and	  economic	  consequences	  of	  chronic	  PTSD.	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Appendix A. Adult screening questionnaire used by the ST programme  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	                  NHS Trauma Response (London bombings) 
Your name:  
Your address:   
  
 Postcode: 
Your telephone (home):                               (mobile):                                
 (work):                                                         Email:
Your occupation:  
Your date of birth:                                  
Your gender:   Are you male?  Are you female? 
 
Do you have any children living with you?   If yes please provide their 
details: 
 Name  Age Are they 
male/female? 
child 1    
child 2     
child 3    
child 4     
child 5    	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On which day were you involved 
in the bombings?      
7 July       21 July        Both days 
 
Where were you on that day(s)? 
 
Which, if any, of the following applied to you?                            yes                   no 
You were injured                                                                                           
You felt that you might be injured or killed                                                  
You saw someone who had been injured or killed       
A family member or close friend was killed                                                
A family member or close friend was injured                                              
You felt that a family member or close friend might be injured or 
killed 
  
You personally witnessed the effects of one of the bombings                       	  
With your consent we would also like to let your G.P know of your involvement in the 
bombings so that you receive the right advice or treatment in the future. Please put a 
cross in the box if you do not wish us to do this   .   
Please add your GP name and address here ( even if you do not wish involvement of your 
G.P) 	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Please	  consider	  the	  following	  reactions	  that	  sometimes	  occur	  after	  a	  
traumatic	  event.	  This	  questionnaire	  is	  concerned	  with	  your	  personal	  
reactions	  to	  the	  London	  bombings	  that	  happened	  in	  July	  2005.	  Please	  
indicate	  whether	  or	  not	  you	  have	  experienced	  any	  of	  the	  following	  AT	  
LEAST	  TWICE	  IN	  THE	  PAST	  WEEK:	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APPENDIX B. Survey questions used in the evaluation of the ST 
programme   
 
 
 
	  
NHS London Bombings Response Evaluation 
 
 
INFORMATION SHEET & CONSENT FORM 
 
 
 
 
 
 
Section A. The first few questions regard your experience with the bombings: 
 
1. On which day were you involved in the bombings?  7 July  21 July  Both 
2. Where were you on that day(s)? 
 
 
 
 
3. Were you injured?       YES NO 
4.  You felt that you might be injured or killed?     YES NO 
5.  You saw someone who had been injured or killed?                 YES NO 
6.  A family member or close friend was killed?                                YES NO 
7.  A family member or close friend was injured?                                                          YES NO 
8.  You felt that a family member or close friend might be injured or killed?  YES NO 
9. You personally witnessed the effects of one of the bombings?   YES NO 
10. Other involvement___________________________________________________________ 
 
Section B(i). This section is about how you’re feeling now: 
 
1. Since completing your treatment, have you experienced any flashbacks relating to the bombings? 
YES NO – go to B(ii) 
2. How often do you experience flashbacks? 
 More than once a day 
 Daily 
 A few times a week 
Client no: 
 
Date: 
Date of Birth (dd/mm/yy):    Gender:  M  F 
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 Weekly 
 Once every couple of weeks 
 Monthly 
 Less often 
 
3. On a scale of 1-10, how similar or different are these flashbacks to those that you experienced before 
treatment? 
 Extremely similar/ Not at all 
 the same similar 
 1 2 3 4 5 6 7 8 9 10 
 
4. In what way(s) are they different? 
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Section B(ii). 
 
1. Have you found that you see the world differently since the bombings, or have the bombings made no 
difference to how you see the world? For example, have you found that you now have different expectations of 
other people, or Government? Do you feel that you cannot trust people or that people are out to get you? Do 
you feel you are part of society? 
NO – go to Q5  A LITTLE A LOT 
 
2. In what way do you see the world differently? 
 
 
 
 
 
3. Is this change…    +VE  -VE  BOTH +VE & -VE 
 
4. Is this change something you feel is relevant to you every day or just occasionally? 
Every day   Occasionally 
 
5. Have you found that you feel different as a person since the bombings, or have the bombings made no 
difference to how you feel as a person? For example, have you found that you now have different priorities or 
values? 
NO – go to Q8  A LITTLE A LOT 
 
6.    In what way do you feel different as a person? 
 
 
 
7.    Is this change…    +VE  -VE  BOTH +VE & -VE 
 
8.    Is this change something you feel is relevant to you every day or just occasionally? 
Every day   Occasionally 
 
 
Section C. This section refers to special services set up for people affected by the bombings: 
 
1. Do you remember being sent information or otherwise hearing about any of these special services for people 
caught up in the bombings? 
a) Family Assistance Centre (7th July Assistance Centre)   YES NO 
b) NHS Direct Assistance Line      YES NO 
c) Screening Team/Charlotte St. Clinic     YES NO 
d) London Rescue Programme      YES NO 
 
2. Did you contact or make use of any of these special services?    
a) Family Assistance Centre (7th July Assistance Centre)   YES NO 
b) NHS Direct Assistance Line      YES NO 
c) Screening Team/Charlotte St. Clinic     YES NO 
d) London Rescue Programme      YES NO 
 
4. If you did not choose to use these services yourself, why was this? 
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a) Do not remember hearing about them     YES NO 
b) Did not feel I needed them      YES NO 
c) Did not have time or opportunity to respond    YES NO 
d) Other (specify) 
 
 
 
 
 
Section D. Your experience with the Screening Team/Charlotte St. Clinic 
 
1. How did you come to hear about the Screening Team/Charlotte St. Clinic? 
a) Friends or family       YES NO 
b) Newspaper or television      YES NO 
c) From NHS Direct       YES NO 
d) From hospital doctor or G.P.     YES NO 
e) You were written to about it     YES NO 
f) Other__________________________________________________________________ 
 
2. If you received a letter about the Screening Team/Charlotte St. Clinic, did this arrive: 
a) Too soon, before you were ready to deal with it? 
b) At about the right time? 
c) Too late, you would have liked to receive it earlier? 
 
3. How satisfied or dissatisfied were you with the information and advice you received from the Screening 
Team/Charlotte St. Clinic when you were first in contact with them? 
a) Satisfied 
b) Neither satisfied nor dissatisfied 
c) Unsatisfied, felt they could have done more 
Details: 
 
 
 
 
 
4. How satisfied or dissatisfied were you with the speed with which the Screening Team/Charlotte St. Clinic 
responded to you? 
a) Satisfied 
b) Neither satisfied nor dissatisfied 
c) Unsatisfied, it took to long 
Details: 
 
 
 
 
 
5. Overall, how satisfied or dissatisfied were you with the service you received from them? 
a) Satisfied 
b) Neither satisfied nor dissatisfied 
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c) Unsatisfied 
 
Details: 
 
 
 
 
 
Section E. Treatment 
 
Treatment clinic:  
Number of sessions:  
Average session duration:  
 
1) Were your treatment sessions: 
 More than once a week 
 Weekly 
 Once every two weeks 
 Monthly 
 Less often 
 Erratic - Sessions erratic:  AT YOUR REQUEST 
      AT CLINICIAN’S RECCOMMENDATION 
      COULD NOT MAKE REGULAR SESSIONS 
 
2) How satisfied or dissatisfied were you with the choice of treatment centre offered? 
a) Satisfied 
b) Neither satisfied nor dissatisfied 
c) Unsatisfied 
 
Details: 
 
 
 
 
 
3) How satisfied or dissatisfied were you with the treatment you received? 
a) Satisfied 
b) Neither satisfied nor dissatisfied 
c) Unsatisfied 
 
Details: 
 
 
 
 
 
4) Do you think you would have approached your G.P. or NHS mental health services for help if you had not 
been in touch with the Screening Team/Charlotte St. Clinic? 
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a) Unlikely to have asked for help at all 
b) Would have asked eventually 
c) Had already contacted my G.P. or mental health services 
Section F. If there was a similar event in the future, the NHS would aim to set up services to support those affected. 
We’d like your opinion on what might be helpful and appropriate: 
 
1. If there was a similar event in the future, would you have any objection to properly qualified NHS 
professionals: 
a) Writing to you with information about such services   YES NO 
b) Telephoning you with information about such services   YES NO 
c) Obtaining your contact details from the Police or other organisations that know you were 
involved 
YES NO 
 
2. Is there any other form of information, advice or support that was not offered to you after 7th July that you think 
would be useful? 
YES NO 
Details: 
 
 
 
 
 
Section G. This section asks about the impact of the bombings on your work and leisure 
 
1. What is your current employment status? 
 Employed full-time    Retired (ill health) 
 Employed part-time    Student 
 Unemployed     Housewife/husband 
 Self-employed     Other____________________ 
 Retired (age) 
 
2. If you are currently employed: 
a) Occupation ____________________ 
b) Job title  ____________________ 
 
3. If you are unemployed/retired: 
a) Do you intend to return to work?     YES NO 
b) How long have you been unemployed/retired?   ____yrs____mths 
 
4. Have you had to reduce your working hours as a result of the bombings?  YES NO 
5. Have you taken sick leave as a result of the bombings?    YES NO 
6. Have you become unemployed as a result of the bombings?    YES NO 
 
 
  July 
05 
A
ug 
05 
Sept 
05 
O
ct 
05 
N
ov 
05 
D
ec 
05 
Jan 
06 
Feb 
06 
M
ar 
06 
A
pr 
06 
M
ay 
06 
Jun 
06 
July 
06 
A
ug 
06 
Sept 
06 
 Reduced 
your working 
               
Indicate in box 
below – ‘PH’ 
for time off due 
to physical 
effects, ‘MH’ 
for mental 
health effects 
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7. Did treatment for PTSD or other mental health issues related to the bombings help you to stay in work, or to 
return to work earlier than you otherwise might have done? 
YES NO – go to Q9 
 
8. Indicate which work-treatment relationship is most appropriate to describe your situation: 
 Treatment prevented me from requiring time off work 
 I had time off work, but treatment helped me return to work more quickly 
 Treatment had no effect on time taken off work 
 Treatment caused me to take more time off work, or to return to work less quickly 
 
 
 
 
 
9. What state benefits (if any) do you currently receive? 
 Income Support     Council Tax Benefit 
 Incapacity Benefit     Housing Benefit 
 Disabled Person’s Tax Credit   Working Tax Credit 
 Severe Disablement Allowance   Statutory Sick Pay 
 Jobseeker’s Allowance    State Retirement Pension 
 Disability Living Allowance – Care Component 
 Disability Living Allowance – Mobility Component 
 Other_____________________________ 
 
10. Are there any other ways in which the bombings have affected your ability to engage in work or leisure 
activities? 
 
hours? 
  Hours 
per 
week 
reduced 
each 
month 
               
 Taken sick 
leave? 
               
 Days missed 
each month 
               
 Become 
unemployed? 
               
 Weeks 
unemployed 
each month 
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11. Is there anything else you would like to add? 
 
 
 
 
Section H. Further contact: 
 
3. Your ethnic origin: 
 Arab     Mixed – White & Asian 
 Asian – Bangladeshi   Mixed – White & Black African 
 Asian – Indian    Mixed – White & Black Caribbean 
 Asian – Pakistani    White - British 
 Black – African    White - Irish 
 Black – Caribbean   White - Other 
 Black – Other    Other (specify)_________________ 
 Chinese 
 
2. May we contact you if we have any further questions? 
YES NO 
 
3. Do you know of anybody else who might like to talk to us? 
YES – leave details NO 
 
4. Would you like us to send you details of our findings when they are published? 
YES NO 
 
 
5. Would you be willing to take part in other research relevant to the London bombings? 
YES NO 
Thank you!  
Please don’t hesitate to get in touch if you have any points you want to make in the future or 
want to contact us for any 
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APPENDIX C. Qualitative study questions  	  
The	  core	  set	  of	  questions	  for	  all	  participants:	  	  1. Can	  you	  tell	  me	  a	  little	  bit	  about	  yourself	  and	  your	  role?	  	  2. PTSD	  can	  have	  a	  serious	  impact	  on	  the	  individual’s	  psychological	  and	  physical	  health.	  Research	  has	  shown	  that	  screening	  might	  be	  a	  valid	  method	  for	  detecting	  the	  disorder.	  Screening	  might	  also	  act	  as	  a	  pathway	  into	  treatment.	  What	  are	  your	  views	  on	  these	  two	  statements?	  	  	  3. What	  do	  you	  think	  would	  be	  the	  best	  way	  and	  setting	  to	  implement	  a	  PTSD	  screening	  policy?	  	  	  	  	  	  	  	  	  -­‐	  prompt	  questions:	  a. Screening	  procedure	  suggestion?	  	  b. Issues	  in	  regard	  to	  referral	  to	  detailed	  assessment	  or	  treatment?	  	  4. For	  someone	  in	  your	  type	  of	  job/role,	  what	  do	  you	  think	  would	  be	  the	  logistical	  and	  organisational	  challenges	  in	  implementing	  such	  a	  policy?	  	  	  5. What	  would	  be	  needed	  to	  overcome	  such	  barriers?	  	  	   6. Is	  there	  anything	  else	  you	  would	  like	  to	  add	  on	  this	  topic?	  	  
	  	  	  	  	  Questions	  specifically	  for	  those	  in	  GP	  practice:	  
	  
• What	  would	  be	  the	  best	  way	  of	  tailoring	  screening	  for	  PTSD	  intervention	  to	  fit	  the	  GP	  practice	  setting;	  
o Screening	  procedure	  suggestion?	  	  
o Issues	  in	  regard	  to	  referral	  to	  detailed	  assessment	  or	  treatment?	  
o 	  Issues	  around	  refusal	  of	  referral,	  screening	  results	  discussion	  and	  provision	  of	  educational	  materials?	  	  
o How	  time	  consuming	  are	  those	  steps?	  
o What	  are	  the	  challenges?	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• GPs	  education	  in	  the	  detection	  of	  PTSD	  and	  in	  improving	  pathways	  into	  treatment	  –	  your	  views	  and	  suggestions	  for	  improvement?	  	  	  Questions	  for	  clinicians:	  	  
• What	  is	  the	  average	  waiting	  time	  for	  trauma-­‐focused	  CBT	  treatment	  at	  your	  clinic?	  How	  does	  this	  compare	  with	  the	  national	  average?	  	  
• In	  your	  experience	  what	  is	  the	  most	  common	  pathway	  into	  treatment?	  Typically,	  how	  long	  after	  the	  onset	  of	  PTSD,	  does	  it	  take	  for	  an	  individual	  to	  have	  a	  specialist	  assessment?	  And	  how	  long	  to	  receive	  treatment?	  
• What	  would	  be	  the	  best	  way	  of	  improving	  the	  pathways	  into	  treatment?	  	  	  
Questions	  for	  academics:	  
	  
• Please	  can	  you	  comment	  on	  the	  characteristics	  of	  the	  appropriate	  instrument	  for	  PTSD	  screening	  in	  GP	  setting?	  
• Is	  there	  a	  possibility	  to	  incorporate	  into	  PTSD	  screening	  	  for	  other	  anxiety	  disorders	  as	  well	  such	  as	  depression,	  GAD,	  travel	  phobia?	  
• Appropriateness	  for	  PTSD	  screening	  in	  general	  population?	  	  
• (Distinction	  between	  war	  and	  non-­‐war	  related	  PTSD	  –	  symptoms,	  treatment	  etc.)	  
• Any	  other	  issues?	  
	  
Questions	  for	  PCT	  commissioners	  and	  policy	  developers:	  	  
• If	  you	  are	  considering	  providing	  a	  particular	  service	  or	  intervention,	  how	  important	  to	  you	  is	  the	  evidence	  base?	  	  	  
• If	  you	  wanted	  to	  introduce	  PTSD	  screening	  in	  your	  area,	  how	  would	  you	  move	  toward	  getting	  it	  in	  place?	  Who	  would	  you	  involve	  in	  the	  decision-­‐making?	  What	  would	  be	  the	  process?	  	  	  
• Anything	  else?	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APPENDIX D. Posttraumatic diagnostic scale  	  
Below	  is	  a	  list	  of	  problems	  that	  people	  sometimes	  have	  after	  experiencing	  a	  
traumatic	  event.	  Read	  each	  one	  carefully	  and	  choose	  the	  answer	  that	  best	  describes	  
how	  often	  that	  problem	  has	  bothered	  you	  IN	  THE	  PAST	  MONTH.	  Rate	  each	  problem	  
with	  respect	  to	  the	  London	  bombings.	  
0	  	  	  	  	  	  Not	  at	  all	  or	  only	  one	  time	  
1	  	  	  	  	  	  Once	  a	  week	  or	  less/once	  in	  a	  while	  
2	  	  	  	  	  2	  to	  4	  times	  a	  week	  /	  half	  the	  time	  
3	  	  	  	  	  5	  or	  more	  times	  a	  week	  /	  almost	  always	  
1*	   Having	  upsetting	  thoughts	  or	  images	  about	  the	  event	  that	  came	  into	  your	  head	  when	  you	  didn’t	  want	  them	  to	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  	  
2*	   Having	  bad	  dreams	  or	  nightmares	  about	  the	  traumatic	  event	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
3*	   Reliving	  the	  traumatic	  event,	  acting	  or	  feeling	  as	  if	  it	  were	  happening	  again	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
4*	   Feeling	  emotionally	  upset	  when	  you	  were	  reminded	  of	  the	  traumatic	  event	  (e.g.	  feeling	  angry,	  scared,	  sad,	  guilty	  etc.)	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
5*	   Experiencing	  physical	  reactions	  when	  you	  were	  reminded	  of	  the	  traumatic	  event	  (e.g.	  break	  into	  sweat,	  heart	  beating	  fast)	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
6	   Trying	  not	  to	  think	  about,	  talk	  about	  or	  have	  feelings	  about	  the	  traumatic	  event	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
7	   Trying	  to	  avoid	  activities,	  people	  or	  places	  that	  remind	  you	  of	  the	  traumatic	  	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
8	   Not	  being	  able	  to	  remember	  an	  important	  part	  of	  the	  traumatic	  event	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
9	   Having	  much	  less	  interest	  or	  participating	  much	  less	  often	  in	  important	  	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
10	   Feeling	  distant	  or	  cut	  off	  from	  people	  around	  you	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
11	   	  Feeling	  emotionally	  numb	  (e.g.	  being	  unable	  to	  cry	  or	  unable	  to	  have	  loving	  feelings)	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
12	   Feeling	  as	  if	  your	  future	  plans	  or	  hopes	  will	  not	  come	  true	  (e.g.	  you	  will	  not	  have	  a	  career,	  marriage,	  children	  or	  a	  long	  life)	  	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
13*	   Having	  rouble	  falling	  or	  staying	  asleep	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	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14	   	  Feeling	  irritable	  or	  having	  fits	  of	  anger	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
15*	   	  Having	  trouble	  concentrating	  (e.g.	  drifting	  in	  and	  out	  of	  conversations,	  losing	  track	  of	  a	  story	  on	  television,	  forgetting	  what	  you	  have	  read)	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
16*	   Being	  overly	  alert	  (e.g.	  checking	  to	  see	  who	  is	  around	  you,	  being	  uncomfortable	  with	  your	  back	  to	  the	  door	  etc.)	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
17*	   Being	  jumpy	  or	  easily	  startled	  (e.g.	  when	  someone	  walks	  up	  behind	  you)	   	  	  	  0	  	  	  1	  	  	  2	  	  	  3	  
 
*Items	  used	  for	  comparison	  with	  TSQ,	  marked	  as	  YES	  on	  TSQ	  scale	  if	  person	  stated	  2	  
or	  more	  on	  PDS	  sale	  per	  item	  	  
From	  Foa,	  E.,	  Cashman,	  L.,	  Jaycox,	  L.,	  &	  Perry,	  K.	  (1997).	  The	  validation	  of	  a	  self-­‐
report	  measure	  of	  PTSD:	  The	  Posttraumatic	  Diagnostic	  Scale.	  Psychological	  
Assessment,	  9,	  445-­‐451.	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APPENDIX E.	  Costs	  and	  outcomes	  best-­‐fit	  explanatory	  models	  for	  early	  
and	  later	  treatment	  groups	   	  	  	  	  	   	  	  	  	   	  	  M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  11716.8	  (15448,	  28086.4)	  Later	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1654.32	  (6924.16,	  12653.6)	  	  
	  
	  
	  
	  
	  
	  
Table	  E.1	  GLM	  on	  total	  costs	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=101	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Timing	  of	  costs	  measurement	   0.09***	  (0.05,	  0.17)	  Treatment	  start	  –	  days	  after	  LB	   -­‐1.95***	  (-­‐2.71,-­‐	  1.20)	  White	  British	   -­‐1.56***	  (-­‐2.18,	  -­‐0.93)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   2.05***(1.13,	  3.05)	  Constant	  	  	  	   7.19***	  (5.26,	  8.63)	  Link	  function	   Log	  Distributional	  family	   Gauss	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   M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1772.5	  (1163.61,	  2700.01)	  Later	  teatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1499.8	  (973.13,	  2310.98	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Table	  E.2	  GLM	  on	  total	  ST	  program	  costs	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=103	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   0.31**	  (0.05,	  0.56)	  Treatment	  start	  –	  days	  after	  LB	   -­‐0.00	  (-­‐0.00,	  0.00)	  Cost	  collection	  date	   0.02	  (-­‐0.00,	  0.00)	  PTSD	  ICD-­‐10	   0.37***(0.06,	  0.66)	  Ethnicity	   -­‐0.35***	  (-­‐0.62,	  -­‐0.09)	  Constant	  	  	  	   7.87***	  (7.26,	  8.40)	  Link	  function	   Log	  Distributional	  family	   Gamma	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  M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1772.5	  (1163.61,	  2700.01)	  Later	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1499.8	  (973.13,	  2310.98)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  Table	  E.3	  GLM	  on	  direct	  costs	  excluding	  ST	  programme	  costs	  	  
Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  
	  	  N=93	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Treatment	  start	  –	  days	  after	  LB	   -­‐0.00	  (-­‐0.00,-­‐0.00)	  Gender	  Male	  vs.	  Female	   0.89**(0.10,	  1.54)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   0.83**(0.09,	  1.57)	  Psychiatric	  comorbidity	   -­‐0.84**(-­‐1.63,	  -­‐0.04)	  Cost	  collection	  time	   0.03	  (-­‐0.03,	  0.07)	  Constant	  	  	  	   6.69***	  (5.26,	  8.17)	  Link	  function	   Log	  	   	  Distributional	  family	   Gamma	  
	   338	  
Table	  E.4	  Two	  stage	  model	  on	  work	  related	  costs	  	  
Potentially	  associated	  factors	   Logistic	  regression	  of	  
reporting	  work	  
related	  costs	  N=	  103	  
observations	  
GLM	  of	  work	  related	  
costs	  due	  to	  LB	  
N=	  68	  observations	  
Odds	  ratio	  
(95%	  confidence	  
interval)	  
Coefficient	  
(95%	  confidence	  
interval)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   3.55***(1.25,	  10.12)	   -­‐	  Number	  of	  previous	  trauma	   	   -­‐	  Total	  number	  of	  sessions	   	  	   0.04***	  (0.01,	  0.08)	  Treatment	  start	  –	  days	  after	  LB	   0.99***(0.99,	  0.99)	   -­‐0.05***	  (-­‐0.00,	  -­‐0.00)	  Psychiatric	  comorbidity	   	   -­‐0.93**(-­‐1.79,	  -­‐0.07)	  Cost	  measurement	  time	   0.99	  (0.91,	  1.07)	   0.05*(-­‐0.00,	  0.10)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   	   0.86**(0.02,	  1.69)	  Constant	   	   8.50***	  (7.06,	  10.87)	  Link	  function	   -­‐	   Log	  Distributional	  family	   -­‐	   Gamma	  Link	  test	  p-­‐value	   -­‐	   	  Pearson’s	  chi-­‐squared	  test	  p-­‐value	   0.49	   	  Hosmer-­‐Lemeshow	  chi-­‐squared	  test	  p-­‐value	   0.23	   	  Likelihood	  ratio	  chi-­‐squared	  p-­‐value	   0.00	   	  Percent	  correctly	  classified	   73.4%	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  26518.82	  (14916.93,	  38121.16)	  	  Later	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6084.03	  (4062.53,	  8105.23)	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Table	  E.5	  GLM	  model	  on	  the	  end	  BDI	  score	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=94	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Finished	  treatment	   -­‐8.41***	  (-­‐12.03,	  -­‐4.48)	  White	  British	   -­‐3.90***(-­‐7.16,	  -­‐0.63)	  BDI	  score	  at	  start	  of	  the	  treatment	   0.43***	  (0.03,	  0.06)	  Time	  elapsed	  to	  treatment	  (days	  since	  LB)	   -­‐0.00	  (-­‐0.01,	  0.00)	  Physical	  comorbidity	   7.39***	  (3.03,	  11.76)	  Constant	   10.87***(4.13,	  17.60)	  Family	   Gauss	  Link	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  10.69	  	  (9.09,	  12.28)	  Late	  treatment	  	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8.62	  	  	  (7.05,	  10.29)	  	  Table	  E.6	  OLS	  model	  for	  pre	  and	  post	  treatment	  difference	  in	  BDI	  score	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=101	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Q3.	  You	  saw	  someone	  who	  has	  been	  injured	  or	  killed?	   4.57*(0.20,	  10.95)	  Finished	  treatment	   -­‐7.24***(-­‐11.39,	  3.10)	  Treatment	  start	  (days	  since	  LB)	   0.01***	  (0.00,	  0.02)	  Having	  a	  premorbid	  condition	   4.12**(-­‐0.03,	  8.29)	  Constant	   -­‐14.68***(-­‐18.41,	  -­‐5.03)	  	  R	  sq	  =	  0.2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  M	  	  	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐14.08	  (-­‐16.76,	  -­‐11.63)	  Later	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐10.54	  (-­‐12.68,	  -­‐7.33	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Table	  E.7	  GLM	  model	  on	  the	  end	  PDS	  score	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=94	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  	   	  White	  British	  relative	  to	  Other	  ethnic	  categories	   -­‐5.80***	  (-­‐0.96,	  -­‐0.15)	  Physical	  comorbidity	   10.68***	  (4.17,	  17.18)	  Finished	  treatment	   -­‐11.90***	  (-­‐1.03,	  -­‐0.48)	  PDS	  score	  at	  start	  of	  the	  treatment	   0.39***	  (0.03,	  0.06)	  Treatment	  time	  elapsed	  –	  days	  since	  LB	   0.00	  (-­‐0.01,	  0.00)	  Constant	   13.81***(5.45,	  22.17)	  Family	   Gauss	  Link	   	  M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  11.08	  (9.65,	  13.47)	  Late	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8.47	  (8.29,	  12.67)	  R	  squared=	  0.4	  	  	  Table	  E.8	  OLS	  model	  for	  pre	  and	  post	  treatment	  difference	  in	  PDS	  score	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=101	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   5.26**	  (0.48,	  10.05)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   -­‐7.52***	  (-­‐11.86,	  -­‐3.19)	  Finished	  treatment	   -­‐12.18***(-­‐17.58,	  -­‐6.78)	  Treatment	  timing	  (later	  vs.	  early)	   0.01**(0.00,	  0.02)	  Constant	   8.78**(1.45,	  14.17)	  R	  sq=0.27	   M	  (95%	  CI)	  Later	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐15.96	  (-­‐17.66,	  -­‐12.25)	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Table	  E.9	  OLS	  model	  for	  depression-­‐free	  days	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=96	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Ethnicity	   	  	  	  0.86***(0.47,	  1.25)	  Number	  of	  previous	  trauma	   -­‐0.30***	  (-­‐0.50,	  -­‐0.10)	  Finished	  treatment	   	  0.58***	  (0.09,	  1.07)	  Treatment	  time	  elapsed	  –	  days	  since	  LB	   	  0.00***(0.00,	  0.00)	  Constant	   	  	  	  4.66	  (3.17,	  5.70)	  Family	   	  	  	  Gamma	  Link	   	  M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  239.18	  (188.65,	  303.47)	  Late	  treatment	  	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  400.10	  (319.29,	  500.67)	  Table	  E.10	  model	  on	  the	  end	  PDS	  score	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=96	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  N	  of	  previous	  trauma	   -­‐58.40***(-­‐110.5,	  -­‐11.70)	  Finished	  treatment	   136.44**	  (15.17,	  257.70)	  Psychiatric	  comorbidity	   -­‐115.68**	  (-­‐259.17,	  -­‐52.1)	  Ethnicity	   146.20***	  (46.03,	  245.48)	  Treatment	  time	  elapsed	  –	  days	  since	  LB	   0.58***(0.30,	  0.86)	  Constant	   198.57**	  (18.17,	  378.70)	  Family	   Gauss	  Link	   Identity	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  M	  	  	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  380.91	  (345.65,	  441.47)	  Late	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  558.46	  (381.29,	  477.67)	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  Table	  E.11	  GLM	  model	  for	  follow-­‐up	  EQ5D	  score	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  coefficient	  	  	  N=95	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   -­‐0.14**	  (-­‐0.28,	  -­‐0.00)	  EQ5D	  at	  assessment	   0.58***	  (0.34,	  0.81)	  Treatment	  timing	  (later	  vs.	  early)	   0.09***	  (0.00,	  0.00)	  Constant	   -­‐0.60**(-­‐0.83,	  -­‐0.37)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  M	  (95%	  CI)	  Early	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.71	  (0.64-­‐0.76)	  Later	  treatment	  group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.85	  (0.79-­‐0.93)	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APPENDIX F. Explanatory models for costs and outcomes between ST 
users - treated compared to screened and assessed only users	  	  Table	  F.1	  Best-­‐fit	  (explanatory)	  GLM	  on	  follow-­‐up	  TSQ	  score	  between	  ST	  users:	  	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Total	  score	  at	  first	  screener	   0.26***(0.12,	  0.39)	  Males	  relative	  to	  Females	   -­‐0.60**	  (-­‐1.15,	  -­‐0.05)	  White	  British	  relative	  to	  Other	  ethnic	  categories	   -­‐0.68***(-­‐1.26,	  -­‐0.11)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   0.63**(0.25,	  1.59)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   -­‐0.65**(-­‐1.23,	  0.06)	  Total	  number	  of	  screeners	   -­‐0.46**(-­‐0.82,	  -­‐0.01)	  Treated	  vs.	  Screened	  and	  assessed	  only	   -­‐1.04***	  (-­‐0.82,-­‐	  0.01)	  Constant	  	  	  	   1.17**	  (-­‐0.05,	  2.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	  	  M	  	  	  	  	  	  	  	  	  (95%	  CI)	  Treated	  1.15	  (0.73,	  1.57)	  	  Screened	  and	  assessed	  only	  3.27(	  1.28,	  5.27)	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  M	  	  	  	  	  	  	  	  	  (95%	  CI)	  Treated	  12979.3	  (735.23,	  2002.60)	  	  Screened	  and	  assessed	  only	  903.64	  (260.35,	  1545.94)	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Table	  F.2	  Explanatory	  GLM	  on	  direct	  costs	  between	  ST	  users:	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.03*	  (-­‐0,00,	  0.06)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   1.57***(0.82,	  2.29)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   -­‐0.80**(-­‐1.43,	  -­‐0.06)	  Treated	  vs.	  Screened	  and	  assessed	  only	   0.44(-­‐0.82,-­‐	  0.01)	  Timing	  of	  follow-­‐up	   0.04*(-­‐0.00,	  0.08)	  Constant	  	  	  	   4.61***	  (2.78,	  6.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	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  M	  	  	  	  	  	  	  	  	  (95%	  CI)	  Treated	  1965.92	  (1104.23,	  2808.60)	  	  Screened	  and	  assessed	  only	  1104.64	  (398.35,	  1928.94)	  	  	  	  	  	  	  	  	  	  	  	  	  
Table	  F.3	  Explanatory	  GLM	  on	  total	  costs	  between	  ST	  users	  (excluding	  cost	  of	  ST	  programme):	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.04**	  (0.01,	  0.08)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   1.70***(0.52,	  2.59)	  Q2.	  You	  felt	  like	  you	  might	  be	  injured	  or	  killed?	   -­‐0.87**(-­‐1.66,	  -­‐0.82)	  Follow-­‐up	  timing	   0.04*(-­‐0.00,	  0.10)	  Treated	  vs.	  Screened	  and	  assessed	  only	   0.41(-­‐0.18,	  1.97)	  Constant	  	  	  	   3.18***	  (1.05,	  5.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	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Table	  F.4	  Explanatory	  GLM	  on	  NHS	  costs	  between	  ST	  users	  (excluding	  cost	  of	  ST	  programme):	  treated	  compared	  to	  screened	  and	  assessed	  only	  users	  	  Potentially	  associated	  factors	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Coefficient	  	  	  N=138	  observations	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (95%	  confidence	  interval)	  Age	   0.05***	  (0.01,	  0.08)	  Q1.	  Being	  injured	  relative	  to	  Not	  being	  injured	   1.07***(0.52,	  1.99)	  Follow-­‐up	  timing	   0.00(-­‐0.04,	  0.04)	  Treated	  vs.	  Screened	  and	  assessed	  only	   1.28**(0.18,	  1.97)	  Constant	  	  	  	   5.84***	  (4.05,	  7.33)	  Link	  function	   Log	  Distributional	  family	   Gamma	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  (95%	  CI)	  Treated	  1369.9	  (735.23,	  2002.60)	  Screened	  and	  assessed	  only	  903.64	  (260.35,	  1540.94)	  
	  
	  
  	  	  
